Document

0001376339-17-000042.txt : 20170301 0001376339-17-000042.hdr.sgml : 20170301 20170301161717 ACCESSION NUMBER: 0001376339-17-000042 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 101 CONFORMED PERIOD OF REPORT: 20161231 FILED AS OF DATE: 20170301 DATE AS OF CHANGE: 20170301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MIMEDX GROUP, INC. CENTRAL INDEX KEY: 0001376339 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 900300868 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35887 FILM NUMBER: 17654341 BUSINESS ADDRESS: STREET 1: 1775 W OAK COMMONS COURT, NE CITY: MARIETTA STATE: GA ZIP: 30062 BUSINESS PHONE: 678-384-6720 MAIL ADDRESS: STREET 1: 1775 W OAK COMMONS COURT, NE CITY: MARIETTA STATE: GA ZIP: 30062 FORMER COMPANY: FORMER CONFORMED NAME: Alynx, Co. DATE OF NAME CHANGE: 20060922 10-K 1 mdxg-20161231x10k.htm 10-K Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K



þ	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2016



o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________to __________

Commission file number 001-35887

MIMEDX GROUP, INC.

(Exact name of registrant as specified in its charter)



Florida		26-2792552
(State or other jurisdiction of incorporation)		(I.R.S. Employer Identification Number)

1775 West Oak Commons Court, NE Marietta, GA		30062
(Address of principal executive offices)		(Zip Code)

(770) 651-9100

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: Common Stock, par value $0.001 per share

Securities registered pursuant to Section 12(g) of the Act: None

(Title of class)

Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes þ No o

Indicate by check mark whether the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No þ

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§229,405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No o

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. þ

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):



Large accelerated filer þ	Accelerated filer o	Non-accelerated filer o	Smaller reporting Company o
	(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ

The aggregate market value of Common Stock held by non-affiliates on June 30, 2016, based upon the last sale price of the shares as reported on the NASDAQ on such date, was approximately $787,686,000.

There were 108,840,839 shares of Common Stock outstanding as of February 15, 2017.

Documents Incorporated by Reference

Portions of the proxy statement relating to the 2017 Annual Meeting of Shareholders, to be filed within 120 days after the end of the fiscal year to which this report relates, are incorporated by reference in Part III of this Report.

Table of Contents



Part I
Item	Description	Page
Item 1.	Business	2
Item 1A.	Risk Factors	17
Item 2.	Properties	31
Item 3.	Legal Proceedings	32
Item 4.	Mine Safety Disclosures	33

Part II
Item 5.	Market for Registrants' Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities	34
Item 6.	Selected Financial Data	37
Item 7.	Management's Discussion and Analysis of Financial Condition and Results of Operations	38
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	46
Item 8.	Financial Statements and Supplementary Data	47
Item 9.	Changes in Disagreements with Accountants on Accounting and Financial Disclosure	80
Item 9A.	Controls and Procedures	80
Item 9B.	Other Information	81

Part III
Item 10.	Directors, Executive Officers and Corporate Governance	82
Item 11.	Executive Compensation	82
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters	82
Item 13.	Certain Relationships and Related Transactions, and Director Independence	82
Item 14.	Principal Accounting Fees and Services	82

Part IV
Item 15.	Exhibits, Financial Statement Schedules	83
Item 16.	Form 10-K Summary	88
Signatures		89

PART I

This Form 10-K and certain information incorporated herein by reference contain forward-looking statements and information within the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. This information includes assumptions made by, and information currently available to management, including statements regarding future economic performance and financial condition, liquidity and capital resources, acceptance of our products by the market, and management’s plans and objectives. In addition, certain statements included in this and our future filings with the Securities and Exchange Commission (“SEC”), in press releases, and in oral and written statements made by us or with our approval, which are not statements of historical fact, are forward-looking statements. Words such as “may,” “could,” “should,” “would,” “believe,” “expect,” “expectation,” “anticipate,” “estimate,” “intend,” “seeks,” “plan,” “project,” “continue,” “predict,” “will,” “should,” and other words or expressions of similar meaning are intended by us to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are found at various places throughout this report and in the documents incorporated herein by reference. These statements are based on our current expectations about future events or results and information that is currently available to us, involve assumptions, risks, and uncertainties, and speak only as of the date on which such statements are made.

Forward-looking statements include, but are not limited to, the following:


•	the advantages of our products;


•	the regulatory pathway for our products;


•	our belief regarding the growth of our direct sales force resulting in increased revenues;


•	expectations regarding Government and other third-party reimbursement for our products;


•	our beliefs regarding our relationships with significant distributors;


•	expectations regarding future revenue growth;


•	our ability to procure sufficient supplies of human tissue to manufacture and process our products;


•	market opportunities for our products and future products;


•	prospects for obtaining additional patents covering our proprietary technology as well as successfully defending our existing patents and prohibiting infringement thereof by third-parties;


•	the outcome of pending litigation and investigations; and


•	our ability to compete effectively.

Actual results and outcomes may differ materially from those expressed or implied in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those discussed in Part I, Item 1A, “Risk Factors,” below. Except as expressly required by the federal securities laws, we undertake no obligation to update any such factors, or to publicly announce the results of, or changes to any of the forward-looking statements contained herein to reflect future events, developments, changed circumstances, or for any other reason.

As used herein, the terms “MiMedx,” “the Company,” “we,” “our” and “us” refer to MiMedx Group, Inc., a Florida corporation, and its consolidated subsidiaries as a combined entity, except where it is clear that the terms mean only MiMedx Group, Inc.

Item 1. Business

Overview

MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human placental tissue, skin and bone. "Innovations in Regenerative Biomaterials" is the framework behind our mission to provide physicians with innovative products that help the body heal itself. MiMedx is the leading global supplier of amniotic tissue products, having supplied over 700,000 allografts to date in Wound Care, Burns, Surgery, Orthopedics, Spine, Sports Medicine, Ophthalmology and Dentistry.

Through our donor program, a mother who is scheduled to deliver a healthy full-term baby via Caesarean section can elect to donate her placental tissue in lieu of having it discarded as medical waste. MiMedx’s procurement network collects the donated human placental tissue which is converted into safe, effective and sterile product at our fully integrated manufacturing facility utilizing our proprietary PURION® Process.

Our biomaterial platform technologies include AmnioFix®, EpiFix®, OrthoFlo, Physio®, and CollaFix™. AmnioFix and EpiFix are our tissue technologies for homologous use processed from human amniotic membrane derived from donated placental tissue. OrthoFlo is our amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material comprised of 100% bone tissue with no added carrier. CollaFix is the next technology platform we plan to commercialize. It is derived from collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair. CollaFix is the only known biological, biodegradable, biomimetic technology that matches human tendon in strength and stiffness.

Our strategic plan aims to provide a more balanced revenue mix and expands our Surgical, Sports Medicine and Orthopedics offerings to include the treatment of joint, ligament and tendon pain in the physician’s office.

Our History

Our current business began on February 8, 2008, when Alynx, Co., our predecessor company, acquired MiMedx, Inc., a Florida-based, privately-held, development-stage medical device company, the assets of which included licenses to two development-stage medical device technology platforms- HydroFix® and CollaFix. On March 31, 2008, Alynx, Co. merged into MiMedx Group, Inc., a Florida corporation and wholly-owned subsidiary that had been formed on February 28, 2008, for purposes of the merger. MiMedx Group, Inc. was the surviving corporation in the merger. In 2010, we commercialized the first medical device product using our HydroFix technology. In 2011 and 2012, we launched additional versions of our HydroFix product line. In January 2011, the Company acquired all of the outstanding equity interests of Surgical Biologics, LLC (“Surgical Biologics”). The acquisition of Surgical Biologics expanded our business by adding allografts and other products processed from human amniotic membrane to our existing medical device product lines based on our HydroFix technology. In 2013, we changed the name of Surgical Biologics to MiMedx Tissue Services, LLC. Due to the relatively small size of the addressable market for our HydroFix product line, we decided to discontinue that product line in the fourth quarter of 2013. Although we have yet to commercialize any products using our CollaFix technology, we continue to believe that technology presents a significant opportunity in the orthopedic and sports medicine markets.

On January 13, 2016, we acquired all of the outstanding common stock of Stability Inc. d/b/a Stability Biologics. The acquisition of Stability was effected by the merger of Stability Inc. into a newly created wholly owned subsidiary of the Company. The new subsidiary was the surviving company in the merger and was subsequently renamed Stability Biologics, LLC ("Stability"). We are working to improve Stability’s manufacturing processes and procedures and integrate its product offerings with our existing surgical, spine and orthopedics portfolio.

For financial information concerning our operating performance, please refer to Management’s Discussion and Analysis of Financial Condition and Results of Operations in Part II, Item 7 of this report and our Consolidated Financial Statements in Part II, Item 8 of this report.

Our Technology and Products

We are the leading supplier of allografts processed from amniotic tissue, having supplied over 700,000 allografts to date for application in Wound Care, Burns, Surgery, Orthopedics, Spine, Sports Medicine, Ophthalmology and Dentistry. Our amniotic membrane products include our own brands, AmnioFix and EpiFix, as well as products that we supply on a private label or “OEM” basis. We continue to research new opportunities for amniotic tissue, and currently have several additional offerings in various stages of conceptualization and development.

Amniotic membrane is considered immunoprivileged and does not elicit an immune response. Natural human amniotic membrane is composed of multiple layers that contain:


•	Structural proteins; including:


◦	Collagen types I, III, IV, V, and VII


◦	Elastin


•	Specialized extracellular matrix proteins; including:


◦	Fibrillin


◦	Fibronectin


◦	Laminins


•	TIMPs 1,2,4, Tissue Inhibitor of Metalloproteinase 1, 2, 4


•	At least 226 Growth Factors; including but not limited to:


◦	Epidermal Growth Factor (EGF)


◦	Transforming Growth Factor Beta (TGF-B)


◦	Fibroblast Growth Factor (FGF)


◦	Platelet Derived Growth Factors AA & BB (PDGF AA&BB)

Published scientific studies show our proprietary technique for processing allografts from amniotic tissue preserves more of the natural characteristics of the tissue than the processes used by many of our competitors. We operate a licensed tissue bank that is registered as a tissue establishment with the United States Food and Drug Administration ("FDA"). We are an accredited member of the American Association of Tissue Banks (“AATB”). We partner with physicians and hospitals to recover donated placental tissue. After consent for donation is obtained, donors are screened for eligibility and the donated

tissue is tested for safety in compliance with federal regulations and AATB standards on communicable disease transmission. All donor records and test results are reviewed by our Medical Director prior to the release of the tissue for processing.

Over several years, we have developed a unique and proprietary technique for processing allografts from the donated placental tissue. The PURION Process produces an allograft that is easy to use and effective. This unique processing technique specifically focuses on preserving the tissue’s bioactive growth factor content, and maintaining the structure and collagen matrix of the tissue. The PURION Process also allows the allograft to be stored at room temperature and have a five-year shelf life. Additionally, each sheet allograft incorporates specialized visual embossments that assist the health care practitioner with proper allograft placement and orientation.

MiMedx is dedicated to providing easy to use, effective allografts that exceed customer expectations. To better satisfy the requirements and expectations of our customers, we maintain strict controls on quality at each step of the process beginning at the time of procurement. We have developed and implemented a Quality Management System in compliance with both FDA regulations and AATB standards.

EpiFix

Our EpiFix allograft is configured for external use. It is used to enhance healing as well as to modulate inflammation. The EpiFix platform has been used to treat chronic wounds, including diabetic foot ulcers, venous stasis ulcers, arterial ulcers and pressure ulcers, burns and surgical wounds. We offer EpiFix in a sheet form as well as a micronized powder form. The powder can be packed into wounds and is particularly useful for tunneling wounds. Some physicians also choose to mix the powder with saline to inject it into the wound bed and wound margins.

AmnioFix

Our AmnioFix allografts are configured for internal use. Currently, our AmnioFix product line consists of three main configurations, AmnioFix, AmnioFix Wrap and AmnioFix Injectable:


•	AmnioFix is provided in a sheet form. It is used to modulate inflammation, enhance healing and to minimize scar tissue formation. It has been used in spine, urology and general surgeries.


•	AmnioFix Wrap also is supplied in a sheet form and is configured for the same purposes as AmnioFix, but is optimized for use as a “wrap” for nerves, tendons or ligaments.


•	AmnioFix Injectable is supplied in micronized powder form used to reduce inflammation while enhancing healing. AmnioFix Injectable has been used to treat conditions such as tendonitis, including plantar fasciitis, lateral epicondylitis, and medial epicondylitis, bursitis, strains and sprains.

EpiCord

EpiCord is a minimally manipulated, dehydrated, non-viable cellular umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue.

AmnioCord

AmnioCord is a minimally manipulated, dehydrated, non-viable cellular umbilical cord allograft for homologous use that provides a protective environment for the healing process.

AmnioFill

AmnioFill is a minimally manipulated, non-viable cellular tissue matrix allograft that contains multiple extracellular matrix proteins, growth factors, cytokines, and other specialty proteins present in placental tissue to help enhance healing.

OEM Products

Currently, allografts for ophthalmic surgery and dental applications are sold on an OEM basis pursuant to agreements whereby we have granted third parties exclusive licenses to some of our technology for use in those fields in specified markets. As further discussed below, we also sell products on a non-exclusive OEM basis to Medtronic for spinal procedures and Zimmer Biomet for spine and orthopedic procedures.

OrthoFlo

OrthoFlo is a human tissue allograft that is derived from amniotic fluid. Amniotic fluid is the liquid contained within the amniotic sac during pregnancy, which protects, cushions, and enhances the mobility of the fetus, and modulates inflammation. Key elements of amniotic fluid include growth factors, carbohydrates, proteins, lipids, electrolytes, and hyaluronic acid. OrthoFlo is provided lyophilized.

CollaFix

Our CollaFix technology combines an innovative means of creating fibers from soluble collagen and a specialized cross-linking process and products from this platform are likely to be classified as medical devices. Initial laboratory and animal testing shows that the cross-linked collagen fibers produce a very strong, biocompatible, and durable construct that can be transformed into biomechanical constructs intended to treat a number of orthopedic soft-tissue trauma and disease disorders. The technology is licensed from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. pursuant to an exclusive, world-wide license to practice and use the technology and to manufacture, have manufactured, market, offer for sale and sell products incorporating the technology. The license of the technology is perpetual, except that the license terminates on a country-by-country basis as to any patent or portion thereof included in the licensed technology upon the expiration of such patent or portion thereof in the applicable country. We are currently working to develop and commercialize products using our CollaFixtechnology and continue to evaluate how best to exploit this technology. We may license rights to specific aspects of our collagen technology to third parties for use in applications and indications that we choose not to exploit ourselves.

We are required to pay a royalty of 3% on all commercial sales revenue from the sale of products incorporating the licensed technology. We also are obligated to pay a $50,000 minimum annual royalty payment over the life of the license.

Physio

Physio is a bone grafting material comprised of 100% bone tissue with no added carrier.

Intellectual Property

Our intellectual property includes owned and licensed patents, owned and licensed patent applications and patents pending, proprietary manufacturing processes and trade secrets, and trademarks associated with our technology. Furthermore, we require employees, consultants and advisors to sign Proprietary Information and Inventions Agreements, as well as Nondisclosure Agreements that assign to us and protect the intellectual property existing and generated from their work or that we may otherwise use or own. We believe that our patents, proprietary manufacturing processes, trade secrets, trademarks, and technology licensing rights provide us with important competitive advantages.

Patents and Patent Applications

Because of the substantial expertise and investment of time, effort and financial resources required to bring new regenerative biomaterial products and implants to the market, the importance of obtaining and maintaining patent protection for significant new technologies, products and processes cannot be underestimated. As of the date of this Form 10-K, we own 33 U.S. patents related to our amniotic tissue technology and products. Approximately, 80 additional patent applications covering aspects of this technology are pending at the United States Patent and Trademark Office and with various international patenting agencies.

Worldwide, our CollaFix and HydroFix technologies are protected with 45 and 14 issued patents, respectively. Additionally, in the U.S. and internationally, there are 30 patent applications pending covering our CollaFix technology.

The vast majority of our domestic patents covering our core amniotic tissue technology and products will not begin to expire until August of 2027.

See discussion below- “Risk Factors” under the heading “Risks Related to Our Intellectual Property.”

Market Overview

Domestic sales currently account for most of our revenue, and we are actively pursuing international expansion. In the United States, Wound Care, Burns, Surgery, Orthopedics, Spine, Sports Medicine, Ophthalmology and Dentistry are our key

markets. For information on the amount of revenues attributed to our Wound Care products and our SSO products for the past three fiscal years, see the discussion of our results of operations in Item 7 of this Form 10-K.

Wound Care

The wound care market includes traditional dressings such as bandages, gauzes and ointments, which are used to treat non-severe wounds and advanced wound care products such as mechanical devices, advanced dressings and biologics, which are used to treat severe wounds or chronic wounds that have not appropriately closed after 4⁵ weeks of treatment with traditional dressings.

In the United States in 2015, there were 6.5 million¹ reported cases of patients suffering from a hard to heal wound with 3.0 million¹ of these patients being a candidate for treatment with an advanced wound care product. Of these 3.0 million patients, MiMedx estimates that 1.4 million suffered from either a diabetic foot ulcer or a venous leg ulcer. The overall cost of treating chronic wounds is rising sharply and in the United States, the current annual estimated cost exceeds $25 billion¹ dollars.

United States Wound Care Market 2015

Source: BioMedGPS LLC

Wound Biologics, which includes Skin and Dermal Substitutes, Topical Delivery/Drugs and Collagen/Active Dressings, is the largest segment of the Advanced Wound Care Market. In the United States in 2015, Wound Biologics sales reached $957 million¹ with Skin and Dermal Substitute Products¹ achieving sales of $587 million¹. Skin and Dermal Substitute Products represent the largest segment of the Advanced Wound Care Market. In 2015, in the United States, there were 589,000¹ applications of a Skin and Dermal Substitute Product accounting for treatment of approximately 200,000¹of the 3.0 million chronic non-healing wounds. Also in 2015, Amniotic Tissue replaced Xenograft¹ as the largest product category in the Skin and Dermal Substitute Market.

In the United States, Skin and Dermal Substitute Market growth is expected to primarily be driven by (a) the aging population (b) the rising incidence of obesity, diabetes and other diseases that compromise blood flow and (c) acceleration in the shift away from using traditional wound care products to using advanced wound care products. We believe physician education and increased understanding of the benefits of new wound care technologies, supported by a growing library of Level 1 Scientific Evidence and the emergence of updated clinical practice guidelines that improve patient care and outcomes, will be the main drivers of this shift. MiMedx estimates that in 2020 the Domestic Skin and Dermal Substitute Market will reach sales of $1.1 billion with Amniotic Tissue capturing 49% market share up from 29%¹ in 2014.

Traditional dressings such as bandages, gauzes and ointments currently represent the “standard of care” for treating chronic wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcers and arterial ulcers. If after four weeks of use,

the wound has not responded appropriately to “standard of care” therapy, clinical research has shown that Advanced Therapy such as a Skin and Dermal Substitute should be introduced into the patient’s treatment plan. According to market data provided by BioMedGPS, MiMedx’s EpiFix is the current product of choice for physicians choosing to use a Skin and Dermal Substitute Product. EpiFix contains essential wound healing factors, extracellular matrix proteins and inflammatory mediators to help modulate inflammation, enhance healing, and reduce scar tissue formation and, unlike some competing technologies, is not limited to a specific wound type. EpiFix stores at ambient temperature for up to five years compared to certain cultured skin substitutes currently on the market that require cryogenic freezer storage and expire within days to months from time of processing. In addition, we market multiple sizes of EpiFix (from 1.5cm² to 49cm²) which minimizes product waste and reduces the overall cost to closure when compared to former market leading products.

Surgical, Sports Medicine and Orthopedics

Our AmnioFix tissue allografts have been used to enhance healing in patients undergoing surgical procedures to help to reduce scar tissue formation in a variety of applications including, but not limited to, plastic surgery, general surgery, gynecological, urology, orthopedics, spine, and sports medicine.

AmnioFix can be used as a barrier membrane in procedures where scar tissue formation may be problematic. AmnioFix Wrap is applied by wrapping target tissues (ligaments, tendons, and or nerves) to create a barrier, which performs two functions: it acts as a neo-sheath to protect the target tissue and provides extracellular matrix proteins, cytokines and chemokines to enhance the wound healing process. AmnioFix provides additional benefits, including anti-inflammatory agents and growth factors that may assist with healing.

Spine/Orthopedics

There are approximately 1.47 million spinal surgeries per year² and most of them potentially could use AmnioFix to reduce scarring and modulate inflammation during the primary procedure, which may reduce time during revisions or follow-up surgeries. A reduction of scar tissue is beneficial if the patient needs to have an additional surgical procedure in the future, as it may facilitate the re-access to the surgical site, as well as help with minimizing scar attachment to the spinal dura in spine surgery. In addition to spinal surgeries, the AmnioFix offerings have been used in Arthoplasty (total joint replacement) of the knee, hip, shoulder, ankle, hand and elbow.

Sports Medicine

There are an estimated 90,000³ peripheral nerve injuries which require repair each year and an estimated 8.4⁴ million patients who have tendinopathy associated with inflammation who potentially could benefit from our AmnioFix products. AmnioFix Wrap is a surgical implant that has multiple features desired by surgeons to support the repair and replacement of ligaments, tendons and repaired nerves. AmnioFix Injectable and AmnioFix Sports Med address the chronic sports/work soft tissue injury market, including but not limited to tennis elbow, golfers elbow, plantar fasciitis, tendonitis, bursitis and sprains. Soft tissue injuries are often caused by either trauma or overuse of the affected area. Micro-tears in the tissue form and become inflamed. Scar tissue may form and impede a full recovery. Steroids are often used as a first line to help the patient cope with the pain and assist with recovery. There are a number of patients who do not get relief with steroids or do not want to use steroids, and over-use of steroids can cause long-term damage to the tissue. AmnioFix Injectable and AmnioFix Sports Med may be used to modulate inflammation and reduce scar tissue formation, while enhancing healing.

Physician Office Pain Management

OrthoFlo, AmnioFix Injectable and AmnioFix Sports Med address chronic pain caused by osteoarthritis or inflammation of and/or damage to a ligament or tendon. After oral non-habit forming pain medication fails to relieve a patient's pain, injecting medicine into the affected joint, ligament or tendon is the next most common treatment option to help a patient cope with their pain. In the United States in 2015, 14.9 million¹ injections were performed to treat pain in the shoulder, spine, foot, ankle, knee, and elbow The majority of these injections were into the knee (7.8 million¹) and elbow (3.2 million¹) with steroid (85%¹) being the most commonly injected product.

Source: BioMedGPS LLC

Because a number of patients do not get relief from steroid injections or do not want to use steroids given their potential to damage human tissue, the pain market is searching for new products that are as effective as steroid in treating these patients but safer. MiMedx OrthoFlo, AmnioFix Injectable and AmnioFix Sports Med lubricate, modulate inflammation and reduce scar tissue formation, while enhancing healing, and are being investigated as potential product candidates for this market.

Market overview numbers derived from the following sources:


1.	BioMedGPS SmartTRAK Business Intelligence


2.	iData 2012, U.S. Market for Spinal Implants


3.	Stabenfeldt, SE, Garcia, AJ, LaPlaca, MC. Thermoreversible laminin-functionalized hydrogel for neural tissue engineering. J of Bio Materials Research. Part A, 2006. 77: p. 718-725


4.	Millenium 2013, clinical articles and management internal estimates


5.	Sheehan P., Jones P., Caselli A., Giurini JM., Veves A. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care 2003;26:1879-1882 [PubMed]

Marketing and Sales

As of February 2017, our field sales force is comprised of approximately 320 sales professionals who call on hospitals, wound care clinics, physician offices and federal health care facilities such as Department of Veterans Affairs and Department of Defense Hospitals. Our direct sales force focuses on the Wound Care market and the SSO (Surgical, Sports Medicine and Orthopedics) market, though, on the SSO side, we have continued to maintain a network of independent sales agents and distributors to sell sports medicine and orthopedic spine specialties lines.

We continue to pursue private label or “OEM” relationship, to date the most notable of which are Medtronic and Zimmer Biomet. In September 2013, we entered into a non-exclusive distribution agreement with Medtronic, Inc. and its wholly-owned subsidiary, SpinalGraft Technologies, LLC (SGT). Under the agreement, MiMedx provides our PURION Processed grafts to Medtronic to be marketed by SGT under the RDX2® brand name for spinal applications throughout the United States.

In September 2014, we entered into a non-exclusive distribution agreement with Zimmer Biomet to distribute AmnioFix under its private label brand, AmnioRepair®. Under the agreement, Zimmer markets AmnioRepair for reconstructive, sports medicine, trauma, extremities and spine applications in the U.S. These partnerships allow us to leverage

the sales and distribution resources of significant industry companies. In the ophthalmic and dental markets, our products are still marketed exclusively through licensee companies in each such field.

Reimbursement

A significant portion of our products are purchased for U.S. Government accounts, which do not depend on reimbursement from third parties. With the exception of Government accounts, most users of our products are physicians, hospitals or ambulatory surgery centers that rely on reimbursement by third-party payers. Accordingly, our growth substantially depends on adequate levels of third-party reimbursement for our products from these payers. In the U.S., such payers include U.S. Governmental programs (e.g., Medicare and Medicaid), private insurance plans, managed care programs and workers’ compensation plans. Governmental payment programs have prescribed coverage criteria and reimbursement rates for medical products, services and procedures. Similarly, private third-party payers have their own coverage criteria and negotiate payment levels for medical products, services and procedures. In addition, in the U.S., an increasing percentage of insured individuals are receiving their medical care through managed care programs, which monitor and may require pre-approval of the products and services that a member receives.

EpiFix Sheet Products and EpiCord

Medicare Coverage

By far, the largest third party payer in the United States is the Medicare program, which is a federally-funded program that provides healthcare coverage for senior citizens and the disabled. The Medicare program is administered by the Centers for Medicare and Medicaid Services (CMS). The CMS has appointed eight Medicare Administrative Contractors (MACs), which are private insurance companies that serve as agents of the CMS in the administration of the Medicare program, including making coverage decisions and paying claims for the designated Medicare jurisdiction. Each MAC has its own standards and process for determining coverage and reimbursement for a procedure or product. Private payers often follow the lead of Governmental payers in making coverage and reimbursement determinations. Therefore, achieving favorable Medicare coverage and reimbursement is usually a significant gating factor for successful coverage and reimbursement for a new product by the private payer.

The coverage and reimbursement framework for products under Medicare is determined in accordance with the Social Security Act and pursuant to regulations promulgated by the CMS, as well as the agency’s regulatory coverage and reimbursement determinations. Ultimately, however, each of the MACs determine whether and on what conditions they will provide coverage for the product. Such decisions are based on their assessments of the science and efficacy of the applicable product. As noted below under the heading “Research and Development,” we have devoted significant resources to clinical studies to provide data to the MACs, as well as other payers, in order to demonstrate the efficacy and clinical effectiveness of our EpiFix sheet products. As of the date of this report, our EpiFix sheet products are eligible for coverage by all eight of the Medicare Contractors.

For Medicare reimbursement purposes, our EpiFix sheet products are classified as “skin substitutes.” Current reimbursement methodology varies between the hospital outpatient department (HOPD) and ambulatory surgery center (ASC) setting versus the physician office. Our EpiFix sheet allografts come in many sizes to appropriately fit the size of the patient’s wound. Some competitive products come in one size only with the product size significantly larger than the wounds they are used to treat. The provider has to cut these products to fit the wound size, with the rest of the product discarded, and, therefore, wasted. Formerly, reimbursement for these products was based on the size of the graft and the Medicare payment for these grafts was costly. In 2014, CMS implemented a new reimbursement methodology in the HOPD and ASC, in part to combat this wastage. Currently, skin substitutes are reimbursed under a “packaged” or “bundled” methodology along with the related application procedure under a two-tier payment system. Thus, in the HOPD setting, providers receive a single payment that reimburses for the application of the product as well as the product itself. CMS also classifies skin substitutes into low cost or high cost groups, based on a weighted per square centimeter average. In 2016, the weighted average mean unit cost to determine the high and low cost group was $25 per sq. cm. The national average packaged rate was $1,371 in 2014, $1,407 in 2015, $1,411 in 2016, and $1,427 in 2017. All skin substitute products administered in the HOPD setting are bundled except for those that have been approved by CMS for pass-through status. This "bundled" payment structure applies only to the HOPD and ASC settings.

Currently, providers that administer EpiFix allografts and other skin substitutes in the physician office setting are reimbursed based on the size of the graft, computed on a per square centimeter basis. The payment rate is calculated using the manufacturer’s reported average sales price (ASP) submitted quarterly to CMS. This payment methodology applies only to physician offices. The Medicare payment rates are updated quarterly based on this ASP information. The skin substitute Medicare payment rate established by statute is ASP plus 6%.

We believe the current payment methodology in the physician office setting at ASP plus 6%, coupled with our success in gaining payer coverage with Medicaid and commercial payers will provide us with opportunities to increase our market share in 2017.

Beginning April 1, 2013 Medicare payments for all items and services, including EpiFix sheet products, have been reduced by 2% under the sequestration required by the Budget Control Act of 2011, Pub. L. No. 112-25, as amended by the American Taxpayer Relief Act of 2012, Pub. L. 112-240. This sequestration is subject to change with the new administration, and is currently under review.

In January 2017, EpiCord was included in the CMS Q Code, Q4131, which is also the Q code specified for EpiFix.

Private Payers

We continue to devote considerable resources to clinical trials to support coverage and reimbursement of our products and have confirmed an increasing number of private payers that reimburse for EpiFix in the physician office, the HOPD, and the ASC settings. Coverage and reimbursement varies according to the patient’s health plan and related benefits. More than 800 health plans currently provide coverage for EpiFix for the treatment of Diabetic Foot Ulcers (DFUs). Venous Leg Ulcers (VLUs) are also covered by a series of payers. At the close of 2016, we reported coverage of over 298 million lives, including all of the Medicare MACs, and over 36 State Medicaid plans. We have established and continue to grow a reimbursement support group to educate and assist providers and patients with regard to reimbursement for our products.

Hospital Use

EpiFix products administered in the hospital setting are bundled when submitted as part of the hospital’s claim under a diagnosis-related group (DRG). In these cases, we continue to educate the hospital that the product is both efficacious, resulting in positive healing outcomes and a reduced length-of-stay, as well as cost-effective.

AmnioFix Sheet Products

Our AmnioFix surgical products are also bundled under a DRG as part of a hospital’s claim related to the length-of-stay. As noted above, with respect to EpiFix, the ability to sell products in the hospital market is dependent upon demonstrating to the hospital that the product’s efficacy results in positive healing outcomes, provides the potential for a reduced length-of-stay, and is cost-effective.

EpiFix and AmnioFix Micronized Products

Currently, our micronized products are available for coverage by only a limited number of commercial and state Medicaid plans.

Other Products

There is currently no specific third-party reimbursement available for OrthoFlo, AmnioCord, AmnioFill or Physio, except to the extent such products are bundled as part of a hospital’s claim under a DRG.

See discussion below- “Risk Factors” under the heading “Our revenues depend on adequate reimbursement from public and private insurers and health systems.”

Customer Concentration

We have significant sales to Government accounts. Some of the Company’s sales to Government accounts, including the Department of Veterans Affairs, are made through a distributor relationship with AvKARE, Inc. ("AvKARE") which is a veteran-owned General Services Administration Federal Supply Schedule (FSS) contractor. The Company's agreement with AvKARE expires, subject to certain for-cause termination rights, on June 30, 2017. The Company may also elect to terminate

the agreement without cause and pay a termination fee to AvKARE as specified in the agreement. Upon termination of the agreement, the parties may mutually agree to extend the agreement or the Company has an obligation to repurchase AvKARE’s remaining inventory, if any, within ninety (90) days in accordance with the terms of the agreement. At the end of the term, the parties expect AvKARE’s inventory to be minimal, based upon AvKARE's obligation to use commercially reasonable efforts to achieve target sales levels over the remaining term of the agreement.

See discussion below- “Risk Factors” under the heading “A significant portion of our revenues and accounts receivable come from Government accounts”.

Competition

Competition in the regenerative medicine field is intense and subject to rapid technological change. Companies within the industry compete on the basis of product efficacy, pricing, and ease of handling/logistics. However, the most important factor is third-party reimbursement, which is difficult to obtain as it is a time-consuming and expensive process. We believe our success in obtaining third-party reimbursement for our products is a significant competitive advantage.

We compete in multiple areas of clinical treatment where regenerative biomaterials may be employed to modulate inflammation, enhance healing and reduce scar tissue formation: advanced wound care treatment, spine, orthopedic, surgery and sports medicine. The EpiFix product line is promoted primarily for external use such as advanced wound healing, while the AmnioFix products are positioned for healing of surgical wounds and have been used in spine, orthopedics, surgical and sports medicine applications.

Advanced wound care therapies employ technologies to aid in wound healing in cases where the healing has stalled or stopped. The primary competitive products in this space include other amniotic membrane allografts, tissue-engineered living skin equivalents, and porcine- or bovine-derived collagen matrix products, among others. In 2016, our main competitor was Organogenesis, Inc., the manufacturer of Dermagraft®, Apligraf® and PuraPly®. These products are tissue-engineered living skin equivalents that require special shipping and/or storage in freezers. The Organogenesis products also come in only one large size each, which is significantly larger than the median wound size for the wounds they are used to treat, resulting in a high cost product, much of which is wasted. We have competed effectively against Dermagraft and Apligraf based on clinical efficacy, cost effectiveness, ease of use and storage of our products. Other smaller competitors include the Osiris Therapeutics, Inc. product Grafix® and other single-layer amnion products.

Smith & Nephew’s Oasis® is the primary competitive product among the porcine- or bovine- derived collagen matrix products. As a collagen it can help with providing a matrix in the wound; however, it offers limited growth factors to enhance healing and due to the porcine origin may cause an immune response in the patient.

The primary competitive products in the SSO market are other amniotic membrane allografts and injectable solutions.

See discussion below- “Risk Factors” under the heading “We are in a highly competitive and evolving field and face competition from well-established tissue processors and medical device manufacturers, as well as new market entrants.”

Government Regulation

FDA Premarket Clearance and Approval Requirements

Tissue Products

The products manufactured and processed by the Company are derived from human tissue. As discussed below, some tissue-based products are regulated solely under Section 361 of the Public Health Service Act as human cells, tissues and cellular and tissue-based products, or HCT/Ps, which do not require premarket clearance or approval by the FDA. Other tissue products are regulated as biologics and, in order to be lawfully marketed in the United States, require an FDA-approved biologics application (BLA).

Products Regulated as HCT/Ps

The FDA has specific regulations governing human cells, tissues and cellular and tissue-based products, or HCT/Ps. An HCT/P is a product containing or consisting of human cells or tissue intended for transplantation into a human patient. HCT/Ps that meet the criteria for regulation solely under Section 361 of the Public Health Service Act (so-called “361 HCT/Ps”) are not subject to any premarket clearance or approval requirements but are subject to post-market regulatory requirements.

To be a 361 HCT/P, a product generally must meet all four of the following criteria:


•	It must be minimally manipulated;


•	It must be intended for homologous use;


•	Its manufacture must not involve combination with another article, except for water, crystalloids or a sterilizing, preserving or storage agent; and


•	It must not have a systemic effect and must not be dependent upon the metabolic activity of living cells for its primary function.

If an HCT/P meets all the above criteria, no FDA review for safety and effectiveness under a drug, device, or biological product marketing application is required. We believe that our amniotic tissue allografts are 361 HCT/Ps, including the micronized versions of EpiFix and AmnioFix.

However, on August 28, 2013, the FDA issued an Untitled Letter alleging that our micronized amniotic tissue allografts do not meet the criteria for regulation solely under Section 361 of the Public Health Service Act and that, as a result, MiMedx would need a biologics license to lawfully market those micronized products. Since the issuance of the Untitled Letter, we have been in discussions with the FDA to communicate its disagreement with the FDA's assertion that our allografts are more than minimally manipulated. To date, the FDA has not changed its position that our micronized products are not eligible for marketing solely under Section 361 of the Public Health Service Act. We continue to market the micronized products but are also pursuing the Biologics License Application (“BLA”) process for certain of our micronized products.

On October 28, 2015, the FDA issued for comment, "Draft Guidance for Industry and FDA Staff: Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products." We submitted comments on this Homologous Use draft guidance as well. On September 12 and 13, 2016, the FDA held a public hearing to obtain input on the Homologous Use draft guidance and the previously released Minimal Manipulation draft guidance, as well as other recently issued guidance documents on HCT/Ps. The Company awaits further decision from FDA on the draft guidances, but anticipates this will be a lengthy process.

See discussion below- “Risk Factors” under the heading “To the extent our products do not qualify for regulation as human cells, tissues and cellular and tissue-based products under Section 361 of the Public Health Service Act, this could result in removal of the applicable products from the market, would make the introduction of new tissue products more expensive and significantly delay the expansion of our tissue product offerings and subject us to additional post-market regulatory requirements.”

Products Regulated as Biologics- The Biologics License Application (BLA) Pathway

The typical steps for obtaining FDA approval of a BLA to market a biologic product in the U.S. include:


•	Completion of preclinical laboratory tests, animal studies and formulations studies under the FDA’s good laboratory practices regulations;


•	Submission to the FDA of an Investigational New Drug Application (IND) for human clinical testing, which must become effective before human clinical trials may begin and which must include independent Institutional Review Board (IRB) approval at each clinical site before the trials may be initiated;


•	Performance of adequate and well-controlled clinical trials in accordance with Good Clinical Practices to establish the safety and efficacy of the product for each indication;


•	Submission to the FDA of a BLA for marketing the product, which includes, among other things, reports of the outcomes and full data sets of the clinical trials, and proposed labeling and packaging for the product;


•	Satisfactory review of the contents of the BLA by the FDA, including the satisfactory resolution of any questions raised during the review;


•	Satisfactory completion of an FDA Advisory Committee review, if applicable;


•	Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with Current Good Manufacturing Practices (cGMP) regulations, to assure that the facilities, methods and controls are adequate to ensure the product’s identity, strength, quality and purity; and


•	FDA approval of the BLA, including agreement on post-marketing commitments, if applicable.

Generally, clinical trials are conducted in three phases, though the phases may overlap or be combined. Phase I trials typically involve a small number of healthy volunteers and are designed to provide information about the product safety and to evaluate the pattern of drug distribution and metabolism within the body. Phase II trials are conducted in a larger but limited group of patients afflicted with a particular disease or condition in order to determine preliminary efficacy, dosage tolerance and optimal dosing and to identify possible adverse effects and safety risks. Dosage studies are designated as Phase IIA and efficacy studies are designated as Phase IIB. Phase III clinical trials are generally large-scale, multi-center, comparative trials conducted with patients who have a particular disease or condition in order to provide statistically valid proof of efficacy, as well as safety and potency. In some cases, the FDA will require Phase IV, or post-marketing trials, to collect additional data after a product is on the market. All phases of clinical trials are subject to extensive record keeping, monitoring, auditing, and reporting requirements. As indicated above, the Company is pursuing the Biologics License Application (“BLA”) process for certain of its micronized products. On July 22, 2014, we filed our first IND application with the FDA. In response to the IND application, the FDA agreed we had sufficient data to begin a Phase IIB clinical trial of our micronized product for a specified indication of use in anticipation of a BLA, which we expect to submit at a future date. The clinical trial was initially powered to enroll approximately 150 patients in 10 - 20 clinical sites in the U.S. We initiated the trial in March of 2015, and have now nearly completed the study, with 13 sites currently enrolling out of a total of 20 engaged. We submitted an Annual Report and Interim Analysis Report to FDA on October 22, 2016. If the endpoint change is accepted by FDA, no additional subjects would be required to complete the enrollment phase of study. Enrollment is otherwise scheduled to be completed within the second quarter of 2017. Preliminary safety information, including laboratory testing in a cohort of participants, continues to demonstrate safety of the product in standard use. The Company anticipates moving ahead with a Phase III filing within the second quarter of 2017.

The process of obtaining an approved BLA requires the expenditure of substantial time, effort and financial resources and may take years to complete. The fee for filing a BLA and the annual user fees payable with respect to any establishment that manufactures biologics and with respect to each approved product are substantial.

See discussion below- “Risk Factors” under the heading “Obtaining and maintaining the necessary regulatory approvals for certain products will be expensive and time-consuming and may impede our ability to fully exploit our technologies.”

Medical Devices

Products from our CollaFix product platform are likely to be classified by the FDA as medical devices. Medical Devices are classified as I, II and III in the U.S., with Class II and III requiring either a 510(k) clearance or Premarket Approval (“PMA”) from the FDA prior to marketing. Devices deemed substantially equivalent to legally marketed devices are deemed to pose relatively less risk and are deemed Class I and II. Manufacturers are required to submit a premarket notification requesting clearance for commercial distribution. This is known as 510(k) clearance, which indicates that the device is substantially equivalent to devices already legally on the market. Most Class I devices are considered very low risk and are exempted from this requirement. Devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or devices deemed not substantially equivalent to a previously 510(k) cleared device or a pre-amendment Class III device for which PMA applications have not been required, are placed in Class III, requiring PMA. Although we may be able to obtain approval for some products through the 510(k) clearance process, in order to fully exploit the CollaFix technology, one or more PMA applications would likely be required.

Like the process of obtaining an approved BLA, the process of obtaining a PMA requires the expenditure of substantial time, effort and financial resources and may take years to complete.

FDA Post Market Regulation

Tissue processors are required to register as an establishment with the FDA. As a registered establishment, we are required to comply with regulations regarding labeling, record keeping, donor eligibility, and screening and testing, process the tissue in accordance with established Good Tissue Practices, and report any adverse reactions attributed to our tissue. Our facilities are also subject to periodic inspections to assess our compliance with the regulations.

Products covered by a BLA, 510(k) clearance, or a PMA are subject to numerous additional regulatory requirements, which include, among others, compliance with cGMP, which imposes certain procedural, substantive and record keeping requirements, labeling regulations, the FDA’s general prohibition against promoting products for unapproved or “off-label” uses, and additional adverse event reporting.

Other Regulation Specific to Tissue Products

We are accredited by the American Association of Tissue Banks (AATB), which has issued operating standards for tissue banking. Compliance with these standards is a requirement in order to become a licensed tissue bank. In addition, some states have their own tissue banking regulations.

See discussion below- “Risk Factors” under the heading "Our business is subject to continuing regulatory compliance by the FDA and other authorities, which is costly and our failure to comply could result in negative effects on our business".

Fraud, Abuse and False Claims

We are directly and indirectly subject to various federal and state laws governing relationships with healthcare providers and pertaining to healthcare fraud and abuse, including anti-kickback laws. In particular, the federal healthcare program Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, arranging for or recommending a good or service for which payment may be made in whole or part under federal healthcare programs, such as the Medicare and Medicaid programs. Penalties for violations include criminal penalties and civil sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other federal healthcare programs. The Anti-Kickback Statute is broad and prohibits many arrangements and practices that are lawful in businesses outside of the healthcare industry. In implementing the statute, the Office of Inspector General of the U.S. Department of Health and Human Services (“OIG”) has issued a series of regulations, known as the “safe harbors.” These safe harbors set forth provisions that, if all their applicable requirements are met, will assure healthcare providers and other parties that they will not be prosecuted under the Anti-Kickback Statute. The failure of a transaction or arrangement to fit precisely within one or more safe harbors does not necessarily mean that it is illegal or that prosecution will be pursued. However, conduct and business arrangements that do not fully satisfy each applicable element of a safe harbor may result in increased scrutiny by Government enforcement authorities, such as the OIG. Many states have laws similar to the federal law.

AdvaMed is one of the primary voluntary U.S. trade associations for medical device manufacturers. This association has established guidelines and protocols for medical device manufacturers in their relationships with healthcare professionals on matters including research and development, product training and education, grants and charitable contributions, support of third-party educational conferences, and consulting arrangements. Adoption of the AdvaMed Code by a medical device manufacturer is voluntary, and while the OIG and other federal and state healthcare regulatory agencies encourage its adoption and may look to the AdvaMed Code, they do not view adoption of the AdvaMed Code as proof of compliance with applicable laws. As part of a Company-wide compliance plan, we have incorporated the principles of the AdvaMed Code in our standard operating procedures, sales force training programs, and relationships with health care professionals. Key to the underlying principles of the AdvaMed Code is the need to focus the relationships between manufacturers and healthcare professionals on matters of training, education and scientific research, and limit payments between manufacturers and healthcare professionals to fair market value for legitimate services provided and payment of modest meal, travel and other expenses for a healthcare professional under limited circumstances. We have incorporated these principles into our relationships with healthcare professionals under our consulting agreements, and our policies regarding payment of travel and lodging expenses, research and educational grant procedures and sponsorship of third-party conferences.

See discussion below- “Risk Factors” under the heading “We and our sales representatives, whether employees or independent contractors, must comply with various federal and state anti-kickback, self-referral, false claims and similar laws, any breach of which could cause a material adverse effect on our business, financial condition and results of operations.”

Manufacturing (Processing)

In early 2014, we expanded our production capacity from one location in Kennesaw, Georgia, by adding a second and significantly larger, manufacturing facility within our headquarters building in Marietta, Georgia. Effective January 2014, our main processing operations were relocated to the Marietta, Georgia facility. The Kennesaw facility serves as a secondary processing site. We also perform research and early stage product and process development activities in our Marietta and Kennesaw, Georgia, locations. Stability maintains a facility in San Antonio, Texas for tissue processing.

We are registered with the FDA as a tissue establishment and are subject to the FDA’s quality system regulations, state regulations, and regulations promulgated by the European Union. Our facilities are subject to periodic unannounced inspections by regulatory authorities, and may undergo compliance inspections conducted by the FDA and corresponding state and foreign agencies.

Placental Donation Program

We have a comprehensive network of hospitals that participate in our placenta donation program. We have a dedicated staff that works at these hospitals, collecting donated placentas from mothers who undergo Cesarean section births and consent to donation. We believe that we will be able to procure an adequate supply of tissue to meet anticipated demand. However, see discussion below- “Risk Factors” under the heading “Our products are dependent on the availability of sufficient quantities of tissue from human donors, and any disruption in supply could adversely affect our business."

Research and Development

Our research and development group has extensive experience in developing products related to our field of interest, and works to design products that are intended to improve patient outcomes, simplify techniques, shorten procedures, reduce hospitalization and rehabilitation times and, as a result, reduce costs. Clinical trials that demonstrate the safety, efficacy and cost effectiveness of our products are key to obtaining broader reimbursement for our products. In addition to our internal staff, we contract with outside labs and physicians who aid us in our research and development process. See Part II, Item 7 below for information regarding expenditures for research and development in each of the last three fiscal years.

In addition to the numerous published scientific studies, our allograft is the first and only dHACM product to meet the requirements of the USP (United States Pharmacopeia) Monograph for amniotic membrane allografts. This monograph includes both EpiFix and AmnioFix sheet products, and is the culmination of several years of work to define specifications, review, and test those specifications to ensure they accurately define the dHACM product with high manufacturing standards.

Environmental Matters

Our tissue preservation activities generate some chemical and biomedical wastes, consisting primarily of diluted alcohols and acids, and human and animal pathological and biological wastes, including human and animal tissue and body fluids removed during laboratory procedures. The chemical and biomedical wastes generated by our tissue processing operations are placed in appropriately constructed and labeled containers and are segregated from other wastes. We contract with third parties for transport, treatment, and disposal of waste. We strive to remain compliant with applicable laws and regulations promulgated by the Resource Conservation and Recovery Act, the U.S. Environmental Protection Agency and similar state agencies.

Employees

As of December 31, 2016, we had approximately 690 employees. We consider our relationships with our employees to be satisfactory. None of our employees is covered by a collective bargaining agreement.

Available Information

Our website address is www.mimedx.com. We make available on this website under “Investors - SEC Filings,” free of charge, our proxy statements, annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports as soon as reasonably practicable after we electronically file or furnish such materials to the SEC. In addition, we post filings of Forms 3, 4, and 5 filed by our directors, executive officers and ten percent or more

shareholders. We also make available on this website under the heading “Investors - Corporate Governance” our Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee Charters as well as our Code of Business Conduct and Ethics.

The reference to our website does not constitute incorporation by reference of any information contained at that site.

Item 1A. Risk Factors

Risks Related to Our Business and Industry

Our operating results may fluctuate significantly as a result of a variety of factors, many of which are outside of our control.

We are subject to the following factors, among others, that may negatively affect our operating results:


•	The announcement or introduction of new products by our competitors;


•	Failure of Government and private health plans to adequately and timely reimburse the users of our products;


•	Removal of our products from the Federal Supply Schedule or change in the prices that Government accounts will pay for our products;


•	Our ability to upgrade and develop our systems and infrastructure to accommodate growth;


•	Our ability to attract and retain key personnel in a timely and cost effective manner;


•	The amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure;


•	Regulation by federal, state or local Governments; and


•	General economic conditions as well as economic conditions specific to the healthcare industry.

We have based our current and future expense levels largely on our investment plans and estimates of future events, although certain of our expense levels are, to a large extent, fixed. We may be unable to adjust spending in a timely manner to compensate for any unexpected revenue shortfall. Accordingly, any significant shortfall in revenue relative to our planned expenditures would have an immediate adverse effect on our business, results of operations and financial condition. Further, as a strategic response to changes in the competitive environment, we may from time to time make certain pricing, service or marketing decisions that could have a material and adverse effect on our business, results of operations and financial condition. Due to the foregoing factors, our revenue and operating results are and will remain difficult to forecast.

We are in a highly competitive and evolving field and face competition from well-established tissue processors and medical device manufacturers, as well as new market entrants.

Our business is in a very competitive and evolving field. Competition from other tissue processors, medical device companies and from research and academic institutions is intense, expected to increase, subject to rapid change, and could be significantly affected by new product introductions. In addition, consolidation in the healthcare industry continues to lead demands for price concessions or to the exclusion of some suppliers from certain of our markets, which could have an adverse effect on our business, results of operations or financial condition. The presence of this competition in our market may lead to pricing pressure, which would make it more difficult to sell our products at a price that will make us profitable or prevent us from selling our products at all. Our failure to compete effectively would have a material and adverse effect on our business, results of operations and financial condition.

Rapid technological change could cause our products to become obsolete and if we do not enhance our product offerings through our research and development efforts, we may be unable to effectively compete.

The technologies underlying our products are subject to rapid and profound technological change. Competition intensifies as technical advances in each field are made and become more widely known. We can give no assurance that others will not develop services, products, or processes with significant advantages over the products, services, and processes that we offer or are seeking to develop. Any such occurrence could have a material and adverse effect on our business, results of operations and financial condition.

We plan to enhance and broaden our product offerings in response to changing customer demands and competitive pressure and technologies. The success of any new product offering or enhancement to an existing product will depend on numerous factors, including our ability to:


•	properly identify and anticipate physician and patient needs;


•	develop and introduce new products or product enhancements in a timely manner;


•	adequately protect our intellectual property and avoid infringing upon the intellectual property rights of third parties;


•	demonstrate the safety and efficacy of new products; and


•	obtain the necessary regulatory clearances or approvals for new products or product enhancements.

If we do not develop and, when necessary, obtain regulatory clearance or approval for new products or product enhancements in time to meet market demand, or if there is insufficient demand for these products or enhancements, our results of operations will suffer. Our research and development efforts may require a substantial investment of time and resources before we are adequately able to determine the commercial viability of a new product, technology, material or other innovation. In addition, even if we are able to successfully develop enhancements or new generations of our products, these enhancements or new generations of products may not produce sales in excess of the costs of development and they may be quickly rendered obsolete by changing customer preferences or the introduction by our competitors of products embodying new technologies or features.

Our products are dependent on the availability of tissue from human donors, and any disruption in supply could adversely affect our business.

The success of our human tissue products depends upon, among other factors, the availability of tissue from human donors. Any failure to obtain tissue from our sources will interfere with our ability to effectively meet demand for our products incorporating human tissue. The processing of human tissue into our products is very labor-intensive and it is therefore difficult to maintain a steady supply stream. The availability of donated tissue could also be adversely impacted by regulatory changes, public opinion of the donor process as well as our own reputation in the industry. The challenges we may face in obtaining adequate supplies of human tissue involve several risks, including limited control over availability, quality and delivery schedules. In addition, any interruption in the supply of any human tissue component could materially harm our ability to manufacture our products until a new source of supply, if any, could be found. We may be unable to find a sufficient alternative supply channel in a reasonable time period or on commercially reasonable terms, if at all, which would have a material adverse effect on our business, results of operations and financial condition.

The products we manufacture and process are derived from human tissue and therefore have the potential for disease transmission.

The utilization of human tissue creates the potential for transmission of communicable disease, including, but not limited to, human immunodeficiency virus (“HIV”), viral hepatitis, syphilis and other viral, fungal or bacterial pathogens. We are required to comply with federal and state regulations intended to prevent communicable disease transmission.

Although we maintain strict quality controls over the procurement and processing of our tissue, there is no assurance that these quality controls will be adequate. In addition, negative publicity concerning disease transmission from other companies' improperly processed donated tissue could have a negative impact on the demand for our products.

We depend on key personnel.

Our success will depend, in part, upon our ability to attract and retain skilled personnel, including sales, managerial and technical personnel. There can be no assurance that we will be able to find and attract additional qualified employees to support our expected growth or retain any such personnel. Our inability to hire and retain qualified personnel or the loss of services of our key personnel may have a material and adverse effect on our business and results of operations.

A significant portion of our revenues and accounts receivable come from Government accounts.

We have significant sales to the Government (whether we are selling our products directly to Government Accounts or through our current or another distributor ). Any disruption of our products on the FSS or a change in the way the Government purchases products like ours or the price it is willing to pay for our products, could materially and adversely affect our business, results of operations and financial condition.

In order to grow revenues from certain of our products, we must expand our relationships with distributors and independent sales representatives, whom we do not control.

We derive significant revenues through our relationships with distributors and independent sales representatives, though, other than our distributor for Government accounts, no one distributor comprised over 5% of our revenues. If such

relationships were terminated for any reason, it could materially and adversely affect our ability to generate revenues and profits. Because the independent distributor often controls the customer relationships within its territory, there is a risk that if our relationship with the distributor ends, our relationship with the customer will be lost. Also, because we do not control a distributor's field sales agents, there is a risk we will be unable to ensure that our sales processes, compliance, and other priorities will be consistently communicated and executed by the distributor. If we fail to maintain relationships with our key distributors, or fail to ensure that our distributors adhere to our sales processes, compliance, and other priorities, this could have an adverse effect on our operations.

We intend to obtain the assistance of additional distributors and independent sales representatives to continue our sales growth with respect to certain of our products. Our success is partially dependent upon our ability to retain and motivate our distributors, independent sales agencies, and their representatives to sell our products in certain territories. They may not be successful in implementing our marketing plans. Some of our distributors and independent sales agencies do not sell our products exclusively and may offer similar products from other companies. Our distributors and independent sales agencies may terminate their contracts with us, may devote insufficient sales efforts to our products, or may focus their sales efforts on other products that produce greater commissions for them, which could have an adverse effect on our operations and operating results. We also may not be able to find additional distributors and independent sales representatives who will agree to market and/or distribute those products on commercially reasonable terms, if at all. If we are unable to establish new distribution and independent sales representative relationships or renew current distribution and sales agency agreements on commercially acceptable terms, our business, financial condition and results of operations could be materially and adversely affected.

We continue to invest significant capital in expanding our internal sales force, and there can be no assurance that these efforts will continue to result in significant increases in sales.

We are engaged in a major initiative to build and further expand our internal sales and marketing capabilities which has contributed to our increased sales. As a result, we continue to invest in a direct sales force for certain of our products to allow us to reach new customers. These expenses impact our operating results, and there can be no assurance that we will continue to be successful in significantly expanding the sales of our products.

Our revenues depend on adequate reimbursement from public and private insurers and health systems.

Our success depends on the extent to which reimbursement for the costs of our products and related treatments will be available from third party payers, such as public and private insurers and health systems. Government and other third-party payers attempt to contain healthcare costs by limiting both coverage and the level of reimbursement of new products. Therefore, significant uncertainty usually exists as to the reimbursement status of new healthcare products. A significant number of public and private insurers and health systems currently do not provide reimbursement for our products. If we are not successful in obtaining adequate reimbursement for our products from these third party payers, the market's acceptance of our products could be adversely affected. Inadequate reimbursement levels also likely would create downward price pressure on our products. Even if we do succeed in obtaining widespread reimbursement for our products, future changes in reimbursement policies could have a negative impact on our business, financial condition and results of operations.

Disruption of our processing could adversely affect our business, financial condition and results of operations.

Our results of operations are dependent upon the continued operation of our processing facilities. Risks that could impact our ability to use these facilities include the occurrence of natural and other disasters, and the need to comply with the requirements of directives from Government agencies, including the FDA. We have a secondary processing facility in Kennesaw, Georgia that also serves as a disaster recovery center. However, the unavailability of our manufacturing and processing facilities could have a material adverse effect on our business, financial condition, and results of operations during the period of such unavailability.

To be commercially successful, we must convince physicians that our products are safe and effective alternatives to existing treatments and that our products should be used in their procedures.

We believe physicians will only adopt our products if they determine, based on experience, clinical data and published peer reviewed journal articles, that the use of our products in a particular procedure is a favorable alternative to conventional methods. Physicians may be slow to change their medical treatment practices for the following reasons, among others:


·	Their lack of experience with prior procedures in the field using our products;


·	Lack of evidence supporting additional patient benefits and our products over conventional methods;


·	Perceived liability risks generally associated with the use of new products and procedures;


·	Limited availability of reimbursement from third party payers; and


·	The time that must be dedicated to training.

In addition, we believe recommendations for and support of our products by influential physicians are essential for market acceptance and adoption. If we do not receive this support or if we are unable to demonstrate favorable long-term clinical data, physicians and hospitals may not use our products, which would significantly reduce our ability to achieve expected revenue and would prevent us from sustaining profitability.

In the course of conducting our business, we must adequately address quality issues that may arise with our products, as well as defects in third-party components included in our products. Although we have established internal procedures to minimize risks that may arise from quality issues, we may not be able to eliminate or mitigate occurrences of these issues and associated liabilities. If the quality of our products does not meet the expectations of physicians or patients, then our brand and reputation could suffer and our business could be adversely impacted.

The formation of PODs could result in increased pricing pressure on our products or harm our ability to sell our products to physicians who own or are affiliated with those distributorships.

Physician-Owned Distributorships ("PODs") are medical product distributors that are owned, directly or indirectly, by physicians. These physicians derive a proportion of their revenue from selling or arranging for the sale of medical products for use in procedures they perform on their own patients at hospitals that agree to purchase from or through the POD, or that otherwise furnish ordering physicians with income that is based directly or indirectly on those orders of medical products. The Office of Inspector General (OIG) of the Department of Health & Human Services has issued a Special Fraud Alert on PODs, indicating that they are inherently suspect under the anti-kickback statute.

We do not directly sell to or distribute any of our products through PODs. The number of PODs in the industry may continue to grow as economic pressures increase throughout the industry, as hospitals, insurers and physicians search for ways to reduce costs, and, in the case of the physicians, search for ways to increase their incomes. These companies and the physicians who own, or partially own, them have significant market knowledge and access to the physicians who use our products and the hospitals that purchase our products, and growth in this area may reduce our ability to compete effectively for business from physicians who own such distributorships.

We will need to expand our organization, and managing growth may be more difficult than expected.

Managing our growth may be more difficult than we expect. We anticipate that a period of significant expansion will be required to penetrate and service the market for our existing and anticipated future products and to continue to develop new products. This expansion will place a significant strain on management, operational and financial resources. To manage the expected growth of our operations and personnel, we must both modify our existing operational and financial systems, procedures and controls and implement new systems, procedures and controls. We must also expand our finance, administrative, and operations staff. Management may be unable to hire, train, retain, motivate and manage necessary personnel or to identify, manage and exploit existing and potential strategic relationships and market opportunities.

We face the risk of product liability claims and may not be able to obtain or maintain adequate product liability insurance.

Our business exposes us to the risk of product liability claims that are inherent in the manufacturing, processing and marketing of medical devices and human tissue products. We may be subject to such claims if our products cause, or appear to have caused, an injury. Claims may be made by patients, healthcare providers or others selling our products. Defending a lawsuit, regardless of merit, could be costly, divert management attention and result in adverse publicity, which could result in the withdrawal of, or reduced acceptance of, our products in the market.

Although we have product liability insurance that we believe is adequate, this insurance is subject to deductibles and coverage limitations and we may not be able to maintain this insurance. Also, it is possible that claims could exceed the limits of our coverage. If we are unable to maintain product liability insurance at an acceptable cost or on acceptable terms with adequate coverage or otherwise protect ourselves against potential product liability claims or we underestimate the amount of insurance we need, we could be exposed to significant liabilities, which may harm our business. A product liability claim or other claim with respect to uninsured liabilities or for amounts in excess of insured liabilities could result in significant costs and significant harm to our business.

We may implement a product recall or voluntary market withdrawal, which could significantly increase our costs, damage

our reputation and disrupt our business.

The manufacturing, marketing and processing of our tissue products involves an inherent risk that our tissue products or processes do not meet applicable quality standards and requirements. In that event, we may voluntarily implement a recall or market withdrawal or may be required to do so by a regulatory authority. A recall or market withdrawal of one of our products would be costly and would divert management resources. A recall or withdrawal of one of our products, or a similar product processed by another entity, also could impair sales of our products as a result of confusion concerning the scope of the recall or withdrawal, or as a result of the damage to our reputation for quality and safety.

Significant disruptions of information technology systems or breaches of information security could adversely affect our business.

We rely to a large extent upon sophisticated information technology systems to operate our business. In the ordinary course of business, we collect, store and transmit large amounts of confidential information (including, but not limited to, personal information and intellectual property). We also have outsourced significant elements of our operations to third parties, including significant elements of our information technology infrastructure and, as a result, we are managing many independent vendor relationships with third parties who may or could have access to our confidential information. The size and complexity of our information technology and information security systems, and those of our third-party vendors with whom we contract (and the large amounts of confidential information that is present on them), make such systems potentially vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees or vendors, or from malicous attacks by third parties. Such attacks are of ever-increasing levels of sophistication and are made by groups and individuals with a wide range of motives (including, but not limited to, industrial espionage and market manipulation) and expertise. While we have invested significantly in the protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions or security breaches. Although we have cyber-insurance coverage that may cover certain events described above, this insurance is subject to deductibles and coverage limitations and we may not be able to maintain this insurance. Also, it is possible that claims could exceed the limits of our coverage. Any interruption or breach in our systems could adversely affect our business operations and/or result in the loss of critical or sensitive confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us or allow third parties to gain material, inside information that they use to trade in our securities.

We may not be successful in commercializing our CollaFix Technology.

We have invested substantial time and resources in developing various additional products using our CollaFix technology. Further commercialization of this technology will require additional development, clinical evaluation, regulatory clearance or approval, significant marketing efforts and substantial additional investment before they can provide us with any revenue. Despite our efforts, any such products may not become commercially successful products for a number of reasons, including:


·	We may not be able to obtain regulatory clearance or approvals for such products, or the approved indication may be narrower than we seek;


·	Such products may not prove to be safe and effective in preclinical or clinical trials;


·	Physicians or hospitals may not receive any reimbursement from third party payers, or the level of reimbursement may be insufficient to support widespread adoption of such products;


·	We may experience delays in our development programs;


·	Any products that are approved may not be accepted in the marketplace by physicians or patients;


·	We may not be able to manufacture any such products in commercial quantities or at an acceptable cost; and


·	Rapid technological change may make such products obsolete.

We may expand our business through acquisitions, licenses, investments, and other commercial arrangements in other companies or technologies, which contain significant risks.

We periodically evaluate strategic opportunities to acquire companies, divisions, technologies, products, and rights through licenses, distribution agreements, investments, and outright acquisitions to grow our business. In connection with one or more of those transactions, we may:


•	Issue additional equity securities that would dilute our stockholders’ value;


•	Use cash that we may need in the future to operate our business;


•	Incur debt that could have terms unfavorable to us or that we might be unable to repay;


•	Structure the transaction in a manner that has unfavorable tax consequences, such as a stock purchase that does not permit a step-up in the tax basis for the assets acquired;


•	Be unable to realize the anticipated benefits, such as increased revenues, cost savings, or synergies from additional sales;


•	Be unable to secure the services of key employees related to the acquisition; and


•	Be unable to succeed in the marketplace with the acquisition.

Any of these items could materially, and adversely affect our revenues, financial condition, and profitability. Business acquisitions also involve the risk of unknown liabilities associated with the acquired business, which could be material. Incurring unknown liabilities or the failure to realize the anticipated benefits of an acquisition could materially, and adversely affect our business if we are unable to recover our initial investment, which could include the cost of acquiring licenses or distribution rights, acquiring products, purchasing initial inventory, or investments in early stage companies. Inability to recover our investment, or any write off of such investment, associated goodwill, or assets, could have a material and adverse effect on our business, results of operations and financial condition.

Our international expansion and operations in foreign markets expose us to risks associated with international sales and operations.

We are actively seeking to expand into foreign markets. Managing a global organization is difficult, time consuming, and expensive. Conducting international operations subjects us to risks that could be different than those faced by us in the United States. The sale and shipment of our products across international borders, as well as the purchase of components and products from international sources, subject us to extensive U.S. and foreign govermental trade, import and export and customs regulations and laws, including but not limited to, the Export Administration Regulations and trade sanctions against embargoed countries, which are administered by the Office of Foreign Assets Control within the Department of the Treasury, as well as the laws and regulations administered by the Department of Commerce. These regulations limit our ability to market, sell, distribute or otherwise transfer our products or technology to prohibited countries or persons.

Compliance with these regulations and law is costly, and failure to comply with applicable legal and regulatory obligations could adversely affect us in a variety of ways that include, but are not limited to, significant criminal, civil and administrative penalties, including imprisonment of individuals, fines and penalties, denial of export privileges, seizure of shipments and restrictions on certain business activities. Also, the failure to comply with applicable legal and regulatory obligations could result in the disruption of our distribution and sales activities.

Other risks inherent in operating in foreign jurisdictions include:


•	lack of familiarity with and unexpected changes in foreign regulatory requirements;


•	lack of stringent protection of intellectual property;


•	obstacles to obtaining domestic and foreign export, import and other governmental approvals, permits and licenses and compliance with foreign laws;


•	potentially adverse tax consequences and the complexities of foreign value-added tax systems;


•	adverse changes in tariffs and trade restrictions;


•	differing multiple payer reimbursement regimes, government payers or patient self-pay system;


•	longer accounts receivable payment cycles and difficulties in collecting accounts receivable;


•	difficulties in managing and staffing international operations;


•	fluctuations in currency exchange rates;


•	the burdens of complying with a wide variety of foreign laws and legal standards;


•	availability of government subsidies or other incentives that benefit competitors in their local markets that are not available to us;


•	increased financial reporting burdens and complexities; and


•	political, social, and economic instability abroad.

These risks may limit or disrupt our expansion, restrict the movement of funds or result in the deprivation of contractual rights or the taking of property by nationalization or expropriation without fair compensation. Operating in international markets also requires significant management attention and financial resources.

New lines of business or new products and services may subject us to additional risks.

From time to time, we may implement or may acquire new lines of business or offer new products and services within existing lines of business. There are risks and uncertainties associated with these efforts, particularly in instances where the markets are not fully developed or are evolving. In developing and marketing new lines of business and new products and services, we may invest significant time and resources. External factors, such as regulatory compliance obligations, competitive alternatives, and shifting market preferences, may also impact the successful implementation of a new line of business or a new product or service. Failure to successfully manage these risks in the development and implementation of new lines of business or new products or services could have a material adverse effect on our business, results of operations and financial condition.

Our future capital needs are uncertain and we may need to raise funds in the future, and such funds may not be available on acceptable terms or at all.

Continued expansion of our business will be expensive and we may seek funds from public and private stock offerings, borrowings under our existing or future credit facilities or other sources. Our capital requirements will depend on many factors, including:


•	the revenues generated by sales of our products;


•	the costs associated with expanding our sales and marketing efforts;


•	the expenses we incur in manufacturing and selling our products;


•	the costs of developing and commercializing new products or technologies;


•	the cost of obtaining and maintaining regulatory approval or clearance of certain products and products in development;


•	the number and timing of acquisitions and other strategic transactions;


•	the costs associated with our planned international expansion;


•	the costs associated with capital expenditures; and


•	unanticipated general and administrative expenses.

As as result of these factors, we may seek to raise capital, and such capital may not be available on favorable terms, or at all. Furthermore, if we issue equity or debt securities to raise capital, our existing shareholders may experience dilution, and the new equity or debt securities may have rights, preferences and privileges senior to those of our existing stockholders. In addition, if we raise capital through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to our products, potential products or proprietary technologies, or grant licenses on terms that are not favorable to use. If we cannot raise capital on acceptable terms, we may not be able to develop to enhance our products, execute our business plan, take advantage of future opportunities, or respond to competitive pressure, changes in our supplier relationships,

or unanticipated customer requirements. Any of these events could adversely affect our ability to achieve our development and commercialization goals, which could have a material adverse effect on our business, results of operations and financial condition.

We have identified a material weakness in our internal control over financial reporting which, if not remediated, could adversely affect our reputation, business or stock price.

In reviewing the Company's tax accounting in preparation for filing this Form 10-K, our management identified a deficiency in our internal control over financial reporting. Our management has concluded that this deficiency constitutes a material weakness in our internal control over financial reporting related to our accounting for income taxes. As described under “Item 9A - Controls and Procedures,” as a result, our management has concluded that internal control over financial reporting was not effective as of December 31, 2016. This was identified during the audit process prior to preparation of the Company's financial statements and,therefore did not result in a material misstatement of the Company’s annual financial statements for the year ended December 31, 2016 or any of our previously issued annual or interim consolidated financial statements.

Although we have developed and are implementing a plan to remediate this material weakness, we cannot assure you that this will occur within the contemplated timeframe. Moreover, we cannot assure you that we will not identify additional material weaknesses in our internal control over financial reporting in the future. If we are unable to remediate the material weakness, our ability to record, process and report financial information accurately, and to prepare financial statements within the time periods specified by the rules and forms of the Securities and Exchange Commission, could be adversely affected. The occurrence of or failure to remediate the material weakness may adversely affect our reputation and business and the market price of our common stock and any other securities we may issue.

Risks Related to Our Intellectual Property

Our ability to protect our intellectual property and proprietary technology through patents and other means is uncertain and may be inadequate, which could have a material and adverse effect on us.

Our success depends significantly on our ability to protect our proprietary rights to the technologies used in our products. We rely on patent protection, as well as a combination of copyright, trade secret and trademark laws and nondisclosure, confidentiality and other contractual restrictions to protect our proprietary technology, including our licensed technology. These legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. In addition, our pending patent applications include claims to material aspects of our products and procedures that are not currently protected by issued patents. The patent application process can be time consuming and expensive. We cannot ensure that any of our pending patent applications will result in issued patents. Competitors may be able to design around our patents or develop products that provide outcomes that are comparable or even superior to ours. Although we have taken steps to protect our intellectual property and proprietary technology, including entering into confidentiality agreements and intellectual property assignment agreements with some of our officers, employees, consultants and advisors, such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements.

The failure to obtain and maintain patents and/or protect our intellectual property rights could have a material and adverse effect on our business, results of operations, and financial condition. Whether a patent is valid is a complex matter of science and law, and therefore we cannot be certain that, if challenged, our patents would be upheld. If one or more of those patents are invalidated, that could reduce or eliminate any competitive advantage we might otherwise have had.

In the event a competitor infringes upon our licensed or pending patent or other intellectual property rights, enforcing those rights may be costly, uncertain, difficult and time consuming. Even if successful, litigation to enforce or defend our intellectual property rights could be expensive and time consuming and could divert our management's attention. Further, bringing litigation to enforce our patents subjects us to the potential for counterclaims. Other companies or entities also have commenced, and may again commence, actions seeking to establish the invalidity of our patents. For example, the defendants in certain of our ongoing patent infringement suits have filed petitions for inter-partes review of certain of our patents with the United States Patent and Trademark Office (USPTO). We intend to defend these actions vigorously, but there is no guarantee of success, and such effort takes financial and time resources from the Company. In the event that one or more of our patents are challenged, a court or the USPTO may invalidate the patent(s) or determine that the patent(s) is not enforceable, which could harm our competitive position. If the USPTO ultimately cancels or narrows the claim in any of our patents through these proceedings, it could prevent or hinder us from being able to enforce them against competitors. Such adverse decisions could negatively impact our future, expected revenue. See Item 3, Legal Proceedings for information regarding our ongoing patent

infringement lawsuits and related inter-partes review proceedings.

In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. This could make it difficult for us to stop infringement of our foreign patents, if obtained, or the misappropriation of our other intellectual property rights. For example, some foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, some countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate.

The prosecution and enforcement of patents licensed to us by third parties are not within our control, and without these technologies, our products may not be successful and our business would be harmed if the patents were infringed or misappropriated.

We have obtained licenses from third parties for patents and patent application rights related to our CollaFix technologies, allowing us to use intellectual property rights owned by or licensed to these third parties. We do not control the maintenance, prosecution, enforcement or strategy for many of these patents or patent application rights and as such are dependent in part on the owners of the intellectual property rights to maintain their viability. Their failure to do so could significantly impair our ability to exploit those technologies.

We may become subject to claims of infringement of the intellectual property rights of others, which could prohibit us from developing our products, require us to obtain licenses from third parties or to develop non-infringing alternatives, and subject us to substantial monetary damages.

Third parties could assert that our products infringe their patents or other intellectual property rights. Whether a product infringes a patent or other intellectual property involves complex legal and factual issues, the determination of which is often uncertain. Therefore, we cannot be certain that we have not infringed the intellectual property rights of others. Because patent applications may take years to issue, there also may be applications now pending of which we are unaware that may later result in issued patents that our products or processes infringe. There also may be existing patents or pending patent applications of which we are unaware that our products or processes may inadvertently infringe.

Any infringement claim could cause us to incur significant costs, place significant strain on our financial resources, divert management's attention from our business and harm our reputation. If the relevant patents in such claim were upheld as valid and enforceable and we were found to infringe, we could be prohibited from selling any product that is found to infringe unless we could obtain licenses to use the technology covered by the patent or other intellectual property or are able to design around the patent or other intellectual property. We may be unable to obtain such a license on terms acceptable to us, if at all, and we may not be able to redesign our products to avoid infringement. A court could also order us to pay compensatory damages for such infringement, plus prejudgment interest and could, in addition, treble the compensatory damages and award attorney fees. These damages could be substantial and could harm our reputation, business, financial condition and operating results. A court also could enter orders that temporarily, preliminarily or permanently enjoin us and our customers from making, using, or selling products, and could enter an order mandating that we undertake certain remedial activities. Depending on the nature of the relief ordered by the court, we could become liable for additional damages to third parties.

We may be subject to damages resulting from claims that we, our employees, or our independent contractors have wrongfully used or disclosed alleged trade secrets, proprietary or confidential information of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors.

Some of our employees were previously employed at other medical device, pharmaceutical or tissue companies. We may also hire additional employees who are currently employed at other medical device, pharmaceutical or tissue companies, including our competitors. Additionally, consultants or other independent agents with which we may contract may be or have been in a contractual arrangement with one or more of our competitors. Although no claims are currently pending, we may be subject to claims that we, our employees, or our independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of these former employers or competitors. In addition, we have been and may in the future be subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these

claims, litigation could result in substantial costs and be a distraction to management. If we fail to defend such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. There can be no assurance that this type of litigation will not continue, and any future litigation or the threat thereof may adversely affect our ability to hire additional direct sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to market existing or new products, which could severely harm our business.

Our License Agreement for our CollaFix technology could be terminated.

Under our license agreement with Shriners' Hospitals for Children and University of South Florida Research Foundation dated January 29, 2007, it is possible for the licensor to terminate the agreement if we breach the license agreement and all of our cure rights are exhausted. If our license agreement were to be terminated, our investment in the CollaFix technology would be lost.

Risks Related to Regulatory Approval of Our Products and Other Government Regulations

To the extent our products do not qualify for regulation as human cells, tissues and cellular and tissue-based products under Section 361 of the Public Health Service Act, this could result in removal of the applicable products from the market, would make the introduction of new tissue products more expensive and significantly delay the expansion of our tissue product offerings and subject us to additional post-market regulatory requirements.

The products we manufacture and process are derived from human tissue. The FDA has specific regulations governing human cells, tissues and cellular and tissue-based products, or HCT/Ps. An HCT/P is a product containing or consisting of human cells or tissue intended for transplantation into a human patient. HCT/Ps that meet the criteria for regulation solely under Section 361 of the Public Health Service Act (so-called “361 HCT/Ps”) are not subject to any premarket clearance or approval requirements and are subject to less stringent post-market regulatory requirements.

If a product is deemed not to be a 361 HCT/P, FDA regulations will require premarket clearance or approval requirements that will involve significant time and cost investments by the Company. Further, there can be no assurance that the FDA will not, at some future point, change its position on current or future products' 361 HCT/P status, and any regulatory reclassification could have adverse consequences for us and make it more difficult or expensive for us to conduct our business by requiring premarket clearance or approval and compliance with additional post-market regulatory requirements with respect to those products. Moreover, increased regulatory scrutiny within the industry in which we operate could lead to increased regulation of HCT/Ps, including 361 HCT/Ps. We also cannot assure you that the FDA will not impose more stringent definitions with respect to products that qualify as 361 HCT/Ps.

See "Government Regulation" in Item 1 for a discussion of 361 HCT/Ps and the FDA's position on our products. If the FDA does allow the Company to continue to market a micronized form of its sheet allografts without a biologics license either prior to or after finalization of the draft guidance documents, it may impose conditions, such as labeling restrictions and compliance with cGMP. Although the Company is preparing for these requirements in connection with its pursuit of a BLA for certain of its micronized products, earlier compliance with these conditions would require significant additional time and cost investments by the Company. It is also possible that the FDA will not allow the Company to market any form of a micronized product without a biologics license even prior to finalization of the draft guidance documents and could even require the Company to recall its micronized products. Revenues from micronized products comprised approximately 10% of the Company's revenues in 2016.

Obtaining and maintaining the necessary regulatory approvals for certain of our products will be expensive and time-consuming and may impede our ability to fully exploit our technologies.

The process of obtaining regulatory clearances or approvals to market a biologic or medical device from the FDA or similar regulatory authorities outside of the United States is costly and time consuming, and there can be no assurance that such clearances or approvals will be granted on a timely basis, or at all. As discussed above, we intend to pursue approval of a Biologics License Application (BLA) for certain of our micronized products. Additionally, the FDA may take the position that some of the other products that we currently market require a BLA as well. Some of the future products and enhancements to our current products that we expect to develop and market may require marketing clearance or approval from the FDA. There can be no assurance, however, that clearance or approval will be granted with respect to any of our products or enhancements or that FDA review will not involve delays that would adversely affect our ability to market such products or enhancements.

associated with clinical trials that cannot be estimated until the IND is approved. Moreover, data obtained from clinical activities are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA may not grant approval on a timely basis, or at all. Additionally, the FDA may limit the indications for use or place other conditions on any approvals that could restrict the commercial application of the products. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.

Like the process of obtaining an approved BLA, the process of obtaining a PMA requires the expenditure of substantial time, effort and financial resources and may take years to complete. The FDA may not grant approval on a timely basis, or at all. Additionally, the FDA may limit the indications for use or place other conditions on any approvals that could restrict the commercial application of the products. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.

Our business is subject to continuing regulatory compliance by the FDA and other authorities, which is costly and our failure to comply could result in negative effects on our business.

As discussed above, the FDA has specific regulations governing our tissue-based products, or HCT/Ps. The FDA has broad post-market and regulatory and enforcement powers. The FDA's regulation of HCT/Ps includes requirements for registration and listing of products, donor screening and testing, processing and distribution (“Current Good Tissue Practices”), labeling, record keeping and adverse-reaction reporting, and inspection and enforcement.

Biologics and medical devices are subject to even more stringent regulation by the FDA. Even if pre-market clearance or approval is obtained, the approval or clearance may place substantial restrictions on the indications for which the product may be marketed or to whom it may be marketed, may require warnings to accompany the product or impose additional restrictions on the sale and/or use of the product. In addition, regulatory approval is subject to continuing compliance with regulatory standards, including the FDA's quality system regulations.

If we fail to comply with the FDA regulations regarding our tissue products or medical devices, the FDA could take enforcement action, including, without limitation, any of the following sanctions and the manufacture of our products or processing of our tissue could be delayed or terminated:


•	Untitled letters, warning letters, fines, injunctions, and civil penalties;


•	Recall or seizure of our products;


•	Operating restrictions, partial suspension or total shutdown of production;


•	Refusing our requests for clearance or approval of new products;


•	Withdrawing or suspending current applications for approval or approvals already granted;


•	Refusal to grant export approval for our products; and


•	Criminal prosecution.

It is likely that the FDA's regulation of HCT/Ps will continue to evolve in the future. Complying with any such new regulatory requirements may entail significant time delays and expense, which could have a material adverse effect on our business.

The American Association of Tissue Banks (“AATB”) has issued operating standards for tissue banking. Compliance with these standards is a requirement in order to become an accredited tissue bank. In addition, some states have their own tissue banking regulations.

In addition, procurement of certain human organs and tissue for transplantation is subject to the restrictions of the National Organ Transplant Act (“NOTA”), which prohibits the transfer of certain human organs, including skin and related tissue for valuable consideration, but permits the reasonable payment associated with the removal, transportation, implantation, processing, preservation, quality control and storage of human tissue and skin. We reimburse tissue banks, hospitals and physicians for their services associated with the recovery, storage and transportation of donated human tissue. Although we have independent third party appraisals that confirm that reasonableness of the service fees we pay, if we were to be found to have violated NOTA's prohibition on the sale or transfer of human tissue for valuable consideration, we would potentially be

subject to criminal enforcement sanctions, which could materially and adversely affect our results of operations.

Finally, as discussed above, we and other manufacturers of skin substitutes are required to provide ASP information to CMS on a quarterly basis. The Medicare payment rates are updated quarterly based on this ASP information. If a manufacturer is found to have made a misrepresentation in the reporting of ASP, such manufacturer is subject to civil monetary penalties of up to $10,000 for each misrepresentation for each day in which the misrepresentation was applied.

We and our sales representatives, whether employees or independent contractors, must comply with various federal and state anti-kickback, self-referral, false claims and similar laws, any breach of which could cause a material adverse effect on our business, financial condition and results of operations.

Our relationships with physicians, hospitals and other healthcare providers are subject to scrutiny under various federal anti-kickback, self-referral, false claims and similar laws, often referred to collectively as healthcare fraud and abuse laws. Healthcare fraud and abuse laws are complex, and even minor, inadvertent violations can give rise to claims that the relevant law has been violated. Possible sanctions for violation of these fraud and abuse laws include monetary fines, civil and criminal penalties, exclusion from federal and state healthcare programs, including Medicare, Medicaid, Veterans Administration health programs, workers' compensation programs and TRICARE (the healthcare system administered by or on behalf of the U.S. Department of Defense for uniformed services beneficiaries, including active duty and their dependents, retirees and their dependents), and forfeiture of amounts collected in violation of such prohibitions. Certain states have similar fraud and abuse laws, imposing substantial penalties for violations. Any Government investigation or a finding of a violation of these laws would likely result in a material adverse effect on the market price of our common stock, as well as our business, financial condition and results of operations.

Anti-kickback laws and regulations prohibit any knowing and willful offer, payment, solicitation or receipt of any form of remuneration in return for the referral of an individual or the ordering or recommending of the use of a product or service for which payment may be made by Medicare, Medicaid or other Government-sponsored healthcare programs. We have entered into consulting agreements, speaker agreements, research agreements and product development agreements with physicians, including some who may order our products or make decisions to use them. In addition, some of these physicians own our stock, which they purchased in arm's length transactions on terms identical to those offered to non-physicians, or received stock awards from us as consideration for services performed by them. While these transactions were structured with the intention of complying with all applicable laws, including state anti-referral laws and other applicable anti-kickback laws, it is possible that regulatory or enforcement agencies or courts may in the future view these transactions as prohibited arrangements that must be restructured or for which we would be subject to other significant civil or criminal penalties. As discussed above, we have incorporated the AdvaMed code principles into our relationships with healthcare professionals under our consulting agreements, and our policies regarding payment of travel and lodging expenses, research and educational grant procedures and sponsorship of third-party conferences. In addition, we have conducted training sessions on these principles. However, there can be no assurance that regulatory or enforcement authorities will view these arrangements as being in compliance with applicable laws or that one or more of our employees or agents will not disregard the rules we have established. Because our strategy relies on the involvement of physicians who consult with us on the design of our products, perform clinical research on our behalf or educate the market about the efficacy and uses of our products, we could be materially impacted if regulatory or enforcement agencies or courts interpret our financial relationships with physicians who refer or order our products to be in violation of applicable laws and determine that we would be unable to achieve compliance with such applicable laws. This could harm our reputation and the reputations of the physicians we engage to provide services on our behalf. In addition, the cost of noncompliance with these laws could be substantial since we could be subject to monetary fines and civil or criminal penalties, and we could also be excluded from federally-funded healthcare programs, including Medicare and Medicaid, for non-compliance.

The Federal False Claims Act (“FCA”) imposes civil liability on any person or entity that submits, or causes the submission of, a false or fraudulent claim to the U.S. Government. Damages under the FCA can be significant and consist of the imposition of fines and penalties. The FCA also allows a private individual or entity with knowledge of past or present fraud against the Federal Government to sue on behalf of the Government to recover the civil penalties and treble damages. The U.S. Department of Justice (“DOJ”) on behalf of the Government has previously alleged that the marketing and promotional practices of pharmaceutical and medical device manufacturers, including the off-label promotion of products or the payment of prohibited kickbacks to doctors, violated the FCA, resulting in the submission of improper claims to federal and state healthcare entitlement programs such as Medicaid. In certain cases, manufacturers have entered into criminal and civil settlements with the federal government under which they entered into plea agreements, paid substantial monetary amounts and entered into corporate integrity agreements that require, among other things, substantial reporting and remedial actions going forward.

In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians for marketing. Some states, such as California, Massachusetts and Vermont, mandate implementation of commercial compliance programs, along with the tracking and reporting of gifts, compensation and other remuneration to physicians. The shifting commercial compliance environment and the need to build and maintain robust and expandable systems to comply with different compliance and/or reporting requirements in multiple jurisdictions increase the possibility that a healthcare company may run afoul of one or more of the requirements.

The scope and enforcement of all of these laws is uncertain and subject to rapid change, especially in light of the lack of applicable precedent and regulations. There can be no assurance that federal or state regulatory or enforcement authorities will not investigate or challenge our current or future activities under these laws. Any investigation or challenge could have a material adverse effect on our business, financial condition and results of operations. Any state or federal regulatory or enforcement review of us, regardless of the outcome, would be costly and time consuming. Additionally, we cannot predict the impact of any changes in these laws, whether these changes are retroactive or will have effect on a going-forward basis only.

We face significant uncertainty in the industry due to Government healthcare reform.

There have been and continue to be proposals by the Federal Government, State Governments, regulators and third party payers to control healthcare costs, and generally, to reform the healthcare system in the United States. There are many programs and requirements for which the details have not yet been fully established or the consequences are not fully understood. These proposals may affect aspects of our business. We also cannot predict what further reform proposals, if any, will be adopted, when they will be adopted, or what impact they may have on us.

We may fail to obtain or maintain foreign regulatory approvals to market our products in other countries.

We currently market our products internationally and intend to expand our international marketing. International jurisdictions require separate regulatory approvals and compliance with numerous and varying regulatory requirements. The approval procedures vary among countries and may involve requirements for additional testing. Certain of our products require clearance or approval by the FDA. However, such clearance or approval does not ensure approval or certification by regulatory authorities in other countries or jurisdictions, and approval or certification by one foreign regulatory authority does not ensure approval or certification by regulatory authorities in other foreign countries or by the FDA. The foreign regulatory approval or certification process may include all of the risks associated with obtaining FDA clearance or approval. We may not obtain foreign regulatory approvals on a timely basis, if at all. We may not be able to file for regulatory approvals or certifications and may not receive necessary approvals to commercialize our products in any market. If we fail to receive necessary approvals or certifications to commercialize our products in foreign jurisdictions on a timely basis, or at all, our business, results of operations and financial condition could be adversely affected.

Risks Related to the Securities Markets and Ownership of Our Common Stock

The price of our common stock has been, and will likely continue to be, volatile.

The market price of our common stock, like that of the securities of many other companies that are in, or are just emerging from, the development stage, has fluctuated over a wide range and it is likely that the price of our common stock will fluctuate in the future. The market price of our common stock could be impacted by a variety of factors, including:


·	Fluctuations in stock market prices and trading volumes of similar companies or of the markets generally;


·	Our ability to successfully launch, market and earn significant revenue from our products;


·	Our ability to obtain additional financing to support our continuing operations;


·	Disclosure of the details and results of regulatory applications and proceedings;


·	Changes in Government regulations or our failure to comply with any such regulations;


·	Additions or departures of key personnel;


·	Our investments in research and development or other corporate resources;


·	Announcements of technological innovations or new commercial products by us or our competitors;


·	Developments in the patents or other proprietary rights owned or licensed by us or our competitors;


·	The timing of new product introductions;


·	Actual or anticipated fluctuations in our operating results, including any restatements of previously reported results;


·	Our ability to effectively and consistently manufacture our products and avoid costs associated with the recall of defective or potentially defective products;


·	Our ability and the ability of our distribution partners to market and sell our products;


·	Changes in reimbursement for our products or the price for our products to our customers;


·	Removal of our products from the Federal Supply Schedule, or changes in how Government accounts purchase products such as ours or in the price for our products to Government accounts;


·	Material amounts of short-selling of our common stock; and


.	The other risks detailed in this Item 1A.

Further, due to the relatively fixed nature of most of our costs, which primarily include personnel costs as well as facilities costs, any unanticipated shortfall in revenue in any fiscal quarter would have an adverse effect on our results of operations in that quarter. These fluctuations could cause the trading price of our stock to be negatively affected. Our quarterly operating results have varied substantially in the past and may vary substantially in the future. In addition, the stock market and certain of the indices on which we are included has been very volatile in the recent past. This volatility is often not related to the operating performance of companies listed thereon and will probably continue in the foreseeable future.

Securities analysts may elect not to report on our common stock or may issue negative reports that adversely affect the stock price.

At this time, six securities analysts provide research coverage of our common stock. However, there is no assurance that these analysts will continue to report on our common stock or that additional analysts will initiate reporting on our common stock. Rules mandated by the Sarbanes-Oxley Act and a global settlement reached in 2003 among the SEC, other regulatory agencies, and a number of investment banks led to a number of fundamental changes in how analysts are reviewed and compensated. In particular, many investment banking firms are required to contract with independent financial analysts for their stock research. If securities analysts discontinue covering our common stock, the lack of research coverage may adversely affect its actual and potential market price. The trading market for our common stock may be affected in part by the research and reports that industry or financial analysts publish about our business. If one or more analysts elect to cover us and then downgrade the stock, the stock price would likely decline rapidly. If one or more of these analysts cease coverage of us, we could lose visibility in the market, which in turn could cause our stock price to decline. This could have a negative effect on the market price of our shares.

Our charges to earnings resulting from acquisition, restructuring and integration costs may materially adversely affect the market value of our common stock.

We account for the completion of our acquisitions using the purchase method of accounting. We allocate the total estimated purchase prices to net tangible assets, amortizable intangible assets and indefinite-lived intangible assets, and based on their fair values as of the date of completion of the acquisitions, record the excess of the purchase price over those fair values as goodwill. Our financial results, including earnings per share, could be adversely affected by a number of financial adjustments required in purchase accounting including the following:


•	We will incur additional amortization expense over the estimated useful lives of certain of the intangible assets acquired in connection with acquisitions during such estimated useful lives.


•	We will incur additional depreciation expense as a result of recording purchased tangible assets.


•	To the extent the value of goodwill or intangible assets becomes impaired, we may be required to incur material charges relating to the impairment of those assets.


•	Cost of sales may increase temporarily following an acquisition as a result of acquired inventory being recorded at its fair market value.


•	Earnings may be affected by changes in estimates of future contingent consideration to be paid when an earn-out is part of the consideration.


•	Earnings may be affected by transaction and implementation costs, which are expensed immediately.

We do not intend to pay cash dividends.

We have never declared or paid cash dividends on our capital stock. We currently expect to use available funds and any future earnings in the development, operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. In addition, the terms of our existing credit facility restrict us from paying dividends. As a result, capital appreciation, if any, of our common stock will be an investor's only source of potential gain from our common stock for the foreseeable future.

We are currently, and may in the future be, subject to other claims and lawsuits that could cause us to incur significant legal expenses and result in harm to our business.

We, as well as certain of our officers and sales representatives, are subject to claims or lawsuits from time to time. Regardless of the outcome, these lawsuits may result in significant legal fees and expenses and could divert management's time and other resources. In addition, the volatility in our stock price may make us more vulnerable to future class action litigation.

The Audit Committee of our Board of Directors engaged outside counsel to conduct an investigation that generally included a review of whether or not we have properly recognized revenue arising out of claims of former employees with whom we are currently in litigation. See Item 3 - Legal Proceedings for a discussion of the litigation. To date, we have incurred significant expense related to legal, accounting, and other professional services in connection with the investigation and related matters, and may continue to incur significant additional expenses with regard to these matters. The expenses incurred, and expected to be incurred, on the investigation, and the diversion of the attention of the management team that has occurred, has adversely affected, and could continue to adversely affect, our business, financial condition and results of operations or cash flows.

As a result of the matters reported above, we are exposed to greater risks associated with litigation, regulatory proceedings and government enforcement actions. Any future such investigations or additional lawsuits may adversely affect our business, financial condition, results of operation and cash flows. Any adverse judgment in or settlement of any pending or any future litigation could require payments that exceed the limits of our available directors’ and officers’ liability insurance, which could have a material adverse effect on our operating results or financial condition.

Provisions of Florida law and anti-takeover provisions in our organizational documents may discourage or prevent a change of control, even if an acquisition would be beneficial to shareholders, which could affect our share price adversely and prevent attempts by shareholders to remove current management.

We are subject to the Florida affiliated transactions statute, which generally requires approval by the disinterested directors or supermajority approval by shareholders for "affiliated transactions" between a corporation and an "interested stockholder." Additionally our organizational documents contain provisions:


·	Authorizing the issuance of preferred stock that can be created and issued by the Board of Directors without prior common stock shareholder approval, with rights senior to those of the common stock;


·	Restricting persons who may call shareholder meetings;


·	Electing directors on a staggered basis; and


.	Allowing the Board to fill vacancies and to fix the number of directors.

These provisions of Florida law and our articles of incorporation and bylaws could negatively affect our share price, prevent attempts by shareholders to remove current management, prohibit or delay mergers or other takeovers or changes of control of the Company and discourage attempts by other companies to acquire us, even if such a transaction would be beneficial to our shareholders.

Item 2. Properties

Our corporate headquarters are located in Marietta, Georgia, where we lease approximately 80,000 square feet of office, laboratory, tissue processing and warehouse space. We also lease (a) approximately 21,000 square feet for a facility in Kennesaw, Georgia, which primarily consists of laboratory, tissue processing and warehouse space; and (b) approximately 26,000 square feet of additional office space in Marietta, Georgia. In addition, Stability leases approximately 3,000 square feet for its corporate offices in Nashville, Tennessee and approximately 15,000 square feet in San Antonio, Texas which consists of its tissue processing center.

Item 3. Legal Proceedings

Former Employee Litigation

On December 13, 2016, the Company filed lawsuits against former employees Jess Kruchoski (in the lawsuit styled MiMedx Group, Inc. v. Academy Medical, LLC, et. al. in the County Court of the Fifteenth Judicial Circuit in and for Palm Beach County, Florida (the “Florida Action”)) and Luke Tornquist (in the lawsuit styled MiMedx Group, Inc., v. Luke Tornquist in the Superior Court for Cobb County, Georgia, which was removed to the United States District Court for the Northern District of Georgia (the “Georgia Action”)). Both the Florida and Georgia Actions assert claims against Messrs. Kruchoski and Tornquist that each of them violated their restrictive covenants entered into with the Company, that each of them misappropriated trade secrets of the Company, that each of them tortiously interfered with contracts between the Company and its customers and employees, and that each of them breached his duty of loyalty owed to the Company, among other claims.

On December 15, 2016, Messrs. Kruchoski and Tornquist filed a lawsuit in the United States District Court of Minnesota (the “Minnesota Action”) against the Company and the Company’s Chairman and Chief Executive Officer, Parker Petit. The plaintiffs in this lawsuit each claimed that their employment with the Company was terminated in retaliation for their complaints about the Company’s alleged business practices in violation of the Dodd-Frank Act, 15 U.S.C. § 78u-6(h); and was an unlawful discharge in violation of Minnesota Statutes Section 181.931 subdivision 1. Mr. Kruchoski also claimed that the termination of his employment with the Company constituted marital status discrimination and familial status discrimination in violation of the Minnesota Human Rights Act. Messrs. Kruchoski and Tornquist also claimed that Mr. Petit tortiously interfered with their employment relationships with the Company.

On January 26, 2017, the Company and Mr. Petit filed motions to dismiss the Minnesota Action. In response, Messrs. Kruchoski and Tornquist voluntarily dismissed the Minnesota Action without prejudice on February 7, 2017. On February 7, 2017, Mr. Tornquist filed his Answer and Counterclaims in the Georgia Action wherein he asserted claims similar to those he had asserted in the Minnesota Action, with the exception that he did not include a claim of tortious interference against Mr. Petit. On February 15, 2017, Mr. Kruchoski filed a new lawsuit in Georgia against MiMedx and Mr. Petit, making many of the same allegations in that suit as were made in the Minnesota suit, with the addition of claims against the Company and Mr. Petit for defamation.

The Company intends to vigorously pursue its claims asserted in the Florida and Georgia Actions and also to vigorously defend against the lawsuits and counterclaims asserted against them.

Patent Litigation

MiMedx continues to diligently enforce its intellectual property against several entities. Currently, there are four actions pending, as described below:

The Liventa Action

On April 22, 2014, the Company filed a patent infringement lawsuit in the United States District Court for the Northern District of Georgia against Liventa Bioscience, Inc. ("Liventa"), Medline Industries, Inc. ("Medline") and Musculoskeletal Transplant Foundation, Inc. ("MTF") for permanent injunctive relief and unspecified damages (the "Liventa Action"). In addition to the allegations of infringement of MiMedx's patents, the lawsuit asserts that Liventa and Medline knowingly and willfully made false and misleading representations about their respective products to providers, patients, and in some cases, prospective investors. Though the terms of the agreement are confidential, the parties have reached a settlement of the false advertising claims for an undisclosed sum. The patent infringement claims are still pending as described below.

MiMedx asserts that Liventa (formerly known as AFCell Medical, Inc.), Medline and MTF infringed and continue to infringe certain of the Company's patents relating to the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts. MTF is the tissue processor while Liventa and Medline are the distributors of the allegedly infringing products. On May 30, 2014, defendants filed answers to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement, invalidity, laches and estoppel. MTF and Medline also filed counterclaims seeking declaratory judgments of non-infringement and invalidity. Defendants filed parallel Inter Partes Review ("IPR") proceedings which are discussed below. We expect the case to go to trial in 2017.

The Bone Bank Action

On May 16, 2014, the Company also filed a patent infringement lawsuit against Transplant Technology, Inc. d/b/a Bone Bank Allografts ("Bone Bank") and Texas Human Biologics, Ltd. ("Biologics") for permanent injunctive relief and unspecified damages (the "Bone Bank Action"). The Bone Bank Action was filed in the United States District Court for the Western District of Texas. This lawsuit similarly asserts that Bone Bank and Biologics infringed certain of the Company's patents through the manufacturing and sale of their placental-derived tissue graft products. On July 10, 2014, Defendants filed an answer to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement and invalidity and filed counterclaims seeking declaratory judgments of non-infringement and invalidity. Defendants also filed parallel IPR proceedings which are further discussed below. Discovery is closed and we expect the case to go to trial in 2017.

The NuTech Action

On March 2, 2015, the Company filed a patent infringement lawsuit against NuTech Medical, Inc. ("NuTech") and DCI Donor Services, Inc. ("DCI") for permanent injunctive relief and unspecified damages. This lawsuit was filed in the United States District Court for the Northern District of Alabama. The lawsuit alleges that NuTech and DCI have infringed and continue to infringe the Company's patents through the manufacture, use, sale, and/or offering of their tissue graft product. The lawsuit also asserts that NuTech knowingly and willfully made false and misleading representations about its products to customers and/or prospective customers. The case is currently in the discovery phase.

The Vivex Action

On April 1, 2016, the Company also filed a patent infringement lawsuit against Vivex BioMedical (“Vivex”) for permanent injunctive relief and unspecified damages (the "Vivex Action"). The lawsuit was filed in the United States District Court for the Northern District of Georgia. The patent at issue is the 8,709,494 patent (the "494" patent). Vivex answered the Company’s complaint and filed counterclaims of non-infringement and invalidity. On January 4, 2017, the Court granted a joint motion to stay the proceedings pending the outcome of the Bone Bank Action.

Pending IPRs

In addition to defending the claims in the pending district court litigations, defendants in the Liventa and Bone Bank cases have challenged certain of the Company's patents in several IPR proceedings to avoid the high burden of proof of proving invalidity by "clear and convincing evidence" in the district court litigations. An inter partes review (or "IPR") is a request for a specialized group within the United States Patent and Trademark Office to review the validity of a plaintiff's patent claims. The defendants in the Bone Bank Action challenged the validity of the Company's 8,597,687 (the "687" patent) and the '494 patent; while the defendants in the Liventa Action challenged the validity of the Company's 8,372,437 and 8,323,701 patents (the "'437" and "'701" patents, respectively).

On June 29, 2015, the Patent Trial and Appeals Board ("PTAB") denied the Bone Bank defendants' request for institution of an IPR with respect to the '494 patent (EpiFix) on all seven challenged grounds. On August 18, 2015, the PTAB also denied the Liventa defendants' request for institution of an IPR with respect to the '701 patent (AmnioFix) on all six challenged grounds. That is, the PTAB decided in each case that the defendants failed to establish a reasonable likelihood that defendants would prevail in showing any of the challenged claims of the '494 or the '701 patent were unpatentable.

On July 10, 2015, the PTAB issued an opinion allowing a review of the '687 patent to proceed, although on only two of the five challenged grounds. On July 7, 2016, the PTAB issued an opinion finding that the challenged claims, which relate to embossment and not configuration, were invalid for obviousness. The Company decided not to appeal the decision, as it impacted a non-core patent. On August 18, 2015, the PTAB issued an opinion allowing a review of the '437 patent to proceed, although only on one of the seven challenged grounds. On August 16, 2016, the PTAB issued an opinion finding that the challenged claims were unpatentable. MiMedx has filed an appeal of the PTAB’s decision regarding the '437 patent.

Item 4. Mine Safety Disclosures

Not applicable.

PART II

Item 5. Market for Registrant's Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities

Our common stock was approved for quotation on the OTC Bulletin Board on July 19, 2007. Only a limited number of shares were traded after the approval of the quotation in July 2007. The common stock was traded with the trading symbol of “AYXC.” Our common stock began trading under the symbol “MDXG” on April 2, 2008. On April 25, 2013, our common stock was approved for trading on the NASDAQ Capital Market.

The following table sets forth, for the periods indicated, the range of high and low sale prices per share of common stock on NASDAQ for the fiscal years ended December 31, 2016 and 2015.



Year Ended December 31, 2016	High		Low
First Quarter	$	9.25	$	7.31
Second Quarter	9.19		6.66
Third Quarter	9.34		7.06
Fourth Quarter	9.99		7.85

Year Ended December 31, 2015	High		Low
First Quarter	$	11.33	$	7.92
Second Quarter	11.93		8.97
Third Quarter	13.20		8.52
Fourth Quarter	10.14		6.71

Based upon information supplied from our transfer agent, there were approximately 756 shareholders of record of our common stock as of February 15, 2017.

Stock Performance Graph

The following graph compares the cumulative total stockholder return on our common stock with the cumulative total stockholder return of the Nasdaq Composite Index and the Nasdaq Biotechnology Index and assumes an investment of $100.00 on December 31, 2011, in each of the common stock, the stocks comprising the Nasdaq Composite Index and the stocks comprising the Nasdaq Biotechnology Index.

ASSUMES $100 INVESTED ON DEC. 31, 2011

ASSUMES NO DIVIDENDS

FISCAL YEAR ENDING DEC. 31, 2016

Purchases of Equity Securities by the Issuer and Affiliated Purchasers



	Total Number of Shares Purchased (a)	Average Price Paid per Share		Total number of shares purchased under publicly announced plan (b)		Total Amount Spent Under the Plan During Each Period		Remaining Amount to be Spent Under the Plan
Total amount remaining October 1, 2016								$	3,935,789

October 1, 2016 - October 31, 2016	18,202	$	—	$	—	$	—	$	3,935,789

November 1, 2016 - November 30, 2016	11,542	$	—	$	—	$	—	$	3,935,789

December 2016 increased spending authorization								6,000,000

December 1, 2016 - December 31, 2016	2,520	$	—	$	—	$	—	$	9,935,789

Total for the quarter	32,264	$	—	$	—	$	—

(a) Shares repurchased during the quarter include 32,264 shares surrendered by employees to satisfy tax withholding

obligations upon vesting of restricted stock.

(b) On May 12, 2014, our Board of Directors authorized the repurchase of up to $10 million of our common stock

from time to time, through December 31, 2014. The Board subsequently extended the program until December 31,

2017. In December 2014, the Board increased the authorization to a total of $20 million and further increased the

authorization in 2015 to a total of $60 million. In December 2016, the Board further increased the authorization to a total of $66 million. In February 2017, the Board authorized a further increase of $20 million, which brings the total amount authorized to $86 million. The timing and amount of repurchases will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.

Item 6. Selected Financial Data

The following selected consolidated financial data was derived from our consolidated financial statements. The data should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Item 7 and Consolidated Financial Statements and notes in Item 8.




	As of December 31, in thousands
		2016		2015		2014		2013			2012
Statement of Operations Data:
Net sales		$	245,015	$	187,296	$	118,223	$	59,181		27,054
Gross margin		212,608		167,094		105,558		49,853			21,865
Operating income (loss)		18,446		24,364		7,100		(2,639		)	(5,355		)
Net income (loss)		11,974		29,446		6,220		(4,112		)	(7,662		)
Net income (loss) per common share - basic		0.11		0.28		0.06		(0.04		)	(0.09		)
Net income (loss) per common share - diluted		$	0.11	$	0.26	$	0.05	$	(0.04	)	$	(0.09	)

				As of December 31, in thousands
		2016		2015		2014		2013			2012
Balance Sheet Data:
Total assets		$	193,263	$	135,913	$	109,259	$	84,694		$	35,183
Working capital		75,806		69,533		67,272		55,781			13,072
Long term liabilities		9,531		1,148		1,526		1,518			10,158
Stockholders' equity		$	133,000	$	107,988	$	89,329	$	73,568		$	20,007

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with the Consolidated Financial Statements and the corresponding notes included in Item 8. Certain percentages presented in this discussion and analysis are calculated from the underlying whole dollar amounts and therefore may not recalculate from the rounded numbers used for disclosure purposes. Some of the information contained in this discussion and analysis or set forth elsewhere in this report includes forward-looking statements that involve risks and uncertainties. You should read the “Risk Factors” section of this report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

The discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires making estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue, and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Overview

Recent Events

FDA Guidance

On December 22, 2014, the FDA issued for comment “Draft Guidance for Industry and FDA Staff: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products.” Essentially, the Minimal Manipulation draft guidance takes the same position with respect to micronized amniotic tissue that it took in the Untitled Letter to the Company 16 months earlier. The Company submitted comments to the Minimal Manipulation draft guidance asserting that the Minimal Manipulation draft guidance represents agency action that goes far beyond the FDA’s statutory authority, is inconsistent with existing HCT/ P regulations and the FDA’s prior positions, and is internally inconsistent and scientifically unsound. On October 28, 2015, the FDA issued for comment, "Draft Guidance for Industry and FDA Staff: Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products." The Company submitted comments on this Homologous Use draft guidance as well. On September 12 and 13, 2016, the FDA held a public hearing to obtain input on the Homologous Use draft guidance and the previously released Minimal Manipulation draft guidance, as well as other recently issued guidance documents on HCT/Ps. The Company awaits further decision from FDA on the draft guidances, but anticipates this will be a lengthy process.

Change in purchasing procedure at Department of Veterans Affairs

In 2016, the Department of Veterans Affairs (“VA”) announced a change in its internal purchasing procedures. Among other things, under the new directive, the VA would require internal pre-authorization by a warranted contracting officer for any implant purchases greater than $3,500, except for implants from VA-owned inventory or a consignment agreement negotiated by a VA contracting officer. Different VA facilities interpreted the new directive differently, and also began implementing different portions of it at different times. Numerous vendors to the VA, including the Company, have requested that the VA provide clarification to its facilities on the new policy in order to minimize disruption in patient care.

Critical Accounting Policies

We believe that of our significant accounting policies, which are described in Note 2 to our financial statements appearing elsewhere in this report, the following accounting policies involve a greater degree of judgment and complexity.

Revenue Recognition and Sales Returns, Discounts, and Allowances Accruals

We sell our products primarily through a combination of a direct sales force, independent stocking distributors and third - party representatives in the U.S. and independent distributors in international markets. We recognize revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. We record revenues from sales to our independent stocking distributors at the time the product is shipped to the distributor. Our stocking distributors, who sell the products to their customers or sub-distributors, contractually take title to the products and assume all risks of ownership at the time of shipment. Our stocking distributors are obligated to pay us the contractually agreed upon invoice price within specified terms regardless of when, if ever, they sell the products. Our stocking distributors do not have any contractual rights of return or exchange other than for defective product or shipping error; however, in limited situations, we do accept returns or exchanges at our discretion.

Some of the Company’s sales to Government accounts, including the Department of Veterans Affairs, are made through a distributor relationship with AvKARE, which is a veteran-owned General Services Administration Federal Supply Schedule (FSS) contractor. The Company's agreement with AvKARE expires, subject to certain for-cause termination rights, on June 30, 2017. The Company may also elect to terminate the agreement without cause and pay a termination fee to AvKARE as specified in the agreement. Upon termination of the agreement, the parties may mutually agree to extend the agreement or the Company has an obligation to repurchase AvKARE’s remaining inventory, if any, within ninety (90) days in accordance with the terms of the Agreement. At the end of the term, the parties expect AvKARE’s inventory to be minimal, based upon AvKARE's obligation to use commercially reasonable efforts to achieve target sales levels over the remaining term of the agreement.

We continually evaluate new and current customers, including our stocking distributors, for collectability based on various factors including past history with the customer, evaluation of their credit worthiness, and current economic conditions. We only record revenue when collectability is reasonably assured. A portion of the Company’s revenue is generated from inventory maintained at hospitals or physician's offices.

We make estimates of potential future sales returns, discounts and allowances related to current period product revenue and these are reflected as a reduction of revenue in the same period revenue is recognized. We base our estimate for sales returns, discounts and allowances on historical sales and product return information, including historical experience and actual and projected trend information as well as projected sales returns based on estimated usage and contractual arrangements with AvKARE. These estimates have historically been consistent with actual results.

Goodwill and Impairment of Long-Lived Assets

Goodwill is the excess of the purchase price over the fair value of net assets of acquired businesses. Goodwill is tested for impairment annually or whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. The test for impairment requires us to make several estimates about fair value, most of which are based on projected future cash flows. Our estimates associated with the goodwill impairment test are considered critical due to the amount of goodwill recorded on our consolidated balance sheets and the judgment required in determining fair value, including projected future cash flows. No goodwill impairment has been recognized during 2016, 2015 or 2014.

Other intangible assets include patents, trademarks, and purchased technology. Intangible assets with a definite life are amortized on a straight-line or accelerated basis, as appropriate, with estimated useful lives ranging from ten to fourteen years, and are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable. Indefinite-lived intangible assets are tested for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable. Refer to Note 8 to the consolidated financial statements in Item 8 for additional information. Our impairment reviews are based on an estimated future cash flow approach that requires significant judgment with respect to future revenue and expense growth rates, selection of appropriate discount rate, asset groupings, and other assumptions and estimates. We use estimates that are consistent with our business plans and a market participant view of the assets being evaluated. Actual results may differ from our estimates. No impairments have been recognized during 2016, 2015 and 2014.

Fair Value Measurements

We record certain financial instruments at fair value, including: cash equivalents and contingent consideration. We may make an irrevocable election to measure other financial instruments at fair value on an instrument-by-instrument basis; although as of December 31, 2016 we have not chosen to make any such elections. Fair value financial instruments are recorded in accordance with the fair value measurement framework.

We also measure certain non-financial assets at fair value on a non-recurring basis. These non-recurring valuations include evaluating assets such as long-lived assets, and non-amortizing intangible assets for impairment; allocating value to assets in an acquired asset group; and applying accounting for business combinations including related earn out liability. We use the fair value measurement framework to value these assets and report the fair values in the periods in which they are recorded or written down.

The fair value measurement framework includes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair values in their broad levels. These levels from highest to lowest priority are as follows:


•	Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities;


•	Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data; and


•	Level 3: Unobservable inputs or valuation techniques that are used when little or no market data is available.

The determination of fair value and the assessment of a measurement’s placement within the hierarchy requires judgment. Level 3 valuations often involve a higher degree of judgment and complexity. Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions. Management’s assumptions could vary depending on the asset or liability valued and the valuation method used. Such assumptions could include: estimates of prices, earnings, costs, earn out assumptions, actions of market participants, market factors, or the weighting of various valuation methods. We may also engage external advisors to assist us in determining fair value, as appropriate.

Although we believe that the recorded fair value of our financial instruments is appropriate, these fair values may not be indicative of net realizable value or reflective of future fair values.

Share-based Compensation

We follow the provisions of FASB Accounting Standards Codification (“ASC”) 718, “Compensation — Stock Compensation” (ASC 718), previously referred to as Statement of Financial Accounting Standards No. 123R — Share-based Payments which requires the measurement and recognition of compensation expense for all share-based payment awards either modified or granted to employees and directors based upon estimated fair values. The Black-Scholes-Merton option-pricing model, consistent with the provisions of ASC 718, was used to determine the fair value of each option granted. Option valuation models require the input of highly subjective assumptions, including the expected stock price volatility. We use projected volatility rates, which are based upon historical volatility rates, trended into future years. Because our stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of our options.

Income Taxes

We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If we

determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.

We record uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

Recently Adopted Accounting Pronouncements

See Note 2 to the consolidated financial statements in Item 8 for recently adopted accounting pronouncements.

Results of Operations for the year ended December 31, 2016, compared to the year ended December 31, 2015

Revenue

We recorded revenue for the year ended December 31, 2016 of $245.0 million, a $57.7 million or 30.8% increase over 2015 revenue of $187.3 million.

Wound Care revenue in 2016 was $184.0 million which represented a $42.9 million, or 30.4%, increase over 2015 revenue of $141.1 million. Surgical, Sports Medicine, and Orthopedics (SSO) revenue in 2016 was $61.0 million which represented a $14.8 million, or 32%, increase over 2015 revenue of $46.2 million.

The increase of $57.7 million in 2016 revenue as compared to 2015 includes approximately $21.1 million in volume from market share gains and market expansion as well as the addition of in excess of 1,600 new customers due to the increase of our direct sales force and new customers added as part of the acquisition of Stability Biologics. Overall pricing was $15.3 million favorable and was impacted by a continued shift from distributor to direct sales and product mix was $ 21.3 million favorable primarily due to the sale of new products including those from Stability Biologics.

We group our products into two categories: Wound Care and Surgical, Sports Medicine & Orthopedics (SSO) for purposes of the required disclosure under ASC 280-10-50-40. Sales for these product categories have been disclosed in Note 17. This grouping of products does not constitute a basis for resource allocation but is information intended to provide the reader with ability to better understand our product categories. These groupings also do not meet the criteria under ASC 280-10-50-1 as separate segment.

Gross Margin

2016 gross margins were 86.8% as compared to 89.2% in 2015. Gross margins decreased due to the impact of one-time inventory costs incurred in connection with the Stability acquisition as well as lower than expected margins in bone and skin products acquired as part of the Stability acquisition, somewhat offset by favorable customer mix and improved manufacturing efficiencies in wound care and other SSO products.

Research and Development Expenses

Our research and development expenses increased approximately $3.6 million, or 42.9%, to $12 million in 2016, compared to approximately $8.4 million in the prior year. The increase is primarily related to increased investments in clinical trials, personnel costs, lab supplies, and consulting fees. We expect research and development expenses to remain in line with current spending on a percentage of sales basis moving forward.

Selling, General and Administrative Expenses

Selling, General and Administrative expenses for 2016 increased approximately $46.6 million, or 34.9%, to $180.0

million compared to $133.4 million for 2015. Selling expense increases were driven primarily by costs associated with the continued build of our direct sales organization for both the Wound Care and SSO markets, where headcount grew by 71 during the year, as well as increased commissions due to higher sales volume. General and administrative expense increases were driven primarily by costs associated with adding personnel to support continued growth including government affairs and other support areas as well as the addition of Stability Biologics personnel and associated costs. Selling, General and Administrative expenses consist of personnel costs, professional fees, sales commissions, sales training costs, industry trade show fees and expenses, product promotions and product literature costs, facilities costs and other sales, marketing and administrative costs, depreciation and amortization, and share-based compensation. Share-based compensation included in Selling, General and

Administrative for the years ended December 31, 2016 and 2015, was approximately $16.7 million and $15.8 million, respectively, an increase of approximately $0.9 million, or 5.7%. Amortization expense related to intangible assets increased approximately $1.2 million, or 133.3%, to $2.1 million for the year ended December 31, 2016, compared to $0.9 million in the prior year due to the acquisition of Stability. We amortize our intangible assets over a period of 4 to 19 years, which we believe represents the remaining useful lives of the patents underlying the licensing rights and intellectual property. We do not amortize goodwill but we test our goodwill at least annually for impairment and periodically evaluate other intangibles for impairment based on events or changes in circumstances as they occur.

Net Interest Expense

We recorded financing and net interest expense of approximately $339,000 during the year ended December 31, 2016, compared with approximately $86,000 of financing and net interest expense during the year ended December 31, 2015. The increase is due to the amortization of deferred financing costs incurred during 2016 related to our $50 million revolving credit facility and commitment and undrawn fees connected to our line of credit. See Note 9 in the consolidated financial statements in Item 8 for further details.

Results of Operations for the year ended December 31, 2015, compared to the year ended December 31, 2014

Revenue

The increase of $69.1 million in 2015 revenue as compared to 2014 includes approximately $81.2 million in volume from both existing customers as well as the addition of over 1,500 new customers due to the increase of our direct sales force, increased use of distributors, taking market share from other suppliers of wound care technologies, as well as market expansion due to the clinical and cost benefits of our EpiFix platform. Growth was also driven by expansion into several new surgical applications with our new AmnioFix platform. Overall pricing was ($17.4) million unfavorable driven by a change in reimbursement for Medicare patients treated in a hospital outpatient setting to a bundled payment system as well as increased sales to distributors. Product mix was favorable by $5.3M primarily due to the sale of new products. Wound Care revenue in 2015 grew by $47.5million, or approximately 51% as compared with 2014. SSO revenue in 2015 grew by $21.6 million, or approximately 88% compared with 2014.

Gross Margin

Gross Margin in 2015 was 89.2% versus 89.3% when compared to the prior year. The slight decrease is due to the expiration of pass through status of our wound care products for Medicare patients in hospital out-patient clinics and ambulatory surgery centers, product and customer sales mix , mostly offset by an increase in direct sales revenue and higher production rates that absorb a greater percentage of fixed manufacturing costs, and continued improvements in manufacturing efficiencies. SSO sales have lower gross margins than Wound Care sales, so we expect cost of sales as a percentage of revenue to increase as SSO sales become a larger percentage of total company sales.

Research and Development Expenses

Our research and development expenses increased approximately $1.4 million, or 19%, to $8.4 million in 2015, compared to approximately $7.0 million in the prior year. The increase is primarily related to increased investments in clinical trials, personnel costs, lab supplies, and consulting fees.

Selling, General and Administrative Expenses

Selling, General and Administrative expenses for 2015 increased approximately $42.9 million, or 47%, to $133.4 million compared to $90.5 million for 2014. Selling expense increases were driven primarily by costs associated with building our direct sales organization for both the Wound Care and SSO markets, where headcount grew by 65 during the year, as well as increased commissions due to higher sales volume. General and administrative expense increases were driven primarily by costs associated with adding personnel to support continued growth, as well as increased patent litigation costs.

Selling, General and Administrative expenses consist of personnel costs, professional fees, sales commissions, sales training costs, industry trade show fees and expenses, product promotions and product literature costs, facilities costs and other sales, marketing and administrative costs, depreciation and amortization, and share-based compensation. Share-based compensation included in Selling, General and Administrative for the years ended December 31, 2015 and 2014, was approximately $15.8 million and $10.5 million, respectively, an increase of approximately $5.3 million, or 50%.

Amortization expense related to intangible assets remained flat at $0.9 million for the year ended December 31, 2015 as compared to the prior year.

Net Interest Expense

We recorded financing and net interest expense of approximately $86,000 during the year ended December 31, 2015, compared with approximately $48,000 of financing and net interest expense during the year ended December 31, 2014. The increase is due to the amortization of deferred financing costs incurred during 2015 related to our $50 million revolving credit facility. See Note 9 in the consolidated financial statements in Item 8 for further details.

Contractual Obligations

Contractual obligations associated with ongoing business activities are expected to result in cash payments in future periods. The table below summarizes the amounts and estimated timing of these future cash payments as of December 31, 2016 (in thousands):



			Less than
Contractual Obligations	TOTAL		1 year		1-3 years		3-5 years		Thereafter
Capital lease obligations	$	31	$	29	$	2	$	—
Operating lease obligations	6,988		2,089		3,894		631		374
Software License	284		95		189		—
Meeting space commitments	1,662		643		1,019		—
	$	8,965	$	2,856	$	5,104	$	631	$	374

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.

Liquidity and Capital Resources

Our net working capital at December 31, 2016, increased $6.3 million to $75.8 million from $69.5 million at December 31, 2015. The increase in working capital was primarily due to our revenue growth resulting in an increase in accounts receivable, mostly offset by cash used for share repurchases. The current ratio (current assets divided by current liabilities) decreased to 2.5 as of December 31, 2016, as compared to 3.6 at December 31, 2015.

On October 12, 2015, the Company and its subsidiaries entered into a Credit Agreement (the "Credit Agreement") with certain lenders and Bank of America, N.A., as administrative agent. The Credit Agreement establishes a senior secured revolving credit facility in favor of the Company, with an aggregate lender commitment of up to $50 million at any time outstanding. As of the date hereof, there are no outstanding revolving loans under the Credit Agreement. The Credit Agreement also provides for an uncommitted incremental facility of up to $35 million, which can be exercised as one or more revolving commitment increases or new term loans, all subject to certain customary terms and conditions set forth in the Credit Agreement. The obligations of the Company under the Credit Agreement are guaranteed by the Company's subsidiaries. Borrowings under the Credit Agreement bear interest at a rate equal to, at the Company’s option, the base rate or LIBOR, in each case plus an applicable margin. The base rate under the Credit Agreement equals the highest of (i) the agent’s prime rate, (ii) the Federal Funds rate plus 0.50%, or (iii) LIBOR for a one month interest period plus 1.0%. The initial applicable margin is 0.50% with respect to base rate borrowings and 1.50% with respect to the LIBOR borrowings. The applicable margin is subject to quarterly pricing adjustments based on the Company’s consolidated leverage ratio. In addition to paying interest on outstanding principal under the facility, the Company is required to pay a commitment fee in respect of committed but unutilized commitments equal to 0.25% per annum initially. The commitment fee is subject to quarterly adjustments based on the Company's consolidated leverage ratio. The Company must pay a fee on outstanding letters of credit under the facility at a rate equal to the applicable margin in respect of LIBOR borrowings plus certain fronting and administrative fees. The maturity date of the revolving credit facility is October 12, 2018. The Credit Agreement provides that the maturity date may be extended up to twice for one additional year each, subject to certain customary terms and conditions set forth in the Credit Agreement, if requested by the Company and agreed-upon by the lenders. The Credit Agreement contains customary covenants and events of default for senior secured credit agreements of this type. The covenants include (a) a requirement for the Company to maintain a maximum consolidated leverage ratio of 2.50:1.00; (b) a requirement for the Company to maintain a minimum consolidated fixed charge coverage ratio of 2.00:1.00; and (c) a requirement for the Company to maintain minimum liquidity of $10 million.

December 31, 2016, there were no outstanding revolving loans under the facility and the Company was in compliance with all of its covenants.

For the twelve months ended December 31, 2016, in connection with the acquisition of Stability, the Company paid approximately $6 million in cash for the initial purchase price, paid off debt of approximately $1.8 million.

For the twelve months ended December 31, 2016, the Company repurchased 1,338,616 shares of its common stock for a purchase price of approximately $10,338,000, before brokerage commissions of approximately $40,000 bringing the total amount spent under the program to approximately $56,064,000 since inception. As of December 31, 2016, the Company had approximately $9,936,000 of availability remaining under the repurchase program. The timing and amount of future repurchases, if any, will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.

In addition, during the twelve months ended December 31, 2016, the Company repurchased 141,658 shares surrendered by employees to satisfy tax withholding obligations upon vesting of restricted stock.

As of December 31, 2016, we had approximately $34.4 million of cash and cash equivalents. We believe that our anticipated cash from operating activities, existing cash and cash equivalents and availability under the Credit Agreement will enable us to meet our operational liquidity needs and fund our planned investing activities for the next year.

Discussion of cash flows

Net cash from operations during the year ended December 31, 2016, increased approximately $7.0 million to $25.8 million, compared to $18.8 million from operating activities for the year ended December 31, 2015, and was primarily attributable to a smaller increase in accounts receivable as compared to the prior year's increase.

Net cash used for investing activities during the year ended December 31, 2016, increased approximately $11.0 million to $11.7 million compared to $0.7 million used in investing activities for the year ended December 31, 2015. The increase was primarily due to the acquisition of Stability.

Net cash flows used for financing activities during the year ended December 31, 2016, was approximately $8.2 million compared to $36.2 million during the year ended December 31, 2015. The decrease is primarily due to a decrease in share repurchases.

Non-GAAP Financial Measures

In addition to our GAAP results, we provide certain Non-GAAP metrics including Adjusted EBITDA, Adjusted Gross Margin, Adjusted Net Income and Adjusted Diluted Net Income per share. We believe that the presentation of these measures provides important supplemental information to management and investors regarding our performance. These measurements are not a substitute for GAAP measurements, although Company management uses these measurements as aids in monitoring the Company's on-going financial performance from quarter-to-quarter and year-to-year on a regular basis and for benchmarking against other medical technology companies. Adjusted EBITDA consists of GAAP Net Income excluding: (i) depreciation and amortization, (ii) interest income and expense, (iii) income taxes, (iv) one time acquisition related costs, (v) the effect of purchase accounting due to acquisitions and (vi) share-based compensation expense. Due to the impact of the acquisition of Stability in January 2016 and the release of the valuation allowance on the deferred tax asset on reported tax expense in 2015 on results, we have decided to provide additional adjusted non-GAAP measures to provide comparability of normal ongoing operating results. Beginning in 2016, we have reported Adjusted Gross Margin, Adjusted Net Income and Adjusted Diluted Net Income per Share to normalize results for comparison purposes. Adjusted Gross Margin consists of GAAP gross margin excluding amortization of inventory fair value step-up. Adjusted Net Income and Adjusted Diluted Net Income per share consists of GAAP net income excluding: (i) one time acquisition related costs, (ii) amortization of inventory fair value step-up, (iii) amortization of intangible assets and (iv) share-based compensation. Reconciliations of GAAP net income to Adjusted EBITDA, GAAP Gross Margin to Adjusted Gross Margin and GAAP Net Income to Adjusted Net Income and Adjusted Diluted Net Income per share for the years ended December 31, 2016, 2015 and 2014 appear in the tables below (in thousands):



	Years Ended December 31
	2016		2015			2014
Net Income (Per GAAP)	$	11,974	$	29,446		$	6,220

Add back (deduct):
Income taxes	6,133		(5,168		)	832
One time costs incurred in connection with acquisition	1,088		—			—
One time inventory costs incurred in connection with acquisition	1,593		—			—
Other interest expense, net	339		86			48
Depreciation expense	3,333		1,799			1,197
Amortization of intangible assets	2,127		933			928
Share-based compensation	17,818		16,896			11,453
Adjusted EBITDA	$	44,405	$	43,992		$	20,678

Reconciliation of "Adjusted Gross Margin" defined as Gross Margin before Amortization of inventory fair value step-up (in thousands):



	Years Ended December 31,
	2016			2015			2014
Gross Margin (Per GAAP)	$	212,608		$	167,094		$	105,558

Non-GAAP Adjustments:
One time inventory costs incurred in connection with acquisition	1,593			—			—
Gross Margin before Amortization of inventory fair value step-up	$	214,201		$	167,094		$	105,558
Adjusted Gross Margin	87.4		%	89.2		%	89.3		%

Reconciliation of "Adjusted Net Income" and "Adjusted Diluted Net Income" per share defined as Net Income less Amortization, One Time Costs and Share-Based Compensation (in thousands, except share and per share data):



	Years Ended December 31,
	2016			2015			2014
Net Income (Per GAAP)	$	11,974		$	29,446		$	6,220

Non-GAAP Adjustments:
Tax rate normalization*	(898		)	(15,374		)	(4,069		)
One time costs incurred in connection with acquisition	1,088			—			—
One time inventory costs incurred in connection with acquisition	1,593			—			—
Amortization of intangible assets	2,127			933			928
Share - based compensation	17,818			16,896			11,453
Estimated income tax impact from adjustments	(9,335		)	(7,495		)	(8,605		)
Adjusted Net Income	$	24,367		$	24,406		$	5,927
Adjusted diluted net income per share	$	0.22		$	0.21		$	0.05
Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities	112,441,709			113,628,482			113,295,504

*Assumes a normalized tax rate of 40% for 2016, 42% for 2015 and 70% for 2014.

Inflation

We do not believe that the rate of inflation has had a material effect on our operating results. However, inflation could adversely affect our future operating results.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

Based on our lack of market risk sensitive instruments outstanding at December 31, 2016, we have determined that there was no material market risk exposure to our consolidated financial position, results of operations or cash flows as of such date.

Item 8. Financial Statements and Supplementary Data



Index to Financial Statements

Reports of Independent Registered Public Accounting Firm	48
Consolidated Balance Sheets – As of December 31, 2016 and December 31, 2015	50
Consolidated Statements of Operations – For the years ended December 31, 2016, 2015 and 2014	51
Consolidated Statements of Stockholders’ Equity – For the years ended December 31, 2016, 2015 and 2014	52
Consolidated Statements of Cash Flows – For the years ended December 31, 2016, 2015 and 2014	53
Notes to Consolidated Financial Statements	54
Schedule II - Valuation and Qualifying Accounts	79

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and

Stockholders of MiMedx Group, Inc.

We have audited the accompanying consolidated balance sheets of MiMedx Group, Inc. and subsidiaries (the Company) as of December 31, 2016 and 2015, and the related consolidated statements of operations, stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2016. We have also audited the accompanying consolidated financial statement schedule for each of the three years in the period ended December 31, 2016 listed in the index at Item 15. These consolidated financial statements and schedule are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements and schedule based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of MiMedx Group, Inc. and subsidiaries as of December 31, 2016 and 2015, and the consolidated results of its operations and its cash flows for each of the three years in the period ended December 31, 2016, in conformity with accounting principles generally accepted in the United States of America. Also, in our opinion, the related consolidated financial statement schedule for each of the three years in the period ended December 31, 2016, when considered in relation to the basic consolidated financial statements taken as a whole, presents fairly, in all material respects, the information set forth therein.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), MiMedx Group, Inc.’s internal control over financial reporting as of December 31, 2016, based on criteria established in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our report dated March 1, 2017 expressed an adverse opinion.



/s/ Cherry Bekaert LLP

Atlanta, Georgia

March 1, 2017

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and

Stockholders of MiMedx Group, Inc.

We have audited MiMedx Group, Inc.’s (the Company) internal control over financial reporting as of December 31, 2016, based on criteria established in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). MiMedx Group, Inc.’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

A material weakness is a control deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. The following material weakness has been identified and included in management’s assessment. Management has identified a material weakness in the design of the Company’s controls over the tax accounting related to an overstatement of an excess tax benefit which if undetected would have resulted in an understatement of income taxes payable. Specifically, management did not have adequate supervision and review of certain technical tax accounting performed by a third party tax specialist in 2016. This material weakness was considered in determining the nature, timing, and extent of audit tests applied in our audit of the 2016 financial statements, and this report does not affect our report dated March 1, 2017, on those financial statements.

In our opinion, because of the effect of the material weakness described above on the achievement of the objectives of the control criteria, MiMedx Group, Inc. has not maintained effective internal control over financial reporting as of December 31, 2016, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets and the related consolidated statements of operations, stockholders’ equity, and cash flows of MiMedx Group, Inc., and our report dated March 1, 2017, expressed an unqualified opinion.



/s/ Cherry Bekaert LLP

Atlanta, Georgia

March 1, 2017

MIMEDX GROUP, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (in thousands, except share data)

	December 31,
	2016			2015
ASSETS
Current assets:
Cash and cash equivalents	$	34,391		$	28,486
Short term investments	—			3,000
Accounts receivable, net	67,151			53,755
Inventory, net	17,814			7,460
Prepaid expenses	5,894			3,394
Other current assets	1,288			215
Total current assets	126,538			96,310
Property and equipment, net of accumulated depreciation	13,786			9,475
Goodwill	20,203			4,040
Intangible assets, net of accumulated amortization	23,268			10,763
Deferred tax asset, net	9,114			14,838
Deferred financing costs and other assets	354			487
Total assets	$	193,263		$	135,913
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	11,436		$	6,633
Accrued compensation	12,365			15,034
Accrued expenses	10,941			4,644
Current portion of earn out liability	8,740			—
Income taxes	5,768			(67		)
Other current liabilities	1,482			533
Total current liabilities	50,732			26,777
Earn out liability	8,710			—
Other liabilities	821			1,148
Total liabilities	60,263			27,925
Commitments and contingencies (Note 16)
Stockholders' equity:
Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding	—			—
Common stock; $0.001 par value; 150,000,000 shares authorized; 110,212,547 issued and 109,862,787 outstanding at December 31, 2016 and 109,467,416 issued and 107,361,471 outstanding at December 31, 2015	110			109
Additional paid-in capital	161,261			163,133
Treasury stock at cost: 349,760 shares at December 31, 2016 and 2,105,945 shares at December 31, 2015	(2,216		)	(17,125		)
Accumulated deficit	(26,155		)	(38,129		)
Total stockholders' equity	133,000			107,988
Total liabilities and stockholders' equity	$	193,263		$	135,913

See notes to consolidated financial statements

MIMEDX GROUP, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data)

	Years Ended December 31,
	2016			2015			2014

Net sales	$	245,015		$	187,296		$	118,223
Cost of sales	32,407			20,202			12,665
Gross margin	212,608			167,094			105,558

Operating expenses:
Research and development expenses	12,038			8,413			7,050
Selling, general and administrative expenses	179,997			133,384			90,480
Amortization of intangible assets	2,127			933			928
Operating income	18,446			24,364			7,100

Other expense, net
Interest expense, net	(339		)	(86		)	(48		)

Income before income tax provision	18,107			24,278			7,052
Income tax provision (expense) benefit	(6,133		)	5,168			(832		)

Net income	$	11,974		$	29,446		$	6,220

Net income per common share - basic	$	0.11		$	0.28		$	0.06

Net income per common share - diluted	$	0.11		$	0.26		$	0.05

Weighted average shares outstanding - basic	105,928,348			105,929,205			105,793,008

Weighted average shares outstanding - diluted	112,441,709			113,628,482			113,295,504

See notes to consolidated financial statements

MIMEDX GROUP, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (in thousands, except share data)

	Common Stock				Additional Paid-in			Treasury Stock					Accumulated
	Shares		Amount		Capital			Shares		Amount			Deficit			Total
Balances, December 31, 2013	104,425,614		$	104	$	147,284		50,000		$	(25	)	$	(73,795	)	$	73,568

Share-based compensation expense	—		—		11,453			—		—			—			11,453
Exercise of stock options	1,653,690		2		2,468			—		—			—			2,470
Exercise of warrants	1,242,416		1		1,112			—		—			—			1,113
Issuance of restricted stock	1,438,569		1		(1		)	—		—			—			—
Shares issued for services performed	15,958		—		117			—		—			—			117
Stock repurchase	—		—		—			936,636		(5,612		)	—			(5,612		)
Net income	—		—		—			—		—			6,220			6,220
Balances, December 31, 2014	108,776,247		$	108	$	162,433		986,636		$	(5,637	)	$	(67,575	)	$	89,329

Share-based compensation expense	—		—		16,896			—		—			—			16,896
Tax benefit of share-based compensation expense	—		—		7,757			—		—			—			7,757
Exercise of stock options	647,656		1		(9,792		)	(1,573,225	)	14,420			—			4,629
Exercise of warrants	—		—		(379		)	(42,400	)	425			—			46
Issuance of restricted stock	34,250		—		(14,547		)	(1,940,009	)	14,547			—			—
Shares Canceled / Forfeited	(2,058	)	—		652			69,949		(652		)	—			—
Shares issued for services performed	11,321		—		113			(5,172	)	51			—			164
Stock repurchase	—		—		—			4,610,166		(40,279		)	—			(40,279		)
Net Income	—		—		—			—		—			29,446			29,446
Balances, December 31, 2015	109,467,416		$	109	$	163,133		2,105,945		$	(17,125	)	$	(38,129	)	$	107,988

Share-based compensation expense					17,818											17,818
Tax benefit of share-based compensation expense					(424		)									(424		)
Exercise of stock options	243,928		—		(3,767		)	(918,544	)	7,261						3,494
Issuance of restricted stock	501,203		1		(17,546		)	(2,210,879	)	17,546						1
Restricted stock shares canceled/forfeited					2,503			377,317		(2,503		)				—
Shares issued for services performed					6			(43,344	)	340						346
Stock repurchase								1,338,616		(10,378		)				(10,378		)
Shares repurchased for tax withholding								141,658		(1,165		)				(1,165		)
Shares issued in conjunction with acquisition					(462		)	(441,009	)	3,808						3,346
Net income													11,974			11,974
Balances, December 31, 2016	110,212,547		$	110	$	161,261		349,760		$	(2,216	)	$	(26,155	)	$	133,000

See notes to consolidated financial statements

MIMEDX GROUP, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands)

	Years Ended December 31,
	2016			2015			2014
Cash flows from operating activities:
Net income	$	11,974		$	29,446		$	6,220
Adjustments to reconcile net income to net cash from operating activities:
Depreciation	3,333			1,799			1,197
Amortization of intangible assets	2,127			933			928
Amortization of inventory fair value step-up	1,485			—			—
Amortization of deferred financing costs	181			42			—
Share-based compensation	17,818			16,896			11,453
Change in deferred income taxes	(594		)	(7,081		)	—
Increase (decrease) in cash, net of effects of acquisition, resulting from changes in:
Accounts receivable	(11,396		)	(27,083		)	(10,579		)
Inventory	(2,837		)	(2,327		)	(1,252		)
Prepaid expenses	(2,400		)	(1,854		)	(203		)
Other current assets	(384		)	(240		)	—
Accounts payable	(3,665		)	3,136			1,287
Accrued compensation	(2,669		)	3,511			5,935
Accrued expenses	6,297			2,140			1,098
Income taxes	5,835			(519		)	452
Other liabilities	723			8			266
Net cash flows from operating activities	25,828			18,807			16,802

Cash flows from investing activities:
Purchases of equipment	(6,269		)	(5,827		)	(2,558		)
Purchase of Stability Inc., net of cash acquired	(7,631		)	—			—
Fixed maturity securities redemption	3,000			6,000			(9,000		)
Patent application costs	(842		)	(851		)	(594		)
Net cash flows from investing activities	(11,742		)	(678		)	(12,152		)

Cash flows from financing activities:
Proceeds from exercise of stock options	3,494			4,629			2,470
Proceeds from exercise of warrants	—			46			1,113
Stock repurchase under repurchase plan	(10,378		)	(40,279		)	(5,612		)
Stock repurchase for tax withholdings on vesting of restricted stock	(1,165		)	—			—
Deferred financing costs	(30		)	(504		)	—
Payments under capital lease obligations	(102		)	(117		)	(117		)
Net cash flows from financing activities	(8,181		)	(36,225		)	(2,146		)

Net change in cash	5,905			(18,096		)	2,504

Cash and cash equivalents, beginning of period	28,486			46,582			44,078
Cash and cash equivalents, end of period	$	34,391		$	28,486		$	46,582

See notes to consolidated financial statements

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE FISCAL YEARS ENDED DECEMBER 31, 2016 AND 2015


1.	Nature of Business

The Company operates in one business segment, Regenerative Biomaterials, which includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. The MiMedx allograft product families include our: dHACM family with AmnioFix® ans EpiFix® brands; Amniotic Fluid family with OrthoFlo brand; Umbilical family with EpiCord® and AmnioCord® brands; Placental Collagen family with CollaFix™ and AmnioFill™ brands; and Bone family with Physio® brand. AmnioFix and EpiFix are our tissue technologies processed from human amniotic membrane; OrthoFlo is an amniotic fluid derived allograft; EpiCord and AmnioCord are derived from the umbilical cord; Physio is a bone grafting material comprised of 100% bone tissue with no added carrier; and CollaFix, our next brand we plan to commercialize, is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.

The Company is focused primarily on the United States but is actively exploring international expansion opportunities. The adoption of the technologies may vary depending on each country’s regulations, but the opportunities to help individuals in the different disease states remain similar and large.


2.	Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported consolidated statements of operations during the reporting period. Actual results could differ from those estimates.

Principles of Consolidation

The accompanying financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries MiMedx, Inc., MiMedx Processing Services, LLC (formerly known as SpineMedica, LLC), MiMedx Tissue Services, LLC (formerly known as Surgical Biologics, LLC) and Stability Biologics, LLC (formerly known as Stability Inc.). All significant inter-company balances and transactions have been eliminated.

Segment Reporting

ASC 280, “Segment Reporting” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company has determined it has one operating segment. Disaggregation of the Company’s operating results is impracticable, because the Company’s research and development activities and its assets overlap, and management reviews its business as a single operating segment. Thus, discrete financial information is not available for more than one operating segment.

Market Concentrations and Credit Risk

The Company places its cash and cash equivalents on deposit with financial institutions in the United States. In July 2010, the Federal Deposit Insurance Corporation (“FDIC”) increased coverage to $250,000 for substantially all depository accounts. As of December 31, 2016 and 2015, the Company had cash and cash equivalents of approximately $33,200,000 and $27,700,000, respectively, in excess of the insured amounts.

Cash and Cash Equivalents

Cash and cash equivalents include cash and FDIC insured certificates of deposit held at various banks with an original maturity of three months or less.

Accounts Receivable

Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.

The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in the Company's existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay.

Inventories

Inventories are valued at the lower of cost or market, using the first–in, first-out (FIFO) method. Inventory is tracked through Raw Material, WIP, and Finished Good stages as the product progresses through various production steps and stocking locations. Labor and overhead costs are absorbed through the various production processes up to when the work order closes. Historical yields and normal capacities are utilized in the calculation of production overhead rates. Reserves for inventory obsolescence are utilized to account for slow-moving inventory as well as inventory no longer needed due to diminished market demand.

Goodwill and Purchased Intangible Assets

Goodwill and purchased intangible assets with indefinite useful lives are not amortized but are tested for impairment at least annually. The Company reviews goodwill and purchased intangible assets with indefinite lives for impairment annually at the beginning of its fourth fiscal quarter and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Potential impairment indicators include a significant change in the business climate, legal factors, operating performance indicators, competition, and the sale of disposition of a significant portion of the business. The Company first assesses certain qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the Company was less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the Company is less than its carrying amount, then the Company would perform a two-step quantitative impairment testing. In the first step, the Company compares the fair value of the Company to its carrying value. The Company determines the fair value utilizing the market approach. Under the market approach, the Company uses its market capitalization which is calculated by taking the Company’s share price times the number of outstanding shares. If the fair value of the Company exceeds the carrying value of the net assets, goodwill is not impaired, and no further testing is required. If the fair value of the Company is less than the carrying value, the Company must perform the second step of the impairment test to measure the amount of impairment loss, if any. In the second step, the Company’s value is allocated to all of the assets and liabilities, including any unrecognized intangible assets, in a hypothetical analysis that calculates the implied fair value of goodwill in the same manner as if the Company was being acquired in a business combination. If the implied fair value of the reporting unit's goodwill is less than the carrying value, the difference is recorded as an impairment loss. The Company has determined that there are no goodwill and indefinite useful lives intangible impairments in 2016 and 2015.

Impairment of Intangible Assets with Finite Lives

The Company reviews purchased intangible assets with finite lives for impairment whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable using a two-step impairment test. In step one, we determine the sum of the undiscounted future cash flows of the assets based on management's estimates and compare it to the carrying value of the assets. If the carrying amount is greater than the sum of the undiscounted cash flows, then the asset is impaired and step two is required. In step two, the impairment loss is calculated as the difference between the fair value of the assets and the carrying value of the assets.

Impairment reviews are based on an estimated future cash flow approach that requires significant judgment with respect to future revenue and expense growth rates, selection of appropriate discount rate, asset groupings, and other assumptions and estimates. The Company uses estimates that are consistent with our business plans and a market participant view of the assets being evaluated. Actual results may differ from our estimates. The Company has determined that there are no intangible assets with finite lives impairments in 2016 and 2015.

Property and Equipment

Property and equipment are recorded at cost and depreciated on a straight-line basis over their estimated useful lives, principally three to seven years. Leasehold improvements are depreciated on a straight-line basis over the lesser of the estimated useful lives or the life of the lease. The Company is party to various lease arrangements for its facility space and equipment. These arrangements include interest, scheduled rent increases and rent holidays which are included in the determination of minimum lease payments when assessing lease classification, and are included in rent expense on a straight line basis over the lease term. See Notes 7 and 16 for further information regarding capital leases, operating leases and rent expense.

Patent Costs

The Company incurs certain legal and related costs in connection with patent applications for tissue based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company. The Company capitalized approximately $842,000 of patent costs during 2016, $851,000 of patent costs during 2015 and $594,000 of patent costs during 2014.

Impairment of Long-lived Assets

The Company evaluates the recoverability of its long-lived assets (property and equipment) whenever adverse events or changes in business climate indicate that the expected undiscounted future cash flows from the related assets may be less than previously anticipated. If the net book value of the related assets exceeds the expected undiscounted future cash flows of the assets, the carrying amount would be reduced to the present value of their expected future cash flows and an impairment loss would be recognized.

Revenue Recognition

The Company sells its products through a combination of a direct sales force, independent stocking distributors and third - party representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. The Company records revenues from sales to our independent stocking distributors at the time the product is shipped to the distributor. Our stocking distributors, who sell the products to their customers or sub-distributors, contractually take title to the products and assume all risks of ownership at the time of shipment. Our stocking distributors are obligated to pay us the contractually agreed upon invoice price within specified terms regardless of when, if ever, they sell the products. Our stocking distributors do not have any contractual rights of return or exchange other than for defective product or shipping error; however, in limited situations, we do accept returns or exchanges at our discretion.

Research and Development Costs

Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies. These costs are expensed as incurred.

Income Taxes

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

The Company recognizes deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.

The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

Share-based Compensation

The Company accounts for its share- based compensation plans in accordance with FASB ASC topic 718 “Compensation- Stock compensation”. FASB ASC 718 requires the measurement and recognition of compensation expense for all share-based awards made to employees and directors, including employee stock options, restricted stock and warrants. Under the provisions of FASB ASC 718, and U. S. Securities and Exchange Commission Staff Accounting Bulleting No. 107, share-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense on a straight line basis over the requisite service period of the entire award (generally the vesting period of the award).

Fair Value of Financial Instruments

The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature and type of these instruments. These financial instruments include cash and cash equivalents, accounts receivable, short term investments, accounts payable and accrued expenses. The carrying cost of the Company’s investments also reflects their fair values due to the type of these investments and the fair value of capital leases approximates their carrying value based upon current rates available to the Company.

Fair Value Measurements

The Company records certain financial instruments at fair value, including: cash equivalents, short term investments and investments. The Company may make an irrevocable election to measure other financial instruments at fair value on an instrument-by-instrument basis; although as of December 31, 2016, the Company has not chosen to make any such elections. Fair value financial instruments are recorded in accordance with the fair value measurement framework.

The Company also measures certain non-financial assets at fair value on a non-recurring basis. These non-recurring valuations include evaluating assets such as long-lived assets, and non-amortizing intangible assets for impairment; allocating value to assets in an acquired asset group, and accounting for business combinations. The Company uses the fair value measurement framework to value these assets and reports these fair values in the periods in which they are recorded or written down.


•	Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities;


•	Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data.


•	Level 3: Unobservable inputs or valuation techniques that are used when little or no market data is available.

The determination of fair value and the assessment of a measurement’s placement within the hierarchy require judgment. Level 3 valuations often involve a higher degree of judgment and complexity. Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions. Management’s assumptions could vary depending on the asset or liability valued and the valuation method used. Such assumptions could include: estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods. The Company may also engage external advisors to assist it in determining fair value, as appropriate.

In connection with the acquisition of Stablity, the Company recorded a liability related to the Earn-Out portion of the purchase consideration. See Note 4, Acquisition, for further discussion of the Earn-Out liability. The Company has classified the Earn-Out liability as a Level 3 liability and the fair value of the Earn-Out liability will be evaluated each reporting period and changes in its fair value will be included in the Company’s results of operations. The fair value of the Earn-Out liability was calculated using a discount rate, approximating the pre-tax cost of debt and corroborated by Monte Carlo simulation, which was then applied to estimated earn out payments. To determine the fair value of the Earn-Out liability, management evaluates assumptions that require significant judgment. Changes in certain inputs to the valuation model, including the Company’s estimate of future revenues, can have a significant impact on the estimated fair value. The fair value recorded for the Earn-Out liability may vary significantly from period to period. This variability may result in the actual liability for a period either above or below the estimates recorded in the Company’s Consolidated Financial Statements, resulting in significant fluctuations in results of operations as a result of the corresponding non-cash gain or loss recorded.

Although the Company believes that the recorded fair value of its financial instruments is appropriate, these fair values may not be indicative of net realizable value or reflective of future fair values.

Recently Issued Accounting Pronouncements

The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs"). In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company is currently assessing the impact the adoption of ASU 2014-09 will have on its consolidated financial statements.

In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments, that eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. ASU 2015-16 is effective for public companies for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The Company has adopted this standard in the first quarter of 2016 and its application is shown in Note 4.

In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company has adopted this standard, prospectively, at the beginning of the fourth quarter 2015 to simplify reporting with the release of the valuation allowance as disclosed in Note 12. Prior periods were not retrospectively adjusted.

In February 2016, the FASB issued Accounting Standards Update ASU No. 2016-02, Leases (Topic 842). The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.

In March 2016, the FASB issued ASU No. 2016-09, "Compensation - Stock Compensation (Topic 718)". The standard is

intended to simplify several areas of accounting for share - based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. This ASU is effective for fiscal years beginning after December 15, 2016. The Company is currently assessing the impact the adoption of ASU 2016-09 will have on its consolidated financial

statements. As of December 31, 2016, the Company does not have any remaining deferred tax assets that will result in an increase to equity upon realization. See Note 12.

In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments”. The update addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for public business entities for fiscal years beginning after December 15, 2017 and for interim periods within those fiscal years. The amendments in this update may be applied retrospectively or prospectively and early adoption is permitted. The Company is currently assessing the impact of the adoption of ASU 2016-15 will have on its consolidated financial statements.

All other ASUs issued and not yet effective for the year ended December 31, 2016, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.


3.	Liquidity and Capital Resources

Net Working Capital

As of December 31, 2016, the Company had approximately $34,391,000 of cash and cash equivalents. The Company reported total current assets of approximately $126,538,000 and current liabilities of approximately $50,732,000 and had net working capital of approximately $75,806,000 as of December 31, 2016.

Overall Liquidity and Capital Resources

The Company's largest cash requirement for the twelve months ended December 31, 2016 was cash for general working capital needs as well as the acquisition of Stability described in Note 4. In addition, the Company's other cash requirements included capital expenditures, and repurchases of the Company's common stock. The Company funded its cash requirements through its existing cash reserves, and its operating activities which generated approximately $25,828,000 during the period. The Company believes that its anticipated cash from operating and financing activities and existing cash and cash equivalents, as well as availability under the Credit Agreement will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next year.

4. Acquisition of Stability Inc.

On January 13, 2016, the Company completed the acquisition of Stability Inc., d/b/a Stability Biologics ("Stability"), a provider of human tissue products to surgeons, facilities, and distributors serving the surgical, spine, and orthopedic sectors of the healthcare industry. As a result of this transaction, the Company acquired all of the outstanding shares of Stability in exchange for

$6,000,000 cash, $3,346,000 in stock, represented by 441,009 shares of our common stock, and assumed debt of $1,771,000. Additional one time costs incurred in connection with the transaction totaled $1,088,000 and are included within selling, general and administrative expenses on the consolidated statements of operations. Contingent consideration may be payable in a formula determined by sales less certain expenses for the years 2016 and 2017. The contingent consideration was valued at $17,450,000 as of December 31, 2016 and is shown in the schedule below as fair value of earn-out. The Company used a third party specialist to assist us with the valuation. The purchase price allocation figures should be attributed to the Company and not to the third party valuation firm. The contingent consideration was classified as a liability.

The Company has evaluated the contingent consideration for accounting purposes under GAAP and has determined that the contingent consideration is within the scope of ASC 480 "Distinguishing Liabilities from Equity" whereby a financial instrument, other than an outstanding share, that embodies a conditional obligation that the issuer may settle by issuing a variable number of its equity shares shall be classified as a liability if, at inception, the monetary value of the obligation is based solely or

predominantly on variations in something other than the fair value of the issuer’s equity shares.

The actual purchase price was based on cash paid, the fair value of our stock on the date of the acquisition, and direct costs

associated with the acquisition. The fair value of stock consideration was determined as set forth below:



Common Share Price at Closing on 1/13/2016		$	8.43
Multiplied by: Number of Common Shares Transferred to the Sellers		441,009
Indicated Value of Equity Consideration (on a Freely Tradable Interest Basis)		$	3,717,706
Less: Marketability Discount @ 10%	[a]	(371,771		)
Fair Value of Equity Consideration Transferred		$	3,345,935
[a] Shares transferred to the Sellers are restricted securities pursuant to Rule 144. As such, the Sellers are prevented from selling the shares for a period of six months. In addition, they are subject to contractual lockups which restrict sales for up to twelve months following the closing of the transaction.

The actual purchase price has been allocated as follows (in thousands):



Cash paid at closing	$	6,000
Working capital adjustment	(480		)
Common stock issued (441,009 shares)	3,346
Assumed debt	1,771
Fair value of earn-out	17,450
Total fair value of purchase price	$	28,087

Net assets acquired:
Debt-free working capital	$	2,456
Other long-term assets	199
Property, plant and equipment	1,375
Deferred tax liability	(5,896		)
Subtotal	(1,866		)
Intangible assets:
Customer relationships	5,330
Patents and know-how	6,790
Trade names and trademarks	450
Non compete agreements	830
Licenses and permits	390
Subtotal	13,790
Goodwill	16,163
Total Assets Purchased	$	28,087

Working capital and other assets were composed of the following (in thousands):
Working capital
Cash	$	140
Prepaid Expenses and other current assets	100
Accounts receivable	2,001
Federal and state taxes receivable	28
Inventory	9,002
Accounts payable and accrued expenses	(8,815		)
Debt-free working capital	$	2,456

Current portion of long term debt	$	(194	)
Long-term debt	(560		)
Line of Credit	(932		)
Shareholder loan	(85		)
Assumed debt	$	(1,771	)

Net working capital	$	685

The acquisition was accounted for as a purchase business combination as defined by FASB Topic 805 - "Business Combinations". The fair value of the contingent consideration is measured as a Level 3 instrument. The contingent consideration liability is recorded at fair value on the acquisition date. Increases or decreases in the fair value of contingent consideration can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measured is based on significant inputs that are not observable in the market, they are categorized as Level 3. The income valuation approach was applied in determining the fair value of the contingent consideration using a discounted cash

flow valuation technique with significant unobservable inputs comprised of projected sales and certain expenses. The values assigned to intangible assets are subject to amortization. The intangible assets were assigned the following lives for amortization purposes:



		Estimated useful life (in years)
Intangible asset:
Customer relationships		12
Patents and know-how		20
Trade name and Trademarks		Indefinite
Non compete agreements		4
Licenses and permits		2

Goodwill consists of the excess of the purchase price paid over the identifiable net assets and liabilities acquired at fair value. Goodwill is attributable to the assembled workforce of Stability and the synergies expected to arise following the acquisition. Goodwill is not expected to be deductible for tax purposes. Goodwill was determined using the residual method based on an independent appraisal of the assets and liabilities acquired in the transaction. Goodwill is tested for impairment on an annual basis as defined by FASB Topic 350 - "Intangibles - Goodwill and Other".

Goodwill reconciliation (in thousands):



Balance at 3/31/16	$	22,912
Goodwill Adjustments (a)	(6,749		)
Balance at 12/31/16	$	16,163
(a) Goodwill is the result of a residual calculation

The changes in the preliminary fair values of the acquired assets and liabilities were due to adjustments made to the prospective financial information ("PFI") to better reflect an expected case from a market participant's perspective. As the earn-out is limited to the gross profit margin for the first two years after the acquisition, the adjustment to the PFI had a decreasing impact on the estimated fair value of the earn-out at the acquisition date, which resulted in a lower total purchase consideration and a reduction of the estimated fair value of the identifiable intangible assets.

During the measurement period, management determined that the initial PFI should be adjusted to better reflect an expected case from a market participant's perspective. At the time of the acquisition, management believed that certain of the acquired company's products had reached certain marketability milestones. Management subsequently concluded that these milestones had indeed not yet been achieved. Also, at the time of the acquisition Management believed that certain manufacturing processes were at standards aligned with our overall company standards. Management subsequently concluded that the standards required improvements. These factors have resulted in a lower revenue trajectory in the periods that apply to the earn-out thus reducing the fair value of the earn-out.

The measurement period adjustments are as follows (in thousands):



	Provisional Per			Measurement Period
	3/31/2016 Form 10Q			Adjustments 2016			Final

Cash paid at closing	$	6,000		$	—		$	6,000
Working capital adjustment	(480		)	—			(480		)
Common stock issued	3,346			—			3,346
Assumed debt	1,771			—			1,771
Fair value of earn-out	25,620			(8,170		)	17,450
Total fair value of purchase price	$	36,257		$	(8,170	)	$	28,087

Net assets acquired:
Debt-free working capital	$	2,179		$	277		$	2,456
Other assets, net	199			—			199
Property, plant and equipment	1,375			—			1,375
Deferred tax liability	(8,268		)	2,372			(5,896		)
Subtotal	$	(4,515	)	$	2,649		$	(1,866	)
Intangible assets:
Customer relationships	$	6,090		$	(760	)	$	5,330
Patents and know-how	9,170			(2,380		)	6,790
Trade names and trademarks	830			(380		)	450
Non compete agreements	1,080			(250		)	830
Licenses and permits	690			(300		)	390
Subtotal	17,860			(4,070		)	13,790
Goodwill	22,912			(6,749		)	16,163
Total Assets Purchased	$	36,257		$	(8,170	)	$	28,087

Pursuant to the terms of the earn-out arrangement, the Company will pay, for each of the years ending December 31, 2016 and 2017, an amount equal to one times the gross profit margin from (a) the net sales of Stability products sold by Stability's or the Company's sales personnel and (b) the net sales of Company products sold by Stability's sales personnel; provided, however, if the amount of such net sales for either earn-out period is less than $12 million, the earn-out amount will decrease to 0.5 times the gross profit margin for such earn-out period. The full details of the earn-out arrangement are set forth in the acquisition agreement which is filed as Exhibit 2.1 to the Company's Form 8-K filed on January 13, 2016.

The following unaudited pro forma summary financial information presents the consolidated results of operations for the Company as if the acquisition had occurred on January 1, 2015. The pro forma results are shown for illustrative purposes only and do not purport to be indicative of the results that would have been reported if the acquisition had occurred on the date indicated or indicative of the results that may occur in the future.

Unaudited pro forma information for the twelve months ended December 31, 2016 and 2015 (in thousands) is as follows:



	Years Ended December 31,
	2016	2015
Revenue	$245,563	$204,481

Net income	$12,611	$24,960

Income per share, fully diluted	$0.11	$0.22

The 2016 supplemental pro forma earnings were adjusted to exclude $1,088,000 of acquisition-related legal, audit and other

costs, net of tax. The 2015 supplemental pro forma earnings were adjusted to include $1,176,000 of amortization costs (net of tax) related to recorded intangible assets with defined useful lives, and $1,485,000 of inventory step-up charges (net of tax) as a result of the acquisition for comparability to 2016. The number of shares outstanding used in calculating the income per share for 2015 was adjusted to include 441,009 shares issued as part of the purchase price and assumed to be issued on January 1, 2015.

As the Company is managed and operates in one segment, and since Stability was merged with the Company's existing operations, the Company has determined that disaggregation of the Company's operating results to provide the amount of revenue and earnings for Stability since the acquisition date is impracticable.


5.	Cash Equivalents and Short Term Investments

Short term investments consisted of approximately $3,000,000 of FDIC insured certificates of deposit held with various financial institutions as of December 31, 2015. The cost of these instruments approximated their fair market value at December 31, 2015. There were no short term investments as of December 31, 2016.


6.	Inventories

Inventories consisted of the following items as of December 31, 2016 and 2015 (in thousands):



	December 31,
	2016			2015
Raw materials	$	1,148		$	602
Work in process	6,677			3,850
Finished goods	10,817			3,405
Inventory, gross	18,642			7,857
Reserve for obsolescence	(828		)	(397		)
Inventory, net	$	17,814		$	7,460


7.	Property and Equipment

Property and equipment consist of the following as of December 31, 2016 and 2015 (in thousands):



	December 31,
	2016			2015
Leasehold improvements	$	3,274		$	2,684
Lab and clean room equipment	8,666			4,564
Furniture and equipment	7,051			4,577
Construction in Progress	3,300			2,629
Property and equipment, gross	22,291			14,454
Less accumulated depreciation	(8,505		)	(4,979		)
Property and equipment, net	$	13,786		$	9,475

Included in property and equipment is approximately $427,000 of capital leases. The corresponding liability of approximately $31,000 is included in other liabilities in the accompanying consolidated balance sheet. Also included is approximately $1,000,000 in leasehold improvements paid for by the landlord of our main operating facility with a corresponding liability included in long term liabilities, which is amortized over the term of the lease. As of December 31, 2016 and 2015, the liability was $188,000 and $361,000, respectively.

Depreciation expense for the years ended December 31, 2016, 2015, and 2014 was approximately $3,333,000, $1,799,000, and $1,197,000, respectively.


8.	Intangible Assets and Royalty Agreement

Intangible assets are summarized as follows (in thousands):



		December 31,
		2016			2015
	Weighted Average Amortization Lives	Cost			Cost
Licenses (a) (b) (c) (d)	7 years	$	1,399		$	1,009
Patents & Know How (b) (d)	19 years	14,839			8,001
Customer & Supplier Relationships (b) (d)	13 years	9,091			3,761
Tradenames & Trademarks (d)	indefinite	1,458			1,008
Non-Compete Agreements	4 years	830			—
In Process Research & Development (b)	various	25			25
Patents in Process (c)	various	2,618			1,823
Total		30,260			15,627
Less Accumulated amortization and impairment charges		(6,992		)	(4,864		)
Net		$	23,268		$	10,763

(a)

On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000. Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of December 31, 2016 the license had a remaining net book value of approximately $10,000.

(b)

On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Tradenames & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. For the twelve months ended December 31, 2016, approximately $48,000 of costs associated with patents granted during the period were capitalized and included in Patents & Know-How subject to amortization over the life of the patents.


(c)	Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.


(d)	On January 13, 2016, the Company acquired Stability. As a result, the Company recorded intangible assets for Patents & Know - How of $6,790,000, Customer Relationships of $5,330,000, Non - compete agreements of $830,000, Tradenames & Trademarks of $450,000 and Licenses of $390,000.

Amortization expense for the years ended December 31, 2016, 2015, and 2014, was approximately $2,127,000, $933,000, and $928,000, respectively.

Expected future amortization of intangible assets as of December 31, 2016, is as follows (in thousands):



	Estimated
	Amortization
Year ending December 31,	Expense
2017	$	2,034
2018	1,829
2019	1,829
2020	1,622
2021	1,622
Thereafter	12,874
	$	21,810


9.	Long-Term Debt

Credit Facility


10.	Net Income Per Share

Basic net income per common share is computed using the weighted-average number of common shares outstanding during the period. Diluted net income per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, warrants and restricted stock using the treasury stock method.

The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except per share data):



	Year Ended December 31,
	2016		2015		2014
Net income	$	11,974	$	29,446	$	6,220
Denominator for basic earnings per share - weighted average shares	105,928,348		105,929,205		105,793,008
Effect of dilutive securities: Stock options, warrants, and restricted stock (a)	6,513,361		7,699,277		7,502,496
Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities	112,441,709		113,628,482		113,295,504
Income per common share - basic	$	0.11	$	0.28	$	0.06
Income per common share - diluted	$	0.11	$	0.26	$	0.05

(a)Securities that are included in the computation of the denominator above, utilizing the treasury stock method for the years ended December 31, 2016, 2015 and 2014 are as follows:



Effect of dilutive securities:	2016	2015	2014
Stock Options	5,845,377	7,121,774	7,035,728
Warrants	—	33,676	226,926
Restricted Stock Awards	667,984	543,827	239,842
	6,513,361	7,699,277	7,502,496


11.	Equity

Stock Incentive Plans

The Company has four share-based compensation plans which provide for the granting of equity awards, including qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors: the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan (the "2016 Plan"), which was approved by shareholders on May 18, 2016; the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the “Assumed 2006 Plan”); the MiMedx Inc. 2007 Assumed Stock Plan (the “Assumed 2007 Plan”); and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the “Assumed 2005 Plan”). The awards are subject to a vesting schedule as set forth in each individual agreement. The Company currently intends to use only the 2016 Plan to make future grants.

Activity with respect to the stock options is summarized as follows:



	Number of Shares		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at January 1, 2016	14,019,629		$	3.62
Granted	—		$	—
Exercised	(1,164,138	)	$	3.02
Unvested options forfeited	(154,200	)	$	6.77
Vested options expired	(148,683	)	$	6.16
Outstanding at December 31, 2016	12,552,608		$	3.61	5.4	$	66,137,378
Vested at December 31, 2016	11,680,455		$	3.33	5.3	$	64,733,964
Vested or expected to vest at December 31, 2016 (a)	12,539,865		$	3.60	5.4	$	66,119,285


(a)	Includes forfeiture adjusted unvested shares.

The intrinsic value of the options exercised during the years ended December 31, 2016, 2015 and 2014 were approximately $6,460,000, $17,181,000, and $10,566,000, respectively.

The intrinsic value of options vested during the years ended December 31, 2016, 2015 and 2014 were approximately $7,378,000, $10,044,000, and $6,615,000, respectively.

Following is a summary of stock options outstanding and exercisable at December 31, 2016:



	Options Outstanding				Options Exercisable
Range of Exercise Prices	Number outstanding	Weighted- Average Remaining Contractual Term (in years)	Weighted- Average Exercise Price		Number Exercisable	Weighted- Average Exercise Price
$0.50 - $0.76	441,429	2.4	$	0.72	441,429	$	0.72
$0.87 - $1.35	4,385,570	4.7	1.19		4,385,570	1.19
$1.40 - $2.45	1,362,424	4.1	1.92		1,362,424	1.92
$2.66 - $3.99	878,680	5.8	3.06		878,680	3.06
$4.19 - $6.38	3,056,069	6.2	5.36		2,937,038	5.34
$6.45- $9.78	2,324,103	7.0	7.30		1,610,485	7.25
$9.90 - $10.99	104,333	7.7	10.42		64,829	10.46
	12,552,608	5.4	$	3.61	11,680,455	$	3.33

A summary of the status of the Company’s unvested stock options as of December 31, 2016 is presented below:



Unvested Stock Options	Number of Shares		Weighted- Average Grant Date Fair Value
Unvested at January 1, 2016	3,067,935		$	3.81
Granted	—		$	—
Cancelled	(154,200	)	$	6.77
Vested	(2,041,582	)	$	3.61
Unvested at December 31, 2016	872,153		$	4.28

Total unrecognized compensation expense at December 31, 2016, was approximately $1,064,000 and will be charged to expense through June 2017.

The fair value of the options granted was estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options. The term of employee options granted is derived using the “simplified method” which computes expected term as the midpoint between the weighted average time to vesting and the contractual maturity. The simplified method was used due to the Company’s lack of sufficient historical data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its equity shares have been publicly traded. The term for non-employee options is generally based upon the contractual term of the option. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.

The assumptions used in calculating the fair value of options granted using the Black-Scholes-Merton option-pricing model are set forth in the following table:



	Year ended December 31,
	2016		2015	2014
Expected volatility	—	%	54.35 - 58.14%	58.14 - 64.50%
Expected life (in years)	0		6	6
Expected dividend yield	—		—	—
Risk-free interest rate	0		1.51 - 1.68%	1.64 - 1.96%

The weighted-average grant date fair value for options granted during the years ended December 31, 2016, 2015 and 2014 were approximately $0.00, $5.15 and $4.18, respectively.

Restricted Stock Awards

Following is summary information for restricted stock awards for the year ended December 31, 2016. Shares vest over a one to three year period. As of December 31, 2016, there was approximately $21,905,000 of total unrecognized stock-based compensation related to time-based, non-vested restricted stock. That expense is expected to be recognized on a straight-line basis over a weighted-average period of 1.9 years.

Additionally, during the twelve months ended December 31, 2016, 43,344 shares of common stock valued at approximately $345,700 were issued under the 2006 Plan to a consultant in return for services performed, and is included in the table that follows.



	Number of Shares		Weighted-Average Grant Date Fair Value
Unvested at January 1, 2016	2,613,267		$	9.14
Granted	2,755,426		$	8.05
Vested	(1,162,931	)	$	8.68
Forfeited	(377,317	)	$	8.71
Unvested at December 31, 2016	3,828,445		$	8.53

For the years ended December 31, 2016, 2015, and 2014 the Company recognized stock-based compensation as follows (in thousands):



	Years Ended December 31,
	2016		2015		2014
Cost of sales	$	426	$	352	$	322
Research and development	647		790		660
Selling, general and administrative	16,745		15,754		10,471
	$	17,818	$	16,896	$	11,453

Warrants

On November 18, 2015, 42,400 common stock warrants representing the balance remaining from those granted in connection with equity share purchases by investors as an additional incentive for providing long - term equity capital to the Company and as additional compensation to consultants and advisors were exercised at an exercise price of $1.09. The warrants were granted at negotiated prices in connection with the equity share purchases and at the market price of the common stock in other instances. The warrants were issued for terms of five years.

Treasury Stock

On May 12, 2014, our Board of Directors authorized the repurchase of up to $10 million of our common stock from time to time, through December 31, 2014. The Board subsequently extended the program until December 31, 2017. In December 2014, the Board increased the authorization to $20 million and further increased the authorization in 2015 to $60 million. In December 2016, the Board further increased the authorization to $66 million. The timing and amount of repurchases will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.

For the year ended December 31, 2016, the Company purchased approximately 1,338,616 shares of its common stock for an aggregate purchase price of approximately $10,338,000 exclusive of commissions of approximately $40,000. As of December 31, 2016, the Company had approximately $9,936,000 remaining under the repurchase program.


12.	Income Taxes

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.

Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands):



	December 31,
	2016			2015
Deferred tax assets and liabilities:
Accruals and prepaids	$	4,992		$	4,606
Intangible assets	(5,130		)	146
Property and equipment	(1,338		)	(1,396		)
R&D and other tax credits	1,219			3,293
Stock Compensation	7,417			7,063
Net operating loss	2,395			1,763
Other	113			145
Net deferred tax assets	$	9,668		$	15,620

Valuation allowance	(554		)	(782		)
	$	9,114		$	14,838

The reconciliation of the Federal statutory income tax rate of 35% to the effective rate is as follows:



	December 31,
	2016		2015
Federal statutory rate	35.00	%	34.00	%
State taxes, net of federal benefit	4.78	%	3.33	%
Non deductible compensation	0.04	%	0.63	%
Meals & entertainment	3.82	%	2.27	%
Equity Compensation	5.51	%	6.39	%
Domestic Production Activities Deduction	(4.71	)%	—	%
Tax Credits	(8.79	)%	(2.84	)%
Prior Period Adjustments	(3.79	)%	—	%
Other	3.27	%	(1.74	)%
Valuation allowance	(1.26	)%	(63.33	)%
	33.87	%	(21.29	)%

Current and deferred income tax expense (benefit) is as follows (in thousands):



	December 31, 2016			December 31, 2015
Current:
Federal	$	4,700		$	8,452
State	1,423			1,218
Total current	6,123			9,670

Deferred:
Federal	26			(13,070		)
State	(16		)	(1,768		)
Total deferred	10			(14,838		)

Total expense	$	6,133		$	(5,168	)

Income taxes are based on estimates of the annual effective tax rate and evaluations of possible future events and transactions and may be subject to subsequent refinement or revision.

Certain items of income and expense are not reported in tax returns and financial statements in the same year. The tax effect of such temporary differences is reported as deferred income taxes. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. The Company establishes a valuation allowance for deferred tax assets for which realization is not likely. As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets.

As of December 31, 2016, our deferred tax assets were primarily the result of accrued liabilities, equity compensation, tax credits and net operating loss carryforwards. A valuation allowance of $554,000 and $782,000 was recorded against our gross deferred tax asset balance as of December 31, 2016, and December 31, 2015, respectively.

At December 31, 2016, the Company had income tax net operating loss ("NOL") carryforwards for federal and state purposes of $2,327,000 and $27,912,000 respectively. At December 31, 2015, the Company has income tax net operating loss ("NOL") carryforwards for federal and state purposes of $579,000 and $27,552,000 respectively. As of December 31, 2016, the Company has recorded a deferred tax asset for both federal and state NOL carryforwards of approximately $815,000 and approximately $1,580,000, respectively. As of December 31, 2015, the Company has recorded a deferred tax asset for both federal and state NOL carryforwards of approximately $197,000 and approximately $1,566,000, respectively. The Company's net operating losses and tax credits are subject to annual limitations due to ownership change limitations provided by Internal Revenue Code Section 382. If not utilized, the federal and state tax loss carryforwards will expire between 2027 and 2035. A valuation allowance remains recorded against the deferred tax asset for certain state net operating loss carryovers in the amount of $554,000 that are not expected to be utilized prior to expiration.

As a result of certain realization requirements of ASC 718, Compensation - Stock Compensation, the table of deferred tax assets and liabilities shown above does not include certain deferred tax assets that arose directly from (or the use of which was postponed by) tax deductions related to equity compensation that were greater than the compensation recognized for financial reporting. During 2016, deferred tax assets in the amount of $1,170,000 were realized resulting in an increase to equity in the same amount. As of December 31, 2016, the Company does not have any remaining deferred tax assets that will result in an increase to equity upon realization. The Company uses ASC 740 ordering when determining when excess tax benefits have been realized.

The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in thousands):



	December 31, 2016		December 31, 2015
Unrecognized tax benefits - January 1	$	170	$	—

Gross increases - tax positions in current period	111		170

Unrecognized tax benefits - December 31	$	281	$	170

Included in the balance of unrecognized tax benefits as of December 31, 2016 and December 31, 2015, are $281,000 and $170,000, respectively, of tax benefits that, if recognized, would affect the effective tax rate. Also included in the balance of unrecognized tax benefits as of December 31, 2016 and December 31, 2015, are $281,000 and $170,000, respectively, of tax benefits that, if recognized, would result in adjustments to other tax accounts, primarily deferred taxes. This amount is recorded in Other Liabilities in the accompanying consolidated balance sheets.

The Company recognizes interest accrued related to unrecognized tax benefits and penalties as income tax expense. Related to the unrecognized tax benefits noted above, the Company accrued no penalties or interest during 2016, and, in total, as of December 31, 2016 has not recognized any liabilities for penalties or interest. During 2015, we also did not accrue any penalties or interest and, in total, as of December 31, 2015, had not recognized any liability for penalties or interest.

The Company is subject to taxation in the US and various state jurisdictions. As of December 31, 2016 the Company’s tax returns for 2013, 2014 and 2015 are subject to examination by the tax authorities. As of December 31, 2016, the Company is generally no longer subject to US federal, state, or local examinations by tax authorities for years before 2013.

13. Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities

Selected cash payments, receipts, and noncash activities are as follows (in thousands):



	Years Ended December 31,
	2016			2015		2014
Cash paid for interest	$	162		$	86	$	48
Income taxes paid	642			2,293		384
Retirement of fixed assets	—			319		—
Deferred financing costs	10			504		—
APIC related tax adjustments	(424		)	7,757		—
Stock issuance of 441,009 shares in connection with acquisition of Stability	3,346			—		—
Stock issuance of 43,344, 16,493 and 15,958 shares in exchange for services performed in 2016, 2015 and 2014, respectively	346			164		117


14.	401k Plan

The Company has a 401(k) plan (the “Plan”) covering employees who have attained 21 years of age and have completed three months of service. Under the Plan, participants may defer up to 100% of their eligible wages to a maximum of $18,000 per year (annual limit for 2015). Employees age 50 or over in 2016 may make additional pre-tax contributions up to $6,000 above and beyond normal plan and legal limits. Annually, the Company may elect to match employee contributions up to 6% of the employee’s compensation. Additionally, the Company may elect to make a discretionary contribution to the Plan. The Company did not provide matching contributions for the years ended December 31, 2016, 2015, and 2014.


15.	Related Party Transactions

On January 13, 2016, when the Company completed the acquisition of Stability Inc., d/b/a Stability Biologics ("Stability") there was an assumed payable of $5,954,555 to a related party. The Company made payments of $1,361,030 during 2016. The payable was further reduced by $3,367,250 as a result of the return or destruction of expired inventory. The outstanding payable at 12/31/16 is $1,226,275 and is included in Accounts Payable. The related party is a limited liability company that is controlled by a former stockholder of Stability Inc. who is now an employee of the Company.


16.	Commitments and Contingencies

Contractual Commitments

In addition to the capital leases noted under Property and Equipment (Note 7), the Company has entered into operating lease agreements for facility space and equipment. These leases expire over the next eight years and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration. The Company also has commitments for meeting space.

The estimated annual lease payment and meeting space commitments are as follows (in thousands):



Year ended December 31,
2017	$	2,827
2018	3,079
2019	2,023
2020	490
2021	141
Thereafter	374
	$	8,934

Rent expense for the years ended December 31, 2016, 2015 and 2014, was approximately $1,764,000, $1,317,000 and $1,130,000, respectively, and is allocated among cost of sales, research and development, and selling, general and administrative expenses.

Letters of Credit

As a condition of the leases for the Company's facilities, we are obligated under standby letters of credit in the amount of approximately $103,000. These obligations are reduced at various times over the lives of the leases.

FDA Untitled Letter, Draft Guidance and Related Litigation

FDA Untitled Letter and Draft Guidance

On August 28, 2013, the FDA issued an Untitled Letter alleging that the Company's micronized allografts do not meet the criteria for regulation solely under Section 361 of the Public Health Service Act and that, as a result, MiMedx would need a biologics license to lawfully market those micronized products. Since the issuance of the Untitled Letter, the Company has been in discussions with the FDA to communicate its disagreement with the FDA's assertion that the Company's allografts are more than minimally manipulated. To date, the FDA has not changed its position that the Company's micronized products are not eligible for marketing solely under Section 361 of the Public Health Service Act. The Company continues to market its micronized products but is also pursuing the Biologics License Application (“BLA”) process for certain of its micronized products.

On October 28, 2015, the FDA issued for comment, "Draft Guidance for Industry and FDA Staff: Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products." The Company submitted comments on this Homologous Use draft guidance as well. On September 12 and 13, 2016, the FDA held a public hearing to obtain input on the Homologous Use draft guidance and the previously released Minimal Manipulation draft guidance, as well as other recently issued guidance documents on HCT/Ps. The Company awaits further decision from FDA on the draft guidances, but anticipates this will be a lengthy process.

If the FDA does allow the Company to continue to market a micronized form of its sheet allografts without a biologics license either prior to or after finalization of the draft guidance documents, it may impose conditions, such as labeling restrictions and compliance with cGMP. Although the Company is preparing for these requirements in connection with its pursuit of a BLA for certain of its micronized products, earlier compliance with these conditions requires significant additional time and cost investments by the Company. It is also possible that the FDA will not allow the Company to market any form of a micronized product without a biologics license even prior to finalization of the draft guidance documents and could even require the Company to recall its micronized products. Revenues from micronized products comprised approximately 10% of the Company's revenues in 2016.

Securities Class Action

Following the publication of the Untitled Letter from the FDA regarding the Company’s micronized products in September 2013, the trading price of the Company’s stock declined and several putative shareholder class action lawsuits were filed against the Company and certain of its executive officers asserting violations of the Securities Exchange Act of 1934. The cases were consolidated in the United States District Court for the Northern District of Georgia. On November 17, 2015, the parties entered into a stipulation of settlement to settle the consolidated case in its entirety. The stipulation of settlement was filed with the Court on November 18, 2015. On November 19, 2015, the Court preliminarily approved the settlement and confirmed the settlement on April 5, 2016. The settlement amount was paid by the Company's insurance carrier.

Former Employee Litigation

same allegations in that suit as were made in the Minnesota suit, with the addition of claims against the Company and Mr. Petit for defamation.

The Company intends to vigorously pursue its claims asserted in the Florida and Georgia Actions and also to vigorously defend against the lawsuits and counterclaims asserted against them.

Patent Litigation

MiMedx continues to diligently enforce its intellectual property against several entities. Currently, there are four actions pending, as described below:

The Liventa Action

The Bone Bank Action

The NuTech Action

The Vivex Action

Pending IPRs


17.	Quarterly Financial Data (Unaudited) (in thousands except per share data)



		First Quarter		Second Quarter		Third Quarter		Fourth Quarter
NET SALES	2016	$	53,367	$	57,342	$	64,429	$	69,877
	2015	40,767		45,679		49,015		51,835

GROSS MARGIN	2016	$	45,421	$	49,948	$	56,432	$	60,807
	2015	35,619		40,590		44,036		46,849

NET INCOME	2016	$	1,197	$	1,975	$	3,321	$	5,481
	2015	4,087		5,430		6,551		13,378

NET INCOME PER COMMON SHARE - BASIC	2016	$	0.01	$	0.02	$	0.03	$	0.05
	2015	0.04		0.05		0.06		0.13

NET INCOME PER COMMON SHARE - DILUTED	2016	$	0.01	$	0.02	$	0.03	$	0.05
	2015	0.04		0.05		0.06		0.11

18. Product Revenue Data

We group our products into two categories: Wound Care and Surgical, Sports Medicine & Orthopedics (SSO) for purposes of the required disclosure under ASC 280-10-50-40. This grouping of products does not constitute a basis for resource allocation but is information intended to provide the reader with ability to better understand the Company's product categories. These groupings also do not meet the criteria under ASC 280-10-50-1 as separate segments.

Net Sales by Categories (in thousands):



	Year Ended December 31,
	2016		2015		2014
Wound Care	$	183,984	$	141,096	$	93,623
Surgical, Sports Medicine & Orthopedics (SSO)	61,031		46,200		24,600
Total	$	245,015	$	187,296	$	118,223

19. Subsequent Events

The Board of Directors in February 2017 authorized an increase of $20 million to the Company's Share Repurchase Program. This action brings the total amount authorized to $86 million since the Share Repurchase Program commenced in May 2014.

Schedule II Valuation and Qualifying Accounts



MIMEDX GROUP, INC. AND SUBSIDIARIES SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS
Years ended December 31, 2016, 2015 and 2014 (in thousands)

	Balance at Beginning of Year		Additions charged to Expense or Revenue		Deductions and write-offs			Balance at End of Year

For the Year ended December 31, 2016
Allowance for doubtful accounts	$	3,270	$	2,127	$	(555	)	$	4,842
Allowance for product returns	1,262		8,319		(4,687		)	4,894
Allowance for obsolescence	397		2,280		(1,849		)	828

For the Year ended December 31, 2015
Allowance for doubtful accounts	$	1,750	$	1,698	$	(178	)	$	3,270
Allowance for product returns	841		3,257		(2,836		)	1,262
Allowance for obsolescence	527		540		(670		)	397

For the Year ended December 31, 2014
Allowance for doubtful accounts	$	407	$	1,357	$	(14	)	$	1,750
Allowance for product returns	215		2,215		(1,589		)	841
Allowance for obsolescence	322		405		(200		)	527

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

Item 9A. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain “disclosure controls and procedures” within the meaning of Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended, or the "Exchange Act". Our disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed by the Company in the reports filed under the Exchange Act, such as this Annual Report on Form 10-K, is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission’s rules and forms. Our disclosure controls and procedures include controls and procedures designed to provide reasonable assurance that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and no evaluation of controls and procedures can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As required by Rule 13a-15(b) of the Exchange Act, prior to filing this Annual Report on Form 10-K, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of the end of the period covered by this Annual Report on Form 10-K. Based on their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our reporting and disclosure controls and procedures were not effective as a result of the material weakness in our internal control over financial reporting discussed below.

Changes in internal controls: There were no changes in our internal control over financial reporting as defined in Exchange Act Rules 13a- 15(f) and 15d-15(f) that occurred during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Material weakness: In reviewing the Company's tax accounting in preparation for filing this Form 10-K, our management identified a deficiency in our internal control over financial reporting that is described below in Management’s Annual Report on Internal Control Over Financial Reporting. Our management has concluded that this deficiency constitutes a material weakness in our internal control over financial reporting related to our accounting for income taxes. This material weakness did not result in a material misstatement of the Company’s annual financial statements for the year ended December 31, 2016. However, management concluded that this material weakness, if un-remediated, could have resulted in a material misstatement of the Company’s annual or interim consolidated financial statements that would not have been prevented or detected by our internal controls. Accordingly, management determined that this control deficiency constituted a material weakness. We have developed a remediation plan for this material weakness, which is described below.

Management’s Annual Report on Internal Control Over Financial Reporting

Our management, including our principal executive officer and principal financial officer, is responsible for establishing and maintaining adequate internal control over financial reporting. Our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework and criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on its evaluation, our management has concluded that our internal control over financial reporting was not effective as of December 31, 2016, due to the material weakness in our internal control over financial reporting related to our accounting for income taxes. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. In reviewing the Company's tax accounting in preparation for filing this Form 10-K, management concluded the Company had a material weakness in the design of our internal control over the tax accounting related to an overstatement of an excess tax benefit which, if undetected could have resulted in an understatement of income taxes payable. Specifically, management did not have adequate supervision and review of certain technical tax accounting performed by a third party tax specialist in 2016. This was identified during the audit process prior to preparation of the Company's financial statements and, therefore did not result in a material misstatement of the Company’s annual financial statements for the year ended December 31, 2016 or any of our previously issued annual or interim consolidated financial

statements. This material weakness, if undetected, could have resulted in an understatement of income taxes payable, resulting in a material misstatement of the Company’s annual consolidated financial statements that would not have been prevented or detected by its internal controls.

The effectiveness of our internal control over financial reporting as of December 31, 2016 has been audited by Cherry Bekaert LLP, an independent registered public accounting firm, as stated in their report which appears in Item 8 of this Annual Report on Form 10-K.

Remediation Plan: Management has begun implementing a remediation plan to address the control deficiency that led to the material weakness. The remediation plan includes the following:


•	Implementing specific review procedures, including the increased involvement of our CFO and Controller as well as the hiring of an internal tax specialist to oversee the work performed by the third - party tax specialists.


•	Strengthening our income tax control with improved documentation standards, technical oversight, and training.

When fully implemented and operational, we believe the measures described above will remediate the material weakness we have identified and generally strengthen our internal control over financial reporting. We currently plan to have our enhanced review procedures and documentation standards in place and operating in the first quarter of 2017. Our goal is to remediate this material weakness by the end of the first quarter of 2017, subject to there being sufficient opportunities to conclude, through testing, that the enhanced control is operating effectively.

Cherry Bekaert LLP, an independent registered accounting firm, as auditors of our financial statements have issued an attestation report on the effectiveness of the Company’s and its subsidiaries’ internal control over financial reporting as of December 31, 2016. Cherry Bekaert LLP's report is included in this report.

Item 9B. Other Information

None.

PART III

Item 10. Directors, Executive Officers and Corporate Governance

Information required by this Item will be contained in our definitive proxy statement relating to our 2017 Annual Meeting of Shareholders under the captions “Executive Officers,” “Election of Directors” and “Section 16(a) Beneficial Ownership Reporting Compliance,” or similar captions which are incorporated herein by reference.

We have adopted our “Code of Business Conduct and Ethics” and a copy is posted on our website at www.mimedx.com. In the event that we amend any of the provisions of this Code of Business Conduct and Ethics that require disclosure under applicable law, SEC rules or listing standards, we intend to disclose such amendment on our website.

Any waiver of the Code of Business Conduct and Ethics for any executive officer or director must be approved by the Board and will be disclosed on a Form 8-K filed with the SEC, along with the reasons for the waiver.

Item 11. Executive Compensation

Information required by this Item will be contained in our definitive proxy statement relating to our 2017 Annual Meeting of Shareholders under the caption “Executive Compensation,” or similar caption which is incorporated herein by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters

Information required by this Item will be contained in our definitive proxy statement relating to our 2017 Annual Meeting of Shareholders under the captions “Stock Ownership",” “Executive Compensation,” and “Equity Compensation Plan Information,” or similar captions which are incorporated herein by reference.

Item 13. Certain Relationships and Related Transactions, and Director Independence

Information required by this Item will be contained in our definitive proxy statement relating to our 2017 Annual Meeting of Shareholders under the captions “Certain Relationships and Related Party Transactions,” and "Election of Directors" or similar captions which are incorporated herein by reference.

Item 14. Principal Accounting Fees and Services

Information required by this Item will be contained in our definitive proxy statement relating to our 2017 Annual Meeting of Shareholders under the captions “Ratification of Appointment of Independent Registered Public Accounting Firm” and “Election of Directors,” or similar captions which are incorporated herein by reference.

PART IV

Item 15. Exhibits, Financial Statement Schedules


(a)	Documents filed as part of this report:


(1)	Financial Statements


(2)	Financial Statement Schedule:

The following Financial Statement Schedule is filed as part of this Report:

Schedule II Valuation and Qualifying Accounts for the years ended December 31, 2016, 2015 and 2014


(3)	Exhibits

See Item 15(b) below. Each management contract or compensation plan has been identified.


(b)	Exhibits



Exhibit Number		Description
2.1##		Agreement and Plan of Merger dated December 22, 2010 by and among MiMedx Group, Inc., MP Holdings Acquisition Sub, LLC, ORCI Acquisition Sub, LLC, Membrane Products Holdings, LLC, Onramp Capital Investments, LLC, each of the OnRamp Members (as defined therein); John R. Daniel, in his capacity as the representative of the Members and Surgical Biologics, LLC (Incorporated by reference to Exhibit 2.2 filed with Registrant's Form 10-K filed on March 31, 2011)
2.2##		Agreement and Plan of Merger dated January 10, 2016, by and among MiMedx Group, Inc., Titan Acquisition Sub I, Inc., Titan Acquisition Sub II, LLC, Stability Inc., certain stockholders of Stability Inc. and Brian Martin as representative of the Stability stockholders (Incorporated by reference to Exhibit 2.1 filed with Registrant's Form 8-K filed on January 13, 2016)
3.1#		Articles of Incorporation of MiMedx Group, Inc., as amended by Articles of Amendment to Articles of Incorporation filed on May 14, 2010, Articles of Amendment to Articles of Incorporation filed on August 8, 2012, Articles of Amendment to Articles of Incorporation filed on November 8, 2012, and Articles of Amendment to Articles of Incorporation filed on May 15, 2015
3.2#		Bylaws of MiMedx Group, Inc., as amended as of December 14, 2016
10.1*		MiMedx Group, Inc. 2006 Assumed Stock Incentive Plan, as amended and restated effective February 25, 2014 (Incorporated by reference to Exhibit 10.2 of the Registrant's Form 8-K filed on March 3, 2014)
10.2*		Form of Restricted Stock Agreement for Non-Employee Directors under the MiMedx Group, Inc. 2006 Assumed Stock Incentive Plan (Incorporated by reference to Exhibit 10.66 to the Registrant's Form 10-Q filed on August 8, 2013)
10.3*		Form of Restricted Stock Agreement under the MiMedx Group, Inc. 2006 Assumed Stock Incentive Plan (Incorporated by reference to Exhibit 10.3 to the Registrant's Form 10-K filed on March 4, 2014)
10.4*		Form of Incentive Stock Option Agreement under the MiMedx Group, Inc. 2006 Assumed Stock Incentive Plan (Incorporated by reference to Exhibit 10.4 to the Registrant's Form 10-K filed on March 4, 2014)
10.5*		Form of Nonqualified Stock Option Agreement under the MiMedx Group, Inc. 2006 Assumed Stock Incentive Plan (Incorporated by reference to Exhibit 10.5 to the Registrant's Form 10-K filed on March 4, 2014)
10.6*		MiMedx, Inc. 2005 Assumed Stock Plan, formerly the SpineMedica Corp. 2005 Employee, Director and Consultant Stock Plan (Incorporated by reference to Exhibit 10.5 filed with the Registrant's Form 8-K filed February 8, 2008)
10.7*		Declaration of Amendment to the MiMedx, Inc. 2005 Assumed Stock Plan (formerly the SpineMedica Corp. 2005 Employee, Director and Consultant Stock Plan) (Incorporated by reference to Exhibit 10.6 filed with the Registrant's Form 8-K filed February 8, 2008)



10.8*		Form of Incentive Stock Option Award Agreement under the MiMedx, Inc. Assumed 2005 Stock Plan (formerly the SpineMedica Corp. 2005 Employee, Director and Consultant Stock Plan), including a list of officers and directors receiving options thereunder (Incorporated by reference to Exhibit 10.7 filed with the Registrant's Form 8-K filed February 8, 2008)
10.9*		Form of Nonqualified Stock Option Award Agreement under the MiMedx, Inc. Assumed 2005 Stock Plan (formerly the SpineMedica Corp. 2005 Employee, Director and Consultant Stock Plan) (Incorporated by reference to Exhibit 10.8 filed with the Registrant's Form 8-K filed February 8, 2008)
10.10*		MiMedx, Inc. Assumed 2007 Stock Plan (formerly the SpineMedica Corp. 2007 Stock Incentive Plan) (Incorporated by reference to Exhibit 10.9 filed with the Registrant's Form 8-K filed February 8, 2008)
10.11*		Declaration of Amendment to the MiMedx, Inc. Assumed 2007 Stock Plan (formerly the SpineMedica Corp. 2007 Stock Incentive Plan) (Incorporated by reference to Exhibit 10.10 filed with the Registrant's Form 8-K filed February 8, 2008)
10.12*		Form of Incentive Stock Option Award Agreement under the MiMedx, Inc. Assumed 2007 Stock Plan (formerly the SpineMedica Corp. 2007 Stock Incentive Plan) (Incorporated by reference to Exhibit 10.11 filed with the Registrant's Form 8-K filed February 8, 2008)
10.13*		Form of Nonqualified Stock Option Award Agreement under the MiMedx, Inc. Assumed 2007 Stock Plan (formerly the SpineMedica Corp. 2007 Stock Incentive Plan) (Incorporated by reference to Exhibit 10.12 filed with the Registrant's Form 8-K filed February 8, 2008)
10.14*		Form of Indemnification Agreement (Incorporated by reference to Exhibit 10.65 filed with the Registrant's Form 8-K filed July 15, 2008)
10.15*		MiMedx Group, Inc. Amended and Restated Assumed 2005 Stock Plan (Incorporated by reference to Exhibit 10.4 filed with the Registrant's Form S-8 filed August 29, 2008)
10.16*		Form of Incentive Stock Option Award Agreement under MiMedx Group, Inc. Amended and Restated Assumed 2005 Stock Plan (Incorporated by reference to Exhibit 10.68 filed with the Registrant's Form 8 -K filed September 4, 2008)
10.17*		Form of Nonqualified Stock Option Award Agreement under MiMedx Group, Inc. Amended and Restated Assumed 2005 Stock Plan (Incorporated by reference to Exhibit 10.69 filed with the Registrant's Form 8 -K filed September 4, 2008)
10.18		Form of MiMedx, Inc. Employee Proprietary Information and Inventions Assignment Agreement (Incorporated by reference to Exhibit 10.13 filed with the Registrant's Form 8-K filed February 8, 2008)
10.19		Technology License Agreement between MiMedx, Inc., Shriners Hospitals for Children, and University of South Florida Research Foundation dated January 29, 2007 (Incorporated by reference to Exhibit 10.32 filed with the Registrant's Form 8-K filed February 8, 2008)
10.20		Form of Amended and Restated Security and Intercreditor Agreement (Incorporated by reference to Exhibit 10.6 filed with Registrant’s Form 8-K filed January 3, 2012)
10.21*		Change of Control Agreement Severance Compensation and Restrictive Covenant Agreement dated November 11, 2011, between MiMedx Group, Inc. and Parker H. Petit (Incorporated by reference to Exhibit 10.91 filed with Registrant’s Form 10-Q filed on November 14, 2011)
10.22*		Change of Control Agreement Severance Compensation and Restrictive Covenant Agreement dated November 11, 2011, between MiMedx Group, Inc. and with William C. Taylor (Incorporated by reference to Exhibit 10.92 filed with Registrant’s Form 10-Q filed on November 14, 2011)
10.23*		First Amendment to Change in Control Severance Compensation and Restrictive Covenant Agreement dated May 9, 2013 by and between MiMedx Group, Inc., and William C. Taylor (Incorporated by reference to Exhibit 10.1 to the Registrant's Form 8-K filed on May 15, 2013)



10.24*		Change of Control Agreement Severance Compensation and Restrictive Covenant Agreement dated November 11, 2011, between MiMedx Group, Inc., and Michael J. Senken (Incorporated by reference to Exhibit 10.93 filed with Registrant’s Form 10-Q filed on November 14, 2011)
10.25*		First Amendment to Change in Control Severance Compensation and Restrictive Covenant Agreement dated May 9, 2013 by and between MiMedx Group, Inc., and Michael J. Senken (Incorporated by reference to Exhibit 10.2 to the Registrant's Form 8-K filed on May 15, 2013)
10.26*		Change in Control Severance Compensation and Restrictive Covenant Agreement dated May 20, 2016 by and between MiMedx Group, Inc., and Alexandra O. Haden (Incorporated by reference to Exhibit 10.1 to the Registrant's Form 8-K filed on May 25, 2016)
10.27*		2013 Management Incentive Plan and 2013 Operating Incentive Plan (Incorporated by reference to Exhibit 10.1 filed with Registrant’s Form 8-K filed March 12, 2013)
10.28*		2014 Management Incentive Plan and 2014 Operating Incentive Plan (Incorporated by reference to Exhibit 10.1 filed with Registrant's Form 8-K filed March 3, 2014)
10.29*		2015 Management Incentive Plan (Incorporated by reference to Exhibit 10.1 to the Registrant's Form 10-Q filed on May 1, 2015)
10.30*		2016 Management Incentive Plan
10.31**		Product Distribution Agreement by and between AvKARE, Inc. and MiMedx Group, Inc. dated April 19, 2012 (Incorporated by reference to Exhibit 10.56 to the Registrant’s Form 10-K filed March 15, 2013)
10.32		First Amendment to Product Distribution Agreement amending that certain Product Distribution Agreement that was effective April 19, 2012 (Incorporated by reference to Exhibit 10.56 filed with the Registrant’s Form 10-Q filed on November 8, 2013)
10.33**		Second Amendment to Product Distribution between MiMedx Group, Inc. and AvKARE, Inc. (Incorporated by reference to Exhibit 10.58 filed with the Registrant’s Form 10-Q filed on November 8, 2013)
10.34**		Third Amendment to Product Distribution Agreement dated April 17, 2015 between MiMedx Group, Inc. and AvKARE, Inc. (Incorporated by reference to Exhibit 10.2 to the Company's 10-Q filed on August 7, 2015)



10.35**		Fourth Amendment to Product Distribution Agreement dated January 1, 2016 between MiMedx Group, Inc. and AvKARE, Inc. (Incorporated by reference to Exhibit 10.2 to the Company's 10-Q filed on May 10, 2016)
10.36		Lease by and between Hub Properties of GA, LLC and MiMedx Group, Inc., effective May 1, 2013 (Incorporated by reference to Exhibit 10.1 to the Registrant's Form 10-Q filed May 10, 2013)
10.37		Credit Agreement dated October 12, 2015, among MiMedx Group, Inc., the Guarantors identified therein, Bank of America, N.A., and the other Lenders party thereto (Incorporated by reference to Exhibit 10.1 to the Registrant's Form 8-K filed on October 13, 2015)
10.38		First Amendment to the Credit Agreement dated October 12, 2015, by and among MiMedx Group, Inc., the Guarantors identified therein, Bank of America, N.A. and the other Lenders party thereto (Incorporated by reference to Exhibit 10.1 to the Registrant's Form 8-K filed on January 13, 2016
10.39		Security and Pledge Agreement dated October 12, 2015, among MiMedx Group, Inc., the Guarantors identified therein and Bank of America, N.A., as administrative agent (Incorporated by reference to Exhibit 10.2 to the Registrant's Form 8-K filed on October 13, 2015)
10.40*		2016 Equity and Cash Incentive Plan (Incorporated herein by reference to Appendix A to the Registrant’s Definitive Proxy Statement on Schedule 14A filed on April 12, 2016
10.41*		Form of Incentive Stock Option Agreement under the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan (Incorporated by reference to Exhibit 10.2 to the Registrant’s Form 10-Q filed August 2, 2016)
10.42*		Form of Restricted Stock Agreement under the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan (Incorporated by reference to Exhibit 10.3 to the Registrant’s Form 10-Q filed August 2, 2016)
10.43*		Form of Nonqualified Stock Option Agreement under the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan (Incorporated by reference to Exhibit 10.4 to the Registrant’s Form 10-Q filed August 2, 2016)
21.1#		Subsidiaries of MiMedx Group, Inc.
23.1#		Consent of Independent Registered Public Accounting Firm
31.1#		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Acts of 2002
31.2#		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Acts of 2002
32.1#		Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2#		Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS#		XBRL Instance Document
101.SCH#		XBRL Taxonomy Extension Schema Document
101.CAL #		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF#		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB#		XBRL Taxonomy Extension Label Linkbase Document
101.PRE#		XBRL Taxonomy Extension Presentation Linkbase Document

Notes



*	Indicates a management contract or compensatory plan or arrangement
#	Filed herewith
**	Certain confidential material appearing in this document, marked by [*****], has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under rule 24b-2 promulgated under the Securities Exchange Act of 1934, as amended.
##	Certain exhibits and schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K, but a copy will be furnished supplementally to the Securities and Exchange Commission upon request.

Item 16. Form 10-K Summary

Not applicable.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



March 1, 2017	MIMEDX GROUP, INC.

	By:	/s/ Michael J. Senken
		Michael J. Senken
		Chief Financial Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.



Signature / Name	Title	Date

/s/: Parker H. Petit	Chief Executive Officer and Chairman	March 1, 2017
Parker H. Petit	(principal executive officer)

/s/: Michael J. Senken	Chief Financial Officer	March 1, 2017
Michael J. Senken	(principal financial and accounting officer)

/s/: Joseph G. Bleser	Director	March 1, 2017
Joseph G. Bleser

/s/: J. Terry Dewberry	Director	March 1, 2017
J. Terry Dewberry

/s/: Charles Evans	Director	March 1, 2017
Charles Evans

/s/: Bruce Hack	Director	March 1, 2017
Bruce Hack

/s/: Charles E. Koob	Director	March 1, 2017
Charles E. Koob

/s/: Larry W. Papasan	Director	March 1, 2017
Larry W. Papasan

/s/: William C. Taylor	Director	March 1, 2017
William C. Taylor

/s/: Neil Yeston	Director	March 1, 2017
Neil Yeston

EX-3.1 2 exhiibit31-xarticlesofmime.htm EXHIBIT 3.1 Exhibit

ARTICLES OF INCORPORATION

MIMEDX GROUP, INC.

Article 1. Name. The name of the Corporation is MIMEDX GROUP, INC.

Article 2. State of Organization. The Corporation is organized pursuant to the provisions of the Florida Business Corporation Act (the “Act”).

Article 3. Capital Stock. The total number of shares of stock which the Corporation shall have authority to issue is not more than 105,000,000 shares of capital stock, of which 100,000,000 shares shall be designated “Common Stock,” at $.001 par value per share, and 5,000,000 shares shall be designated as “Preferred Stock,” at $.001 par value per share.

The designations and the preferences, conversion and other rights, voting powers, restrictions, provisions as to dividends, qualifications, redemption rights and other terms and conditions of the shares of each class of stock are as follows:

3.1 Preferred Stock. The Preferred Stock may be issued from time to time by the Board of Directors as shares of one or more series. The description of shares of each series of Preferred Stock, including any preferences, conversion and other rights, voting powers, restrictions, provisions as to dividends, qualifications, redemption rights and any other terms and conditions shall be as set forth in resolutions adopted by the Board of Directors, and articles of amendment to these Articles of Incorporation shall be filed shall be filed with the Department of State of the State of Florida as required by law to be filed with respect to the issuance of such Preferred Stock, prior to the issuance of any shares of such series.

The Board of Directors is expressly authorized, at any time, by adopting resolutions providing for the issuance of, or providing for a change in the number of, shares of any particular series of Preferred Stock and, if and to the extent from time to time required by law, by filing articles of amendment to these Articles of Incorporation which are effective without shareholder action, to increase or decrease the number of shares included in each series of Preferred Stock, but not below the number of shares then issued, and to set or change in any one or more respects the designations, preferences, conversion or other rights, voting powers, restrictions, provisions as to dividends, qualifications, redemption rights or other terms and conditions relating to the shares of each such series. The authority of the Board of Directors with respect to each series of Preferred Stock shall include, but not be limited to, setting or changing the following:




(a)	the annual dividend rate, if any, on shares of such series, the times of payment and the date from which dividends shall be accumulated, if dividends are to be cumulative;




(b)	whether the shares of such series shall be redeemable and, if so, the redemption price and the terms and conditions of such redemption;




(c)	the obligation, if any, of the Corporation to redeem shares of such series pursuant to a sinking fund;




(d)	whether shares of such series shall be convertible into, or exchangeable for, shares of stock of any other class or classes and, if so, the terms and conditions of such conversion or exchange, including the price or prices or the rate or rates of conversion or exchange and the terms of adjustment, if any;




(e)	whether the shares of such series shall have voting rights, in addition to the voting rights provided by law, and, if so, the extent of such voting rights;




(f)	the rights of the shares of stock series in the event of voluntary or involuntary liquidation, dissolution or winding-up of the Corporation; and




(g)	any other relative rights, powers, preferences, qualifications, limitations or restrictions thereof relating to such series.

3.2 Common Stock. Subject to all of the rights of the Preferred Stock as expressly provided herein, by law or by the Board of Directors pursuant to this Article 3, the Common Stock of the Corporation shall possess all such rights and privileges as are afforded to capital stock by applicable law, including, but not limited to, the following rights and privileges:




(a)	dividends may be declared and paid or set apart for payment upon the Common Stock out of any assets or funds of the Corporation legally available for the payment of dividends;




(b)	the holders of Common Stock shall have the right to vote for the election of Directors and on all other matters requiring shareholder action, each share being entitled to one vote; and




(c)	upon the voluntary or involuntary liquidation, dissolution or winding-up of the Corporation, the net assets of the Corporation available for distribution shall be distributed pro rata to the holders of the Common Stock in accordance with their respective rights and interests.

Article 5. Principal Office. The initial principal office of the Corporation shall be at 1234 Airport Road, Suite 105, Destin, Okaloosa County, Florida 32541.

Article 6. Director’s Liability. No Director shall have any personal liability to the Corporation or to its shareholders for monetary damages for breach of duty of care or other duty as a Director, by reason of any act or omission, except that this provision shall not eliminate or limit the liability of a Director for liabilities of a Director imposed by Section 607.0831 of the Act.

Article 7. No Preemptive Rights. No holder of any of the shares of any class of stock of the Corporation shall be entitled as of right to subscribe for, purchase, or otherwise acquire any shares of any class of stock of the Corporation which the Corporation proposes to issue or any rights or options which the Corporation proposes to grant for the purchase of shares of any class of stock of the Corporation or for the purchase of any shares, bonds, securities, or obligations of the Corporation which are convertible into or exchangeable for, or which carry any rights to subscribe for, purchase, or otherwise acquire shares of any class of stock of the Corporation; and any and all of such shares, bonds, securities, or obligations of the Corporation, whether now or hereafter authorized or created, may be issued, or may be reissued if the same have been reacquired and if their reissue is not prohibited, and any and all of such rights and options may be granted by the Board of Directors to such individuals and entities, and for such lawful consideration, and on such terms, as the Board of Directors in its discretion may determine, without first offering the same, or any thereof, to any said holder.

Article 8. Indemnification. Each person who is or was a Director or Officer of the Corporation, and each person who is or was a Director or Officer of the Corporation who at the request of the Corporation is serving or has served as an officer, director, partner, joint venturer, trustee, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall be indemnified by the Corporation against those expenses (including attorneys’ fees), judgments, fines, penalties and amounts paid in settlement which are allowed to be paid or reimbursed by the Corporation under the laws of the State of Florida and which are actually and reasonably incurred in connection with any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, in which such person may be involved by reason of his being or having been a Director or Officer of this Corporation or of such other enterprises.

The indemnification provided herein shall not be deemed to limit the right of the Corporation to indemnify any other person for any liability, including obligations to pay a judgment, settlement, penalty, fine (including and excise tax assessed with respect to any employee benefit plan), and expenses actually and reasonably incurred (including attorneys’ fees), to the fullest extent permitted by law, both as to action in such person’s official capacity and as to action in another capacity while holding such office.

Notwithstanding anything contained herein to the contrary, this Article is intended to provide indemnification to each Director and Officer of the Corporation to the fullest extent authorized by the Act, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader rights than said statute permitted the Corporation to provide prior thereto). Neither any amendment nor repeal of this Article 8 shall eliminate or reduce the effect of this Article 8, with respect to any matter occurring, or any action or proceeding accruing or arising or that, but for this Article 8, would accrue or arise, prior to such amendment, repeal or adoption of an inconsistent provision.

Article 9. Special Meeting of Shareholders. Special meetings of the shareholders for any purpose may be called at the request in writing of shareholders owning not less than 50% of all votes entitled to be cast on any issue proposed to be considered at the proposed meeting by delivering one or more written demands for the meeting which are signed, dated and delivered to the Secretary of the Corporation and describe the purposes for which the meeting is to be held.

Article 10. Board Vacancies. Any vacancies occurring on the Board of Directors for any reason (including death, resignation, disqualification, removal or other causes) and any newly created directorships resulting from an increase in the authorized number of Directors may be filled only by vote of a majority of the remaining members of the Board of Directors, even if less than a quorum, at any meeting of the Board of Directors. Notwithstanding the immediately preceding sentence, the Board of Directors may by resolution determine that any such vacancies or newly created directorships shall be filled by the shareholders of the Corporation.

Article 11. Incorporator. The name and the address of the Incorporator is Steve Gorlin, 1234 Airport Road, Suite 105, Destin, Okaloosa County, Florida 32541.

IN WITNESS WHEREOF, the undersigned has executed these Articles of Incorporation effective as of February 28, 2008.






	By:		/s/ Steve Gorlin
	Name:		Steve Gorlin
	Title:		Incorporator

ARTICLES OF AMENDMENT

TO THE

ARTICLES OF INCORPORATION

MIMEDX GROUP, INC.

MiMedx Group, Inc., a corporation organized and existing under the laws of the State of Florida, hereby certifies as follows:




1.	The name of the corporation is MiMedx Group, Inc. (the “Corporation”).




2.	Pursuant to Section 607.1003 of the Florida Business Corporation Act (the “Act”), these Articles of Amendment (“Articles of Amendment”) amend the Articles of Incorporation of the Corporation filed in the Office of the Department of State of the State of Florida on February 28, 2008, as amended by the Articles of Merger filed in the Office of the Department of State of the State of Florida on March 31, 2008 (as amended, the “Amended Articles”).




3.	These Articles of Amendment were duly adopted by the Board of Directors of the Corporation in accordance with the provisions of Section 607.1003 of the Act March 31, 2010.




4.	These Articles of Amendment were duly approved by holders of a majority of the outstanding shares of the Common Stock of the Corporation in accordance with the provisions of Section 607.1003 of the Act and the Amended Articles on May 11, 2010.




5.	The Amended Articles are hereby amended by deleting Article 10 in its entirety, and inserting the following text in lieu thereof:




(a)	The number of directors shall consist of not less than three members, the exact number of which shall be fixed from time to time by resolution adopted by the Board of Directors; provided, that no decrease in the number of directors shall have the effect of shortening the term of any incumbent director. Directors shall be natural persons 18 years of age or older, but need not be residents of the State of Florida or shareholders of the Corporation.




(b)	The members of the Board of Directors elected at the 2010 annual meeting of Shareholders shall be divided into three classes, designated as Class I, Class II, and Class III as specified in the resolution adopted by Shareholders at such meeting. Each Class shall consist, as nearly as may be possible, of one-third of the total number of directors constituting the entire Board of Directors. The Class I directors elected at the 2010 annual meeting of Shareholders shall be deemed elected for a three-year term, Class II directors for a two-year term, and Class III directors for a one-year term. Each director shall hold office until the next annual meeting of Shareholders upon which his/her term expires and until his/her successor is elected and qualified, or until his/her earlier death, resignation or removal. At each succeeding annual meeting of Shareholders, successor directors to the Class of directors whose term expires at that annual meeting of Shareholders shall be elected for a three-year term. If the number of directors has changed, any increase or decrease shall be apportioned among the Classes so as to maintain the number of directors in each Class as nearly equal as possible.




(c)	Any vacancies occurring on the Board of Directors, including a vacancy resulting from an increase in the number of directors, may be filled only by the affirmative vote of a majority of the remaining members of the Board of Directors, even if less than a quorum, at any meeting of the Board of Directors. Notwithstanding the immediately preceding sentence, the Board of Directors may by resolution determine that any such vacancies shall be filled by the Shareholders of the Corporation. A director elected to fill a vacancy occurring on the Board of Directors, including a vacancy resulting from an increase in the number of directors, shall hold office until the next annual meeting of Shareholders upon which his/her term expires and until his/her successor is elected and qualified, or until his/her earlier death, resignation or removal.




(d)	A director may be removed from office only for cause as hereinafter defined and at a meeting of Shareholders called expressly for that purpose by a vote of the holders of 66-2/3% of the shares cast that are entitled to vote at an election of directors. For purposes of this provision, “cause" shall mean (i) a conviction of a felony regardless of whether it relates to the Corporation or its securities; (ii) declaration of incompetency or unsound mind by court order; or (iii) commission of an action that constitutes intentional misconduct or a knowing violation of law that, in either case, results in a material injury to the Corporation.”

IN WITNESS WHEREOF, the undersigned has executed these Articles of Amendment on May 14, 2010.






	MIMEDX GROUP, INC.

	By:		/s/ Parker H. Petit
	Name:		Parket H. Petit
	Its:		Chairman & CEO

ARTICLES OF AMENDMENT

TO THE

ARTICLES OF INCORPORATION

MIMEDX GROUP, INC.

MiMedx Group, Inc., a corporation organized and existing under the laws of the State of Florida, hereby certifies as follows:




1.	The name of the corporation is MiMedx Group, Inc. (the “Corporation”).




2.	Pursuant to Section 607.1003 of the Florida Business Corporation Act (the “Act”), these Articles of Amendment (“Articles of Amendment”) amend the Articles of Incorporation of the Corporation filed in the Office of the Department of State of the State of Florida on February 28, 2008, as amended by the Articles of Merger filed in the Office of the Department of State of the State of Florida on March 31, 2008, and the Articles of Amendment filed in the Office of the Department of State of the State of Florida on May 14, 2010, (as amended, the “Amended Articles”).




3.	These Articles of Amendment were duly adopted by the Board of Directors of the Corporation on November 14, 2011, in accordance with the provisions of Section 607.1003 of the Act.




4.	These Articles of Amendment were duly approved by holders of a majority of the outstanding shares of the Common Stock of the Corporation in accordance with the provisions of Section 607.1003 of the Act and the Amended Articles on December 14, 2011.




5.	The Amended Articles are hereby amended by deleting the first paragraph of Article 3 in its entirety, and inserting the following text in lieu thereof:

IN WITNESS WHEREOF, the undersigned has executed these Articles of Amendment on August 8, 2012.






	MIMEDX GROUP, INC.

	By:		/s/ Michael J. Senken
	Name:		Michael J. Senken
	Its:		Chief Financial Officer

ARTICLES OF AMENDMENT

TO THE

ARTICLES OF INCORPORATION

MIMEDX GROUP, INC.

MiMedx Group, Inc., a corporation organized and existing under the laws of the State of Florida, hereby certifies as follows:




1.	The name of the corporation is MiMedx Group, Inc. (the “Corporation”).




2.	Pursuant to Section 607.1003 of the Florida Business Corporation Act (the “Act”), these Articles of Amendment (“Articles of Amendment”) amend the Articles of Incorporation of the Corporation filed in the Office of the Department of State of the State of Florida on February 28, 2008, as amended by the Articles of Merger filed in the Office of the Department of State of the State of Florida on March 31, 2008, the Articles of Amendment filed in the Office of the Department of State of the State of Florida on May 14, 2010, and the Articles of Amendment filed in the Office of the Department of State of the State of Florida on August 8, 2012 (as amended, the “Amended Articles”).




3.	These Articles of Amendment were duly adopted by the Board of Directors of the Corporation in accordance with the provisions of Section 607.1003 of the Act on August 2, 2012.




4.	These Articles of Amendment were duly approved by holders of a majority of the outstanding shares of the Common Stock of the Corporation in accordance with the provisions of Section 607.1003 of the Act and the Amended Articles on October 31, 2012.




5.	The Amended Articles are hereby amended by deleting the first paragraph of Article 3 in its entirety, and inserting the following text in lieu thereof:

Article 3. Capital Stock. The total number of shares of stock which the Corporation shall have authority to issue is not more than 135,000,000 shares of capital stock, of which 130,000,000 shares shall be designated “Common Stock,” at $.001 par value per share, and 5,000,000 shares shall be designated as “Preferred Stock,” at $.001 par value per share.

IN WITNESS WHEREOF, the undersigned has executed these Articles of Amendment on October 31, 2012.






	MIMEDX GROUP, INC.

	By:		/s/ Roberta L. McCaw
	Name:		Roberta l. McCaw
	Its:		Secretary

Articles of Amendment to the Articles of Incorporation

MiMedx Group, Inc.

MiMedx Group, Inc., a corporation organized and existing under the laws of the State of Florida, hereby certifies as follows:

1. The name of the corporation is MiMedx Group, Inc. (the “Company”).

2. Pursuant to Section 607.1003 of the Florida Business Corporation Act (the “Act”), these Articles of Amendment (“Articles of Amendment”) amend the Articles of Incorporation of the Company filed in the Office of the Department of State of the State of Florida on February 28, 2008, as amended by the Articles of Merger filed in the Office of the Department of State of the State of Florida on March 31, 2008, the Articles of Amendment filed in the Office of the Department of State of the State of Florida on May 14, 2010, the Articles of Amendment filed in the Office of the Department of State of the State of Florida on August 8, 2012, and the Articles of Amendment filed in the Office of the Department of State of the State of Florida on October 31, 2012 (as amended, the “Amended Articles”).

3. These Articles of Amendment were duly adopted by the Board of Directors of the Corporation in accordance with the provisions of Section 607.1003 of the Act on March 24, 2015.

4. These Articles of Amendment were duly approved by the shareholders of Company in accordance with the provisions of Section 607.1003 of the Act and the Amended Articles on May 14, 2015.

5. The Amended Articles are hereby amended by deleting the first paragraph of Article 3 in its entirety, and inserting the following text in lieu thereof:

"Article 3. Capital Stock. The total number of shares of stock which the Corporation shall have authority to issue is not more than 155,000,000 shares of capital stock, of which 150,000,000 shares shall be designated “Common Stock,” at $.001 par value per share, and 5,000,000 shares shall be designated as “Preferred Stock,” at $.001 par value per share.

IN WITNESS WHEREOF, the undersigned has executed these Articles of Amendment on May 15, 2015.

MIMEDX GROUP, INC.

By: /s/ Alexandra O. Haden

Name: Alexandra O. Haden

Its: Secretary

EX-3.2 3 exhibit32-xmimedxxbylaws.htm EXHIBIT 3.2 Exhibit

Effective as of December 14, 2016

BYLAWS

MIMEDX GROUP, INC.

ARTICLE I

Corporate Offices

Section 1. Principal and Registered Offices. The principal office of the Corporation shall be located at such place as the Board of Directors may specify from time to time. The Corporation shall have and continuously maintain a registered office and registered agent in accordance with the provisions of Section 607.0501 of the Florida Business Corporation Act, as amended (or any successor statute) (the “Act”).

Section 2. Other Offices. The Corporation may have offices at such other places, either within or without the State of Florida, as the Board of Directors may from time to time determine.

ARTICLE II

Meetings of Shareholders

Section 1. Place of Meeting. Meetings of shareholders shall be held at the principal office of the Corporation or at such other place or places, either within or without the State of Florida, as the Board of Directors shall designate. In the absence of any such designation, meetings of shareholders shall be held at the principal executive office of the Corporation.

Section 2. Annual Meeting. The annual meeting of shareholders shall be held each year on a date and at a time designated by the Board of Directors. At the annual meeting, directors shall be elected and any other proper business may be transacted.

Section 3. Special Meeting. A special meeting of the shareholders for any purpose or purposes may be called at any time by the Chairman of the Board or the Chief Executive Officer, and shall be called by the Secretary at the written request of, or by resolution adopted by: (a) a majority of the Board of Directors; or (b) the holders of 50% of the outstanding shares of capital stock of the Corporation entitled to vote at such meeting, in which case, such request shall state the purpose of the proposed meeting.

Section 4. Notice of Meetings. Except as otherwise provided by applicable law, written, printed, or electronic notice, stating the place, date and hour of the meeting and, in the case of a special meeting, the purpose or purposes of the meeting, shall be given not less than ten (10) days nor more than sixty (60) days before the date of the meeting to each shareholder of record entitled to vote at the meeting, except that no notice of a meeting need be given to any shareholder for which notice is not required to be given under applicable law. Such notice shall be given either personally, by first-class mail, by telegraphic or other written communication, or by a form of electronic transmission then consented to by the shareholder to whom the notice is given. If notice is mailed at least 30 days before the date of the meeting, the notice may be mailed by a class of United States mail other than first class. Notices not personally delivered shall be sent charges prepaid and shall be addressed to the shareholder at the address of such shareholder appearing on the books of the Corporation or given by the shareholder to the Corporation for the purpose of notice. Notice shall be deemed to have been given at the time when delivered personally, deposited in the mail, sent by telegram or other means of written communication, or electronically transmitted to the shareholder in a manner authorized by the shareholder.

Section 5. Proxies. Each shareholder entitled to vote at a meeting of shareholders may authorize another person or persons to act for him or her by proxy, but no such proxy shall be voted or acted upon after eleven (11) months from its date, unless the proxy provides for a longer period. The revocability of a proxy that states on its face that it is irrevocable shall be governed by the provisions of Section 607.0722 of the Act.

Section 6. Quorum. Except as otherwise provided by law, the holders of a majority of the issued and outstanding shares of capital stock of the Corporation entitled to vote at a meeting of shareholders, present in person or represented by proxy, shall constitute a quorum for the transaction of business at such meeting. In the absence of a quorum, the chairman of the meeting shall have the power to adjourn the meeting in accordance with Article II, Section 7, of these bylaws. If a quorum is initially present, the shareholders may continue to transact business until adjournment, notwithstanding the withdrawal of enough shareholders to leave less than a quorum, if any action taken is approved by a majority of the shareholders initially constituting a quorum for that meeting.

Section 7. Adjourned Meeting. When a meeting is adjourned to another time and place, unless these bylaws otherwise require, notice need not be given of the adjourned meeting if the time and place thereof are announced at the meeting at which the adjournment is taken. At the adjourned meeting, the Corporation may transact any business that may have been transacted at the original meeting. If a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each shareholder of record as of such new record date entitled to vote at the meeting.

Section 8. Voting of Shares. Each outstanding share of voting capital stock of the Corporation shall be entitled to one vote on each matter submitted to a vote at a meeting of the shareholders, except as otherwise provided in the Articles of Incorporation of the Corporation. Except as otherwise provided by law, the Articles of Incorporation of the Corporation or these bylaws, if a quorum is present:

(I) a nominee for director shall be elected by a majority of the votes cast by the shares entitled to vote on the election; provided, however that directors shall be elected by a plurality of the votes cast by the shares entitled to vote in the election at such meeting if the number of nominees for director exceeds the number of directors to be elected. In the event an incumbent director fails to receive a majority of the votes cast (unless, as provided above, the director election standard is a plurality of the votes cast), the incumbent director shall promptly tender his or her resignation to the Board of Directors. The Nominating and Corporate Governance Committee of the Board of Directors will make a recommendation to the Board of Directors on whether to accept or reject the resignation, or whether other action should be taken. The Board of Directors, taking into account the recommendation of the Nominating and Corporate Governance Committee, will determine whether to accept or reject such resignation, or what other action should be taken, within 100 days from the date of the certification of election results; and

(II) action on any matter other than the election of directors shall be approved if the votes cast by the holders of shares represented at the meeting and entitled to vote on the subject matter favoring the action exceed the votes cast opposing the action.

Section 9. Shareholder Nominations and Proposals. Nominations for election as a director and proposals for shareholder action may be made only by shareholders of the Corporation of record at the time of the giving of notice provided for herein and shall be made in writing and shall be delivered or mailed to the Secretary of the Corporation: (a) in the case of an annual meeting of shareholders that is called for a date that is within thirty (30) days before or after the anniversary date of the immediately preceding annual meeting of shareholders, not less than one hundred twenty (120) days prior to such anniversary date; and (b) in the case of an annual meeting of shareholders that is called for a date that is not within thirty (30) days before or after the anniversary date of the immediately preceding annual meeting of shareholders, or in the case of a special meeting of shareholders, not later than the close of business on the tenth (10th) day following the day on which the notice of meeting was mailed or public disclosure of the date of the meeting was made, whichever occurs first. Such notification shall contain a written statement of the shareholder’s proposal and of the reasons therefor, his name and address and number of shares owned, and, in the case of the nomination of a director, nominations shall contain the following information to the extent known by the notifying shareholder: (i) the name, age and address of each proposed nominee; (ii) the principal occupation of each proposed nominee; (iii) the nominee’s qualifications to serve as a director; (iv) such other information relating to such nominee as required to be disclosed in solicitation of proxies for the election of directors pursuant to the rules and regulations of the Securities and Exchange Commission; (v) the name and residence address of the notifying shareholder; and (vi) the number of shares owned by the notifying shareholder, and shall be accompanied by the nominee’s written consent to being named a nominee and serving as a director if elected. A shareholder making any proposal shall also comply with all applicable requirements of the Securities Exchange Act of 1934, as amended. Nominations or proposals not made in accordance herewith may be disregarded by the chairman of the meeting in his discretion, and upon his instructions all votes cast for each such nominee or for such proposal may be disregarded.

Section 10. Record Date for Shareholder Notice. The Board of Directors may fix a date as the record date for the purpose of determining shareholders entitled to notice of or to vote at any meeting of shareholders. Such record date shall not precede the date on which the Board of Directors adopted the resolution fixing the record date and shall not be more than seventy (70) days or less than ten (10) days prior to the date of such meeting. If the Board of Directors does not fix a record date, the record date for determining shareholders entitled to notice of or to vote at a meeting of shareholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. The determination of shareholders of record entitled to notice of or to vote at a meeting of shareholders shall apply to any adjournment of the meeting unless the Board of Directors fixes a new record date for the adjourned meeting.

Section 11. List of Shareholders. It shall be the duty of the Secretary or other officer of the Corporation who shall have charge of the stock records, either directly or through a transfer agent appointed by the Board of Directors, to prepare and make, at least ten (10) days before every meeting of shareholders, a complete list of shareholders entitled to vote at such meeting arranged in alphabetical order, and showing the address of each shareholder and the number of shares registered in the name of each shareholder. Such list shall be open to the examination of any shareholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten (10) days prior to the meeting, either at the Corporation’s principal office or at a place specified in the notice of the meeting. The list shall also be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any shareholder who is present.

Section 12. Inspectors of Elections.

(a) Appointment of Inspectors of Election. In advance of any meeting of shareholders, the Board of Directors may appoint one or more persons, other than nominees for office, as inspectors of election to act at such meeting or any adjournment thereof. If inspectors of election are not so appointed, the chairman of any such meeting may, and on the request of any shareholder or his proxy shall, appoint inspectors of election at the meeting. In case any person appointed as inspector fails to appear or fails or refuses to act, the vacancy may be filled by appointment by the Board of Directors in advance of the meeting, or at the meeting by the chairman of the meeting.

(b) Duties of Inspectors. The inspectors of election shall determine the number of shares outstanding and the voting power of each, the shares represented at the meeting, the existence of a quorum, the authenticity, validity and effect of proxies and ballots, receive votes, ballots or consents, count and tabulate all votes and ballots, determine the results, retain for a reasonable period a record of the disposition of any challenges made to any determination by the inspectors, certify their determination of the number of shares represented at the meeting and their count of all votes and ballots, and do such acts as may be proper to conduct the election or vote with fairness to all shareholders. The inspectors of election shall perform their duties impartially, in good faith, to the best of their ability and as expeditiously as is practical.

(c) Vote of Inspectors. If there are more than one inspectors of election, the decision, act or certificate of a majority is effective in all respects as the decision, act or certificate of all.

(d) Report of Inspectors. On request of the chairman of the meeting or of any shareholder or his proxy, the inspectors shall make a report in writing of any challenge or question or matter determined by them and execute a certificate of any fact found by them. Any report or certificate made by them is prima facie evidence of the facts stated herein.

Section 13. Action Without Meeting. Any action that the shareholders could take at a meeting may be taken without a meeting if one or more written consents, setting forth the action taken, shall be signed and dated, before or after such action, by the holders of outstanding stock of each voting group entitled to vote thereon having not less than the minimum number of votes with respect to each voting group that would be necessary to authorize or take such action at a meeting at which all voting groups and shares entitled to vote thereon were present and voted. The consent shall be delivered to the Corporation for inclusion in the minutes or filing with the corporate records. The Corporation shall give notice of any action so taken within ten (10) days of the date of such action to those shareholders entitled to vote thereon who did not give their written consent and to those shareholders not entitled to vote thereon.

Section 14. Remote Communication. If authorized by the Board of Directors, and subject to such guidelines and procedures as the Board of Directors may adopt, shareholders and proxy holders not physically present at an annual or special meeting of shareholders may, by means of remote communication:

(a) Participate in such meeting of shareholders.

(b) Be deemed present in person and vote at such meeting, whether the meeting is to be held at a designated place or solely by means of remote communication, provided that:

(i) the Corporation shall implement reasonable measures to verify that each person deemed present and permitted to vote at the meeting by means of remote communication is a shareholder or proxy holder;

(ii) the Corporation shall implement reasonable measures to provide such shareholders or proxy holders a reasonable opportunity to participate in the meeting and to vote on matters submitted to the shareholders, including, without limitation, an opportunity to communicate and to read or hear the proceedings of the meeting substantially concurrently with such proceedings; and

(iii) if any shareholder or proxy holder votes or takes other action at the meeting by means of remote communication, a record of such vote or other action shall be maintained by the Corporation.

ARTICLE III

Board of Directors

Section 1. General Powers. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors except as otherwise provided by law, the Articles of Incorporation of the Corporation or these bylaws.

Section 2. Number, Term and Qualification. As provided in the Articles of Incorporation, the number of directors shall consist of not less than three members, the exact number of which shall be fixed from time to time by resolution adopted by the Board of Directors; provided, that no decrease in the number of directors shall have the effect of shortening the term of any incumbent director. The members of the Board of Directors elected at the 2010 annual meeting of shareholders shall be divided into three classes, designated as Class I, Class II, and Class III as specified in the resolution adopted by shareholders at such meeting. Each Class shall consist, as nearly as may be possible, of one-third of the total number of directors constituting the entire Board of Directors. The Class I directors elected at the 2010 annual meeting of shareholders shall be deemed elected for a three-year term, Class II directors for a two-year term, and Class III directors for a one-year term. Each director shall hold office until the next annual meeting of shareholders upon which his/her term expires and until his/her successor is elected and qualified, or until his/her earlier death, resignation or removal. At each succeeding annual meeting of shareholders, successor directors to the Class of directors whose term expires at that annual meeting of shareholders shall be elected for a three-year term. If the number of directors has changed, any increase or decrease shall be apportioned among the Classes so as to maintain the number of directors in each Class as nearly equal as possible. Directors shall be natural persons 18 years of age or older, but need not be residents of the State of Florida or shareholders of the Corporation.

Section 3. Removal. As provided in the Articles of Incorporation, a director may be removed from office only for cause as hereinafter defined and at a meeting of shareholders called expressly for that purpose by a vote of the holders of 66- 2/3 % of the shares cast that are entitled to vote at an election of directors. For purposes of this provision, “cause” shall mean (i) a conviction of a felony regardless of whether it relates to the Corporation or its securities; (ii) declaration of incompetency or unsound mind by court order; or (iii) commission of an action that constitutes intentional misconduct or a knowing violation of law that, in either case, results in a material injury to the Corporation.

Section 4. Resignation. Any director of the Corporation may resign at any time by giving written notice to the Chairman of the Board, the Chief Executive Officer or the Secretary of the Corporation. Such resignation shall be effective upon the giving of such notice or at such later time as shall be specified therein. The acceptance of such resignation shall not be necessary to make it effective.

Section 5. Vacancies. As provided in the Articles of Incorporation, any vacancies occurring on the Board of Directors, including a vacancy resulting from an increase in the number of directors, may be filled only by the affirmative vote of a majority of the remaining members of the Board of Directors, even if less than a quorum, at any meeting of the Board of Directors. Notwithstanding the immediately preceding sentence, the Board of Directors may by resolution determine that any such vacancies shall be filled by the shareholders of the Corporation. A director elected to fill a vacancy occurring on the Board of Directors, including a vacancy resulting from an increase in the number of directors, shall hold office until the next annual meeting of shareholders upon which his/her term expires and until his/her successor is elected and qualified, or until his/her earlier death, resignation or removal.

Section 6. Compensation. Directors and members of committees may receive such compensation, if any, for their services as such and may be reimbursed for expenses of attendance at meetings of the Board or a committee as may be fixed or determined by resolution of the Board of Directors. Any director may serve the Corporation in any other capacity and receive compensation therefor.

ARTICLE IV

Meetings of Directors

Section 1. Annual Meetings. The annual meeting of the Board of Directors for the purpose of electing officers and transacting such other business as may be brought before the meeting shall be held immediately following the annual meeting of the shareholders at the place where such meeting is held. Notice of annual meetings shall not be required.

Section 2. Regular Meetings. The Board of Directors may by resolution provide for the holding of regular meetings of the Board on specified dates and at specified times. If any date for which a regular meeting is scheduled shall be a legal holiday, the meeting shall be held on the next business day that is not a legal holiday. Regular meetings of the Board of Directors shall be held at the principal executive office of the Corporation or at such other place as may be determined by resolution of the Board of Directors. Notice of regular meetings shall not be required.

Section 3. Special Meetings. Special meetings of the Board of Directors may be called by or at the request of the Chairman of the Board, the Chief Executive Officer, or the Secretary. Such meetings may be held at the time and place designated in the notice of the meeting.

Section 4. Notice of Special Meetings. Notice of the time and place of special meetings shall be given to each director: (a) in a writing mailed not less than five days before such meeting addressed to the residence or usual place of business of a director; (b) by facsimile, telecopy or telegram sent not less than two days before such meeting to the residence or usual place of business of a director; or (c) in person or by telephone delivered not less than one day before such meeting, or (d) by electronic mail or other electronic means, during normal business hours, not less than one day before such meeting. Attendance by a director at a meeting for which notice is required shall constitute a waiver of notice, except where a director attends the meeting for the express purpose of objecting to the transaction of any business because the meeting is not lawfully called. Except as otherwise herein provided, neither the business to be transacted at, nor the purpose of, any special meeting of the Board of Directors need be specified in the notice of such meeting.

Section 5. Quorum. A majority of the Board of Directors shall constitute a quorum for the transaction of business at a meeting of the Board of Directors. If a quorum is initially present, the Board of Directors may continue to transact business, notwithstanding the withdrawal of enough directors to leave less than a quorum, if any action taken is approved by a majority of the directors initially constituting a quorum for that meeting.

Section 6. Adjourned Meeting. A majority of the directors present, whether or not constituting a quorum, may adjourn any meeting of the Board of Directors to another time and place. Notice of the time and place of holding an adjourned meeting of the Board of Directors need not be given unless the meeting is adjourned for more than forty-eight (48) hours. If the meeting is adjourned for more than forty-eight (48) hours, then notice of the time and place of the adjourned meeting shall be given before the adjourned meeting takes place, in the manner specified in Article IV, Section 4 of these bylaws, to the directors who were not present at the time of the adjournment.

Section 7. Manner of Acting. Except as otherwise provided by law, these bylaws or the Articles of Incorporation of the Corporation, the act of the majority of the directors present at a duly held meeting at which a quorum is present shall be the act of the Board of Directors.

Section 8. Action Without Meeting. Any action required or permitted to be taken at any meeting of the Board of Directors may be taken without a meeting if all members of the Board of Directors consent thereto in writing, and the writing or writings are filed with the minutes of proceedings of the Board of Directors, whether done before or after the action is taken. Such unanimous written consent shall have the same force and effect as a unanimous vote at a meeting, and may be stated as such in any articles, certificates or documents filed with the Department of State of Florida or any other State wherein the Corporation may do business.

Section 9. Presumption of Assent. A director of the Corporation who is present at a meeting of the Board of Directors at which action on any corporate matter is taken shall be presumed to have assented to the action taken unless such director objects at the beginning of the meeting (or promptly upon his or her arrival) to the holding the meeting or the transacting of specified business at the meeting or such director votes against such action or abstains from voting in respect of such matter.

Section 10. Meeting by Use of Conference Telephone. Any one or more directors may participate in a meeting of the Board of Directors by means of a conference telephone or similar communications device which allows all persons participating in the meeting to hear each other, and such participation in a meeting shall be deemed presence in person at such meeting, except where a person participates in the meeting for the express purpose of objecting to the transaction of any business on the ground that the meeting is not lawfully called or convened.

ARTICLE V

Committees

Section 1. Designation of Committees. The Board of Directors may, by resolution passed by a majority of the Board of Directors, designate one or more committees, each committee to consist of one or more of the directors of the Corporation. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. Any such committee, to the extent provided in these bylaws or in the resolution of the Board of Directors establishing the same, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation; provided, however, that no such committee shall have the power or authority to: (a) approve or recommend to shareholders actions or proposals required by the Act to be approved by shareholders; (b) fill vacancies on the Board of Directors or any committee thereof; (c) authorize or approve the reacquisition of shares unless pursuant to a general formula or method specified by the Board of Directors; (d) authorize or approve the issuance or sale or contract for the sale of shares, or determine the designation and relative rights, preferences and limitations of a voting group, except that the Board of Directors may authorize a committee to do so within specifically prescribed limits; or (e) adopt, amend or repeal these bylaws. Such committees or committees shall have such name or names as may be determined from time to time by resolution adopted by the Board of Directors.

Section 2. Minutes. Each committee shall keep minutes of its proceedings and shall report thereon to the Board of Directors when required.

Section 3. Meetings and Action of Committees. Meetings and actions of committees shall be governed by, and held in accordance with, the following provisions of Article IV of these bylaws: Section 2 (regular meetings), Section 3 (special meetings), Section 4 (notice of special meetings), Section 5 (quorum), Section 6 (adjourned meeting), Section 7 (manner of acting), Section 8 (action without meeting) and Section 10 (meeting by use of conference telephone), with such changes in the context of such bylaws as are necessary to substitute the committee and its members for the Board of Directors and its members; provided, however, that the time of regular meetings of committees may be determined either by resolution of the Board of Directors or by resolution of the committee, that special meetings of committees may also be called by resolution of the Board of Directors, and that notice of special meetings of committees shall also be given to all alternative members, who shall have the right to attend all meetings of the committee. The Board of Directors may adopt rules for the governance of any committee not inconsistent with the provisions of these bylaws.

ARTICLE VI

Officers

Section 1. Titles. The officers of the Corporation shall be elected by the Board of Directors and shall consist of a Chairman of the Board, a Chief Executive Officer, a President, a Chief Financial Officer, a Secretary, and a Treasurer. The Board of Directors may also elect a Controller and one or more Vice Presidents and Assistant Secretaries, Assistant Treasurers and such other officers as it shall deem necessary. Except as otherwise provided in these bylaws, the additional officers shall have the authority and perform the duties as from time to time may be prescribed by the Board of Directors. Any two or more offices may be held by the same individual, but no officer may act in more than one capacity where action of two or more officers is required.

Section 2. Election and Term. The officers of the Corporation shall be elected by the Board of Directors at the annual meeting of the Board held each year immediately following the annual meeting of the shareholders, and each officer shall hold office until the next annual meeting at which officers are to be elected and until his successor is elected and qualified, or until his earlier resignation or removal pursuant to these bylaws.

Section 3. Removal. Any officer or agent elected or appointed by the Board of Directors may be removed, with or without cause, by the Board of Directors, but removal shall be without prejudice to any contract rights of the individual removed. Election or appointment of an officer or agent shall not of itself create contract rights.

Section 4. Resignation. Any officer of the Corporation may resign at any time by giving written notice to the Corporation. Such resignation shall be effective upon the giving of such notice or at such later time as shall be specified therein. The acceptance of such resignation shall not be necessary to make it effective.

Section 5. Vacancies. Any vacancies among the officers for any reason (including death, resignation, disqualification, removal or other causes) may be filled by the Board of Directors in the manner prescribed in these bylaws for regular elections to that office.

Section 6. Compensation. The compensation of the officers shall be fixed by or under the direction of the Board of Directors. No officer shall be prevented from receiving such compensation by reason of the fact that such officer is also a director of the Corporation.

Section 7. Chairman of the Board. The Chairman of the Board shall have general executive powers, as well as the specific powers conferred by these bylaws. Except as otherwise provided in these bylaws, he shall preside at all meetings of the Board of Directors. The Chairman of the Board may but need not be an employee of the Corporation.

Section 8. Chief Executive Officer. The Chief Executive Officer shall have general charge of the business and affairs of the Corporation. The Chief Executive Officer may perform such acts, not inconsistent with the applicable law or the provisions of these bylaws, usually performed by the principal executive officer of a corporation and may sign and execute all authorized notes, bonds, contracts and other obligations in the name of the Corporation. The Chief Executive Officer shall have such other powers and perform such other duties as the Board of Directors shall designate or as may be provided by applicable law or elsewhere in these bylaws.

Section 9. President. The President shall have responsibility for the day-to-day operations of the business of the Corporation and shall report to the Chief Executive Officer. The President may perform such acts, not inconsistent with the applicable law or the provisions of these bylaws, usually performed by the chief operating officer of a corporation and may sign and execute all authorized notes, bonds, contracts and other obligations in the name of the Corporation. The President shall have such other powers and perform such other duties as the Board of Directors shall designate or as may be provided by applicable law or elsewhere in these bylaws, and in the event of the disability or death of the Chief Executive Officer, he shall perform the duties of the Chief Executive Officer unless and until a new Chief Executive Officer is elected by the directors.

Section 10. Chief Financial Officer. The Chief Financial Officer of the Corporation shall keep and maintain, or cause to be kept and maintained, adequate and correct books and records of accounts of the properties and business transactions of the Corporation, including accounts of its assets, liabilities, receipts, disbursements, gains, losses, capital, retained earnings and shares. The books of account shall at all reasonable times be open to inspection by any director for a purpose reasonably related to his position as a director. The Chief Financial Officer shall render to the Chief Executive Officer and Board of Directors, whenever they may request it, an account of the transactions of the Corporation and of the financial condition of the Corporation. The Chief Financial Officer shall have such other powers and perform such other duties as the Board of Directors shall designate or as may be provided by applicable law or elsewhere in these bylaws.

Section 11. Vice Presidents. Each Vice President shall have such powers and perform such duties as shall be assigned to him by the Board of Directors.

Section 12. Secretary. The Secretary shall keep, or cause to be kept, accurate records of the acts and proceedings of all meetings of shareholders and of the Board of Directors and shall give all notices required by law and by these bylaws. The Secretary shall have general charge of the corporate books and records and of the corporate seal and shall affix the corporate seal to any lawfully executed instrument requiring it. The Secretary shall have general charge of the stock transfer books of the Corporation and shall keep, or cause to be kept, at the principal office of the Corporation a record of shareholders, showing the name and address of each shareholder and the number and class of the shares held by each shareholder. The Secretary shall sign such instruments as may require the signature of the Secretary, and in general may perform such acts, not inconsistent with the applicable law or the provisions of these bylaws, usually performed by the secretary of a corporation. The Secretary shall have such other powers and perform such other duties as the Board of Directors shall designate from time to time.

Section 13. Assistant Secretaries. Each Assistant Secretary shall have such powers and perform such duties as may be assigned by the Board of Directors, and the Assistant Secretaries shall exercise the powers of the Secretary during that officer’s absence or inability to act.

Section 14. Treasurer. The Treasurer shall have the custody of the corporate funds and securities and shall keep and maintain, or cause to be kept and maintained, full and accurate accounts of receipts and disbursements. The Treasurer shall deposit all monies and other valuables in the name and to the credit of the Corporation in such depositories as may be designated by the Board of Directors. The Treasurer shall disburse funds of the Corporation as may be ordered by the Board of Directors, the Chief Executive Officer or the President, taking proper vouchers for such disbursements. The Treasurer shall also have such powers and perform such duties incident to the office as may be assigned from time to time by the Board of Directors.

Section 15. Assistant Treasurers. Each Assistant Treasurer shall have such powers and perform such duties as may be assigned by the Board of Directors, and the Assistant Treasurers shall exercise the powers of the Treasurer during that officer’s absence or inability to act.

Section 16. Controller and Assistant Controllers. The Controller shall have charge of the accounting affairs of the Corporation and shall have such other powers and perform such other duties as the Board of Directors shall designate. The Controller shall report to the Chief Financial Officer. Each Assistant Controller shall have such powers and perform such duties as may be assigned by the Board of Directors, and the Assistant Controllers shall exercise the powers of the Controller during that officer’s absence or inability to act.

Section 17. Voting Upon Stocks. Unless otherwise ordered by the Board of Directors, the Chairman of the Board and the Chief Executive Officer shall have full power and authority on behalf of the Corporation to attend, act and vote at meetings of the shareholders of any Corporation in which this Corporation may hold stock, and at such meetings shall possess and may exercise any and all rights and powers incident to the ownership of such stock and which, as the owner, the Corporation might have possessed and exercised. The Board of Directors may by resolution from time to time confer such power and authority upon any other person or persons.

ARTICLE VII

Capital Stock

Section 1. Certificated and Uncertificated Shares

(a) The interest of each shareholder may but need not be evidenced by a certificate or certificates representing shares of the Corporation which shall be in such form as the Board of Directors may from time to time adopt and shall be numbered and entered into the books of the Corporation as they are issued. Each certificate representing shares shall set forth upon the face thereof the following:

(i) the name of the Corporation;

(ii) that the Corporation is organized under the laws of the State of Florida;

(iii) the name or names of the person or persons to whom the certificate is issued;

(iv) the number and class of shares, and the designation of the series, if any, which the certificate represents;

(v) if different classes of shares or different series within a class are authorized, then the designations, relative rights, preferences, and limitations determined for each series (and the authority of the Board of Directors to determine variations for future series) must be summarized on the front or back of each certificate, or, alternatively, each certificate may state conspicuously on its front or back that the Corporation will furnish the shareholder a full statement of this information on request and without charge; and

(vi) if any shares represented by the certificates are subject to any restrictions on the transfer or the registration of transfer of shares, then such restrictions shall be noted conspicuously on the front or back of such certificates.

(b) Each certificate shall be signed, either manually or in facsimile, by the Chairman of the Board, the Chief Executive Officer, the President or a Vice President and the Secretary or an Assistant Secretary and may be sealed with the seal of the Corporation or a facsimile thereof. If a certificate is countersigned by a transfer agent or registered by a registrar, other than the Corporation itself or an employee of the Corporation, the signature of any such officer of the Corporation may be a facsimile. In case any officer or officers who shall have signed, or whose facsimile signature or signatures shall have been used on, any such certificate or certificates shall cease to be such officer or officers of the Corporation, whether because of death, resignation, or otherwise, before such certificate or certificates shall have been delivered by the Corporation, such certificate or certificates may nevertheless be delivered as though the person or persons who signed such certificate or certificates or whose facsimile signatures shall have been used thereon had not ceased to be such officer or officers.

(c) Unless the Corporation’s Articles of Incorporation provide otherwise, the Board of Directors may authorize the issue of some or all of the shares of the Corporation of any or all of its classes or series without certificates. Such authorization shall not affect shares already represented by certificates until they are surrendered to the Corporation.

(d) Within a reasonable time after the issue or transfer of shares without certificates, the Corporation shall send the shareholder then owning such shares a written statement of the information required to be placed on certificates by Section 1(a) of Article VII of these Bylaws and applicable law.

Section 2. Transfer of Shares. Transfer of record of shares of stock of the Corporation shall be made on the stock transfer books of the Corporation only upon surrender of the certificate for the shares sought to be transferred by the record holder or by a duly authorized agent, transferee or legal representative. All certificates surrendered for transfer shall be cancelled before new certificates for the transferred shares shall be issued.

Section 3. Restrictions on Transfer of Shares. The Corporation shall have the power to enter into and perform any agreement with any shareholders of the Corporation to restrict the transfer of shares of stock of the Corporation of any one or more classes owned by such shareholders in any manner not prohibited by the Act.

Section 4. Transfer Agent and Registrar. The Board of Directors may appoint one or more transfer agents and one or more registrars of transfers and may require all stock certificates to be signed or countersigned by the transfer agent and registered by the registrar of transfers.

Section 5. Regulations. The Board of Directors shall have power and authority to make rules and regulations as it may deem expedient concerning the issue, transfer and registration of certificates for shares of capital stock of the Corporation.

Section 6. Lost Certificates. The Board of Directors may authorize the issuance of a new certificate in place of a certificate claimed to have been lost or destroyed, upon receipt of an affidavit from the person explaining the loss or destruction. When authorizing issuance of a new certificate, the Board of Directors may require the claimant to give the Corporation a bond in a sum as it may direct to indemnify the Corporation against loss from any claim with respect to the certificate claimed to have been lost or destroyed; or the Board of Directors may, by resolution reciting that the circumstances justify such action, authorize the issuance of the new certificate without requiring a bond.

ARTICLE VIII

General Provisions

Section 1. Dividends. The Board of Directors may from time to time declare, and the Corporation may pay, dividends on its outstanding shares in the manner and upon the terms and conditions provided by law.

Section 2. Record Date for Purposes Other Than Shareholder Notice. The Board of Directors may fix a date as the record date for the purpose of determining shareholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the shareholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action. Such record date shall not precede the date upon which the resolution fixing the record date is adopted and shall not be more than seventy (70) days prior to such action. If no record date is fixed by the Board of Directors, the record date for determining shareholders for any such purpose shall be at the close of business on the date on which the Board of Directors adopts the resolution relating thereto.

Section 3. Seal. The seal of the Corporation may have inscribed thereon the name of the Corporation and “Florida” around the perimeter, and the words “Corporate Seal” in the center.

Section 4. Notice. Notice to directors and shareholders shall be deemed given: (a) if mailed, when deposited in the United States mail, postage prepaid, directed to the shareholder or director at such shareholder’s or director’s address as it appears on the records of the Corporation; (b) if by facsimile telecommunication, when directed to a number at which the shareholder or director has consented to receive notice; (c) if by electronic mail, when directed to an electronic mail address at which the shareholder or director has consented to receive notice; (d) if by a posting on an electronic network together with separate notice to the shareholder or director of such specific posting, upon the later of (1) such posting and (2) the giving of such separate notice; and (e) if by any other form of electronic transmission, when directed to the shareholder or director in a manner consented to by such shareholder or director.

Section 5. Waiver of Notice. Whenever notice is required to be given to a shareholder, director or other person under the provisions of these bylaws, the Articles of Incorporation of the Corporation or by applicable law, a waiver in writing signed by the person or persons entitled to the notice, whether before or after the time stated in the notice, shall be equivalent to giving the notice.

Section 6. Depositories and Checks. All funds of the Corporation shall be deposited in the name of the Corporation in such bank, banks or other financial institutions as the Board of Directors may from time to time designate and shall be drawn out on checks, drafts or other orders signed on behalf of the Corporation by such person or persons as the Board of Directors may from time to time designate.

Section 7. Bond. The Board of Directors may by resolution require any or all officers, agents and employees of the Corporation to give bond to the Corporation, with sufficient sureties, conditioned on the faithful performance of the duties of their respective offices or positions, and to comply with such other conditions as may from time to time be required by the Board of Directors.

Section 8. Fiscal Year. The fiscal year of the Corporation shall be the period ending on December 31 of each year or such other period as the Board of Directors shall from time to time determine.

Section 9. Indemnification of Directors and Officers. Each person who is or was a director or officer of the Corporation, and each person who is or was a director or officer of the Corporation who at the request of the Corporation is serving or has served as an officer, director, partner, joint venturer, trustee, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall be indemnified by the Corporation against those expenses (including attorneys’ fees), judgments, fines, penalties and amounts paid in settlement which are allowed to be paid or reimbursed by the Corporation under the laws of the State of Florida and which are actually and reasonably incurred in connection with any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, in which such person may be involved by reason of his being or having been a director or officer of this Corporation or of such other enterprises.

The Corporation may enter into indemnification agreements with members of the Board of Directors or officers which may provide for further or expanded indemnification rights or otherwise modify the rights provided under this Section 9.

Notwithstanding anything contained herein to the contrary, this Section 9 is intended to provide indemnification to each director and officer of the Corporation to the fullest extent authorized by the Act, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader rights than said statute permitted the Corporation to provide prior thereto). Neither any amendment nor repeal of this Section 9 shall eliminate or reduce the effect of this Section 9, with respect to any matter occurring, or any action or proceeding accruing or arising or that, but for this Section 9, would accrue or arise, prior to such amendment, repeal or adoption of an inconsistent provision.

Section 10. Amendments. Except as otherwise provided herein, these bylaws may be amended or repealed and new bylaws may be adopted by the affirmative vote of the holders of a majority of the capital stock issued and outstanding and entitled to vote at any meeting of shareholders or by resolution adopted by the affirmative vote of not less than a majority of the number of directors of the Corporation.

EX-21.1 4 mdxg-20161231x10xkex211.htm EXHIBIT 21.1 Exhibit

EXHIBIT 21.1

MiMedx Group, Inc.
List of Subsidiaries



Company	Jurisdiction of Organization
MiMedx, Inc.	Florida
MiMedx Processing Services, LLC	Florida
MiMedx Tissue Services, LLC	Georgia
Stability Biologics, LLC	Georgia

EX-23.1 5 mdxg-20161231x10xkex231con.htm EXHIBIT 23.1 Exhibit

Consent of Independent Registered Public Accounting Firm

We hereby consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333-153255, 333-183991, 333-189784, 333-199841, and 333-211900 and Form S-3 No. 333-189785) of our reports dated March 1, 2017, included in this Annual Report on Form 10-K of MiMedx Group, Inc. and Subsidiaries (the Company) relating to the consolidated balance sheets of the Company as of December 31, 2016 and 2015, and the related consolidated statements of operations, stockholders’ equity, and cash flows and the related consolidated financial statement schedule for each of the three years in the period ended December 31, 2016, and the effectiveness of internal control over financial reporting for the Company as of December 31, 2016.

/s/ Cherry Bekaert LLP

Atlanta, Georgia

March 1, 2017

EX-31.1 6 mdxg-20161231x10xkex311.htm EXHIBIT 31.1 Exhibit

EXHIBIT 31.1

Section 302 Certification

I, Parker H. Petit, certify that:


1.	I have reviewed this annual report on Form 10-K of MiMedx Group, Inc.;


2.	Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;


3.	Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;


4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


(a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared,


(b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles,


(c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation, and


(d)	disclosed in this annual report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):


(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 1, 2017



	/s/: Parker H. Petit
	Parker H. Petit
	Chief Executive Officer
	(principal executive officer)

EX-31.2 7 mdxg-20161231x10xkex312.htm EXHIBIT 31.2 Exhibit

EXHIBIT 31.2

Section 302 Certification

I, Michael J. Senken, certify that:


1.	I have reviewed this annual report on Form 10-K of MiMedx Group, Inc.;


2.	Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;


3.	Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;


4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


(a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared,


(b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles,


(c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation, and


(d)	disclosed in this annual report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):


(a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


(b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 1, 2017



	/s/: Michael J. Senken
	Michael J. Senken
	Chief Financial Officer
	(principal financial officer)

EX-32.1 8 mdxg-20161231x10xkex321.htm EXHIBIT 32.1 Exhibit

Exhibit 32.1

Section 906 Certification

The undersigned Parker H. Petit, the Chief Executive Officer of MiMedx Group, Inc. (the “Company”), has executed this certification in connection with the filing with the Securities and Exchange Commission of the Company’s Annual Report on Form 10-K for the year ending December 31, 2016 (the “Report”). The undersigned hereby certifies, to the best of his knowledge, that:


(1)	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 1, 2017



	/s/: Parker H. Petit
	Parker H. Petit
	Chief Executive Officer
	(principal executive officer)

EX-32.2 9 mdxg-20161231x10xkex322.htm EXHIBIT 32.2 Exhibit

Exhibit 32.2

Section 906 Certification

The undersigned Michael J. Senken, the Chief Financial Officer of MiMedx Group, Inc. (the “Company”), has executed this certification in connection with the filing with the Securities and Exchange Commission of the Company’s Annual Report on Form 10-K for the year ending December 31, 2016 (the “Report”). The undersigned hereby certifies, to the best of his knowledge, that:


(1)	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 1, 2017



	/s/: Michael J. Senken
	Michael J. Senken
	Chief Financial Officer
	(principal financial officer)

EX-101.INS 10 mdxg-20161231.xml XBRL INSTANCE DOCUMENT 0001376339 2016-01-01 2016-12-31 0001376339 2016-06-30 0001376339 2017-02-15 0001376339 2016-12-31 0001376339 2015-12-31 0001376339 2015-01-01 2015-12-31 0001376339 2014-01-01 2014-12-31 0001376339 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0001376339 us-gaap:CommonStockMember 2013-12-31 0001376339 us-gaap:CommonStockMember 2016-01-01 2016-12-31 0001376339 us-gaap:CommonStockMember 2014-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-12-31 0001376339 us-gaap:TreasuryStockMember 2016-12-31 0001376339 us-gaap:TreasuryStockMember 2016-01-01 2016-12-31 0001376339 us-gaap:CommonStockMember 2014-01-01 2014-12-31 0001376339 2014-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0001376339 us-gaap:CommonStockMember 2015-01-01 2015-12-31 0001376339 us-gaap:RetainedEarningsMember 2015-12-31 0001376339 us-gaap:TreasuryStockMember 2015-01-01 2015-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-12-31 0001376339 us-gaap:RetainedEarningsMember 2014-12-31 0001376339 us-gaap:RetainedEarningsMember 2013-12-31 0001376339 2013-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001376339 us-gaap:TreasuryStockMember 2014-12-31 0001376339 us-gaap:RetainedEarningsMember 2015-01-01 2015-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0001376339 us-gaap:CommonStockMember 2016-12-31 0001376339 us-gaap:TreasuryStockMember 2014-01-01 2014-12-31 0001376339 us-gaap:TreasuryStockMember 2015-12-31 0001376339 us-gaap:TreasuryStockMember 2013-12-31 0001376339 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0001376339 us-gaap:CommonStockMember 2015-12-31 0001376339 us-gaap:RetainedEarningsMember 2016-12-31 0001376339 us-gaap:RetainedEarningsMember 2014-01-01 2014-12-31 0001376339 us-gaap:PatentsMember 2015-01-01 2015-12-31 0001376339 2010-07-31 0001376339 us-gaap:PatentsMember 2016-01-01 2016-12-31 0001376339 us-gaap:PatentsMember 2014-01-01 2014-12-31 0001376339 us-gaap:MinimumMember 2016-01-01 2016-12-31 0001376339 us-gaap:MaximumMember 2016-01-01 2016-12-31 0001376339 mdxg:StabilityBiologicsLLCMember 2016-04-01 2016-12-31 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:LicensingAgreementsMember 2016-03-31 0001376339 mdxg:StabilityBiologicsLLCMember 2016-01-01 2016-03-31 0001376339 mdxg:StabilityBiologicsLLCMember 2016-12-31 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:TrademarksAndTradeNamesMember 2016-12-31 0001376339 mdxg:StabilityBiologicsLLCMember 2016-03-31 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:PatentsMember 2016-12-31 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:TrademarksAndTradeNamesMember 2016-04-01 2016-12-31 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:CustomerRelationshipsMember 2016-03-31 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:PatentsMember 2016-03-31 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:PatentsMember 2016-04-01 2016-12-31 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:NoncompeteAgreementsMember 2016-04-01 2016-12-31 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:LicensingAgreementsMember 2016-04-01 2016-12-31 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:LicensingAgreementsMember 2016-12-31 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:NoncompeteAgreementsMember 2016-03-31 0001376339 mdxg:StabilityBiologicsLLCMember 2016-01-01 2016-12-31 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:CustomerRelationshipsMember 2016-04-01 2016-12-31 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:TrademarksAndTradeNamesMember 2016-03-31 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:CustomerRelationshipsMember 2016-12-31 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:NoncompeteAgreementsMember 2016-12-31 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:PatentsMember 2016-01-13 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:LicensingAgreementsMember 2016-01-13 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:CustomerRelationshipsMember 2016-01-13 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:NoncompeteAgreementsMember 2016-01-13 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember 2016-01-13 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:TrademarksAndTradeNamesMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember mdxg:ShareholderDebtMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:PatentsMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:LineOfCreditMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:LoansPayableMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:CustomerRelationshipsMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:LicensingAgreementsMember 2016-01-13 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:NoncompeteAgreementsMember 2016-01-13 0001376339 us-gaap:FairValueAdjustmentToInventoryMember 2015-01-01 2015-12-31 0001376339 mdxg:StabilityBiologicsLLCMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-13 2016-01-13 0001376339 us-gaap:ProFormaMember 2015-01-01 2015-12-31 0001376339 us-gaap:ScenarioForecastMember 2017-01-01 2017-12-31 0001376339 us-gaap:CertificatesOfDepositMember 2016-12-31 0001376339 us-gaap:CertificatesOfDepositMember 2015-12-31 0001376339 us-gaap:AssetsHeldUnderCapitalLeasesMember 2016-12-31 0001376339 mdxg:LeaseholdImprovementsPaidbyOthersMember 2015-12-31 0001376339 mdxg:LeaseholdImprovementsPaidbyOthersMember 2016-12-31 0001376339 us-gaap:ConstructionInProgressMember 2016-12-31 0001376339 us-gaap:FurnitureAndFixturesMember 2015-12-31 0001376339 us-gaap:EquipmentMember 2016-12-31 0001376339 us-gaap:EquipmentMember 2015-12-31 0001376339 us-gaap:FurnitureAndFixturesMember 2016-12-31 0001376339 us-gaap:LeaseholdImprovementsMember 2015-12-31 0001376339 us-gaap:ConstructionInProgressMember 2015-12-31 0001376339 us-gaap:LeaseholdImprovementsMember 2016-12-31 0001376339 mdxg:ShrinersHospitalsForChildrenAndUniversityOfSouthFloridaResearchFoundationInc.Member us-gaap:LicensingAgreementsMember 2016-12-31 0001376339 mdxg:ShrinersHospitalsForChildrenAndUniversityOfSouthFloridaResearchFoundationInc.Member us-gaap:LicensingAgreementsMember 2007-01-28 2007-01-29 0001376339 mdxg:SurgicalBiologicsMember us-gaap:TrademarksAndTradeNamesMember 2011-01-05 0001376339 mdxg:SurgicalBiologicsMember us-gaap:PatentsMember 2016-01-01 2016-12-31 0001376339 mdxg:SurgicalBiologicsMember us-gaap:InProcessResearchAndDevelopmentMember 2011-01-05 0001376339 mdxg:ShrinersHospitalsForChildrenAndUniversityOfSouthFloridaResearchFoundationInc.Member us-gaap:LicensingAgreementsMember 2007-01-29 0001376339 mdxg:SurgicalBiologicsMember us-gaap:CustomerRelationshipsMember 2011-01-05 0001376339 mdxg:SurgicalBiologicsMember us-gaap:LicensingAgreementsMember 2011-01-05 0001376339 mdxg:SurgicalBiologicsMember us-gaap:PatentsMember 2011-01-05 0001376339 us-gaap:InProcessResearchAndDevelopmentMember 2016-12-31 0001376339 us-gaap:PatentsMember 2015-12-31 0001376339 mdxg:PatentsinProcessMember 2016-12-31 0001376339 mdxg:PatentsinProcessMember 2015-12-31 0001376339 us-gaap:PatentsMember 2016-12-31 0001376339 us-gaap:InProcessResearchAndDevelopmentMember 2015-12-31 0001376339 us-gaap:CustomerRelationshipsMember 2016-01-01 2016-12-31 0001376339 us-gaap:LicensingAgreementsMember 2016-12-31 0001376339 us-gaap:LicensingAgreementsMember 2016-01-01 2016-12-31 0001376339 us-gaap:CustomerRelationshipsMember 2016-12-31 0001376339 us-gaap:TrademarksAndTradeNamesMember 2016-12-31 0001376339 us-gaap:TrademarksAndTradeNamesMember 2015-12-31 0001376339 us-gaap:NoncompeteAgreementsMember 2015-12-31 0001376339 us-gaap:NoncompeteAgreementsMember 2016-12-31 0001376339 us-gaap:NoncompeteAgreementsMember 2016-01-01 2016-12-31 0001376339 us-gaap:LicensingAgreementsMember 2015-12-31 0001376339 us-gaap:CustomerRelationshipsMember 2015-12-31 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember us-gaap:MaximumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-10-12 2015-10-12 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember 2015-10-12 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember us-gaap:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-10-12 2015-10-12 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember 2016-12-31 0001376339 us-gaap:RevolvingCreditFacilityMember mdxg:CreditAgreementMember 2015-10-12 2015-10-12 0001376339 us-gaap:WarrantMember 2015-01-01 2015-12-31 0001376339 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-12-31 0001376339 us-gaap:ConvertibleNotesPayableMember 2014-01-01 2014-12-31 0001376339 us-gaap:WarrantMember 2014-01-01 2014-12-31 0001376339 us-gaap:WarrantMember 2016-01-01 2016-12-31 0001376339 us-gaap:ConvertibleNotesPayableMember 2016-01-01 2016-12-31 0001376339 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-12-31 0001376339 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-12-31 0001376339 us-gaap:ConvertibleNotesPayableMember 2015-01-01 2015-12-31 0001376339 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-12-31 0001376339 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-12-31 0001376339 us-gaap:CostOfSalesMember 2016-01-01 2016-12-31 0001376339 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-12-31 0001376339 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-12-31 0001376339 us-gaap:CostOfSalesMember 2014-01-01 2014-12-31 0001376339 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2014-01-01 2014-12-31 0001376339 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-01-01 2015-12-31 0001376339 us-gaap:CostOfSalesMember 2015-01-01 2015-12-31 0001376339 2014-05-12 0001376339 us-gaap:RestrictedStockMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0001376339 us-gaap:RestrictedStockMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0001376339 us-gaap:WarrantMember 2015-11-18 0001376339 us-gaap:CommonStockMember mdxg:ConsultantMember 2016-01-01 2016-12-31 0001376339 us-gaap:RestrictedStockMember 2016-12-31 0001376339 us-gaap:WarrantMember 2015-11-18 2015-11-18 0001376339 us-gaap:RestrictedStockMember 2016-01-01 2016-12-31 0001376339 mdxg:PriceRange7Member 2016-12-31 0001376339 mdxg:PriceRange4Member 2016-01-01 2016-12-31 0001376339 mdxg:PriceRange5Member 2016-01-01 2016-12-31 0001376339 mdxg:PriceRange5Member 2016-12-31 0001376339 mdxg:PriceRange1Member 2016-12-31 0001376339 mdxg:PriceRange7Member 2016-01-01 2016-12-31 0001376339 mdxg:PriceRange6Member 2016-01-01 2016-12-31 0001376339 mdxg:PriceRange2Member 2016-12-31 0001376339 mdxg:PriceRange3Member 2016-12-31 0001376339 mdxg:PriceRange4Member 2016-12-31 0001376339 mdxg:PriceRange6Member 2016-12-31 0001376339 mdxg:PriceRange2Member 2016-01-01 2016-12-31 0001376339 mdxg:PriceRange1Member 2016-01-01 2016-12-31 0001376339 mdxg:PriceRange3Member 2016-01-01 2016-12-31 0001376339 us-gaap:RestrictedStockMember 2015-12-31 0001376339 us-gaap:MaximumMember 2014-01-01 2014-12-31 0001376339 us-gaap:MaximumMember 2015-01-01 2015-12-31 0001376339 us-gaap:MinimumMember 2014-01-01 2014-12-31 0001376339 us-gaap:MinimumMember 2015-01-01 2015-12-31 0001376339 us-gaap:DomesticCountryMember 2016-12-31 0001376339 us-gaap:DomesticCountryMember 2015-12-31 0001376339 us-gaap:StateAndLocalJurisdictionMember 2016-12-31 0001376339 us-gaap:StateAndLocalJurisdictionMember 2015-12-31 0001376339 mdxg:BoneBankActionMember us-gaap:PendingLitigationMember 2015-07-10 0001376339 us-gaap:StandbyLettersOfCreditMember 2016-12-31 0001376339 mdxg:LiventaAction437PatentMember us-gaap:PendingLitigationMember 2015-08-18 0001376339 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2016-01-01 2016-12-31 0001376339 mdxg:BoneBankActionMember us-gaap:PendingLitigationMember 2015-06-29 0001376339 us-gaap:PendingLitigationMember 2016-12-31 0001376339 mdxg:LiventaAction701PatentMember us-gaap:PendingLitigationMember 2015-08-18 0001376339 2015-04-01 2015-06-30 0001376339 2015-07-01 2015-09-30 0001376339 2015-01-01 2015-03-31 0001376339 2016-01-01 2016-03-31 0001376339 2016-07-01 2016-09-30 0001376339 2016-10-01 2016-12-31 0001376339 2016-04-01 2016-06-30 0001376339 2015-10-01 2015-12-31 0001376339 mdxg:WoundCareMember 2016-01-01 2016-12-31 0001376339 mdxg:SurgicalSportsMedicineOrthopedicsSSOMember 2015-01-01 2015-12-31 0001376339 mdxg:WoundCareMember 2015-01-01 2015-12-31 0001376339 mdxg:WoundCareMember 2014-01-01 2014-12-31 0001376339 mdxg:SurgicalSportsMedicineOrthopedicsSSOMember 2016-01-01 2016-12-31 0001376339 mdxg:SurgicalSportsMedicineOrthopedicsSSOMember 2014-01-01 2014-12-31 0001376339 us-gaap:SubsequentEventMember 2017-02-28 0001376339 us-gaap:SubsequentEventMember 2017-02-01 2017-02-28 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2014-12-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2015-01-01 2015-12-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2016-01-01 2016-12-31 0001376339 mdxg:AllowanceforObsolescenceMember 2016-01-01 2016-12-31 0001376339 mdxg:AllowanceforObsolescenceMember 2014-01-01 2014-12-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2014-01-01 2014-12-31 0001376339 mdxg:AllowanceforObsolescenceMember 2015-01-01 2015-12-31 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2015-01-01 2015-12-31 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2016-01-01 2016-12-31 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2013-12-31 0001376339 mdxg:AllowanceforObsolescenceMember 2015-12-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2016-12-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2015-12-31 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2015-12-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2014-12-31 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2014-01-01 2014-12-31 0001376339 mdxg:AllowanceforObsolescenceMember 2014-12-31 0001376339 us-gaap:AllowanceForDoubtfulAccountsMember 2016-12-31 0001376339 mdxg:AllowanceforObsolescenceMember 2016-12-31 0001376339 us-gaap:AllowanceForSalesReturnsMember 2013-12-31 0001376339 mdxg:AllowanceforObsolescenceMember 2013-12-31 mdxg:Business_Segment iso4217:USD xbrli:shares mdxg:plan xbrli:pure mdxg:segment iso4217:USD xbrli:shares mdxg:claim false --12-31 FY 2016 2016-12-31 10-K 0001376339 108840839 Yes Large Accelerated Filer 787686000 MIMEDX GROUP, INC. No Yes 371771 3345935 3346000 3346000 3346000 0.5 1 1 12000000 -8170000 -8170000 277000 -2372000 -760000 -300000 -250000 -2380000 -380000 -8170000 2649000 2001000 28000 2179000 2456000 2456000 -4515000 -1866000 -1866000 685000 0.03 75806000 3367250 0 6000 1 1170000 4864000 6992000 35000000 1 2 18000 P50Y P21Y P3M 4 594000 851000 842000 40000 P30D 1361030 1242416 -42400 1113000 1112000 1000 46000 -379000 425000 20000000 170000 281000 P5Y 0 319000 0

6633000

11436000

53755000

67151000

-67000

5768000

4644000

10941000

4979000

8505000

P13Y

P7Y

P4Y

P19Y

163133000

161261000

7757000

-424000

1165000

11453000

322000

660000

10471000

16896000

352000

790000

15754000

17818000

426000

647000

16745000

504000

10000

42000

181000

928000

933000

1176000

2127000

7502496

239842

7035728

226926

7699277

543827

7121774

33676

6513361

667984

5845377

135913000

193263000

96310000

126538000

441009

0.22

0.11

8.43

24960000

1485000

12611000

204481000

245563000

1088000

28087000

36257000

28087000

3717706

1771000

25620000

17450000

200000

17450000

8740000

8710000

-480000

-4070000

140000

100000

8815000

194000

8268000

5896000

830000

450000

17860000

13790000

6090000

690000

1080000

9170000

5330000

390000

830000

6790000

5330000

390000

830000

6790000

9002000

1771000

85000

932000

560000

199000

1375000

36257000

28087000

44078000

46582000

28486000

34391000

2504000

-18096000

5905000

250000

27700000

33200000

1.09

42400

0.001

150000000

109467416

110212547

107361471

109862787

109000

110000

0.10

8934000

374000

141000

490000

2827000

3079000

2023000

12665000

20202000

32407000

8452000

4700000

9670000

6123000

1218000

1423000

0.0225

0.015

P3Y

487000

354000

-13070000

26000

500000

-14838000

10000

-7081000

-594000

-1768000

-16000

146000

-5130000

15620000

9668000

14838000

9114000

1763000

2395000

197000

815000

1566000

1580000

145000

113000

3293000

1219000

7063000

7417000

4606000

4992000

782000

554000

1396000

1338000

0.06

1197000

1799000

3333000

1226275

5954555

0.06

0.04

0.05

0.06

0.13

0.28

0.01

0.02

0.03

0.05

0.11

0.05

0.04

0.05

0.06

0.11

0.26

0.01

0.02

0.03

0.05

0.11

-0.2129

0.3387

0.34

0.35

-0.6333

-0.0126

0.0000

0.0471

0.0227

0.0382

0.0063

0.0004

0.0639

0.0551

-0.0174

0.0327

0.0000

-0.0379

0.0333

0.0478

0.0284

0.0879

15034000

12365000

P1Y10M24D

21905000

1064000

0.1

P12Y

P2Y

P4Y

P20Y

12874000

2034000

1622000

1829000

3761000

1009000

8001000

9091000

1399000

830000

14839000

3761000

13000

7690000

5330000

390000

830000

6790000

21810000

10000

594000

851000

842000

48000

4040000

22912000

20203000

16163000

-6749000

105558000

35619000

40590000

44036000

46849000

167094000

45421000

49948000

56432000

60807000

212608000

7052000

24278000

18107000

7757000

-424000

832000

-5168000

6133000

384000

2293000

642000

1287000

3136000

-3665000

10579000

27083000

11396000

1098000

2140000

6297000

452000

-519000

5835000

5935000

3511000

-2669000

1252000

2327000

2837000

240000

384000

266000

8000

723000

203000

1854000

2400000

1823000

25000

1008000

2618000

25000

1458000

25000

1008000

450000

15627000

30260000

10763000

23268000

48000

86000

339000

48000

86000

162000

3405000

10817000

7857000

18642000

7460000

17814000

602000

1148000

397000

828000

3850000

6677000

1485000

1130000

1317000

1764000

P8Y

103000

27925000

60263000

135913000

193263000

26777000

50732000

50000000

-2146000

-36225000

-8181000

-12152000

-678000

-11742000

16802000

18807000

25828000

6220000

4087000

5430000

6551000

13378000

29446000

1197000

1975000

3321000

5481000

11974000

7100000

24364000

18446000

579000

27552000

2327000

27912000

215000

1288000

533000

1482000

1148000

361000

821000

188000

31000

10338000

504000

30000

1165000

6000000

7631000

117000

102000

996000

2558000

5827000

6269000

0.001

5000000

3394000

5894000

-5612000

-40279000

-10378000

-9000000

6000000

3000000

2470000

4629000

3494000

1113000

46000

14454000

2629000

4564000

4577000

2684000

22291000

3300000

8666000

7051000

3274000

9475000

13786000

1000000

427000

P7Y

P3Y

7050000

8413000

12038000

-38129000

-26155000

50000

118223000

24600000

93623000

40767000

45679000

49015000

51835000

187296000

46200000

141096000

53367000

57342000

64429000

69877000

245015000

61031000

183984000

90480000

133384000

179997000

11453000

16896000

17818000

P3Y

P1Y

377317

8.71

2755426

8.05

2613267

3828445

9.14

8.53

1162931

8.68

0.6450

0.5814

0.5435

0.0000

0.0196

0.0168

0.0164

0.0151

12539865

3.33

10566000

17181000

6460000

148683

154200

4.18

5.15

0.00

66137378

14019629

12552608

3.62

3.61

66119285

11680455

3.60

64733964

3.02

6.16

6.77

0.00

0.50

0.87

1.40

2.66

4.19

6.45

9.90

11680455

441429

4385570

1362424

878680

2937038

1610485

64829

12552608

441429

4385570

1362424

878680

3056069

2324103

104333

0.76

1.35

2.45

3.99

6.38

9.78

10.99

P6Y

P0Y

3067935

872153

154200

6.77

3.81

4.28

P5Y3M18D

P5Y4M24D

6615000

10044000

7378000

2041582

3.61

3.33

0.72

1.19

1.92

3.06

5.34

7.25

10.46

3.61

0.72

1.19

1.92

3.06

5.36

7.30

10.42

P5Y4M24D

P2Y4M24D

P4Y8M12D

P4Y1M6D

P5Y9M18D

P6Y2M12D

P7Y

P7Y8M12D

104425614

50000

108776247

986636

109467416

2105945

110212547

349760

141658

3000000

441009

15958

16493

11321

-5172

43344

-43344

-2058

69949

377317

1438569

34250

-1940009

501203

-2210879

1653690

647656

-1573225

1164138

243928

-918544

3346000

-462000

3808000

117000

164000

113000

51000

346000

6000

345700

340000

-652000

652000

-2503000

2503000

-1000

1000

-14547000

14547000

1000

-17546000

1000

17546000

11453000

16896000

17818000

2470000

2468000

2000

4629000

-9792000

1000

14420000

3494000

-3767000

7261000

20000000

60000000

66000000

10000000

86000000

9936000

73568000

147284000

104000

-73795000

-25000

89329000

162433000

108000

-67575000

-5637000

107988000

163133000

109000

-38129000

-17125000

133000000

161261000

110000

-26155000

-2216000

2105945

349760

936636

4610166

1338616

17125000

2216000

5612000

40279000

10378000

170000

281000

170000

111000

170000

281000

322000

407000

215000

527000

1750000

841000

397000

3270000

1262000

828000

4842000

4894000

405000

1357000

2215000

540000

1698000

3257000

2280000

2127000

8319000

200000

14000

1589000

670000

178000

2836000

1849000

555000

4687000

7502496

7699277

6513361

113295504

113628482

112441709

105793008

105929205

105928348

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unaudited pro forma information for the </font><font style="font-family:inherit;font-size:10pt;">twelve months ended December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands) is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:517px;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:284px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:112px;" rowspan="1" colspan="1"></td><td style="width:112px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$245,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$204,481</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$12,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$24,960</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per share, fully diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.22</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Acquisition of Stability Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 13, 2016, the Company completed the acquisition of Stability Inc., d/b/a Stability Biologics ("Stability"), a provider of human tissue products to surgeons, facilities, and distributors serving the surgical, spine, and orthopedic sectors of the healthcare industry. As a result of this transaction, the Company acquired all of the outstanding shares of Stability in exchange for</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$6,000,000</font><font style="font-family:inherit;font-size:10pt;"> cash, </font><font style="font-family:inherit;font-size:10pt;">$3,346,000</font><font style="font-family:inherit;font-size:10pt;"> in stock, represented by </font><font style="font-family:inherit;font-size:10pt;">441,009</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, and assumed debt of </font><font style="font-family:inherit;font-size:10pt;">$1,771,000</font><font style="font-family:inherit;font-size:10pt;">. Additional one time costs incurred in connection with the transaction totaled </font><font style="font-family:inherit;font-size:10pt;">$1,088,000</font><font style="font-family:inherit;font-size:10pt;"> and are included within selling, general and administrative expenses on the consolidated statements of operations. Contingent consideration may be payable in a formula determined by sales less certain expenses for the years 2016 and 2017. The contingent consideration was valued at </font><font style="font-family:inherit;font-size:10pt;">$17,450,000</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and is shown in the schedule below as fair value of earn-out. The Company used a third party specialist to assist us with the valuation. The purchase price allocation figures should be attributed to the Company and not to the third party valuation firm. The contingent consideration was classified as a liability.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has evaluated the contingent consideration for accounting purposes under GAAP and has determined that the contingent consideration is within the scope of ASC 480 "Distinguishing Liabilities from Equity" whereby a financial instrument, other than an outstanding share, that embodies a conditional obligation that the issuer may settle by issuing a variable number of its equity shares shall be classified as a liability if, at inception, the monetary value of the obligation is based solely or</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">predominantly on variations in something other than the fair value of the issuer’s equity shares.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The actual purchase price was based on cash paid, the fair value of our stock on the date of the acquisition, and direct costs</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">associated with the acquisition. The fair value of stock consideration was determined as set forth below:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:609px;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:461px;" rowspan="1" colspan="1"></td><td style="width:32px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:103px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common Share Price at Closing on 1/13/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Multiplied by: Number of Common Shares Transferred to the Sellers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,009</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicated Value of Equity Consideration (on a Freely Tradable Interest Basis)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,717,706</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Marketability Discount @ 10%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(371,771</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair Value of Equity Consideration Transferred </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,345,935</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a] Shares transferred to the Sellers are restricted securities pursuant to Rule 144. As such, the Sellers are prevented from selling the shares for a period of six months. In addition, they are subject to contractual lockups which restrict sales for up to twelve months following the closing of the transaction.</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The actual purchase price has been allocated as follows (in thousands):</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:636px;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:470px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:143px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid at closing</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(480</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock issued (441,009 shares)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,771</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of earn-out</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,450</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fair value of purchase price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,087</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt-free working capital</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,896</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,866</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents and know-how</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,790</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade names and trademarks</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non compete agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">830</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses and permits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">390</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,790</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Assets Purchased</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,087</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital and other assets were composed of the following (in thousands):</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid Expenses and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal and state taxes receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,002</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt-free working capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,456</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(194</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Line of Credit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(932</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholder loan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,771</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net working capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">685</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The acquisition was accounted for as a purchase business combination as defined by FASB Topic 805 - "Business Combinations". The fair value of the contingent consideration is measured as a Level 3 instrument. The contingent consideration liability is recorded at fair value on the acquisition date. Increases or decreases in the fair value of contingent consideration can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measured is based on significant inputs that are not observable in the market, they are categorized as Level 3. The income valuation approach was applied in determining the fair value of the contingent consideration using a discounted cash flow valuation technique with significant unobservable inputs comprised of projected sales and certain expenses. The values assigned to intangible assets are subject to amortization. The intangible assets were assigned the following lives for amortization purposes:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:617px;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:444px;" rowspan="1" colspan="1"></td><td style="width:40px;" rowspan="1" colspan="1"></td><td style="width:133px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated useful life (in years)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible asset:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents and know-how</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade name and Trademarks</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indefinite</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non compete agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses and permits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill consists of the excess of the purchase price paid over the identifiable net assets and liabilities acquired at fair value. Goodwill is attributable to the assembled workforce of Stability and the synergies expected to arise following the acquisition. Goodwill is not expected to be deductible for tax purposes. Goodwill was determined using the residual method based on an independent appraisal of the assets and liabilities acquired in the transaction. Goodwill is tested for impairment on an annual basis as defined by FASB Topic 350 - "Intangibles - Goodwill and Other".</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill reconciliation (in thousands): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:638px;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:444px;" rowspan="1" colspan="1"></td><td style="width:10px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:170px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at 3/31/16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,912</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill Adjustments (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,749</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at 12/31/16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,163</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Goodwill is the result of a residual calculation</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The changes in the preliminary fair values of the acquired assets and liabilities were due to adjustments made to the prospective financial information ("PFI") to better reflect an expected case from a market participant's perspective. As the earn-out is limited to the gross profit margin for the first two years after the acquisition, the adjustment to the PFI had a decreasing impact on the estimated fair value of the earn-out at the acquisition date, which resulted in a lower total purchase consideration and a reduction of the estimated fair value of the identifiable intangible assets.</font></div><div style="line-height:120%;text-align:left;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the measurement period, management determined that the initial PFI should be adjusted to better reflect an expected case from a market participant's perspective. At the time of the acquisition, management believed that certain of the acquired company's products had reached certain marketability milestones. Management subsequently concluded that these milestones had indeed not yet been achieved. Also, at the time of the acquisition Management believed that certain manufacturing processes were at standards aligned with our overall company standards. Management subsequently concluded that the standards required improvements. These factors have resulted in a lower revenue trajectory in the periods that apply to the earn-out thus reducing the fair value of the earn-out.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The measurement period adjustments are as follows (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:614px;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:197px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:119px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:13px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:119px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:111px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Provisional Per</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Measurement Period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3/31/2016 Form 10Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjustments 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Final</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid at closing</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(480</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(480</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock issued</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,771</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,771</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of earn-out</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fair value of purchase price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,257</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,170</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,087</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt-free working capital</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">277</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,268</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,372</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,896</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,649</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,866</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,090</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(760</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents and know-how</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,170</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,380</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,790</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade names and trademarks</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(380</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non compete agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,080</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(250</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">830</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses and permits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">690</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(300</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">390</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,860</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,070</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,790</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,912</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,749</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Assets Purchased</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,257</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,170</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,087</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the terms of the earn-out arrangement, the Company will pay, for each of the years ending December 31, 2016 and 2017, an amount equal to </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> times the gross profit margin from (a) the net sales of Stability products sold by Stability's or the Company's sales personnel and (b) the net sales of Company products sold by Stability's sales personnel; provided, however, if the amount of such net sales for either earn-out period is less than </font><font style="font-family:inherit;font-size:10pt;">$12 million</font><font style="font-family:inherit;font-size:10pt;">, the earn-out amount will decrease to </font><font style="font-family:inherit;font-size:10pt;">0.5</font><font style="font-family:inherit;font-size:10pt;"> times the gross profit margin for such earn-out period. The full details of the earn-out arrangement are set forth in the acquisition agreement which is filed as Exhibit 2.1 to the Company's Form 8-K filed on January 13, 2016.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following unaudited pro forma summary financial information presents the consolidated results of operations for the Company as if the acquisition had occurred on January 1, 2015. The pro forma results are shown for illustrative purposes only and do not purport to be indicative of the results that would have been reported if the acquisition had occurred on the date indicated or indicative of the results that may occur in the future.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unaudited pro forma information for the </font><font style="font-family:inherit;font-size:10pt;">twelve months ended December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands) is as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:517px;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:284px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:112px;" rowspan="1" colspan="1"></td><td style="width:112px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$245,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$204,481</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$12,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$24,960</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per share, fully diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.22</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 supplemental pro forma earnings were adjusted to exclude </font><font style="font-family:inherit;font-size:10pt;">$1,088,000</font><font style="font-family:inherit;font-size:10pt;"> of acquisition-related legal, audit and other</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs, net of tax. The 2015 supplemental pro forma earnings were adjusted to include </font><font style="font-family:inherit;font-size:10pt;">$1,176,000</font><font style="font-family:inherit;font-size:10pt;"> of amortization costs (net of tax) related to recorded intangible assets with defined useful lives, and </font><font style="font-family:inherit;font-size:10pt;">$1,485,000</font><font style="font-family:inherit;font-size:10pt;"> of inventory step-up charges (net of tax) as a result of the acquisition for comparability to 2016. The number of shares outstanding used in calculating the income per share for 2015 was adjusted to include </font><font style="font-family:inherit;font-size:10pt;">441,009</font><font style="font-family:inherit;font-size:10pt;"> shares issued as part of the purchase price and assumed to be issued on January 1, 2015.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As the Company is managed and operates in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment, and since Stability was merged with the Company's existing operations, the Company has determined that disaggregation of the Company's operating results to provide the amount of revenue and earnings for Stability since the acquisition date is impracticable.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The acquisition was accounted for as a purchase business combination as defined by FASB Topic 805 - "Business Combinations". The fair value of the contingent consideration is measured as a Level 3 instrument. The contingent consideration liability is recorded at fair value on the acquisition date. Increases or decreases in the fair value of contingent consideration can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measured is based on significant inputs that are not observable in the market, they are categorized as Level 3. The income valuation approach was applied in determining the fair value of the contingent consideration using a discounted cash flow valuation technique with significant unobservable inputs comprised of projected sales and certain expenses. The values assigned to intangible assets are subject to amortization.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents include cash and FDIC insured certificates of deposit held at various banks with an original maturity of three months or less.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities</font></div><div style="line-height:120%;padding-bottom:13px;text-indent:24px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">Selected cash payments, receipts, and noncash activities are as follows (in thousands)</font><font style="font-family:inherit;font-size:11pt;">:</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes paid</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">642</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,293</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">384</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Retirement of fixed assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred financing costs </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">504</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">APIC related tax adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,757</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock issuance of 441,009 shares in connection with acquisition of Stability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,346</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock issuance of 43,344, 16,493 and 15,958 shares in exchange for services performed in 2016, 2015 and 2014, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Incentive Plans</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> share-based compensation plans which provide for the granting of equity awards, including qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors: the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan (the "2016 Plan"), which was approved by shareholders on May 18, 2016; the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the “Assumed 2006 Plan”); the MiMedx Inc. 2007 Assumed Stock Plan (the “Assumed 2007 Plan”); and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the “Assumed 2005 Plan”). The awards are subject to a vesting schedule as set forth in each individual agreement. The Company currently intends to use only the 2016 Plan to make future grants. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activity with respect to the stock options is summarized as follows:</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,019,629</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,164,138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested options forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(154,200</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.77</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested options expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(148,683</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,552,608</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.61</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,137,378</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,680,455</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,733,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested or expected to vest at December 31, 2016 (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,539,865</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.60</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,119,285</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Includes forfeiture adjusted unvested shares.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:4px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The intrinsic value of the options exercised during the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> were approximately </font><font style="font-family:inherit;font-size:10pt;">$6,460,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$17,181,000</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$10,566,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:4px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The intrinsic value of options vested during the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> were approximately </font><font style="font-family:inherit;font-size:10pt;">$7,378,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$10,044,000</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$6,615,000</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:4px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following is a summary of stock options outstanding and exercisable at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.50 - $0.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.87 - $1.35</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,385,570</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,385,570</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.40 - $2.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,362,424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,362,424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.66 - $3.99</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">878,680</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">878,680</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.19 - $6.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,056,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,937,038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$6.45- $9.78</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,324,103</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,610,485</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.90 - $10.99</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,333</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,829</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,552,608</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.61</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,680,455</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.33</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the status of the Company’s unvested stock options as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> is presented below:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unvested Stock Options</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of<br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-<br clear="none"/>Average<br clear="none"/>Grant Date Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,067,935</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(154,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,041,582</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.61</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">872,153</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total unrecognized compensation expense at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, was approximately </font><font style="font-family:inherit;font-size:10pt;">$1,064,000</font><font style="font-family:inherit;font-size:10pt;"> and will be charged to expense through June 2017.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the options granted was estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.  Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options.  The term of employee options granted is derived using the “simplified method” which computes expected term as the midpoint between the weighted average time to vesting and the contractual maturity. The simplified method was used due to the Company’s lack of sufficient historical data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its equity shares have been publicly traded.  The term for non-employee options is generally based upon the contractual term of the option.  The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assumptions used in calculating the fair value of options granted using the Black-Scholes-Merton option-pricing model are set forth in the following table:</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.66861598440545%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54.35 - 58.14%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58.14 - 64.50%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.51 - 1.68%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.64 - 1.96%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted-average grant date fair value for options granted during the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> were approximately </font><font style="font-family:inherit;font-size:10pt;">$0.00</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$5.15</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.18</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Awards</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following is summary information for restricted stock awards for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">. Shares vest over a </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> year period. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, there was approximately </font><font style="font-family:inherit;font-size:10pt;">$21,905,000</font><font style="font-family:inherit;font-size:10pt;"> of total unrecognized stock-based compensation related to time-based, non-vested restricted stock.  That expense is expected to be recognized on a straight-line basis over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">1.9 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, during the twelve months ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">43,344</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock valued at approximately </font><font style="font-family:inherit;font-size:10pt;">$345,700</font><font style="font-family:inherit;font-size:10pt;"> were issued under the 2006 Plan to a consultant in return for services performed, and is included in the table that follows.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of<br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average Grant Date<br clear="none"/> Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,613,267</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,755,426</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.05</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,162,931</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(377,317</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.71</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,828,445</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> the Company recognized stock-based compensation as follows (in thousands):  </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.49122807017544%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">426</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">352</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">790</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">660</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,745</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,754</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,471</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,818</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,896</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,453</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> On November 18, 2015, </font><font style="font-family:inherit;font-size:10pt;">42,400</font><font style="font-family:inherit;font-size:10pt;"> common stock warrants representing the balance remaining from those granted in connection with equity share purchases by investors as an additional incentive for providing long - term equity capital to the Company and as additional compensation to consultants and advisors were exercised at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.09</font><font style="font-family:inherit;font-size:10pt;">. The warrants were granted at negotiated prices in connection with the equity share purchases and at the market price of the common stock in other instances. The warrants were issued for terms of </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Treasury Stock</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> On May 12, 2014, our Board of Directors authorized the repurchase of up to </font><font style="font-family:inherit;font-size:10pt;">$10 million</font><font style="font-family:inherit;font-size:10pt;"> of our common stock from time to time, through December 31, 2014. The Board subsequently extended the program until December 31, 2017. In December 2014, the Board increased the authorization to </font><font style="font-family:inherit;font-size:10pt;">$20 million</font><font style="font-family:inherit;font-size:10pt;"> and further increased the authorization in 2015 to </font><font style="font-family:inherit;font-size:10pt;">$60 million</font><font style="font-family:inherit;font-size:10pt;">. In December 2016, the Board further increased the authorization to </font><font style="font-family:inherit;font-size:10pt;">$66 million</font><font style="font-family:inherit;font-size:10pt;">. The timing and amount of repurchases will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company purchased approximately </font><font style="font-family:inherit;font-size:10pt;">1,338,616</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock for an aggregate purchase price of approximately </font><font style="font-family:inherit;font-size:10pt;">$10,338,000</font><font style="font-family:inherit;font-size:10pt;"> exclusive of commissions of approximately </font><font style="font-family:inherit;font-size:10pt;">$40,000</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had approximately </font><font style="font-family:inherit;font-size:10pt;">$9,936,000</font><font style="font-family:inherit;font-size:10pt;"> remaining under the repurchase program.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company records certain financial instruments at fair value, including: cash equivalents, short term investments and investments.  The Company may make an irrevocable election to measure other financial instruments at fair value on an instrument-by-instrument basis; although as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company has not chosen to make any such elections.  Fair value financial instruments are recorded in accordance with the fair value measurement framework.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also measures certain non-financial assets at fair value on a non-recurring basis.  These non-recurring valuations include evaluating assets such as long-lived assets, and non-amortizing intangible assets for impairment; allocating value to assets in an acquired asset group, and accounting for business combinations.  The Company uses the fair value measurement framework to value these assets and reports these fair values in the periods in which they are recorded or written down.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value measurement framework includes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair values in their broad levels.  These levels from highest to lowest priority are as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Level 3: Unobservable inputs or valuation techniques that are used when little or no market data is available.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The determination of fair value and the assessment of a measurement’s placement within the hierarchy require judgment. Level 3 valuations often involve a higher degree of judgment and complexity.  Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions.  Management’s assumptions could vary depending on the asset or liability valued and the valuation method used.  Such assumptions could include: estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods.  The Company may also engage external advisors to assist it in determining fair value, as appropriate.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the acquisition of Stablity, the Company recorded a liability related to the Earn-Out portion of the purchase consideration. See Note 4, Acquisition, for further discussion of the Earn-Out liability. The Company has classified the Earn-Out liability as a Level 3 liability and the fair value of the Earn-Out liability will be evaluated each reporting period and changes in its fair value will be included in the Company’s results of operations. The fair value of the Earn-Out liability was calculated using a discount rate, approximating the pre-tax cost of debt and corroborated by Monte Carlo simulation, which was then applied to estimated earn out payments. To determine the fair value of the Earn-Out liability, management evaluates assumptions that require significant judgment. Changes in certain inputs to the valuation model, including the Company’s estimate of future revenues, can have a significant impact on the estimated fair value. The fair value recorded for the Earn-Out liability may vary significantly from period to period. This variability may result in the actual liability for a period either above or below the estimates recorded in the Company’s Consolidated Financial Statements, resulting in significant fluctuations in results of operations as a result of the corresponding non-cash gain or loss recorded.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although the Company believes that the recorded fair value of its financial instruments is appropriate, these fair values may not be indicative of net realizable value or reflective of future fair values.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The intangible assets were assigned the following lives for amortization purposes:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:617px;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:444px;" rowspan="1" colspan="1"></td><td style="width:40px;" rowspan="1" colspan="1"></td><td style="width:133px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated useful life (in years)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible asset:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents and know-how</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade name and Trademarks</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indefinite</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non compete agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses and permits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intangible Assets and Royalty Agreement</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets are summarized as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted<br clear="none"/>Average<br clear="none"/>Amortization<br clear="none"/>Lives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Licenses (a) (b) (c) (d)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,399</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,009</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Patents & Know How (b) (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,839</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Customer & Supplier Relationships (b) (d)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,761</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Tradenames & Trademarks (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,458</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,008</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Non-Compete Agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">In Process Research & Development (b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">various</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents in Process (c)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">various</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,618</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,823</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,260</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,627</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Less Accumulated amortization and impairment charges</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,992</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,864</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,268</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,763</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of </font><font style="font-family:inherit;font-size:10pt;">$996,000</font><font style="font-family:inherit;font-size:10pt;">.  Within </font><font style="font-family:inherit;font-size:10pt;">30 days</font><font style="font-family:inherit;font-size:10pt;"> after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional </font><font style="font-family:inherit;font-size:10pt;">$200,000</font><font style="font-family:inherit;font-size:10pt;"> to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;"> on all commercial sales revenue from the licensed products. The Company is also obligated to pay a </font><font style="font-family:inherit;font-size:10pt;">$50,000</font><font style="font-family:inherit;font-size:10pt;"> minimum annual royalty payment over the life of the license. As of December 31, 2016 the license had a remaining net book value of approximately </font><font style="font-family:inherit;font-size:10pt;">$10,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for Customer & Supplier Relationships of </font><font style="font-family:inherit;font-size:10pt;">$3,761,000</font><font style="font-family:inherit;font-size:10pt;">, Patents & Know-How of </font><font style="font-family:inherit;font-size:10pt;">$7,690,000</font><font style="font-family:inherit;font-size:10pt;">, Licenses of </font><font style="font-family:inherit;font-size:10pt;">$13,000</font><font style="font-family:inherit;font-size:10pt;">, Tradenames & Trademarks of </font><font style="font-family:inherit;font-size:10pt;">$1,008,000</font><font style="font-family:inherit;font-size:10pt;"> and In-Process Research & Development of </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;">. For the twelve months ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, approximately </font><font style="font-family:inherit;font-size:10pt;">$48,000</font><font style="font-family:inherit;font-size:10pt;"> of costs associated with patents granted during the period were capitalized and included in Patents & Know-How subject to amortization over the life of the patents.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 13, 2016, the Company acquired Stability. As a result, the Company recorded intangible assets for Patents & Know - How of </font><font style="font-family:inherit;font-size:10pt;">$6,790,000</font><font style="font-family:inherit;font-size:10pt;">, Customer Relationships of </font><font style="font-family:inherit;font-size:10pt;">$5,330,000</font><font style="font-family:inherit;font-size:10pt;">, Non - compete agreements of </font><font style="font-family:inherit;font-size:10pt;">$830,000</font><font style="font-family:inherit;font-size:10pt;">, Tradenames & Trademarks of </font><font style="font-family:inherit;font-size:10pt;">$450,000</font><font style="font-family:inherit;font-size:10pt;"> and Licenses of </font><font style="font-family:inherit;font-size:10pt;">$390,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization expense for the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, was approximately </font><font style="font-family:inherit;font-size:10pt;">$2,127,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$933,000</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$928,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected future amortization of intangible assets as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expense</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,034</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,829</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,829</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,622</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,622</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,874</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,810</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs"). In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company is currently assessing the impact the adoption of ASU 2014-09 will have on its consolidated financial statements. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments, that eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. ASU 2015-16 is effective for public companies for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The Company has adopted this standard in the first quarter of 2016 and its application is shown in Note 4.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company has adopted this standard, prospectively, at the beginning of the fourth quarter 2015 to simplify reporting with the release of the valuation allowance as disclosed in Note 12. Prior periods were not retrospectively adjusted.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued Accounting Standards Update ASU No. 2016-02, Leases (Topic 842). The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases.  ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years.  The guidance may be adopted prospectively or retrospectively and early adoption is permitted.  The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, "Compensation - Stock Compensation (Topic 718)". The standard is</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">intended to simplify several areas of accounting for share - based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. This ASU is effective for fiscal years beginning after December 15, 2016. The Company is currently assessing the impact the adoption of ASU 2016-09 will have on its consolidated financial statements. As of December 31, 2016, the Company does not have any remaining deferred tax assets that will result in an increase to equity upon realization. See Note 12.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments”. The update addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for public business entities for fiscal years beginning after December 15, 2017 and for interim periods within those fiscal years. The amendments in this update may be applied retrospectively or prospectively and early adoption is permitted. The Company is currently assessing the impact of the adoption of ASU 2016-15 will have on its consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All other ASUs issued and not yet effective for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment consist of the following as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab and clean room equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,666</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,564</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,051</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in Progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,300</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,629</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, gross</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,291</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,454</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,505</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,979</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,786</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,475</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarterly Financial Data (Unaudited) (in thousands except per share data)</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fourth</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarter</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">NET SALES</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,367</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,342</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,767</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,679</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,015</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,835</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">GROSS MARGIN</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,421</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,948</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,432</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,807</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,619</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,036</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">NET INCOME </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,087</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,430</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,551</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,378</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET INCOME <br clear="none"/>PER COMMON SHARE - BASIC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> NET INCOME <br clear="none"/> PER COMMON SHARE - DILUTED</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="padding-bottom:13px;padding-top:8px;padding-left:48px;text-align:justify;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities that are included in the computation of the denominator above, utilizing the treasury stock method for the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and 2014 are as follows:    </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:90.234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:64%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">    Stock Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,845,377</font></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,121,774</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,035,728</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">    Warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,676</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,926</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">    Restricted Stock Awards</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">667,984</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">543,827</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">239,842</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,513,361</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,699,277</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,502,496</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The actual purchase price has been allocated as follows (in thousands):</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:636px;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:470px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:143px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid at closing</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(480</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock issued (441,009 shares)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,771</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of earn-out</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,450</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fair value of purchase price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,087</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt-free working capital</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,896</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,866</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents and know-how</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,790</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade names and trademarks</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non compete agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">830</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses and permits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">390</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,790</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,163</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Assets Purchased</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,087</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital and other assets were composed of the following (in thousands):</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid Expenses and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal and state taxes receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,002</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt-free working capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,456</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(194</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Line of Credit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(932</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shareholder loan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,771</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net working capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">685</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of stock consideration was determined as set forth below:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:609px;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:461px;" rowspan="1" colspan="1"></td><td style="width:32px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:103px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common Share Price at Closing on 1/13/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Multiplied by: Number of Common Shares Transferred to the Sellers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,009</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicated Value of Equity Consideration (on a Freely Tradable Interest Basis)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,717,706</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Marketability Discount @ 10%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a]</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(371,771</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair Value of Equity Consideration Transferred </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,345,935</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[a] Shares transferred to the Sellers are restricted securities pursuant to Rule 144. As such, the Sellers are prevented from selling the shares for a period of six months. In addition, they are subject to contractual lockups which restrict sales for up to twelve months following the closing of the transaction.</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-indent:24px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">Selected cash payments, receipts, and noncash activities are as follows (in thousands)</font><font style="font-family:inherit;font-size:11pt;">:</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income taxes paid</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">642</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,293</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">384</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Retirement of fixed assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred financing costs </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">504</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">APIC related tax adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,757</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock issuance of 441,009 shares in connection with acquisition of Stability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,346</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock issuance of 43,344, 16,493 and 15,958 shares in exchange for services performed in 2016, 2015 and 2014, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current and deferred income tax expense (benefit) is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:62.890625%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,452</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   State</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,423</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,218</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">      Total current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,123</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,670</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   Federal</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,070</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">   State</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,768</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">      Total deferred</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,838</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,133</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,168</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Deferred tax assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accruals and prepaids</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,992</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,606</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,130</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">146</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,396</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">R&D and other tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,219</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,293</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock Compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,417</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,063</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,395</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,763</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,668</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,620</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(554</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(782</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,114</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,838</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except per share data):</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,446</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator for basic earnings per share - weighted average shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,928,348</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,929,205</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,793,008</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive securities: Stock options, warrants, and restricted stock (a)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,513,361</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,699,277</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,502,496</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,441,709</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,628,482</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,295,504</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per common share - basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income per common share - diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.26</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="padding-bottom:13px;padding-top:8px;padding-left:48px;text-align:justify;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">Securities that are included in the computation of the denominator above, utilizing the treasury stock method for the years ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> and 2014 are as follows:    </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:90.234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:64%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">    Stock Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,845,377</font></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,121,774</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,035,728</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">    Warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,676</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226,926</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">    Restricted Stock Awards</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">667,984</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">543,827</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">239,842</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,513,361</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,699,277</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,502,496</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The reconciliation of the Federal statutory income tax rate of </font><font style="font-family:inherit;font-size:10pt;">35%</font><font style="font-family:inherit;font-size:10pt;"> to the effective rate is as follows:</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:68.5546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State taxes, net of federal benefit</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.78</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non deductible compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.63</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Meals & entertainment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity Compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.51</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.39</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Domestic Production Activities Deduction</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4.71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax Credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8.79</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.84</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior Period Adjustments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.27</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.74</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.26</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(63.33</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33.87</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21.29</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net Sales by Categories (in thousands): </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:634px;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:294px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:95px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:6px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:96px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:84px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wound Care</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">183,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">141,096</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Surgical, Sports Medicine & Orthopedics (SSO)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,031</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">245,015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">187,296</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">118,223</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following items as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,677</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,850</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,817</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,405</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory, gross</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,642</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,857</font></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reserve for obsolescence</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(828</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(397</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventory, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,814</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,460</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fourth</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quarter</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">NET SALES</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,367</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,342</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,767</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,679</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,015</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,835</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">GROSS MARGIN</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,421</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,948</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,432</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,807</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,619</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,036</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">NET INCOME </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,481</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,087</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,430</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,551</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,378</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NET INCOME <br clear="none"/>PER COMMON SHARE - BASIC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> NET INCOME <br clear="none"/> PER COMMON SHARE - DILUTED</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.01</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.03</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.04</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.05</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.11</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The measurement period adjustments are as follows (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:614px;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:197px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:119px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:13px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:119px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td><td style="width:8px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:111px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Provisional Per</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Measurement Period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3/31/2016 Form 10Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adjustments 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Final</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid at closing</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital adjustment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(480</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(480</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock issued</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,771</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,771</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of earn-out</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fair value of purchase price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,257</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,170</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,087</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt-free working capital</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">277</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,268</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,372</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,896</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,649</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,866</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,090</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(760</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents and know-how</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,170</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,380</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,790</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade names and trademarks</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(380</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non compete agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,080</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(250</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">830</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses and permits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">690</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(300</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">390</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subtotal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,860</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,070</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,790</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,912</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,749</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Assets Purchased</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,257</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,170</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,087</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following is a summary of stock options outstanding and exercisable at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Range of Exercise Prices</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.50 - $0.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.87 - $1.35</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,385,570</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,385,570</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.40 - $2.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,362,424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,362,424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.66 - $3.99</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">878,680</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">878,680</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.06</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.19 - $6.38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,056,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,937,038</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$6.45- $9.78</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,324,103</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,610,485</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.90 - $10.99</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,333</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,829</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,552,608</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.61</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,680,455</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.33</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activity with respect to the stock options is summarized as follows:</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.22027290448344%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,019,629</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,164,138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.02</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested options forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(154,200</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.77</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested options expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(148,683</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,552,608</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.61</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,137,378</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,680,455</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,733,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested or expected to vest at December 31, 2016 (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,539,865</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.60</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,119,285</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Includes forfeiture adjusted unvested shares.</font></div></td></tr></table></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The assumptions used in calculating the fair value of options granted using the Black-Scholes-Merton option-pricing model are set forth in the following table:</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.66861598440545%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54.35 - 58.14%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58.14 - 64.50%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (in years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.51 - 1.68%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.64 - 1.96%</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits - January 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">          Gross increases - tax positions in current period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits - December 31</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Schedule II Valuation and Qualifying Accounts</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MIMEDX GROUP, INC. AND SUBSIDIARIES</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS</font></div></td></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> Years ended December 31, 2016, 2015 and 2014 (in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at <br clear="none"/>Beginning of Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions charged to Expense or Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deductions <br clear="none"/>and write-offs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at<br clear="none"/> End of Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the Year ended December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,270</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,127</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(555</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,842</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for product returns</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,894</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for obsolescence</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">397</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,280</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,849</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">828</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the Year ended December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,698</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for product returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">841</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,257</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,836</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,262</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for obsolescence</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">527</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(670</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">397</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the Year ended December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">407</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,357</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for product returns</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">215</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,215</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,589</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">841</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance for obsolescence</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">322</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">405</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(200</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">527</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected future amortization of intangible assets as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expense</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,034</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,829</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,829</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,622</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,622</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,874</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,810</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

EX-101.SCH 11 mdxg-20161231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2183100 - Disclosure - 401k Plan link:presentationLink link:calculationLink link:definitionLink 2483401 - Disclosure - 401k Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Acquisition of Stability Inc. link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Acquisition of Stability Inc. - Fair Value of Stock Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 2404406 - Disclosure - Acquisition of Stability Inc. - Goodwill Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2404405 - Disclosure - Acquisition of Stability Inc. - Intangible Assets Acquired as Part of Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 2404407 - Disclosure - Acquisition of Stability Inc. - Measurement Period Adjustments (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Acquisition of Stability Inc. - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - Acquisition of Stability Inc. - Preliminarily Allocation of Purchase Price (Details) link:presentationLink link:calculationLink link:definitionLink 2404408 - Disclosure - Acquisition of Stability Inc. - Pro Forma Information (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Acquisition of Stability Inc. (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Cash Equivalents and Short Term Investments link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - Cash Equivalents and Short Term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2185100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2485403 - Disclosure - Commitments and Contingencies - Estimated Annual Lease, Royalty, and Employment Agreement Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2485402 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2385301 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2160100 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 2460403 - Disclosure - Equity - Activity of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 2460406 - Disclosure - Equity - Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2460404 - Disclosure - Equity - Exercise Price Ranges (Details) link:presentationLink link:calculationLink link:definitionLink 2460402 - Disclosure - Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2460408 - Disclosure - Equity - Recognized Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2460407 - Disclosure - Equity - Summary of Restricted Stock Awards (Details) link:presentationLink link:calculationLink link:definitionLink 2460405 - Disclosure - Equity - Summary of Unvested Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 2360301 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2165100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2465402 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2465405 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2465403 - Disclosure - Income Taxes - Reconciliation of the Federal Statutory Income Tax (Details) link:presentationLink link:calculationLink link:definitionLink 2465406 - Disclosure - Income Taxes - Reconciliation of unrecognized tax benefits (Details) link:presentationLink link:calculationLink link:definitionLink 2465404 - Disclosure - Income Taxes - Schedule of current and deferred income tax expense (benefit) (Details) link:presentationLink link:calculationLink link:definitionLink 2365301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Intangible Assets and Royalty Agreement link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - Intangible Assets and Royalty Agreement - Expected Future Amortization of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Intangible Assets and Royalty Agreement - Intangible Asssets Activity Summary (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Intangible Assets and Royalty Agreement - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Intangible Assets and Royalty Agreement (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Liquidity and Capital Resources link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Liquidity and Capital Resources (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 2409401 - Disclosure - Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Nature of Business link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Nature of Business (Details) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Net Income Per Share link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Net Income Per Share - Computation of Basic and Dilutive Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Net Income Per Share - Summary of Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Net Income Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2187100 - Disclosure - Product Revenue Data link:presentationLink link:calculationLink link:definitionLink 2487402 - Disclosure - Product Revenue Data (Details) link:presentationLink link:calculationLink link:definitionLink 2387301 - Disclosure - Product Revenue Data (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2186100 - Disclosure - Quarterly Financial Data (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2486402 - Disclosure - Quarterly Financial Data (Unaudited) (Details) link:presentationLink link:calculationLink link:definitionLink 2386301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables) link:presentationLink link:calculationLink link:definitionLink 2184100 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 2484401 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 2189100 - Schedule - Schedule II - Valuation and Qualifying Accounts link:presentationLink link:calculationLink link:definitionLink 2489401 - Schedule - Schedule II - Valuation and Qualifying Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2188100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2488401 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 2170100 - Disclosure - Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities link:presentationLink link:calculationLink link:definitionLink 2470402 - Disclosure - Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Details) link:presentationLink link:calculationLink link:definitionLink 2370301 - Disclosure - Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 mdxg-20161231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 13 mdxg-20161231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 14 mdxg-20161231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Stability Biologics, LLC Stability Biologics, LLC [Member] Stability Biologics, LLC Business Acquisition [Line Items] Business Acquisition [Line Items] Common stock issued, price per share (in dollars per share) Business Acquisition, Share Price Common stock issued (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Common stock issued in acquisition Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Less: Marketability Discount @ 10% Business Combination, Consideration Transferred, Equity Interests Issued And Issuable, Discount Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Discount Fair Value of Equity Consideration Transferred Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Fair Value Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Fair Value Marketability discount Fair Value Inputs, Discount for Lack of Marketability Income Tax Disclosure [Abstract] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Federal Domestic Tax Authority [Member] State State and Local Jurisdiction [Member] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Federal statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Valuation allowance Deferred Tax Assets, Valuation Allowance Income tax net operating loss carryforwards Operating Loss Carryforwards Deferred tax assets, operating loss carryforwards, domestic Deferred Tax Assets, Operating Loss Carryforwards, Domestic Deferred tax assets, operating loss carryforwards, state Deferred Tax Assets, Operating Loss Carryforwards, State and Local Realized deferred tax assets Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Amount Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Amount Stock compensation Deferred Tax Assets that Would Impact Equity, Share-based Compensation Deferred Tax Assets that Would Impact Equity, Share-based Compensation Unrecognized tax benefits that would affect effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Adjustments to tax accounts Unrecognized Tax Benefits that Would Impact Other Tax Accounts Unrecognized Tax Benefits that Would Impact Other Tax Accounts Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Credit Agreement Credit Agreement [Member] Credit Agreement [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Uncommitted incremental facility Line of Credit Facility, Uncommitted Incremental Facility Line of Credit Facility, Uncommitted Incremental Facility Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Debt issuance costs Debt Issuance Costs, Net Debt term Debt Instrument, Term Outstanding line of credit Long-term Line of Credit Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Restricted Stock Restricted Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Unvested, beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Unvested, end of period (in shares) Weighted- Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Unvested, beginning of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Unvested, end of period (in dollars per share) Property, Plant and Equipment [Abstract] Property and equipment Property, Plant and Equipment [Table Text Block] Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table] Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table] Exercise Price Range [Axis] Exercise Price Range [Axis] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] $0.50 - $0.76 Price Range 1 [Member] Price Range 1 [Member] $0.87 - $1.35 Price Range 2 [Member] Price Range 2 [Member] $1.40 - $2.45 Price Range 3 [Member] Price Range 3 [Member] $2.66 - $3.99 Price Range 4 [Member] Price Range 4 [Member] $4.19 - $6.38 Price Range 5 [Member] Price Range 5 [Member] $6.45- $9.78 Price Range 6 [Member] Price Range 6 [Member] $9.90 - $10.99 Price Range 7 [Member] Price Range 7 [Member] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] Exercise price range, lower range limit (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Exercise price range, upper range limit (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Number of outstanding options (in shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options Outstanding options, weighted average remaining contractual term Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term Outstanding options, weighted average exercise price (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price Number of exercisable options (in shares) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options Exercisable options, weighted average exercise price (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Accounting Policies [Abstract] Concentration Risk [Table] Concentration Risk [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Patents Patents [Member] Market Concentrations and Credit Risk [Line Items] Concentration Risk [Line Items] Number of business segments Number of Operating Segments FDIC insured amount Cash, FDIC Insured Amount Cash and cash equivalents uninsured amount Cash, Uninsured Amount Goodwill impairment Goodwill, Impairment Loss impairment of indefinite useful lives intangible Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Impairment of intangible assets with finite lives Impairment of Intangible Assets, Finite-lived Property and equipment estimated useful life Property, Plant and Equipment, Useful Life Intangible assets, net of accumulated amortization Finite-Lived Intangible Assets, Period Increase (Decrease) Goodwill and Intangible Assets Disclosure [Abstract] 2017 Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months 2018 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2019 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Five Thereafter Finite-Lived Intangible Assets, Amortization Expense, after Year Five Net book value Finite-Lived Intangible Assets, Net Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Document and Entity Information [Abstract] -- None. No documentation exists for this element. -- Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Voluntary Filers Entity Current Reporting Status Entity Current Reporting Status Entity Public Float Entity Public Float Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Selling, general and administrative Selling, General and Administrative Expenses [Member] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Forecast Scenario, Forecast [Member] Pro Forma Pro Forma [Member] Nonrecurring Adjustment [Axis] Nonrecurring Adjustment [Axis] Nonrecurring Adjustment [Domain] Nonrecurring Adjustment [Domain] Fair Value Adjustment to Inventory Fair Value Adjustment to Inventory [Member] Cash paid at closing Payments to Acquire Businesses, Gross Fair Value of Equity Consideration Transferred Assumed debt Business Combination, Consideration Transferred, Liabilities Incurred Acquisition related costs Business Combination, Acquisition Related Costs Fair value of earn-out Business Combination, Contingent Consideration, Liability Gross profit margin multiplier Business Combination, Contingent Consideration, Liability, Gross Profit Margin Multiplier Business Combination, Contingent Consideration, Liability, Gross Profit Margin Multiplier Net sales for earn-out period (less than) Business Combination, Contingent Consideration, Minimum Net Sales For Earn Out Period, To Avoid Reduction In Gross Profit Multiplier, Amount Business Combination, Contingent Consideration, Minimum Net Sales For Earn Out Period, To Avoid Reduction In Gross Profit Multiplier, Amount Gross profit margin multiplier, low Business Combination, Contingent Consideration Arrangements, Gross Profit Multiplier If Net Sales Target Not Achieved Business Combination, Contingent Consideration Arrangements, Gross Profit Multiplier If Net Sales Target Not Achieved Amortization of intangible assets Amortization of Intangible Assets Net income Business Acquisition, Pro Forma Net Income (Loss) Statement of Financial Position [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Treasury stock, shares (in shares) Treasury Stock, Shares Earnings Per Share [Abstract] Net income Net Income (Loss) Attributable to Parent Denominator for basic earnings per share - weighted average shares (in shares) Weighted Average Number of Shares Outstanding, Basic Effect of dilutive securities: Stock options, warrants, and restricted stock (in shares) Weighted Average Number Diluted Shares Outstanding Adjustment Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities (in shares) Weighted Average Number of Shares Outstanding, Diluted Income per common share - basic (in dollars per share) Earnings Per Share, Basic Income per common share - diluted (in dollars per share) Earnings Per Share, Diluted Customer relationships Customer Relationships [Member] Patents and know-how Non-Compete Agreements Noncompete Agreements [Member] Licenses and permits Licensing Agreements [Member] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Tradenames & Trademarks Trademarks and Trade Names [Member] Working capital adjustment Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred Common stock issued (441,009 shares) Total fair value of purchase price Business Combination, Consideration Transferred Net assets acquired: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] Debt-free working capital Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Debt-free Working Capital Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Debt-free Working Capital Other long term assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Property, plant and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent Subtotal Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets, Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets, Net Intangible assets: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract] Finite-Lived intangibles assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Indefinite-lived intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Subtotal Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Goodwill Goodwill Total Assets Purchased Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Measurement Period Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments [Abstract] Fair value of earn-out Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Contingent Consideration, Liabilities Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Contingent Consideration, Liabilities EX-101.PRE 15 mdxg-20161231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 16 mdxg-20141_chartx41044a03.jpg begin 644 mdxg-20141_chartx41044a03.jpg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end GRAPHIC 17 uspaininjectionmarket2015.jpg begin 644 uspaininjectionmarket2015.jpg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uswoundcaremarket2015v1.jpg begin 644 uswoundcaremarket2015v1.jpg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htm IDEA: XBRL DOCUMENT v3.6.0.2

Document and Entity Information - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2016

Feb. 15, 2017

Jun. 30, 2016

Document and Entity Information [Abstract]

Entity Registrant Name MIMEDX GROUP, INC.

Entity Central Index Key 0001376339

Current Fiscal Year End Date --12-31

Entity Filer Category Large Accelerated Filer

Document Type 10-K

Document Period End Date Dec. 31, 2016

Document Fiscal Year Focus 2016

Document Fiscal Period Focus FY

Amendment Flag false

Entity Common Stock, Shares Outstanding 108,840,839

Entity Well-known Seasoned Issuer Yes

Entity Voluntary Filers No

Entity Current Reporting Status Yes

Entity Public Float $ 787,686

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.
+ References
No definition available.
+ Details

Name: dei_EntityPublicFloat

Namespace Prefix: dei_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
No definition available.
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
-- None. No documentation exists for this element. --
+ References
No definition available.
+ Details

Name: mdxg_DocumentAndEntityInformationAbstract

Namespace Prefix: mdxg_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 20 R2.htm IDEA: XBRL DOCUMENT v3.6.0.2

CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands

Dec. 31, 2016

Dec. 31, 2015

Current assets:

Cash and cash equivalents $ 34,391 $ 28,486

Short term investments 0 3,000

Accounts receivable, net 67,151 53,755

Inventory, net 17,814 7,460

Prepaid expenses 5,894 3,394

Other current assets 1,288 215

Total current assets 126,538 96,310

Property and equipment, net of accumulated depreciation 13,786 9,475

Goodwill 20,203 4,040

Intangible assets, net of accumulated amortization 23,268 10,763

Deferred tax asset, net 9,114 14,838

Deferred financing costs and other assets 354 487

Total assets 193,263 135,913

Current liabilities:

Accounts payable 11,436 6,633

Accrued compensation 12,365 15,034

Accrued expenses 10,941 4,644

Current portion of earn out liability 8,740 0

Income taxes 5,768 (67)

Other current liabilities 1,482 533

Total current liabilities 50,732 26,777

Earn out liability 8,710 0

Other liabilities 821 1,148

Total liabilities 60,263 27,925

Commitments and contingencies

Stockholders' equity:

Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding 0 0

Common stock; $0.001 par value; 150,000,000 shares authorized; 110,212,547 issued and 109,862,787 outstanding at December 31, 2016 and 109,467,416 issued and 107,361,471 outstanding at December 31, 2015 110 109

Additional paid-in capital 161,261 163,133

Treasury stock at cost: 349,760 shares at December 31, 2016 and 2,105,945 shares at December 31, 2015 (2,216) (17,125)

Accumulated deficit (26,155) (38,129)

Total stockholders' equity 133,000 107,988

Total liabilities and stockholders' equity $ 193,263 $ 135,913

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.15(a))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_AccountsPayableCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(15)(b)(1))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(1))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_AccruedIncomeTaxesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph b
-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph b
-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred cost assets and assets classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredCostsAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(c)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64834752&loc=SL49117168-202975
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765
+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Assets
-URI http://asc.fasb.org/extlink&oid=6509628

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1)(g))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(4))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29,30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656
+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 21 R3.htm IDEA: XBRL DOCUMENT v3.6.0.2

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares

Dec. 31, 2016

Dec. 31, 2015

Stockholders' equity:

Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001

Preferred stock, shares authorized (in shares) 5,000,000 5,000,000

Preferred stock, shares issued (in shares) 0 0

Preferred stock, shares outstanding (in shares) 0 0

Common stock, par value (in dollars per share) $ 0.001 $ 0.001

Common stock, shares authorized (in shares) 150,000,000 150,000,000

Common stock, shares issued (in shares) 110,212,547 109,467,416

Common stock, shares outstanding (in shares) 109,862,787 107,361,471

Treasury stock, shares (in shares) 349,760 2,105,945

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29,30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655
+ Details

Name: us-gaap_TreasuryStockShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 22 R4.htm IDEA: XBRL DOCUMENT v3.6.0.2

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Income Statement [Abstract]

Net sales $ 245,015 $ 187,296 $ 118,223

Cost of sales 32,407 20,202 12,665

Gross margin 212,608 167,094 105,558

Operating expenses:

Research and development expenses 12,038 8,413 7,050

Selling, general and administrative expenses 179,997 133,384 90,480

Amortization of intangible assets 2,127 933 928

Operating income 18,446 24,364 7,100

Other expense, net

Interest expense, net (339) (86) (48)

Income before income tax provision 18,107 24,278 7,052

Income tax provision (expense) benefit (6,133) 5,168 (832)

Net income $ 11,974 $ 29,446 $ 6,220

Net income per common share - basic (in dollars per share) $ 0.11 $ 0.28 $ 0.06

Net income per common share - diluted (in dollars per share) $ 0.11 $ 0.26 $ 0.05

Weighted average shares outstanding - basic (in shares) 105,928,348 105,929,205 105,793,008

Weighted average shares outstanding - diluted (in shares) 112,441,709 113,628,482 113,295,504

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total costs related to goods produced and sold during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=65016374&loc=d3e4984-109258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Income Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6515339
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Weighted-Average Number of Common Shares Outstanding
-URI http://asc.fasb.org/extlink&oid=6528421
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 23 R5.htm IDEA: XBRL DOCUMENT v3.6.0.2

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands

Total

Common Stock

Additional Paid-in

Treasury Stock

Accumulated Deficit

Balance, beginning of period (in shares) at Dec. 31, 2013 104,425,614 50,000

Balance, beginning of period at Dec. 31, 2013 $ 73,568 $ 104 $ 147,284 $ (25) $ (73,795)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Share-based compensation expense 11,453 11,453

Exercise of stock options (in shares) 1,653,690

Exercise of stock options 2,470 $ 2 2,468

Exercise of warrants (in shares) 1,242,416

Exercise of warrants 1,113 $ 1 1,112

Issuance of restricted stock (in shares) 1,438,569

Issuance of restricted stock $ 0 $ 1 (1)

Shares issued for services performed (in shares) 15,958 15,958

Shares issued for services performed $ 117 117

Stock repurchase (in shares) 936,636

Stock repurchase (5,612) $ (5,612)

Shares issued in conjunction with acquisition 0

Net income 6,220 6,220

Balance, end of period (in shares) at Dec. 31, 2014 108,776,247 986,636

Balance, end of period at Dec. 31, 2014 89,329 $ 108 162,433 $ (5,637) (67,575)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Share-based compensation expense 16,896 16,896

Exercise of stock options (in shares) 647,656 (1,573,225)

Exercise of stock options 4,629 $ 1 (9,792) $ 14,420

Exercise of warrants (in shares) (42,400)

Exercise of warrants 46 (379) $ 425

Issuance of restricted stock (in shares) 34,250 (1,940,009)

Issuance of restricted stock $ 0 (14,547) $ 14,547

Shares issued for services performed (in shares) 16,493 11,321 (5,172)

Shares issued for services performed $ 164 113 $ 51

Stock repurchase (in shares) 4,610,166

Stock repurchase (40,279) $ (40,279)

Tax benefit of share-based compensation expense 7,757 7,757

Restricted stock shares canceled/forfeited (in shares) (2,058) 69,949

Restricted stock shares canceled/forfeited 0 652 $ (652)

Shares issued in conjunction with acquisition 0

Net income 29,446 29,446

Balance, end of period (in shares) at Dec. 31, 2015 109,467,416 2,105,945

Balance, end of period at Dec. 31, 2015 107,988 $ 109 163,133 $ (17,125) (38,129)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Share-based compensation expense $ 17,818 17,818

Exercise of stock options (in shares) 1,164,138 243,928 (918,544)

Exercise of stock options $ 3,494 (3,767) $ 7,261

Issuance of restricted stock (in shares) 501,203 (2,210,879)

Issuance of restricted stock $ 1 $ 1 (17,546) $ 17,546

Shares issued for services performed (in shares) 43,344 (43,344)

Shares issued for services performed $ 346 6 $ 340

Stock repurchase (in shares) 1,338,616 1,338,616

Stock repurchase $ (10,378) $ (10,378)

Tax benefit of share-based compensation expense (424) (424)

Restricted stock shares canceled/forfeited (in shares) 377,317

Restricted stock shares canceled/forfeited 0 2,503 $ (2,503)

Shares repurchased for tax withholding (in shares) 141,658

Shares repurchased for tax withholding $ (1,165) $ (1,165)

Shares issued in conjunction with acquisition (in shares) (441,009) (441,009)

Shares issued in conjunction with acquisition $ 3,346 (462) $ 3,808

Net income 11,974 11,974

Balance, end of period (in shares) at Dec. 31, 2016 110,212,547 349,760

Balance, end of period at Dec. 31, 2016 $ 133,000 $ 110 $ 161,261 $ (2,216) $ (26,155)

X

- Definition
The number of shares issued during the period upon the exercise of warrants.
+ References
No definition available.
+ Details

Name: mdxg_StockIssuedDuringPeriodSharesExerciseOfWarrants

Namespace Prefix: mdxg_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued during the period upon the exercise of warrants.
+ References
No definition available.
+ Details

Name: mdxg_StockIssuedDuringPeriodValueExerciseOfWarrants

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) in additional paid in capital (APIC) resulting from a tax benefit (deficiency) associated with an share-based compensation plan other than an employee stock ownership plan (ESOP).
+ References
No definition available.
+ Details

Name: us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of adjustment to stockholders' equity associated with an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.
+ References
No definition available.
+ Details

Name: us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
For net-share settlement of share-based awards when the employer settles employees' income tax withholding obligations, this element represents the number of shares the employees use to repay the employer.
+ References
No definition available.
+ Details

Name: us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of stock issued during the period pursuant to acquisitions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares related to Restricted Stock Award forfeited during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued pursuant to acquisitions during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock related to Restricted Stock Awards forfeited during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate value of stock related to Restricted Stock Awards issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Number of shares that have been repurchased during the period and are being held in treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
+ Details

Name: us-gaap_TreasuryStockSharesAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_TreasuryStockValueAcquiredCostMethod

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 24 R6.htm IDEA: XBRL DOCUMENT v3.6.0.2

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Cash flows from operating activities:

Net income $ 11,974 $ 29,446 $ 6,220

Adjustments to reconcile net income to net cash from operating activities:

Depreciation 3,333 1,799 1,197

Amortization of intangible assets 2,127 933 928

Amortization of inventory fair value step-up 1,485 0 0

Amortization of deferred financing costs 181 42 0

Share-based compensation 17,818 16,896 11,453

Change in deferred income taxes (594) (7,081) 0

Increase (decrease) in cash, net of effects of acquisition, resulting from changes in:

Accounts receivable (11,396) (27,083) (10,579)

Inventory (2,837) (2,327) (1,252)

Prepaid expenses (2,400) (1,854) (203)

Other current assets (384) (240) 0

Accounts payable (3,665) 3,136 1,287

Accrued compensation (2,669) 3,511 5,935

Accrued expenses 6,297 2,140 1,098

Income taxes 5,835 (519) 452

Other liabilities 723 8 266

Net cash flows from operating activities 25,828 18,807 16,802

Cash flows from investing activities:

Purchases of equipment (6,269) (5,827) (2,558)

Purchase of Stability Inc., net of cash acquired (7,631) 0 0

Fixed maturity securities redemption 3,000 6,000 (9,000)

Patent application costs (842) (851) (594)

Net cash flows from investing activities (11,742) (678) (12,152)

Cash flows from financing activities:

Proceeds from exercise of stock options 3,494 4,629 2,470

Proceeds from exercise of warrants 0 46 1,113

Stock repurchase under repurchase plan (10,378) (40,279) (5,612)

Stock repurchase for tax withholdings on vesting of restricted stock (1,165) 0 0

Deferred financing costs (30) (504) 0

Payments under capital lease obligations (102) (117) (117)

Net cash flows from financing activities (8,181) (36,225) (2,146)

Net change in cash 5,905 (18,096) 2,504

Cash and cash equivalents, beginning of period 28,486 46,582 44,078

Cash and cash equivalents, end of period $ 34,391 $ 28,486 $ 46,582

X

- Definition
Payments for Application Costs, Patent
+ References
No definition available.
+ Details

Name: mdxg_PaymentsforApplicationCostsPatent

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906
+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred income tax expense (benefit) and income tax credits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=65896087&loc=d3e11374-113907

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_DeferredIncomeTaxesAndTaxCredits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedTaxesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInDeferredCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in current assets classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOtherCurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) in operating liabilities classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66092785&loc=d3e4542-108314

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 1C
-URI http://asc.fasb.org/extlink&oid=68049868&loc=SL66093883-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=68049868&loc=SL66093879-108312
+ Details

Name: us-gaap_InventoryWriteDown

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3574-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3574-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfDebtIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133
+ Details

Name: us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for payments to acquire rented equipment which is recorded as an asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133
+ Details

Name: us-gaap_PaymentsToAcquireEquipmentOnLease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for acquisition of machinery and equipment.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133
+ Details

Name: us-gaap_PaymentsToAcquireMachineryAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net cash inflow or outflow resulting from the entity's share transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585
+ Details

Name: us-gaap_ProceedsFromRepurchaseOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow from the sale or maturity of long-term held-to-maturity securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66010992&loc=d3e26853-111562

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228
+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock warrants.
+ References
No definition available.
+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 25 R7.htm IDEA: XBRL DOCUMENT v3.6.0.2

Nature of Business
12 Months Ended

Dec. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Business
Nature of Business

The Company operates in one business segment, Regenerative Biomaterials, which includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. The MiMedx allograft product families include our: dHACM family with AmnioFix® ans EpiFix® brands; Amniotic Fluid family with OrthoFlo brand; Umbilical family with EpiCord® and AmnioCord® brands; Placental Collagen family with CollaFix™ and AmnioFill™ brands; and Bone family with Physio® brand. AmnioFix and EpiFix are our tissue technologies processed from human amniotic membrane; OrthoFlo is an amniotic fluid derived allograft; EpiCord and AmnioCord are derived from the umbilical cord; Physio is a bone grafting material comprised of 100% bone tissue with no added carrier; and CollaFix, our next brand we plan to commercialize, is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.

The Company is focused primarily on the United States but is actively exploring international expansion opportunities.  The adoption of the technologies may vary depending on each country’s regulations, but the opportunities to help individuals in the different disease states remain similar and large.

X

- Definition
The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6003-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 2A
-URI http://asc.fasb.org/extlink&oid=64851502&loc=SL51803626-108592
+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R8.htm IDEA: XBRL DOCUMENT v3.6.0.2

Significant Accounting Policies
12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Significant Accounting Policies
Significant Accounting Policies
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported consolidated statements of operations during the reporting period.  Actual results could differ from those estimates.
Principles of Consolidation
The accompanying financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries MiMedx, Inc., MiMedx Processing Services, LLC (formerly known as SpineMedica, LLC), MiMedx Tissue Services, LLC (formerly known as Surgical Biologics, LLC) and Stability Biologics, LLC (formerly known as Stability Inc.). All significant inter-company balances and transactions have been eliminated.
Segment Reporting
ASC 280, “Segment Reporting” requires use of the “management approach” model for segment reporting.  The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company has determined it has one operating segment.  Disaggregation of the Company’s operating results is impracticable, because the Company’s research and development activities and its assets overlap, and management reviews its business as a single operating segment.  Thus, discrete financial information is not available for more than one operating segment.
Market Concentrations and Credit Risk
The Company places its cash and cash equivalents on deposit with financial institutions in the United States.  In July 2010, the Federal Deposit Insurance Corporation (“FDIC”) increased coverage to $250,000 for substantially all depository accounts. As of December 31, 2016 and 2015, the Company had cash and cash equivalents of approximately $33,200,000 and $27,700,000, respectively, in excess of the insured amounts.
Cash and Cash Equivalents
Cash and cash equivalents include cash and FDIC insured certificates of deposit held at various banks with an original maturity of three months or less.

Accounts Receivable
Accounts receivable represent amounts due from customers for which revenue has been recognized.  Generally, the Company does not require collateral or any other security to support its receivables.
The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in the Company's existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay.
Inventories
Inventories are valued at the lower of cost or market, using the first–in, first-out (FIFO) method.  Inventory is tracked through Raw Material, WIP, and Finished Good stages as the product progresses through various production steps and stocking locations. Labor and overhead costs are absorbed through the various production processes up to when the work order closes. Historical yields and normal capacities are utilized in the calculation of production overhead rates.  Reserves for inventory obsolescence are utilized to account for slow-moving inventory as well as inventory no longer needed due to diminished market demand.
Goodwill and Purchased Intangible Assets
Goodwill and purchased intangible assets with indefinite useful lives are not amortized but are tested for impairment at least annually. The Company reviews goodwill and purchased intangible assets with indefinite lives for impairment annually at the beginning of its fourth fiscal quarter and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Potential impairment indicators include a significant change in the business climate, legal factors, operating performance indicators, competition, and the sale of disposition of a significant portion of the business. The Company first assesses certain qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the Company was less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the Company is less than its carrying amount, then the Company would perform a two-step quantitative impairment testing. In the first step, the Company compares the fair value of the Company to its carrying value. The Company determines the fair value utilizing the market approach. Under the market approach, the Company uses its market capitalization which is calculated by taking the Company’s share price times the number of outstanding shares. If the fair value of the Company exceeds the carrying value of the net assets, goodwill is not impaired, and no further testing is required. If the fair value of the Company is less than the carrying value, the Company must perform the second step of the impairment test to measure the amount of impairment loss, if any. In the second step, the Company’s value is allocated to all of the assets and liabilities, including any unrecognized intangible assets, in a hypothetical analysis that calculates the implied fair value of goodwill in the same manner as if the Company was being acquired in a business combination. If the implied fair value of the reporting unit's goodwill is less than the carrying value, the difference is recorded as an impairment loss. The Company has determined that there are no goodwill and indefinite useful lives intangible impairments in 2016 and 2015.

Impairment of Intangible Assets with Finite Lives
The Company reviews purchased intangible assets with finite lives for impairment whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable using a two-step impairment test. In step one, we determine the sum of the undiscounted future cash flows of the assets based on management's estimates and compare it to the carrying value of the assets. If the carrying amount is greater than the sum of the undiscounted cash flows, then the asset is impaired and step two is required. In step two, the impairment loss is calculated as the difference between the fair value of the assets and the carrying value of the assets.
Impairment reviews are based on an estimated future cash flow approach that requires significant judgment with respect to future revenue and expense growth rates, selection of appropriate discount rate, asset groupings, and other assumptions and estimates. The Company uses estimates that are consistent with our business plans and a market participant view of the assets being evaluated. Actual results may differ from our estimates. The Company has determined that there are no intangible assets with finite lives impairments in 2016 and 2015.
Property and Equipment
Property and equipment are recorded at cost and depreciated on a straight-line basis over their estimated useful lives, principally three to seven years.  Leasehold improvements are depreciated on a straight-line basis over the lesser of the estimated useful lives or the life of the lease. The Company is party to various lease arrangements for its facility space and equipment. These arrangements include interest, scheduled rent increases and rent holidays which are included in the determination of minimum lease payments when assessing lease classification, and are included in rent expense on a straight line basis over the lease term. See Notes 7 and 16 for further information regarding capital leases, operating leases and rent expense.
Patent Costs
The Company incurs certain legal and related costs in connection with patent applications for tissue based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company. The Company capitalized approximately $842,000 of patent costs during 2016, $851,000 of patent costs during 2015 and $594,000 of patent costs during 2014.
Impairment of Long-lived Assets
The Company evaluates the recoverability of its long-lived assets (property and equipment) whenever adverse events or changes in business climate indicate that the expected undiscounted future cash flows from the related assets may be less than previously anticipated.  If the net book value of the related assets exceeds the expected undiscounted future cash flows of the assets, the carrying amount would be reduced to the present value of their expected future cash flows and an impairment loss would be recognized.
Revenue Recognition
The Company sells its products through a combination of a direct sales force, independent stocking distributors and third - party representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. The Company records revenues from sales to our independent stocking distributors at the time the product is shipped to the distributor. Our stocking distributors, who sell the products to their customers or sub-distributors, contractually take title to the products and assume all risks of ownership at the time of shipment. Our stocking distributors are obligated to pay us the contractually agreed upon invoice price within specified terms regardless of when, if ever, they sell the products. Our stocking distributors do not have any contractual rights of return or exchange other than for defective product or shipping error; however, in limited situations, we do accept returns or exchanges at our discretion.
Some of the Company’s sales to Government accounts, including the Department of Veterans Affairs, are made through a distributor relationship with AvKARE, which is a veteran-owned General Services Administration Federal Supply Schedule (FSS) contractor. The Company's agreement with AvKARE expires, subject to certain for-cause termination rights, on June 30, 2017. The Company may also elect to terminate the agreement without cause and pay a termination fee to AvKARE as specified in the agreement. Upon termination of the agreement, the parties may mutually agree to extend the agreement or the Company has an obligation to repurchase AvKARE’s remaining inventory, if any, within ninety (90) days in accordance with the terms of the Agreement. At the end of the term, the parties expect AvKARE’s inventory to be minimal, based upon AvKARE's obligation to use commercially reasonable efforts to achieve target sales levels over the remaining term of the agreement.
We continually evaluate new and current customers, including our stocking distributors, for collectability based on various factors including past history with the customer, evaluation of their credit worthiness, and current economic conditions. We only record revenue when collectability is reasonably assured. A portion of the Company’s revenue is generated from inventory maintained at hospitals or physician's offices.
We make estimates of potential future sales returns, discounts and allowances related to current period product revenue and these are reflected as a reduction of revenue in the same period revenue is recognized. We base our estimate for sales returns, discounts and allowances on historical sales and product return information, including historical experience and actual and projected trend information as well as projected sales returns based on estimated usage and contractual arrangements with AvKARE. These estimates have historically been consistent with actual results.
Research and Development Costs
Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies.  These costs are expensed as incurred.
Income Taxes
The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.
The Company recognizes deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.
The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.
Share-based Compensation
The Company accounts for its share- based compensation plans in accordance with FASB ASC topic 718 “Compensation- Stock compensation”. FASB ASC 718 requires the measurement and recognition of compensation expense for all share-based awards made to employees and directors, including employee stock options, restricted stock and warrants. Under the provisions of FASB ASC 718, and U. S. Securities and Exchange Commission Staff Accounting Bulleting No. 107, share-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense on a straight line basis over the requisite service period of the entire award (generally the vesting period of the award).
Fair Value of Financial Instruments
The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature and type of these instruments. These financial instruments include cash and cash equivalents, accounts receivable, short term investments, accounts payable and accrued expenses. The carrying cost of the Company’s investments also reflects their fair values due to the type of these investments and the fair value of capital leases approximates their carrying value based upon current rates available to the Company.
Fair Value Measurements
The Company records certain financial instruments at fair value, including: cash equivalents, short term investments and investments.  The Company may make an irrevocable election to measure other financial instruments at fair value on an instrument-by-instrument basis; although as of December 31, 2016, the Company has not chosen to make any such elections.  Fair value financial instruments are recorded in accordance with the fair value measurement framework.
The Company also measures certain non-financial assets at fair value on a non-recurring basis.  These non-recurring valuations include evaluating assets such as long-lived assets, and non-amortizing intangible assets for impairment; allocating value to assets in an acquired asset group, and accounting for business combinations.  The Company uses the fair value measurement framework to value these assets and reports these fair values in the periods in which they are recorded or written down.
The fair value measurement framework includes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair values in their broad levels.  These levels from highest to lowest priority are as follows:
•
Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities;
•
Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data.
•
Level 3: Unobservable inputs or valuation techniques that are used when little or no market data is available.
The determination of fair value and the assessment of a measurement’s placement within the hierarchy require judgment. Level 3 valuations often involve a higher degree of judgment and complexity.  Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions.  Management’s assumptions could vary depending on the asset or liability valued and the valuation method used.  Such assumptions could include: estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods.  The Company may also engage external advisors to assist it in determining fair value, as appropriate.
In connection with the acquisition of Stablity, the Company recorded a liability related to the Earn-Out portion of the purchase consideration. See Note 4, Acquisition, for further discussion of the Earn-Out liability. The Company has classified the Earn-Out liability as a Level 3 liability and the fair value of the Earn-Out liability will be evaluated each reporting period and changes in its fair value will be included in the Company’s results of operations. The fair value of the Earn-Out liability was calculated using a discount rate, approximating the pre-tax cost of debt and corroborated by Monte Carlo simulation, which was then applied to estimated earn out payments. To determine the fair value of the Earn-Out liability, management evaluates assumptions that require significant judgment. Changes in certain inputs to the valuation model, including the Company’s estimate of future revenues, can have a significant impact on the estimated fair value. The fair value recorded for the Earn-Out liability may vary significantly from period to period. This variability may result in the actual liability for a period either above or below the estimates recorded in the Company’s Consolidated Financial Statements, resulting in significant fluctuations in results of operations as a result of the corresponding non-cash gain or loss recorded.
Although the Company believes that the recorded fair value of its financial instruments is appropriate, these fair values may not be indicative of net realizable value or reflective of future fair values.
Recently Issued Accounting Pronouncements
The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs"). In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company is currently assessing the impact the adoption of ASU 2014-09 will have on its consolidated financial statements.
In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments, that eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. ASU 2015-16 is effective for public companies for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The Company has adopted this standard in the first quarter of 2016 and its application is shown in Note 4.
In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company has adopted this standard, prospectively, at the beginning of the fourth quarter 2015 to simplify reporting with the release of the valuation allowance as disclosed in Note 12. Prior periods were not retrospectively adjusted.
In February 2016, the FASB issued Accounting Standards Update ASU No. 2016-02, Leases (Topic 842). The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.
In March 2016, the FASB issued ASU No. 2016-09, "Compensation - Stock Compensation (Topic 718)". The standard is
intended to simplify several areas of accounting for share - based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. This ASU is effective for fiscal years beginning after December 15, 2016. The Company is currently assessing the impact the adoption of ASU 2016-09 will have on its consolidated financial statements. As of December 31, 2016, the Company does not have any remaining deferred tax assets that will result in an increase to equity upon realization. See Note 12.

In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments”. The update addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for public business entities for fiscal years beginning after December 15, 2017 and for interim periods within those fiscal years. The amendments in this update may be applied retrospectively or prospectively and early adoption is permitted. The Company is currently assessing the impact of the adoption of ASU 2016-15 will have on its consolidated financial statements.
All other ASUs issued and not yet effective for the year ended December 31, 2016, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18861-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18854-107790
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R9.htm IDEA: XBRL DOCUMENT v3.6.0.2

Liquidity and Capital Resources
12 Months Ended

Dec. 31, 2016

Liquidity and Capital Resources [Abstract]

Liquidity and Capital Resources
Liquidity and Capital Resources
Net Working Capital
As of December 31, 2016, the Company had approximately $34,391,000 of cash and cash equivalents.  The Company reported total current assets of approximately $126,538,000 and current liabilities of approximately $50,732,000 and had net working capital of approximately $75,806,000 as of December 31, 2016.
Overall Liquidity and Capital Resources
  The Company's largest cash requirement for the twelve months ended December 31, 2016 was cash for general working capital needs as well as the acquisition of Stability described in Note 4. In addition, the Company's other cash requirements included capital expenditures, and repurchases of the Company's common stock. The Company funded its cash requirements through its existing cash reserves, and its operating activities which generated approximately $25,828,000 during the period. The Company believes that its anticipated cash from operating and financing activities and existing cash and cash equivalents, as well as availability under the Credit Agreement will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next year.

X

- Definition
Liquidity and Capital Resources [Abstract]
+ References
No definition available.
+ Details

Name: mdxg_LiquidityandCapitalResourcesAbstract

Namespace Prefix: mdxg_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Liquidity and Capital Resources [Text Block]
+ References
No definition available.
+ Details

Name: mdxg_LiquidityandCapitalResourcesTextBlock

Namespace Prefix: mdxg_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R10.htm IDEA: XBRL DOCUMENT v3.6.0.2

Acquisition of Stability Inc.
12 Months Ended

Dec. 31, 2016

Business Combinations [Abstract]

Acquisition of Stability Inc.
Acquisition of Stability Inc.

On January 13, 2016, the Company completed the acquisition of Stability Inc., d/b/a Stability Biologics ("Stability"), a provider of human tissue products to surgeons, facilities, and distributors serving the surgical, spine, and orthopedic sectors of the healthcare industry. As a result of this transaction, the Company acquired all of the outstanding shares of Stability in exchange for
$6,000,000 cash, $3,346,000 in stock, represented by 441,009 shares of our common stock, and assumed debt of $1,771,000. Additional one time costs incurred in connection with the transaction totaled $1,088,000 and are included within selling, general and administrative expenses on the consolidated statements of operations. Contingent consideration may be payable in a formula determined by sales less certain expenses for the years 2016 and 2017. The contingent consideration was valued at $17,450,000 as of December 31, 2016 and is shown in the schedule below as fair value of earn-out. The Company used a third party specialist to assist us with the valuation. The purchase price allocation figures should be attributed to the Company and not to the third party valuation firm. The contingent consideration was classified as a liability.

The Company has evaluated the contingent consideration for accounting purposes under GAAP and has determined that the contingent consideration is within the scope of ASC 480 "Distinguishing Liabilities from Equity" whereby a financial instrument, other than an outstanding share, that embodies a conditional obligation that the issuer may settle by issuing a variable number of its equity shares shall be classified as a liability if, at inception, the monetary value of the obligation is based solely or
predominantly on variations in something other than the fair value of the issuer’s equity shares.

The actual purchase price was based on cash paid, the fair value of our stock on the date of the acquisition, and direct costs
associated with the acquisition. The fair value of stock consideration was determined as set forth below:

Common Share Price at Closing on 1/13/2016

$
8.43

Multiplied by: Number of Common Shares Transferred to the Sellers

441,009

Indicated Value of Equity Consideration (on a Freely Tradable Interest Basis)

$
3,717,706

Less: Marketability Discount @ 10%
[a]
(371,771
)
Fair Value of Equity Consideration Transferred

$
3,345,935

[a] Shares transferred to the Sellers are restricted securities pursuant to Rule 144. As such, the Sellers are prevented from selling the shares for a period of six months. In addition, they are subject to contractual lockups which restrict sales for up to twelve months following the closing of the transaction.

The actual purchase price has been allocated as follows (in thousands):

Cash paid at closing

$
6,000

Working capital adjustment

(480
)
Common stock issued (441,009 shares)

3,346

Assumed debt

1,771

Fair value of earn-out

17,450

Total fair value of purchase price

$
28,087

Net assets acquired:

Debt-free working capital

$
2,456

Other long-term assets

199

Property, plant and equipment

1,375

Deferred tax liability

(5,896
)
Subtotal

(1,866
)
Intangible assets:

Customer relationships

5,330

Patents and know-how

6,790

Trade names and trademarks

450

Non compete agreements

830

Licenses and permits

390

Subtotal

13,790

Goodwill

16,163

Total Assets Purchased

$
28,087

Working capital and other assets were composed of the following (in thousands):

Working capital

Cash

$
140

Prepaid Expenses and other current assets

100

Accounts receivable

2,001

Federal and state taxes receivable

28

Inventory

9,002

Accounts payable and accrued expenses

(8,815
)
Debt-free working capital

$
2,456

Current portion of long term debt

$
(194
)
Long-term debt

(560
)
Line of Credit

(932
)
Shareholder loan

(85
)
Assumed debt

$
(1,771
)

Net working capital

$
685

The acquisition was accounted for as a purchase business combination as defined by FASB Topic 805 - "Business Combinations". The fair value of the contingent consideration is measured as a Level 3 instrument. The contingent consideration liability is recorded at fair value on the acquisition date. Increases or decreases in the fair value of contingent consideration can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measured is based on significant inputs that are not observable in the market, they are categorized as Level 3. The income valuation approach was applied in determining the fair value of the contingent consideration using a discounted cash flow valuation technique with significant unobservable inputs comprised of projected sales and certain expenses. The values assigned to intangible assets are subject to amortization. The intangible assets were assigned the following lives for amortization purposes:

Estimated useful life (in years)
Intangible asset:

Customer relationships

12
Patents and know-how

20
Trade name and Trademarks

Indefinite
Non compete agreements

4
Licenses and permits

2

Goodwill consists of the excess of the purchase price paid over the identifiable net assets and liabilities acquired at fair value. Goodwill is attributable to the assembled workforce of Stability and the synergies expected to arise following the acquisition. Goodwill is not expected to be deductible for tax purposes. Goodwill was determined using the residual method based on an independent appraisal of the assets and liabilities acquired in the transaction. Goodwill is tested for impairment on an annual basis as defined by FASB Topic 350 - "Intangibles - Goodwill and Other".

Goodwill reconciliation (in thousands):
Balance at 3/31/16

$
22,912

Goodwill Adjustments (a)

(6,749
)
Balance at 12/31/16

$
16,163

(a) Goodwill is the result of a residual calculation

The changes in the preliminary fair values of the acquired assets and liabilities were due to adjustments made to the prospective financial information ("PFI") to better reflect an expected case from a market participant's perspective. As the earn-out is limited to the gross profit margin for the first two years after the acquisition, the adjustment to the PFI had a decreasing impact on the estimated fair value of the earn-out at the acquisition date, which resulted in a lower total purchase consideration and a reduction of the estimated fair value of the identifiable intangible assets.

During the measurement period, management determined that the initial PFI should be adjusted to better reflect an expected case from a market participant's perspective. At the time of the acquisition, management believed that certain of the acquired company's products had reached certain marketability milestones. Management subsequently concluded that these milestones had indeed not yet been achieved. Also, at the time of the acquisition Management believed that certain manufacturing processes were at standards aligned with our overall company standards. Management subsequently concluded that the standards required improvements. These factors have resulted in a lower revenue trajectory in the periods that apply to the earn-out thus reducing the fair value of the earn-out.

The measurement period adjustments are as follows (in thousands):

Provisional Per

Measurement Period

3/31/2016 Form 10Q

Adjustments 2016

Final

Cash paid at closing

$
6,000

$
—

$
6,000

Working capital adjustment

(480
)

—

(480
)
Common stock issued

3,346

—

3,346

Assumed debt

1,771

—

1,771

Fair value of earn-out

25,620

(8,170
)

17,450

Total fair value of purchase price

$
36,257

$
(8,170
)

$
28,087

Net assets acquired:

Debt-free working capital

$
2,179

$
277

$
2,456

Other assets, net

199

—

199

Property, plant and equipment

1,375

—

1,375

Deferred tax liability

(8,268
)

2,372

(5,896
)
Subtotal

$
(4,515
)

$
2,649

$
(1,866
)
Intangible assets:

Customer relationships

$
6,090

$
(760
)

$
5,330

Patents and know-how

9,170

(2,380
)

6,790

Trade names and trademarks

830

(380
)

450

Non compete agreements

1,080

(250
)

830

Licenses and permits

690

(300
)

390

Subtotal

17,860

(4,070
)

13,790

Goodwill

22,912

(6,749
)

16,163

Total Assets Purchased

$
36,257

$
(8,170
)

$
28,087

Pursuant to the terms of the earn-out arrangement, the Company will pay, for each of the years ending December 31, 2016 and 2017, an amount equal to one times the gross profit margin from (a) the net sales of Stability products sold by Stability's or the Company's sales personnel and (b) the net sales of Company products sold by Stability's sales personnel; provided, however, if the amount of such net sales for either earn-out period is less than $12 million, the earn-out amount will decrease to 0.5 times the gross profit margin for such earn-out period. The full details of the earn-out arrangement are set forth in the acquisition agreement which is filed as Exhibit 2.1 to the Company's Form 8-K filed on January 13, 2016.

The following unaudited pro forma summary financial information presents the consolidated results of operations for the Company as if the acquisition had occurred on January 1, 2015. The pro forma results are shown for illustrative purposes only and do not purport to be indicative of the results that would have been reported if the acquisition had occurred on the date indicated or indicative of the results that may occur in the future.

Unaudited pro forma information for the twelve months ended December 31, 2016 and 2015 (in thousands) is as follows:

Years Ended December 31,

2016
2015
Revenue

$245,563
$204,481

Net income

$12,611
$24,960

Income per share, fully diluted

$0.11
$0.22

The 2016 supplemental pro forma earnings were adjusted to exclude $1,088,000 of acquisition-related legal, audit and other
costs, net of tax. The 2015 supplemental pro forma earnings were adjusted to include $1,176,000 of amortization costs (net of tax) related to recorded intangible assets with defined useful lives, and $1,485,000 of inventory step-up charges (net of tax) as a result of the acquisition for comparability to 2016. The number of shares outstanding used in calculating the income per share for 2015 was adjusted to include 441,009 shares issued as part of the purchase price and assumed to be issued on January 1, 2015.

As the Company is managed and operates in one segment, and since Stability was merged with the Company's existing operations, the Company has determined that disaggregation of the Company's operating results to provide the amount of revenue and earnings for Stability since the acquisition date is impracticable.

X

- Definition
The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479
+ Details

Name: us-gaap_BusinessCombinationDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R11.htm IDEA: XBRL DOCUMENT v3.6.0.2

Cash Equivalents and Short Term Investments
12 Months Ended

Dec. 31, 2016

Cash and Cash Equivalents [Abstract]

Cash Equivalent and Short Term Investments
Cash Equivalents and Short Term Investments
Short term investments consisted of approximately $3,000,000 of FDIC insured certificates of deposit held with various financial institutions as of December 31, 2015. The cost of these instruments approximated their fair market value at December 31, 2015. There were no short term investments as of December 31, 2016.

X

- References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.
+ References
No definition available.
+ Details

Name: us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R12.htm IDEA: XBRL DOCUMENT v3.6.0.2

Inventories
12 Months Ended

Dec. 31, 2016

Inventory Disclosure [Abstract]

Inventories
Inventories

Inventories consisted of the following items as of December 31, 2016 and 2015 (in thousands):

December 31,

2016

2015
Raw materials
$
1,148

$
602

Work in process
6,677

3,850

Finished goods
10,817

3,405

Inventory, gross
18,642

7,857

Reserve for obsolescence
(828
)

(397
)
Inventory, net
$
17,814

$
7,460

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R13.htm IDEA: XBRL DOCUMENT v3.6.0.2

Property and Equipment
12 Months Ended

Dec. 31, 2016

Property, Plant and Equipment [Abstract]

Property and Equipment
Property and Equipment
Property and equipment consist of the following as of December 31, 2016 and 2015 (in thousands):

December 31,

2016

2015
Leasehold improvements
$
3,274

$
2,684

Lab and clean room equipment
8,666

4,564

Furniture and equipment
7,051

4,577

Construction in Progress
3,300

2,629

Property and equipment, gross
22,291

14,454

Less accumulated depreciation
(8,505
)

(4,979
)
Property and equipment, net
$
13,786

$
9,475

Included in property and equipment is approximately $427,000 of capital leases. The corresponding liability of approximately $31,000 is included in other liabilities in the accompanying consolidated balance sheet. Also included is approximately $1,000,000 in leasehold improvements paid for by the landlord of our main operating facility with a corresponding liability included in long term liabilities, which is amortized over the term of the lease. As of December 31, 2016 and 2015, the liability was $188,000 and $361,000, respectively.
Depreciation expense for the years ended December 31, 2016, 2015, and 2014 was approximately $3,333,000, $1,799,000, and $1,197,000, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13-14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2921-110230

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R14.htm IDEA: XBRL DOCUMENT v3.6.0.2

Intangible Assets and Royalty Agreement
12 Months Ended

Dec. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets and Royalty Agreement
Intangible Assets and Royalty Agreement
Intangible assets are summarized as follows (in thousands):

December 31,

2016

2015

Weighted
Average
Amortization
Lives

Cost

Cost
Licenses (a) (b) (c) (d)

7 years

$
1,399

$
1,009

Patents & Know How (b) (d)

19 years

14,839

8,001

Customer & Supplier Relationships (b) (d)

13 years

9,091

3,761

Tradenames & Trademarks (d)

indefinite

1,458

1,008

Non-Compete Agreements

4 years

830

—

In Process Research & Development (b)

various

25

25

Patents in Process (c)

various

2,618

1,823

Total

30,260

15,627

Less Accumulated amortization and impairment charges

(6,992
)

(4,864
)
Net

$
23,268

$
10,763

(a)
On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000.  Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of December 31, 2016 the license had a remaining net book value of approximately $10,000.
(b)
On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Tradenames & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. For the twelve months ended December 31, 2016, approximately $48,000 of costs associated with patents granted during the period were capitalized and included in Patents & Know-How subject to amortization over the life of the patents.
(c)
Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.
(d)
On January 13, 2016, the Company acquired Stability. As a result, the Company recorded intangible assets for Patents & Know - How of $6,790,000, Customer Relationships of $5,330,000, Non - compete agreements of $830,000, Tradenames & Trademarks of $450,000 and Licenses of $390,000.

Amortization expense for the years ended December 31, 2016, 2015, and 2014, was approximately $2,127,000, $933,000, and $928,000, respectively.
Expected future amortization of intangible assets as of December 31, 2016, is as follows (in thousands):

Estimated

Amortization
Year ending December 31,
Expense
2017
$
2,034

2018
1,829

2019
1,829

2020
1,622

2021
1,622

Thereafter
12,874

$
21,810

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all or part of the information related to intangible assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275
+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R15.htm IDEA: XBRL DOCUMENT v3.6.0.2

Long-Term Debt
12 Months Ended

Dec. 31, 2016

Debt Disclosure [Abstract]

Long-Term Debt
Long-Term Debt
Credit Facility
On October 12, 2015, the Company and its subsidiaries entered into a Credit Agreement (the "Credit Agreement") with certain lenders and Bank of America, N.A., as administrative agent. The Credit Agreement establishes a senior secured revolving credit facility in favor of the Company with a maturity date of October 12, 2018 and an aggregate lender commitment of up to $50 million. The Credit Agreement also provides for an uncommitted incremental facility of up to $35 million, which can be exercised as one or more revolving commitment increases or new term loans, all subject to certain customary terms and conditions set forth in the Credit Agreement. The obligations of the Company under the Credit Agreement are guaranteed by the Company's subsidiaries. The obligations of the loan parties under the Credit Agreement and the other credit documents are secured by liens on and security interests in substantially all of the assets of each of the loan parties and a pledge of the equity interests of each subsidiary owned by a loan party, subject to certain customary exclusions. Borrowings under the facility will bear interest at LIBOR plus 1.5% to 2.25%. Fees paid in connection with the initiation of the credit facility totaled approximately $500,000. These deferred financing costs are being amortized to interest expense over the three-year life of the facility. The Credit Agreement contains customary representations, warranties, covenants, and events of default, including restrictions on certain payments of dividends by the Company. As of December 31, 2016, there were no outstanding revolving loans under the credit facility. As of December 31, 2016, the Company was in compliance with all covenants under the Credit Agreement.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20,22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R16.htm IDEA: XBRL DOCUMENT v3.6.0.2

Net Income Per Share
12 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

Net Income Per Share
Net Income Per Share
Basic net income per common share is computed using the weighted-average number of common shares outstanding during the period.  Diluted net income per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, warrants and restricted stock using the treasury stock method.
The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except per share data):

Year Ended December 31,

2016

2015

2014
Net income
$
11,974

$
29,446

$
6,220

Denominator for basic earnings per share - weighted average shares
105,928,348

105,929,205

105,793,008

Effect of dilutive securities: Stock options, warrants, and restricted stock (a)
6,513,361

7,699,277

7,502,496

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities
112,441,709

113,628,482

113,295,504

Income per common share - basic
$
0.11

$
0.28

$
0.06

Income per common share - diluted
$
0.11

$
0.26

$
0.05

(a)Securities that are included in the computation of the denominator above, utilizing the treasury stock method for the years ended December 31, 2016, 2015 and 2014 are as follows:
Effect of dilutive securities:
2016

2015

2014
    Stock Options
5,845,377

7,121,774

7,035,728

    Warrants
—

33,676

226,926

    Restricted Stock Awards
667,984

543,827

239,842

6,513,361

7,699,277

7,502,496

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=65016374&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R17.htm IDEA: XBRL DOCUMENT v3.6.0.2

Equity
12 Months Ended

Dec. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Equity
Equity
Stock Incentive Plans
The Company has four share-based compensation plans which provide for the granting of equity awards, including qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors: the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan (the "2016 Plan"), which was approved by shareholders on May 18, 2016; the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the “Assumed 2006 Plan”); the MiMedx Inc. 2007 Assumed Stock Plan (the “Assumed 2007 Plan”); and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the “Assumed 2005 Plan”). The awards are subject to a vesting schedule as set forth in each individual agreement. The Company currently intends to use only the 2016 Plan to make future grants.

Activity with respect to the stock options is summarized as follows:

Number of
Shares

Weighted-
Average
Exercise
Price

Weighted-
Average
Remaining
Contractual
Term
(in years)

Aggregate
Intrinsic
Value
Outstanding at January 1, 2016
14,019,629

$
3.62

Granted
—

$
—

Exercised
(1,164,138
)

$
3.02

Unvested options forfeited
(154,200
)

$
6.77

Vested options expired
(148,683
)

$
6.16

Outstanding at December 31, 2016
12,552,608

$
3.61

5.4

$
66,137,378

Vested at December 31, 2016
11,680,455

$
3.33

5.3

$
64,733,964

Vested or expected to vest at December 31, 2016 (a)
12,539,865

$
3.60

5.4

$
66,119,285

(a)
Includes forfeiture adjusted unvested shares.
The intrinsic value of the options exercised during the years ended December 31, 2016, 2015 and 2014 were approximately $6,460,000, $17,181,000, and $10,566,000, respectively.
The intrinsic value of options vested during the years ended December 31, 2016, 2015 and 2014 were approximately $7,378,000, $10,044,000, and $6,615,000, respectively.

Following is a summary of stock options outstanding and exercisable at December 31, 2016:

Options Outstanding

Options Exercisable
Range of Exercise Prices
Number outstanding

Weighted-
Average
Remaining
Contractual
Term
(in years)

Weighted-
Average
Exercise
Price

Number Exercisable

Weighted-
Average
Exercise Price
$0.50 - $0.76
441,429

2.4

$
0.72

441,429

$
0.72

$0.87 - $1.35
4,385,570

4.7

1.19

4,385,570

1.19

$1.40 - $2.45
1,362,424

4.1

1.92

1,362,424

1.92

$2.66 - $3.99
878,680

5.8

3.06

878,680

3.06

$4.19 - $6.38
3,056,069

6.2

5.36

2,937,038

5.34

$6.45- $9.78
2,324,103

7.0

7.30

1,610,485

7.25

$9.90 - $10.99
104,333

7.7

10.42

64,829

10.46

12,552,608

5.4

$
3.61

11,680,455

$
3.33

A summary of the status of the Company’s unvested stock options as of December 31, 2016 is presented below:
Unvested Stock Options
Number of
Shares

Weighted-
Average
Grant Date Fair Value
Unvested at January 1, 2016
3,067,935

$
3.81

Granted
—

$
—

Cancelled
(154,200
)

$
6.77

Vested
(2,041,582
)

$
3.61

Unvested at December 31, 2016
872,153

$
4.28

Total unrecognized compensation expense at December 31, 2016, was approximately $1,064,000 and will be charged to expense through June 2017.
The fair value of the options granted was estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.  Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options.  The term of employee options granted is derived using the “simplified method” which computes expected term as the midpoint between the weighted average time to vesting and the contractual maturity. The simplified method was used due to the Company’s lack of sufficient historical data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its equity shares have been publicly traded.  The term for non-employee options is generally based upon the contractual term of the option.  The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.
The assumptions used in calculating the fair value of options granted using the Black-Scholes-Merton option-pricing model are set forth in the following table:

Year ended December 31,

2016

2015

2014
Expected volatility
—
%

54.35 - 58.14%

58.14 - 64.50%

Expected life (in years)
0

6

6

Expected dividend yield
—

—

—

Risk-free interest rate
0

1.51 - 1.68%

1.64 - 1.96%

The weighted-average grant date fair value for options granted during the years ended December 31, 2016, 2015 and 2014 were approximately $0.00, $5.15 and $4.18, respectively.
Restricted Stock Awards
Following is summary information for restricted stock awards for the year ended December 31, 2016. Shares vest over a one to three year period. As of December 31, 2016, there was approximately $21,905,000 of total unrecognized stock-based compensation related to time-based, non-vested restricted stock.  That expense is expected to be recognized on a straight-line basis over a weighted-average period of 1.9 years.
Additionally, during the twelve months ended December 31, 2016, 43,344 shares of common stock valued at approximately $345,700 were issued under the 2006 Plan to a consultant in return for services performed, and is included in the table that follows.

Number of
Shares

Weighted-Average Grant Date
Fair Value
Unvested at January 1, 2016

2,613,267

$
9.14

Granted

2,755,426

$
8.05

Vested

(1,162,931
)

$
8.68

Forfeited

(377,317
)

$
8.71

Unvested at December 31, 2016

3,828,445

$
8.53

For the years ended December 31, 2016, 2015, and 2014 the Company recognized stock-based compensation as follows (in thousands):

Years Ended December 31,

2016

2015

2014
Cost of sales
$
426

$
352

$
322

Research and development
647

790

660

Selling, general and administrative
16,745

15,754

10,471

$
17,818

$
16,896

$
11,453

Warrants
On November 18, 2015, 42,400 common stock warrants representing the balance remaining from those granted in connection with equity share purchases by investors as an additional incentive for providing long - term equity capital to the Company and as additional compensation to consultants and advisors were exercised at an exercise price of $1.09. The warrants were granted at negotiated prices in connection with the equity share purchases and at the market price of the common stock in other instances. The warrants were issued for terms of five years.
Treasury Stock
On May 12, 2014, our Board of Directors authorized the repurchase of up to $10 million of our common stock from time to time, through December 31, 2014. The Board subsequently extended the program until December 31, 2017. In December 2014, the Board increased the authorization to $20 million and further increased the authorization in 2015 to $60 million. In December 2016, the Board further increased the authorization to $66 million. The timing and amount of repurchases will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.
For the year ended December 31, 2016, the Company purchased approximately 1,338,616 shares of its common stock for an aggregate purchase price of approximately $10,338,000 exclusive of commissions of approximately $40,000. As of December 31, 2016, the Company had approximately $9,936,000 remaining under the repurchase program.

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65895303&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68057994&loc=d3e25284-112666

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 36 R18.htm IDEA: XBRL DOCUMENT v3.6.0.2

Income Taxes
12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Income Taxes
Income Taxes
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.
Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands):

December 31,

2016

2015
Deferred tax assets and liabilities:

Accruals and prepaids
$
4,992

$
4,606

Intangible assets
(5,130
)

146

Property and equipment
(1,338
)

(1,396
)
R&D and other tax credits
1,219

3,293

Stock Compensation
7,417

7,063

Net operating loss
2,395

1,763

Other
113

145

Net deferred tax assets
$
9,668

$
15,620

Valuation allowance
(554
)

(782
)

$
9,114

$
14,838

The reconciliation of the Federal statutory income tax rate of 35% to the effective rate is as follows:

December 31,

2016

2015
Federal statutory rate
35.00
%

34.00
%
State taxes, net of federal benefit
4.78
%

3.33
%
Non deductible compensation
0.04
%

0.63
%
Meals & entertainment
3.82
%

2.27
%
Equity Compensation
5.51
%

6.39
%
Domestic Production Activities Deduction
(4.71
)%

—
%
Tax Credits
(8.79
)%

(2.84
)%
Prior Period Adjustments
(3.79
)%

—
%
Other
3.27
%

(1.74
)%
Valuation allowance
(1.26
)%

(63.33
)%

33.87
%

(21.29
)%

Current and deferred income tax expense (benefit) is as follows (in thousands):

December 31, 2016

December 31, 2015

Current:

   Federal
$
4,700

$
8,452

   State
1,423

1,218

      Total current
6,123

9,670

Deferred:

   Federal
26

(13,070
)
   State
(16
)
(1,768
)
      Total deferred
10

(14,838
)

Total expense
$
6,133

$
(5,168
)

Income taxes are based on estimates of the annual effective tax rate and evaluations of possible future events and transactions and may be subject to subsequent refinement or revision.
Certain items of income and expense are not reported in tax returns and financial statements in the same year. The tax effect of such temporary differences is reported as deferred income taxes. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. The Company establishes a valuation allowance for deferred tax assets for which realization is not likely. As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets.

As of December 31, 2016, our deferred tax assets were primarily the result of accrued liabilities, equity compensation, tax credits and net operating loss carryforwards. A valuation allowance of $554,000 and $782,000 was recorded against our gross deferred tax asset balance as of December 31, 2016, and December 31, 2015, respectively.
At December 31, 2016, the Company had income tax net operating loss ("NOL") carryforwards for federal and state purposes of $2,327,000 and $27,912,000 respectively. At December 31, 2015, the Company has income tax net operating loss ("NOL") carryforwards for federal and state purposes of $579,000 and $27,552,000 respectively. As of December 31, 2016, the Company has recorded a deferred tax asset for both federal and state NOL carryforwards of approximately $815,000 and approximately $1,580,000, respectively. As of December 31, 2015, the Company has recorded a deferred tax asset for both federal and state NOL carryforwards of approximately $197,000 and approximately $1,566,000, respectively. The Company's net operating losses and tax credits are subject to annual limitations due to ownership change limitations provided by Internal Revenue Code Section 382. If not utilized, the federal and state tax loss carryforwards will expire between 2027 and 2035. A valuation allowance remains recorded against the deferred tax asset for certain state net operating loss carryovers in the amount of $554,000 that are not expected to be utilized prior to expiration.

As a result of certain realization requirements of ASC 718, Compensation - Stock Compensation, the table of deferred tax assets and liabilities shown above does not include certain deferred tax assets that arose directly from (or the use of which was postponed by) tax deductions related to equity compensation that were greater than the compensation recognized for financial reporting. During 2016, deferred tax assets in the amount of $1,170,000 were realized resulting in an increase to equity in the same amount. As of December 31, 2016, the Company does not have any remaining deferred tax assets that will result in an increase to equity upon realization. The Company uses ASC 740 ordering when determining when excess tax benefits have been realized.

The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in thousands):

December 31, 2016

December 31, 2015
Unrecognized tax benefits - January 1
$
170

$
—

          Gross increases - tax positions in current period
111

170

Unrecognized tax benefits - December 31
$
281

$
170

Included in the balance of unrecognized tax benefits as of December 31, 2016 and December 31, 2015, are $281,000 and $170,000, respectively, of tax benefits that, if recognized, would affect the effective tax rate. Also included in the balance of unrecognized tax benefits as of December 31, 2016 and December 31, 2015, are $281,000 and $170,000, respectively, of tax benefits that, if recognized, would result in adjustments to other tax accounts, primarily deferred taxes. This amount is recorded in Other Liabilities in the accompanying consolidated balance sheets.

The Company recognizes interest accrued related to unrecognized tax benefits and penalties as income tax expense. Related to the unrecognized tax benefits noted above, the Company accrued no penalties or interest during 2016, and, in total, as of December 31, 2016 has not recognized any liabilities for penalties or interest. During 2015, we also did not accrue any penalties or interest and, in total, as of December 31, 2015, had not recognized any liability for penalties or interest.

The Company is subject to taxation in the US and various state jurisdictions. As of December 31, 2016 the Company’s tax returns for 2013, 2014 and 2015 are subject to examination by the tax authorities. As of December 31, 2016, the Company is generally no longer subject to US federal, state, or local examinations by tax authorities for years before 2013.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32718-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R19.htm IDEA: XBRL DOCUMENT v3.6.0.2

Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities
12 Months Ended

Dec. 31, 2016

Supplemental Cash Flow Elements [Abstract]

Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities
Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities
Selected cash payments, receipts, and noncash activities are as follows (in thousands):

Years Ended December 31,

2016

2015

2014
Cash paid for interest
$
162

$
86

$
48

Income taxes paid
642

2,293

384

Retirement of fixed assets
—

319

—

Deferred financing costs
10

504

—

APIC related tax adjustments
(424
)

7,757

—

Stock issuance of 441,009 shares in connection with acquisition of Stability
3,346

—

—

Stock issuance of 43,344, 16,493 and 15,958 shares in exchange for services performed in 2016, 2015 and 2014, respectively
346

164

117

X

- Definition
The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586
+ Details

Name: us-gaap_CashFlowSupplementalDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowElementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R20.htm IDEA: XBRL DOCUMENT v3.6.0.2

401k Plan
12 Months Ended

Dec. 31, 2016

Compensation and Retirement Disclosure [Abstract]

401k Plan
401k Plan
The Company has a 401(k) plan (the “Plan”) covering employees who have attained 21 years of age and have completed three months of service. Under the Plan, participants may defer up to 100% of their eligible wages to a maximum of $18,000 per year (annual limit for 2015). Employees age 50 or over in 2016 may make additional pre-tax contributions up to $6,000 above and beyond normal plan and legal limits.  Annually, the Company may elect to match employee contributions up to 6% of the employee’s compensation.  Additionally, the Company may elect to make a discretionary contribution to the Plan. The Company did not provide matching contributions for the years ended December 31, 2016, 2015, and 2014.

X

- References
No definition available.
+ Details

Name: us-gaap_CompensationAndRetirementDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for pension and other postretirement benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 80
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65897934&loc=d3e2410-114920

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39675-114964

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66047640&loc=d3e39622-114963
+ Details

Name: us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R21.htm IDEA: XBRL DOCUMENT v3.6.0.2

Related Party Transactions
12 Months Ended

Dec. 31, 2016

Related Party Transactions [Abstract]

Related Party Transactions
Related Party Transactions
On January 13, 2016, when the Company completed the acquisition of Stability Inc., d/b/a Stability Biologics ("Stability") there was an assumed payable of $5,954,555 to a related party. The Company made payments of $1,361,030 during 2016. The payable was further reduced by $3,367,250 as a result of the return or destruction of expired inventory. The outstanding payable at 12/31/16 is $1,226,275 and is included in Accounts Payable. The related party is a limited liability company that is controlled by a former stockholder of Stability Inc. who is now an employee of the Company.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R22.htm IDEA: XBRL DOCUMENT v3.6.0.2

Commitments and Contingencies
12 Months Ended

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies
Commitments and Contingencies
Contractual Commitments
In addition to the capital leases noted under Property and Equipment (Note 7), the Company has entered into operating lease agreements for facility space and equipment. These leases expire over the next eight years and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration. The Company also has commitments for meeting space.
The estimated annual lease payment and meeting space commitments are as follows (in thousands):
Year ended December 31,

2017
$
2,827

2018
3,079

2019
2,023

2020
490

2021
141

Thereafter
374

$
8,934

Rent expense for the years ended December 31, 2016, 2015 and 2014, was approximately $1,764,000, $1,317,000 and $1,130,000, respectively, and is allocated among cost of sales, research and development, and selling, general and administrative expenses.
Letters of Credit
As a condition of the leases for the Company's facilities, we are obligated under standby letters of credit in the amount of approximately $103,000. These obligations are reduced at various times over the lives of the leases.
FDA Untitled Letter, Draft Guidance and Related Litigation

FDA Untitled Letter and Draft Guidance

On August 28, 2013, the FDA issued an Untitled Letter alleging that the Company's micronized allografts do not meet the criteria for regulation solely under Section 361 of the Public Health Service Act and that, as a result, MiMedx would need a biologics license to lawfully market those micronized products. Since the issuance of the Untitled Letter, the Company has been in discussions with the FDA to communicate its disagreement with the FDA's assertion that the Company's allografts are more than minimally manipulated. To date, the FDA has not changed its position that the Company's micronized products are not eligible for marketing solely under Section 361 of the Public Health Service Act. The Company continues to market its micronized products but is also pursuing the Biologics License Application (“BLA”) process for certain of its micronized products.

On December 22, 2014, the FDA issued for comment “Draft Guidance for Industry and FDA Staff: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products.” Essentially the Minimal Manipulation draft guidance takes the same position with respect to micronized amniotic tissue that it took in the Untitled Letter to MiMedx 16 months earlier. The Company submitted comments asserting that the Minimal Manipulation draft guidance represents agency action that goes far beyond the FDA’s statutory authority, is inconsistent with existing HCT/P regulations and the FDA’s prior positions, and is internally inconsistent and scientifically unsound.

On October 28, 2015, the FDA issued for comment, "Draft Guidance for Industry and FDA Staff: Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products." The Company submitted comments on this Homologous Use draft guidance as well. On September 12 and 13, 2016, the FDA held a public hearing to obtain input on the Homologous Use draft guidance and the previously released Minimal Manipulation draft guidance, as well as other recently issued guidance documents on HCT/Ps. The Company awaits further decision from FDA on the draft guidances, but anticipates this will be a lengthy process.

If the FDA does allow the Company to continue to market a micronized form of its sheet allografts without a biologics license either prior to or after finalization of the draft guidance documents, it may impose conditions, such as labeling restrictions and compliance with cGMP. Although the Company is preparing for these requirements in connection with its pursuit of a BLA for certain of its micronized products, earlier compliance with these conditions requires significant additional time and cost investments by the Company. It is also possible that the FDA will not allow the Company to market any form of a micronized product without a biologics license even prior to finalization of the draft guidance documents and could even require the Company to recall its micronized products. Revenues from micronized products comprised approximately 10% of the Company's revenues in 2016.

Securities Class Action

Following the publication of the Untitled Letter from the FDA regarding the Company’s micronized products in September 2013, the trading price of the Company’s stock declined and several putative shareholder class action lawsuits were filed against the Company and certain of its executive officers asserting violations of the Securities Exchange Act of 1934. The cases were consolidated in the United States District Court for the Northern District of Georgia. On November 17, 2015, the parties entered into a stipulation of settlement to settle the consolidated case in its entirety. The stipulation of settlement was filed with the Court on November 18, 2015. On November 19, 2015, the Court preliminarily approved the settlement and confirmed the settlement on April 5, 2016. The settlement amount was paid by the Company's insurance carrier.

Former Employee Litigation

On December 13, 2016, the Company filed lawsuits against former employees Jess Kruchoski (in the lawsuit styled MiMedx Group, Inc. v. Academy Medical, LLC, et. al. in the County Court of the Fifteenth Judicial Circuit in and for Palm Beach County, Florida (the “Florida Action”)) and Luke Tornquist (in the lawsuit styled MiMedx Group, Inc., v. Luke Tornquist in the Superior Court for Cobb County, Georgia, which was removed to the United States District Court for the Northern District of Georgia (the “Georgia Action”)). Both the Florida and Georgia Actions assert claims against Messrs. Kruchoski and Tornquist that each of them violated their restrictive covenants entered into with the Company, that each of them misappropriated trade secrets of the Company, that each of them tortiously interfered with contracts between the Company and its customers and employees, and that each of them breached his duty of loyalty owed to the Company, among other claims.

On December 15, 2016, Messrs. Kruchoski and Tornquist filed a lawsuit in the United States District Court of Minnesota (the “Minnesota Action”) against the Company and the Company’s Chairman and Chief Executive Officer, Parker Petit. The plaintiffs in this lawsuit each claimed that their employment with the Company was terminated in retaliation for their complaints about the Company’s alleged business practices in violation of the Dodd-Frank Act, 15 U.S.C. § 78u-6(h); and was an unlawful discharge in violation of Minnesota Statutes Section 181.931 subdivision 1. Mr. Kruchoski also claimed that the termination of his employment with the Company constituted marital status discrimination and familial status discrimination in violation of the Minnesota Human Rights Act. Messrs. Kruchoski and Tornquist also claimed that Mr. Petit tortiously interfered with their employment relationships with the Company.

On January 26, 2017, the Company and Mr. Petit filed motions to dismiss the Minnesota Action. In response, Messrs. Kruchoski and Tornquist voluntarily dismissed the Minnesota Action without prejudice on February 7, 2017. On February 7, 2017, Mr. Tornquist filed his Answer and Counterclaims in the Georgia Action wherein he asserted claims similar to those he had asserted in the Minnesota Action, with the exception that he did not include a claim of tortious interference against Mr. Petit. On February 15, 2017, Mr. Kruchoski filed a new lawsuit in Georgia against MiMedx and Mr. Petit, making many of the same allegations in that suit as were made in the Minnesota suit, with the addition of claims against the Company and Mr. Petit for defamation.

The Company intends to vigorously pursue its claims asserted in the Florida and Georgia Actions and also to vigorously defend against the lawsuits and counterclaims asserted against them.

Patent Litigation

MiMedx continues to diligently enforce its intellectual property against several entities. Currently, there are four actions pending, as described below:

The Liventa Action

On April 22, 2014, the Company filed a patent infringement lawsuit in the United States District Court for the Northern District of Georgia against Liventa Bioscience, Inc. ("Liventa"), Medline Industries, Inc. ("Medline") and Musculoskeletal Transplant Foundation, Inc. ("MTF") for permanent injunctive relief and unspecified damages (the "Liventa Action"). In addition to the allegations of infringement of MiMedx's patents, the lawsuit asserts that Liventa and Medline knowingly and willfully made false and misleading representations about their respective products to providers, patients, and in some cases, prospective investors. Though the terms of the agreement are confidential, the parties have reached a settlement of the false advertising claims for an undisclosed sum. The patent infringement claims are still pending as described below.

MiMedx asserts that Liventa (formerly known as AFCell Medical, Inc.), Medline and MTF infringed and continue to infringe certain of the Company's patents relating to the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts. MTF is the tissue processor while Liventa and Medline are the distributors of the allegedly infringing products. On May 30, 2014, defendants filed answers to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement, invalidity, laches and estoppel. MTF and Medline also filed counterclaims seeking declaratory judgments of non-infringement and invalidity. Defendants filed parallel Inter Partes Review ("IPR") proceedings which are discussed below. We expect the case to go to trial in 2017.

The Bone Bank Action

On May 16, 2014, the Company also filed a patent infringement lawsuit against Transplant Technology, Inc. d/b/a Bone Bank Allografts ("Bone Bank") and Texas Human Biologics, Ltd. ("Biologics") for permanent injunctive relief and unspecified damages (the "Bone Bank Action"). The Bone Bank Action was filed in the United States District Court for the Western District of Texas. This lawsuit similarly asserts that Bone Bank and Biologics infringed certain of the Company's patents through the manufacturing and sale of their placental-derived tissue graft products. On July 10, 2014, Defendants filed an answer to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement and invalidity and filed counterclaims seeking declaratory judgments of non-infringement and invalidity. Defendants also filed parallel IPR proceedings which are further discussed below. Discovery is closed and we expect the case to go to trial in 2017.

The NuTech Action

On March 2, 2015, the Company filed a patent infringement lawsuit against NuTech Medical, Inc. ("NuTech") and DCI Donor Services, Inc. ("DCI") for permanent injunctive relief and unspecified damages. This lawsuit was filed in the United States District Court for the Northern District of Alabama. The lawsuit alleges that NuTech and DCI have infringed and continue to infringe the Company's patents through the manufacture, use, sale, and/or offering of their tissue graft product. The lawsuit also asserts that NuTech knowingly and willfully made false and misleading representations about its products to customers and/or prospective customers. The case is currently in the discovery phase.

The Vivex Action

On April 1, 2016, the Company also filed a patent infringement lawsuit against Vivex BioMedical (“Vivex”) for permanent injunctive relief and unspecified damages (the "Vivex Action"). The lawsuit was filed in the United States District Court for the Northern District of Georgia. The patent at issue is the 8,709,494 patent (the "494" patent). Vivex answered the Company’s complaint and filed counterclaims of non-infringement and invalidity. On January 4, 2017, the Court granted a joint motion to stay the proceedings pending the outcome of the Bone Bank Action.

Pending IPRs

In addition to defending the claims in the pending district court litigations, defendants in the Liventa and Bone Bank cases have challenged certain of the Company's patents in several IPR proceedings to avoid the high burden of proof of proving invalidity by "clear and convincing evidence" in the district court litigations. An inter partes review (or "IPR") is a request for a specialized group within the United States Patent and Trademark Office to review the validity of a plaintiff's patent claims. The defendants in the Bone Bank Action challenged the validity of the Company's 8,597,687 (the "687" patent) and the '494 patent; while the defendants in the Liventa Action challenged the validity of the Company's 8,372,437 and 8,323,701 patents (the "'437" and "'701" patents, respectively).

On June 29, 2015, the Patent Trial and Appeals Board ("PTAB") denied the Bone Bank defendants' request for institution of an IPR with respect to the '494 patent (EpiFix) on all seven challenged grounds. On August 18, 2015, the PTAB also denied the Liventa defendants' request for institution of an IPR with respect to the '701 patent (AmnioFix) on all six challenged grounds. That is, the PTAB decided in each case that the defendants failed to establish a reasonable likelihood that defendants would prevail in showing any of the challenged claims of the '494 or the '701 patent were unpatentable.

On July 10, 2015, the PTAB issued an opinion allowing a review of the '687 patent to proceed, although on only two of the five challenged grounds. On July 7, 2016, the PTAB issued an opinion finding that the challenged claims, which relate to embossment and not configuration, were invalid for obviousness. The Company decided not to appeal the decision, as it impacted a non-core patent. On August 18, 2015, the PTAB issued an opinion allowing a review of the '437 patent to proceed, although only on one of the seven challenged grounds. On August 16, 2016, the PTAB issued an opinion finding that the challenged claims were unpatentable. MiMedx has filed an appeal of the PTAB’s decision regarding the '437 patent.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73718637&loc=d3e25287-109308
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R23.htm IDEA: XBRL DOCUMENT v3.6.0.2

Quarterly Financial Data (Unaudited)
12 Months Ended

Dec. 31, 2016

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Data (Unaudited)
Quarterly Financial Data (Unaudited) (in thousands except per share data)

First
Quarter

Second
Quarter

Third
Quarter

Fourth
Quarter
NET SALES

2016

$
53,367

$
57,342

$
64,429

$
69,877

2015

40,767

45,679

49,015

51,835

GROSS MARGIN

2016

$
45,421

$
49,948

$
56,432

$
60,807

2015

35,619

40,590

44,036

46,849

NET INCOME

2016

$
1,197

$
1,975

$
3,321

$
5,481

2015

4,087

5,430

6,551

13,378

NET INCOME
PER COMMON SHARE - BASIC

2016

$
0.01

$
0.02

$
0.03

$
0.05

2015

0.04

0.05

0.06

0.13

NET INCOME
PER COMMON SHARE - DILUTED

2016

$
0.01

$
0.02

$
0.03

$
0.05

2015

0.04

0.05

0.06

0.11

X

- References
No definition available.
+ Details

Name: us-gaap_QuarterlyFinancialInformationDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68076893&loc=d3e1570-108306

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305
+ Details

Name: us-gaap_QuarterlyFinancialInformationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R24.htm IDEA: XBRL DOCUMENT v3.6.0.2

Product Revenue Data
12 Months Ended

Dec. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Product Revenue Data
Product Revenue Data

We group our products into two categories: Wound Care and Surgical, Sports Medicine & Orthopedics (SSO) for purposes of the required disclosure under ASC 280-10-50-40. This grouping of products does not constitute a basis for resource allocation but is information intended to provide the reader with ability to better understand the Company's product categories. These groupings also do not meet the criteria under ASC 280-10-50-1 as separate segments.

Net Sales by Categories (in thousands):

Year Ended December 31,

2016

2015

2014
Wound Care

$
183,984

$
141,096

$
93,623

Surgical, Sports Medicine & Orthopedics (SSO)

61,031

46,200

24,600

Total

$
245,015

$
187,296

$
118,223

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599
+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R25.htm IDEA: XBRL DOCUMENT v3.6.0.2

Subsequent Events
12 Months Ended

Dec. 31, 2016

Subsequent Events [Abstract]

Subsequent Events
Subsequent Events

The Board of Directors in February 2017 authorized an increase of $20 million to the Company's Share Repurchase Program. This action brings the total amount authorized to $86 million since the Share Repurchase Program commenced in May 2014.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R26.htm IDEA: XBRL DOCUMENT v3.6.0.2

Schedule II - Valuation and Qualifying Accounts
12 Months Ended

Dec. 31, 2016

Valuation and Qualifying Accounts [Abstract]

Schedule II - Valuation and Qualifying Accounts
Schedule II Valuation and Qualifying Accounts
MIMEDX GROUP, INC. AND SUBSIDIARIES
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS
Years ended December 31, 2016, 2015 and 2014 (in thousands)

Balance at
Beginning of Year

Additions charged to Expense or Revenue

Deductions
and write-offs

Balance at
End of Year

For the Year ended December 31, 2016

Allowance for doubtful accounts

$
3,270

$
2,127

$
(555
)

$
4,842

Allowance for product returns

1,262

8,319

(4,687
)

4,894

Allowance for obsolescence

397

2,280

(1,849
)

828

For the Year ended December 31, 2015

Allowance for doubtful accounts

$
1,750

$
1,698

$
(178
)

$
3,270

Allowance for product returns

841

3,257

(2,836
)

1,262

Allowance for obsolescence

527

540

(670
)

397

For the Year ended December 31, 2014

Allowance for doubtful accounts

$
407

$
1,357

$
(14
)

$
1,750

Allowance for product returns

215

2,215

(1,589
)

841

Allowance for obsolescence

322

405

(200
)

527

X

- Definition
The entire disclosure for any allowance and reserve accounts (their beginning and ending balances, as well as a reconciliation by type of activity during the period). Alternatively, disclosure of the required information may be within the footnotes to the financial statements or a supplemental schedule to the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09)
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690
+ Details

Name: us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ValuationAndQualifyingAccountsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 45 R27.htm IDEA: XBRL DOCUMENT v3.6.0.2

Significant Accounting Policies (Policies)
12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported consolidated statements of operations during the reporting period.  Actual results could differ from those estimates.

Principles of Consolidation
Principles of Consolidation
The accompanying financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries MiMedx, Inc., MiMedx Processing Services, LLC (formerly known as SpineMedica, LLC), MiMedx Tissue Services, LLC (formerly known as Surgical Biologics, LLC) and Stability Biologics, LLC (formerly known as Stability Inc.). All significant inter-company balances and transactions have been eliminated.

Segment Reporting
Segment Reporting
ASC 280, “Segment Reporting” requires use of the “management approach” model for segment reporting.  The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company has determined it has one operating segment.  Disaggregation of the Company’s operating results is impracticable, because the Company’s research and development activities and its assets overlap, and management reviews its business as a single operating segment.  Thus, discrete financial information is not available for more than one operating segment.

Market Concentrations and Credit Risk
Market Concentrations and Credit Risk
The Company places its cash and cash equivalents on deposit with financial institutions in the United States.  In July 2010, the Federal Deposit Insurance Corporation (“FDIC”) increased coverage to $250,000 for substantially all depository accounts.

Cash and Cash Equivalents
Cash and Cash Equivalents
Cash and cash equivalents include cash and FDIC insured certificates of deposit held at various banks with an original maturity of three months or less.

Accounts Receivable
Accounts Receivable
Accounts receivable represent amounts due from customers for which revenue has been recognized.  Generally, the Company does not require collateral or any other security to support its receivables.
The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in the Company's existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay.

Inventories
Inventories
Inventories are valued at the lower of cost or market, using the first–in, first-out (FIFO) method.  Inventory is tracked through Raw Material, WIP, and Finished Good stages as the product progresses through various production steps and stocking locations. Labor and overhead costs are absorbed through the various production processes up to when the work order closes. Historical yields and normal capacities are utilized in the calculation of production overhead rates.  Reserves for inventory obsolescence are utilized to account for slow-moving inventory as well as inventory no longer needed due to diminished market demand.

Goodwill and Purchased Intangible Assets
Goodwill and Purchased Intangible Assets
Goodwill and purchased intangible assets with indefinite useful lives are not amortized but are tested for impairment at least annually. The Company reviews goodwill and purchased intangible assets with indefinite lives for impairment annually at the beginning of its fourth fiscal quarter and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Potential impairment indicators include a significant change in the business climate, legal factors, operating performance indicators, competition, and the sale of disposition of a significant portion of the business. The Company first assesses certain qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the Company was less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the Company is less than its carrying amount, then the Company would perform a two-step quantitative impairment testing. In the first step, the Company compares the fair value of the Company to its carrying value. The Company determines the fair value utilizing the market approach. Under the market approach, the Company uses its market capitalization which is calculated by taking the Company’s share price times the number of outstanding shares. If the fair value of the Company exceeds the carrying value of the net assets, goodwill is not impaired, and no further testing is required. If the fair value of the Company is less than the carrying value, the Company must perform the second step of the impairment test to measure the amount of impairment loss, if any. In the second step, the Company’s value is allocated to all of the assets and liabilities, including any unrecognized intangible assets, in a hypothetical analysis that calculates the implied fair value of goodwill in the same manner as if the Company was being acquired in a business combination. If the implied fair value of the reporting unit's goodwill is less than the carrying value, the difference is recorded as an impairment loss.

Impairment of Intangible Assets with Finite Lives
Impairment of Intangible Assets with Finite Lives
The Company reviews purchased intangible assets with finite lives for impairment whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable using a two-step impairment test. In step one, we determine the sum of the undiscounted future cash flows of the assets based on management's estimates and compare it to the carrying value of the assets. If the carrying amount is greater than the sum of the undiscounted cash flows, then the asset is impaired and step two is required. In step two, the impairment loss is calculated as the difference between the fair value of the assets and the carrying value of the assets.
Impairment reviews are based on an estimated future cash flow approach that requires significant judgment with respect to future revenue and expense growth rates, selection of appropriate discount rate, asset groupings, and other assumptions and estimates. The Company uses estimates that are consistent with our business plans and a market participant view of the assets being evaluated. Actual results may differ from our estimates.

Property and Equipment
Property and Equipment
Property and equipment are recorded at cost and depreciated on a straight-line basis over their estimated useful lives, principally three to seven years.  Leasehold improvements are depreciated on a straight-line basis over the lesser of the estimated useful lives or the life of the lease. The Company is party to various lease arrangements for its facility space and equipment. These arrangements include interest, scheduled rent increases and rent holidays which are included in the determination of minimum lease payments when assessing lease classification, and are included in rent expense on a straight line basis over the lease term.

Patent Costs
Patent Costs
The Company incurs certain legal and related costs in connection with patent applications for tissue based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company.

Impairment of Long-lived Assets
Impairment of Long-lived Assets
The Company evaluates the recoverability of its long-lived assets (property and equipment) whenever adverse events or changes in business climate indicate that the expected undiscounted future cash flows from the related assets may be less than previously anticipated.  If the net book value of the related assets exceeds the expected undiscounted future cash flows of the assets, the carrying amount would be reduced to the present value of their expected future cash flows and an impairment loss would be recognized.

Revenue Recognition
Revenue Recognition
The Company sells its products through a combination of a direct sales force, independent stocking distributors and third - party representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. The Company records revenues from sales to our independent stocking distributors at the time the product is shipped to the distributor. Our stocking distributors, who sell the products to their customers or sub-distributors, contractually take title to the products and assume all risks of ownership at the time of shipment. Our stocking distributors are obligated to pay us the contractually agreed upon invoice price within specified terms regardless of when, if ever, they sell the products. Our stocking distributors do not have any contractual rights of return or exchange other than for defective product or shipping error; however, in limited situations, we do accept returns or exchanges at our discretion.
Some of the Company’s sales to Government accounts, including the Department of Veterans Affairs, are made through a distributor relationship with AvKARE, which is a veteran-owned General Services Administration Federal Supply Schedule (FSS) contractor. The Company's agreement with AvKARE expires, subject to certain for-cause termination rights, on June 30, 2017. The Company may also elect to terminate the agreement without cause and pay a termination fee to AvKARE as specified in the agreement. Upon termination of the agreement, the parties may mutually agree to extend the agreement or the Company has an obligation to repurchase AvKARE’s remaining inventory, if any, within ninety (90) days in accordance with the terms of the Agreement. At the end of the term, the parties expect AvKARE’s inventory to be minimal, based upon AvKARE's obligation to use commercially reasonable efforts to achieve target sales levels over the remaining term of the agreement.
We continually evaluate new and current customers, including our stocking distributors, for collectability based on various factors including past history with the customer, evaluation of their credit worthiness, and current economic conditions. We only record revenue when collectability is reasonably assured. A portion of the Company’s revenue is generated from inventory maintained at hospitals or physician's offices.
We make estimates of potential future sales returns, discounts and allowances related to current period product revenue and these are reflected as a reduction of revenue in the same period revenue is recognized. We base our estimate for sales returns, discounts and allowances on historical sales and product return information, including historical experience and actual and projected trend information as well as projected sales returns based on estimated usage and contractual arrangements with AvKARE. These estimates have historically been consistent with actual results.

Research and Development Costs
Research and Development Costs
Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies.  These costs are expensed as incurred.

Income Taxes
Income Taxes
The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.
The Company recognizes deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.
The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

Share-based Compensation
Share-based Compensation
The Company accounts for its share- based compensation plans in accordance with FASB ASC topic 718 “Compensation- Stock compensation”. FASB ASC 718 requires the measurement and recognition of compensation expense for all share-based awards made to employees and directors, including employee stock options, restricted stock and warrants. Under the provisions of FASB ASC 718, and U. S. Securities and Exchange Commission Staff Accounting Bulleting No. 107, share-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense on a straight line basis over the requisite service period of the entire award (generally the vesting period of the award).

Fair Value of Financial Instruments
Fair Value of Financial Instruments
The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature and type of these instruments. These financial instruments include cash and cash equivalents, accounts receivable, short term investments, accounts payable and accrued expenses. The carrying cost of the Company’s investments also reflects their fair values due to the type of these investments and the fair value of capital leases approximates their carrying value based upon current rates available to the Company.

Fair Value Measurements
Fair Value Measurements
The Company records certain financial instruments at fair value, including: cash equivalents, short term investments and investments.  The Company may make an irrevocable election to measure other financial instruments at fair value on an instrument-by-instrument basis; although as of December 31, 2016, the Company has not chosen to make any such elections.  Fair value financial instruments are recorded in accordance with the fair value measurement framework.
The Company also measures certain non-financial assets at fair value on a non-recurring basis.  These non-recurring valuations include evaluating assets such as long-lived assets, and non-amortizing intangible assets for impairment; allocating value to assets in an acquired asset group, and accounting for business combinations.  The Company uses the fair value measurement framework to value these assets and reports these fair values in the periods in which they are recorded or written down.
The fair value measurement framework includes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair values in their broad levels.  These levels from highest to lowest priority are as follows:
•
Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities;
•
Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data.
•
Level 3: Unobservable inputs or valuation techniques that are used when little or no market data is available.
The determination of fair value and the assessment of a measurement’s placement within the hierarchy require judgment. Level 3 valuations often involve a higher degree of judgment and complexity.  Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions.  Management’s assumptions could vary depending on the asset or liability valued and the valuation method used.  Such assumptions could include: estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods.  The Company may also engage external advisors to assist it in determining fair value, as appropriate.
In connection with the acquisition of Stablity, the Company recorded a liability related to the Earn-Out portion of the purchase consideration. See Note 4, Acquisition, for further discussion of the Earn-Out liability. The Company has classified the Earn-Out liability as a Level 3 liability and the fair value of the Earn-Out liability will be evaluated each reporting period and changes in its fair value will be included in the Company’s results of operations. The fair value of the Earn-Out liability was calculated using a discount rate, approximating the pre-tax cost of debt and corroborated by Monte Carlo simulation, which was then applied to estimated earn out payments. To determine the fair value of the Earn-Out liability, management evaluates assumptions that require significant judgment. Changes in certain inputs to the valuation model, including the Company’s estimate of future revenues, can have a significant impact on the estimated fair value. The fair value recorded for the Earn-Out liability may vary significantly from period to period. This variability may result in the actual liability for a period either above or below the estimates recorded in the Company’s Consolidated Financial Statements, resulting in significant fluctuations in results of operations as a result of the corresponding non-cash gain or loss recorded.
Although the Company believes that the recorded fair value of its financial instruments is appropriate, these fair values may not be indicative of net realizable value or reflective of future fair values.

Recently Issued Accounting Pronouncements
Recently Issued Accounting Pronouncements
The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs"). In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company is currently assessing the impact the adoption of ASU 2014-09 will have on its consolidated financial statements.
In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments, that eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. ASU 2015-16 is effective for public companies for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The Company has adopted this standard in the first quarter of 2016 and its application is shown in Note 4.
In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company has adopted this standard, prospectively, at the beginning of the fourth quarter 2015 to simplify reporting with the release of the valuation allowance as disclosed in Note 12. Prior periods were not retrospectively adjusted.
In February 2016, the FASB issued Accounting Standards Update ASU No. 2016-02, Leases (Topic 842). The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.
In March 2016, the FASB issued ASU No. 2016-09, "Compensation - Stock Compensation (Topic 718)". The standard is
intended to simplify several areas of accounting for share - based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. This ASU is effective for fiscal years beginning after December 15, 2016. The Company is currently assessing the impact the adoption of ASU 2016-09 will have on its consolidated financial statements. As of December 31, 2016, the Company does not have any remaining deferred tax assets that will result in an increase to equity upon realization. See Note 12.

In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments”. The update addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for public business entities for fiscal years beginning after December 15, 2017 and for interim periods within those fiscal years. The amendments in this update may be applied retrospectively or prospectively and early adoption is permitted. The Company is currently assessing the impact of the adoption of ASU 2016-15 will have on its consolidated financial statements.
All other ASUs issued and not yet effective for the year ended December 31, 2016, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.

Acquisitions
The acquisition was accounted for as a purchase business combination as defined by FASB Topic 805 - "Business Combinations". The fair value of the contingent consideration is measured as a Level 3 instrument. The contingent consideration liability is recorded at fair value on the acquisition date. Increases or decreases in the fair value of contingent consideration can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measured is based on significant inputs that are not observable in the market, they are categorized as Level 3. The income valuation approach was applied in determining the fair value of the contingent consideration using a discounted cash flow valuation technique with significant unobservable inputs comprised of projected sales and certain expenses. The values assigned to intangible assets are subject to amortization.

Net Income Per Share
Net Income Per Share
Basic net income per common share is computed using the weighted-average number of common shares outstanding during the period.  Diluted net income per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, warrants and restricted stock using the treasury stock method.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 05
-Paragraph 4
-Subparagraph (a)-(d)
-URI http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457
+ Details

Name: us-gaap_BusinessCombinationsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 305
-SubTopic 10
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 55
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6875567&loc=d3e14489-108613

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68064133&loc=d3e61082-112788

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 825
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28088331&loc=SL29635902-196195

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13531-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68064133&loc=d3e61044-112788
+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64809438&loc=d3e5614-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.3A-03)
-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.3A-02)
-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828
+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for determining the fair value of financial instruments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13279-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 60
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260
+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.CC)
-URI http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 05
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=64802544&loc=d3e202-110218
+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32840-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32809-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=75116654&loc=d3e32247-109318

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=75116654&loc=d3e32280-109318
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_IntangibleAssetsFiniteLivedPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66092785&loc=d3e4492-108314

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66092785&loc=d3e4556-108314

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section S99
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751
+ Details

Name: us-gaap_LegalCostsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65890831&loc=d3e10133-111534

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(5))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66008989&loc=d3e4975-111524
+ Details

Name: us-gaap_ReceivablesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Research and Development
-URI http://asc.fasb.org/extlink&oid=6523717
+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition for the sale of goods, which is a transaction between an entity delivering a tangible good to a purchaser. The entity also may disclose its treatment of any unearned or deferred revenue that arises from the transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2197222

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.B.Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 15
-Section 25
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68076378&loc=d3e47119-111625
+ Details

Name: us-gaap_RevenueRecognitionSalesOfGoods

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for segment reporting.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790
+ Details

Name: us-gaap_SegmentReportingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(f)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6061-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6132-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R28.htm IDEA: XBRL DOCUMENT v3.6.0.2

Acquisition of Stability Inc. (Tables)
12 Months Ended

Dec. 31, 2016

Business Combinations [Abstract]

Schedule of acquisition of Stability Inc.
The actual purchase price has been allocated as follows (in thousands):

Cash paid at closing

$
6,000

Working capital adjustment

(480
)
Common stock issued (441,009 shares)

3,346

Assumed debt

1,771

Fair value of earn-out

17,450

Total fair value of purchase price

$
28,087

Net assets acquired:

Debt-free working capital

$
2,456

Other long-term assets

199

Property, plant and equipment

1,375

Deferred tax liability

(5,896
)
Subtotal

(1,866
)
Intangible assets:

Customer relationships

5,330

Patents and know-how

6,790

Trade names and trademarks

450

Non compete agreements

830

Licenses and permits

390

Subtotal

13,790

Goodwill

16,163

Total Assets Purchased

$
28,087

Working capital and other assets were composed of the following (in thousands):

Working capital

Cash

$
140

Prepaid Expenses and other current assets

100

Accounts receivable

2,001

Federal and state taxes receivable

28

Inventory

9,002

Accounts payable and accrued expenses

(8,815
)
Debt-free working capital

$
2,456

Current portion of long term debt

$
(194
)
Long-term debt

(560
)
Line of Credit

(932
)
Shareholder loan

(85
)
Assumed debt

$
(1,771
)

Net working capital

$
685

The fair value of stock consideration was determined as set forth below:

Common Share Price at Closing on 1/13/2016

$
8.43

Multiplied by: Number of Common Shares Transferred to the Sellers

441,009

Indicated Value of Equity Consideration (on a Freely Tradable Interest Basis)

$
3,717,706

Less: Marketability Discount @ 10%
[a]
(371,771
)
Fair Value of Equity Consideration Transferred

$
3,345,935

[a] Shares transferred to the Sellers are restricted securities pursuant to Rule 144. As such, the Sellers are prevented from selling the shares for a period of six months. In addition, they are subject to contractual lockups which restrict sales for up to twelve months following the closing of the transaction.

Finite-lived and indefinite-lived intangible assets acquired
The intangible assets were assigned the following lives for amortization purposes:

Estimated useful life (in years)
Intangible asset:

Customer relationships

12
Patents and know-how

20
Trade name and Trademarks

Indefinite
Non compete agreements

4
Licenses and permits

2

Goodwill reconciliation
Goodwill reconciliation (in thousands):
Balance at 3/31/16

$
22,912

Goodwill Adjustments (a)

(6,749
)
Balance at 12/31/16

$
16,163

(a) Goodwill is the result of a residual calculation

Measurement period adjustments
The measurement period adjustments are as follows (in thousands):

Provisional Per

Measurement Period

3/31/2016 Form 10Q

Adjustments 2016

Final

Cash paid at closing

$
6,000

$
—

$
6,000

Working capital adjustment

(480
)

—

(480
)
Common stock issued

3,346

—

3,346

Assumed debt

1,771

—

1,771

Fair value of earn-out

25,620

(8,170
)

17,450

Total fair value of purchase price

$
36,257

$
(8,170
)

$
28,087

Net assets acquired:

Debt-free working capital

$
2,179

$
277

$
2,456

Other assets, net

199

—

199

Property, plant and equipment

1,375

—

1,375

Deferred tax liability

(8,268
)

2,372

(5,896
)
Subtotal

$
(4,515
)

$
2,649

$
(1,866
)
Intangible assets:

Customer relationships

$
6,090

$
(760
)

$
5,330

Patents and know-how

9,170

(2,380
)

6,790

Trade names and trademarks

830

(380
)

450

Non compete agreements

1,080

(250
)

830

Licenses and permits

690

(300
)

390

Subtotal

17,860

(4,070
)

13,790

Goodwill

22,912

(6,749
)

16,163

Total Assets Purchased

$
36,257

$
(8,170
)

$
28,087

Business acquisition pro forma information
Unaudited pro forma information for the twelve months ended December 31, 2016 and 2015 (in thousands) is as follows:

Years Ended December 31,

2016
2015
Revenue

$245,563
$204,481

Net income

$12,611
$24,960

Income per share, fully diluted

$0.11
$0.22

X

- Definition
Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)-(3)
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463
+ Details

Name: us-gaap_BusinessAcquisitionProFormaInformationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463
+ Details

Name: us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267
+ Details

Name: us-gaap_ScheduleOfGoodwillTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472
+ Details

Name: us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R29.htm IDEA: XBRL DOCUMENT v3.6.0.2

Inventories (Tables)
12 Months Ended

Dec. 31, 2016

Inventory Disclosure [Abstract]

Inventory
Inventories consisted of the following items as of December 31, 2016 and 2015 (in thousands):

December 31,

2016

2015
Raw materials
$
1,148

$
602

Work in process
6,677

3,850

Finished goods
10,817

3,405

Inventory, gross
18,642

7,857

Reserve for obsolescence
(828
)

(397
)
Inventory, net
$
17,814

$
7,460

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(c))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R30.htm IDEA: XBRL DOCUMENT v3.6.0.2

Property and Equipment (Tables)
12 Months Ended

Dec. 31, 2016

Property, Plant and Equipment [Abstract]

Property and equipment
Property and equipment consist of the following as of December 31, 2016 and 2015 (in thousands):

December 31,

2016

2015
Leasehold improvements
$
3,274

$
2,684

Lab and clean room equipment
8,666

4,564

Furniture and equipment
7,051

4,577

Construction in Progress
3,300

2,629

Property and equipment, gross
22,291

14,454

Less accumulated depreciation
(8,505
)

(4,979
)
Property and equipment, net
$
13,786

$
9,475

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R31.htm IDEA: XBRL DOCUMENT v3.6.0.2

Intangible Assets and Royalty Agreement (Tables)
12 Months Ended

Dec. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible assets activity summary
Intangible assets are summarized as follows (in thousands):

December 31,

2016

2015

Weighted
Average
Amortization
Lives

Cost

Cost
Licenses (a) (b) (c) (d)

7 years

$
1,399

$
1,009

Patents & Know How (b) (d)

19 years

14,839

8,001

Customer & Supplier Relationships (b) (d)

13 years

9,091

3,761

Tradenames & Trademarks (d)

indefinite

1,458

1,008

Non-Compete Agreements

4 years

830

—

In Process Research & Development (b)

various

25

25

Patents in Process (c)

various

2,618

1,823

Total

30,260

15,627

Less Accumulated amortization and impairment charges

(6,992
)

(4,864
)
Net

$
23,268

$
10,763

(a)
On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000.  Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor.  Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of December 31, 2016 the license had a remaining net book value of approximately $10,000.
(b)
On January 5, 2011, the Company acquired Surgical Biologics, LLC.  As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Tradenames & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. For the twelve months ended December 31, 2016, approximately $48,000 of costs associated with patents granted during the period were capitalized and included in Patents & Know-How subject to amortization over the life of the patents.
(c)
Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.
(d)
On January 13, 2016, the Company acquired Stability. As a result, the Company recorded intangible assets for Patents & Know - How of $6,790,000, Customer Relationships of $5,330,000, Non - compete agreements of $830,000, Tradenames & Trademarks of $450,000 and Licenses of $390,000.

Estimated future amortization expense of intangible assets
Expected future amortization of intangible assets as of December 31, 2016, is as follows (in thousands):

Estimated

Amortization
Year ending December 31,
Expense
2017
$
2,034

2018
1,829

2019
1,829

2020
1,622

2021
1,622

Thereafter
12,874

$
21,810

X

- Definition
Tabular disclosure of intangible assets activity, which may be broken down by segment or major class.
+ References
No definition available.
+ Details

Name: mdxg_ScheduleOfIntangibleAssetsActivityTableTextBlock

Namespace Prefix: mdxg_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R32.htm IDEA: XBRL DOCUMENT v3.6.0.2

Net Income Per Share (Tables)
12 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

Computation of basic and diluted net loss per share
The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except per share data):

Year Ended December 31,

2016

2015

2014
Net income
$
11,974

$
29,446

$
6,220

Denominator for basic earnings per share - weighted average shares
105,928,348

105,929,205

105,793,008

Effect of dilutive securities: Stock options, warrants, and restricted stock (a)
6,513,361

7,699,277

7,502,496

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities
112,441,709

113,628,482

113,295,504

Income per common share - basic
$
0.11

$
0.28

$
0.06

Income per common share - diluted
$
0.11

$
0.26

$
0.05

(a)Securities that are included in the computation of the denominator above, utilizing the treasury stock method for the years ended December 31, 2016, 2015 and 2014 are as follows:
Effect of dilutive securities:
2016

2015

2014
    Stock Options
5,845,377

7,121,774

7,035,728

    Warrants
—

33,676

226,926

    Restricted Stock Awards
667,984

543,827

239,842

6,513,361

7,699,277

7,502,496

Summary of antidilutive securities
Securities that are included in the computation of the denominator above, utilizing the treasury stock method for the years ended December 31, 2016, 2015 and 2014 are as follows:
Effect of dilutive securities:
2016

2015

2014
    Stock Options
5,845,377

7,121,774

7,035,728

    Warrants
—

33,676

226,926

    Restricted Stock Awards
667,984

543,827

239,842

6,513,361

7,699,277

7,502,496

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R33.htm IDEA: XBRL DOCUMENT v3.6.0.2

Equity (Tables)
12 Months Ended

Dec. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock options activity
Activity with respect to the stock options is summarized as follows:

Number of
Shares

Weighted-
Average
Exercise
Price

Weighted-
Average
Remaining
Contractual
Term
(in years)

Aggregate
Intrinsic
Value
Outstanding at January 1, 2016
14,019,629

$
3.62

Granted
—

$
—

Exercised
(1,164,138
)

$
3.02

Unvested options forfeited
(154,200
)

$
6.77

Vested options expired
(148,683
)

$
6.16

Outstanding at December 31, 2016
12,552,608

$
3.61

5.4

$
66,137,378

Vested at December 31, 2016
11,680,455

$
3.33

5.3

$
64,733,964

Vested or expected to vest at December 31, 2016 (a)
12,539,865

$
3.60

5.4

$
66,119,285

(a)
Includes forfeiture adjusted unvested shares.

Summary of stock options outstanding and exercisable
Following is a summary of stock options outstanding and exercisable at December 31, 2016:

Options Outstanding

Options Exercisable
Range of Exercise Prices
Number outstanding

Weighted-
Average
Remaining
Contractual
Term
(in years)

Weighted-
Average
Exercise
Price

Number Exercisable

Weighted-
Average
Exercise Price
$0.50 - $0.76
441,429

2.4

$
0.72

441,429

$
0.72

$0.87 - $1.35
4,385,570

4.7

1.19

4,385,570

1.19

$1.40 - $2.45
1,362,424

4.1

1.92

1,362,424

1.92

$2.66 - $3.99
878,680

5.8

3.06

878,680

3.06

$4.19 - $6.38
3,056,069

6.2

5.36

2,937,038

5.34

$6.45- $9.78
2,324,103

7.0

7.30

1,610,485

7.25

$9.90 - $10.99
104,333

7.7

10.42

64,829

10.46

12,552,608

5.4

$
3.61

11,680,455

$
3.33

Unvested stock options roll forward
A summary of the status of the Company’s unvested stock options as of December 31, 2016 is presented below:
Unvested Stock Options
Number of
Shares

Weighted-
Average
Grant Date Fair Value
Unvested at January 1, 2016
3,067,935

$
3.81

Granted
—

$
—

Cancelled
(154,200
)

$
6.77

Vested
(2,041,582
)

$
3.61

Unvested at December 31, 2016
872,153

$
4.28

Fair value of options valuation assumptions
The assumptions used in calculating the fair value of options granted using the Black-Scholes-Merton option-pricing model are set forth in the following table:

Year ended December 31,

2016

2015

2014
Expected volatility
—
%

54.35 - 58.14%

58.14 - 64.50%

Expected life (in years)
0

6

6

Expected dividend yield
—

—

—

Risk-free interest rate
0

1.51 - 1.68%

1.64 - 1.96%

Restricted stock awards roll forward
Following is summary information for restricted stock awards for the year ended December 31, 2016. Shares vest over a one to three year period. As of December 31, 2016, there was approximately $21,905,000 of total unrecognized stock-based compensation related to time-based, non-vested restricted stock.  That expense is expected to be recognized on a straight-line basis over a weighted-average period of 1.9 years.
Additionally, during the twelve months ended December 31, 2016, 43,344 shares of common stock valued at approximately $345,700 were issued under the 2006 Plan to a consultant in return for services performed, and is included in the table that follows.

Number of
Shares

Weighted-Average Grant Date
Fair Value
Unvested at January 1, 2016

2,613,267

$
9.14

Granted

2,755,426

$
8.05

Vested

(1,162,931
)

$
8.68

Forfeited

(377,317
)

$
8.71

Unvested at December 31, 2016

3,828,445

$
8.53

Allocation of share-based compensation
For the years ended December 31, 2016, 2015, and 2014 the Company recognized stock-based compensation as follows (in thousands):

Years Ended December 31,

2016

2015

2014
Cost of sales
$
426

$
352

$
322

Research and development
647

790

660

Selling, general and administrative
16,745

15,754

10,471

$
17,818

$
16,896

$
11,453

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the change in stock options.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R34.htm IDEA: XBRL DOCUMENT v3.6.0.2

Income Taxes (Tables)
12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Deferred tax assets and liabilities
Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands):

December 31,

2016

2015
Deferred tax assets and liabilities:

Accruals and prepaids
$
4,992

$
4,606

Intangible assets
(5,130
)

146

Property and equipment
(1,338
)

(1,396
)
R&D and other tax credits
1,219

3,293

Stock Compensation
7,417

7,063

Net operating loss
2,395

1,763

Other
113

145

Net deferred tax assets
$
9,668

$
15,620

Valuation allowance
(554
)

(782
)

$
9,114

$
14,838

Reconciliation of the Federal statutory income tax
The reconciliation of the Federal statutory income tax rate of 35% to the effective rate is as follows:

December 31,

2016

2015
Federal statutory rate
35.00
%

34.00
%
State taxes, net of federal benefit
4.78
%

3.33
%
Non deductible compensation
0.04
%

0.63
%
Meals & entertainment
3.82
%

2.27
%
Equity Compensation
5.51
%

6.39
%
Domestic Production Activities Deduction
(4.71
)%

—
%
Tax Credits
(8.79
)%

(2.84
)%
Prior Period Adjustments
(3.79
)%

—
%
Other
3.27
%

(1.74
)%
Valuation allowance
(1.26
)%

(63.33
)%

33.87
%

(21.29
)%

Schedule of current and deferred income tax expense (benefit)
Current and deferred income tax expense (benefit) is as follows (in thousands):

December 31, 2016

December 31, 2015

Current:

   Federal
$
4,700

$
8,452

   State
1,423

1,218

      Total current
6,123

9,670

Deferred:

   Federal
26

(13,070
)
   State
(16
)
(1,768
)
      Total deferred
10

(14,838
)

Total expense
$
6,133

$
(5,168
)

Reconciliation of unrecognized tax benefits
The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in thousands):

December 31, 2016

December 31, 2015
Unrecognized tax benefits - January 1
$
170

$
—

          Gross increases - tax positions in current period
111

170

Unrecognized tax benefits - December 31
$
281

$
170

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319
+ Details

Name: us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319
+ Details

Name: us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319
+ Details

Name: us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the change in unrecognized tax benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 55
-Paragraph 217
-URI http://asc.fasb.org/extlink&oid=75116239&loc=d3e36027-109320

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-URI http://asc.fasb.org/extlink&oid=65882285&loc=SL6600010-109319
+ Details

Name: us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R35.htm IDEA: XBRL DOCUMENT v3.6.0.2

Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Tables)
12 Months Ended

Dec. 31, 2016

Supplemental Cash Flow Elements [Abstract]

Supplemental disclosure of cash flow and non-cash investing and financing activities
Selected cash payments, receipts, and noncash activities are as follows (in thousands):

Years Ended December 31,

2016

2015

2014
Cash paid for interest
$
162

$
86

$
48

Income taxes paid
642

2,293

384

Retirement of fixed assets
—

319

—

Deferred financing costs
10

504

—

APIC related tax adjustments
(424
)

7,757

—

Stock issuance of 441,009 shares in connection with acquisition of Stability
3,346

—

—

Stock issuance of 43,344, 16,493 and 15,958 shares in exchange for services performed in 2016, 2015 and 2014, respectively
346

164

117

X

- Definition
Tabular disclosure of supplemental cash flow information for the periods presented.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowElementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 54 R36.htm IDEA: XBRL DOCUMENT v3.6.0.2

Commitments and Contingencies (Tables)
12 Months Ended

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Estimated annual lease, royalty, and employment agreement expenses
The estimated annual lease payment and meeting space commitments are as follows (in thousands):
Year ended December 31,

2017
$
2,827

2018
3,079

2019
2,023

2020
490

2021
141

Thereafter
374

$
8,934

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the aggregate amount of payments due on known contractual obligations for the five years following the date of the latest balance sheet and the combined aggregate amount of maturities of known contractual obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-K (SK)
-Number 229
-Section 303
-Paragraph a
-Subparagraph 5
+ Details

Name: us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 55 R37.htm IDEA: XBRL DOCUMENT v3.6.0.2

Quarterly Financial Data (Unaudited) (Tables)
12 Months Ended

Dec. 31, 2016

Quarterly Financial Information Disclosure [Abstract]

Schedule of quarterly financial information

First
Quarter

Second
Quarter

Third
Quarter

Fourth
Quarter
NET SALES

2016

$
53,367

$
57,342

$
64,429

$
69,877

2015

40,767

45,679

49,015

51,835

GROSS MARGIN

2016

$
45,421

$
49,948

$
56,432

$
60,807

2015

35,619

40,590

44,036

46,849

NET INCOME

2016

$
1,197

$
1,975

$
3,321

$
5,481

2015

4,087

5,430

6,551

13,378

NET INCOME
PER COMMON SHARE - BASIC

2016

$
0.01

$
0.02

$
0.03

$
0.05

2015

0.04

0.05

0.06

0.13

NET INCOME
PER COMMON SHARE - DILUTED

2016

$
0.01

$
0.02

$
0.03

$
0.05

2015

0.04

0.05

0.06

0.11

X

- References
No definition available.
+ Details

Name: us-gaap_QuarterlyFinancialInformationDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)-(j)
-URI http://asc.fasb.org/extlink&oid=68076893&loc=d3e1280-108306
+ Details

Name: us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 56 R38.htm IDEA: XBRL DOCUMENT v3.6.0.2

Product Revenue Data (Tables)
12 Months Ended

Dec. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Net sales by categories
Net Sales by Categories (in thousands):

Year Ended December 31,

2016

2015

2014
Wound Care

$
183,984

$
141,096

$
93,623

Surgical, Sports Medicine & Orthopedics (SSO)

61,031

46,200

24,600

Total

$
245,015

$
187,296

$
118,223

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599
+ Details

Name: us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 57 R39.htm IDEA: XBRL DOCUMENT v3.6.0.2

Nature of Business (Details) - 12 months ended Dec. 31, 2016

Business_Segment

segment

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Number of business segments 1 1

X

- Definition
Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfOperatingSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 58 R40.htm IDEA: XBRL DOCUMENT v3.6.0.2

Significant Accounting Policies (Details)
12 Months Ended

Dec. 31, 2016

USD ($)

Dec. 31, 2016

USD ($)

Business_Segment

Dec. 31, 2016

USD ($)

segment

Dec. 31, 2016

USD ($)

Dec. 31, 2015

USD ($)

Dec. 31, 2014

USD ($)

Jul. 31, 2010

USD ($)

Market Concentrations and Credit Risk [Line Items]

Number of business segments 1 1

FDIC insured amount $ 250,000

Cash and cash equivalents uninsured amount $ 33,200,000 $ 33,200,000 $ 33,200,000 $ 33,200,000 $ 27,700,000

Goodwill impairment 0

impairment of indefinite useful lives intangible 0 0

Impairment of intangible assets with finite lives 0 0

Patents

Market Concentrations and Credit Risk [Line Items]

Intangible assets, net of accumulated amortization $ 842,000 $ 851,000 $ 594,000

Minimum

Market Concentrations and Credit Risk [Line Items]

Property and equipment estimated useful life 3 years

Maximum

Market Concentrations and Credit Risk [Line Items]

Property and equipment estimated useful life 7 years

X

- Definition
The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.
+ References
No definition available.
+ Details

Name: us-gaap_CashFDICInsuredAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.
+ References
No definition available.
+ Details

Name: us-gaap_CashUninsuredAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ConcentrationRiskLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13777-109266

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267
+ Details

Name: us-gaap_GoodwillImpairmentLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275
+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsFinitelived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275
+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfOperatingSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 59 R41.htm IDEA: XBRL DOCUMENT v3.6.0.2

Liquidity and Capital Resources (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Liquidity and Capital Resources [Abstract]

Cash and cash equivalents $ 34,391 $ 28,486 $ 46,582 $ 44,078

Total current assets 126,538 96,310

Total current liabilities 50,732 26,777

Net working capital 75,806

Net cash flows from operating activities $ 25,828 $ 18,807 $ 16,802

X

- Definition
Current Assets and Liabilities, Net
+ References
No definition available.
+ Details

Name: mdxg_CurrentAssetsandLiabilitiesNet

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Liquidity and Capital Resources [Abstract]
+ References
No definition available.
+ Details

Name: mdxg_LiquidityandCapitalResourcesAbstract

Namespace Prefix: mdxg_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

XML 60 R42.htm IDEA: XBRL DOCUMENT v3.6.0.2

Acquisition of Stability Inc. - Narrative (Details)
3 Months Ended 12 Months Ended

Jan. 13, 2016

USD ($)

shares

Mar. 31, 2016

USD ($)

Dec. 31, 2017

Dec. 31, 2016

USD ($)

Business_Segment

Dec. 31, 2016

USD ($)

Dec. 31, 2016

USD ($)

segment

Dec. 31, 2016

USD ($)

Dec. 31, 2015

USD ($)

Dec. 31, 2014

USD ($)

Business Acquisition [Line Items]

Gross profit margin multiplier 1

Net sales for earn-out period (less than) $ 12,000,000

Gross profit margin multiplier, low 0.5

Amortization of intangible assets 2,127,000 $ 933,000 $ 928,000

Net income 12,611,000 24,960,000

Number of business segments 1 1

Fair Value Adjustment to Inventory

Business Acquisition [Line Items]

Net income 1,485,000

Forecast

Business Acquisition [Line Items]

Gross profit margin multiplier 1

Pro Forma

Business Acquisition [Line Items]

Amortization of intangible assets $ 1,176,000

Stability Biologics, LLC

Business Acquisition [Line Items]

Cash paid at closing $ 6,000,000 $ 6,000,000 6,000,000

Fair Value of Equity Consideration Transferred $ 3,345,935 3,346,000 3,346,000

Common stock issued (in shares) | shares 441,009

Assumed debt $ 1,771,000 1,771,000 1,771,000

Acquisition related costs 1,088,000

Fair value of earn-out 17,450,000 $ 25,620,000 $ 17,450,000 $ 17,450,000 $ 17,450,000 $ 17,450,000

Stability Biologics, LLC | Selling, general and administrative

Business Acquisition [Line Items]

Acquisition related costs $ 1,088,000

X

- Definition
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Fair Value
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableFairValue

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Business Combination, Contingent Consideration Arrangements, Gross Profit Multiplier If Net Sales Target Not Achieved
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationContingentConsiderationArrangementsGrossProfitMultiplierIfNetSalesTargetNotAchieved

Namespace Prefix: mdxg_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition
Business Combination, Contingent Consideration, Liability, Gross Profit Margin Multiplier
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationContingentConsiderationLiabilityGrossProfitMarginMultiplier

Namespace Prefix: mdxg_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition
Business Combination, Contingent Consideration, Minimum Net Sales For Earn Out Period, To Avoid Reduction In Gross Profit Multiplier, Amount
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationContingentConsiderationMinimumNetSalesForEarnOutPeriodToAvoidReductionInGrossProfitMultiplierAmount

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of shares of equity interests issued or issuable to acquire entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479
+ Details

Name: us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)-(3)
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463
+ Details

Name: us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 25
-Paragraph 23
-URI http://asc.fasb.org/extlink&oid=73531572&loc=d3e1043-128460
+ Details

Name: us-gaap_BusinessCombinationAcquisitionRelatedCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477
+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of liability recognized arising from contingent consideration in a business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfOperatingSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireBusinessesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonrecurringAdjustmentAxis=us-gaap_FairValueAdjustmentToInventoryMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=us-gaap_ProFormaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=mdxg_StabilityBiologicsLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 61 R43.htm IDEA: XBRL DOCUMENT v3.6.0.2

Acquisition of Stability Inc. - Fair Value of Stock Consideration (Details) - Stability Biologics, LLC - USD ($)
3 Months Ended 12 Months Ended

Jan. 13, 2016

Mar. 31, 2016

Dec. 31, 2016

Business Acquisition [Line Items]

Common stock issued, price per share (in dollars per share) $ 8.43

Common stock issued (in shares) 441,009

Common stock issued in acquisition $ 3,717,706

Less: Marketability Discount @ 10% (371,771)

Fair Value of Equity Consideration Transferred $ 3,345,935 $ 3,346,000 $ 3,346,000

Marketability discount 10.00%

X

- Definition
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Discount
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableDiscount

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Fair Value
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableFairValue

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares of equity interests issued or issuable to acquire entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479
+ Details

Name: us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionSharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477
+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Adjustment to the discount rate used to measure fair value for lack of ability to convert business interests into cash quickly.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueInputsDiscountForLackOfMarketability

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=mdxg_StabilityBiologicsLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 62 R44.htm IDEA: XBRL DOCUMENT v3.6.0.2

Acquisition of Stability Inc. - Preliminarily Allocation of Purchase Price (Details) - USD ($)
3 Months Ended 12 Months Ended

Jan. 13, 2016

Mar. 31, 2016

Dec. 31, 2016

Dec. 31, 2015

Intangible assets:

Goodwill $ 20,203,000 $ 4,040,000

Stability Biologics, LLC

Business Combination, Consideration Transferred [Abstract]

Cash paid at closing $ 6,000,000 $ 6,000,000 6,000,000

Working capital adjustment (480,000) (480,000) (480,000)

Common stock issued (441,009 shares) $ 3,345,935 3,346,000 3,346,000

Common stock issued (in shares) 441,009

Assumed debt $ 1,771,000 1,771,000 1,771,000

Fair value of earn-out 17,450,000 25,620,000 17,450,000

Total fair value of purchase price 28,087,000 36,257,000 28,087,000

Net assets acquired:

Debt-free working capital 2,456,000 2,179,000 2,456,000

Other long-term assets 199,000 199,000 199,000

Property, plant and equipment 1,375,000 1,375,000 1,375,000

Deferred tax liability (5,896,000) (8,268,000) (5,896,000)

Subtotal (1,866,000) (4,515,000) (1,866,000)

Intangible assets:

Subtotal 13,790,000 17,860,000 13,790,000

Goodwill 16,163,000 22,912,000 16,163,000

Total Assets Purchased 28,087,000 36,257,000 28,087,000

Cash 140,000

Prepaid Expenses and other current assets 100,000

Accounts receivable 2,001,000

Federal and state taxes receivable 28,000

Inventory 9,002,000

Accounts payable and accrued expenses (8,815,000)

Debt-free working capital 2,456,000 2,179,000 2,456,000

Current portion of long term debt (194,000)

Assumed debt 1,771,000

Net working capital 685,000

Other long term assets 199,000 199,000 199,000

Stability Biologics, LLC | Long-term debt

Intangible assets:

Long-term debt (560,000)

Stability Biologics, LLC | Line of Credit

Intangible assets:

Long-term debt (932,000)

Stability Biologics, LLC | Shareholder loan

Intangible assets:

Long-term debt (85,000)

Stability Biologics, LLC | Tradenames & Trademarks

Intangible assets:

Indefinite-lived intangible assets 450,000 830,000 450,000

Stability Biologics, LLC | Customer relationships

Intangible assets:

Finite-Lived intangibles assets 5,330,000 6,090,000 5,330,000

Stability Biologics, LLC | Patents and know-how

Intangible assets:

Finite-Lived intangibles assets 6,790,000 9,170,000 6,790,000

Stability Biologics, LLC | Non-Compete Agreements

Intangible assets:

Finite-Lived intangibles assets 830,000 1,080,000 830,000

Stability Biologics, LLC | Licenses and permits

Intangible assets:

Finite-Lived intangibles assets $ 390,000 $ 690,000 $ 390,000

X

- Definition
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Fair Value
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableFairValue

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Accounts Receivable
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsAccountsReceivable

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Income Taxes Receivable
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsIncomeTaxesReceivable

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Debt-free Working Capital
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedDebtfreeWorkingCapital

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets, Net
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedTangibleAssetsNet

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Working Capital
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedWorkingCapital

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of shares of equity interests issued or issuable to acquire entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479
+ Details

Name: us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477
+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferred1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferredAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477
+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of liability recognized arising from contingent consideration in a business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472
+ Details

Name: us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary difference assumed at the acquisition date that are classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of intangible assets, excluding goodwill, acquired at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of identifiable intangible assets recognized as of the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 55
-Paragraph 37
-URI http://asc.fasb.org/extlink&oid=73531372&loc=d3e2207-128464

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of inventory recognized as of the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 55
-Paragraph 37
-URI http://asc.fasb.org/extlink&oid=73531372&loc=d3e2207-128464
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of property, plant, and equipment recognized as of the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 55
-Paragraph 37
-URI http://asc.fasb.org/extlink&oid=73531372&loc=d3e2207-128464
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64834752&loc=SL49117168-202975
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireBusinessesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=mdxg_StabilityBiologicsLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=mdxg_ShareholderDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 63 R45.htm IDEA: XBRL DOCUMENT v3.6.0.2

Acquisition of Stability Inc. - Intangible Assets Acquired as Part of Acquisition (Details) - Stability Biologics, LLC

Jan. 13, 2016

Customer relationships

Finite-Lived Intangible Assets [Line Items]

Estimated useful life (in years) 12 years

Patents and know-how

Finite-Lived Intangible Assets [Line Items]

Estimated useful life (in years) 20 years

Non-Compete Agreements

Finite-Lived Intangible Assets [Line Items]

Estimated useful life (in years) 4 years

Licenses and permits

Finite-Lived Intangible Assets [Line Items]

Estimated useful life (in years) 2 years

X

- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=mdxg_StabilityBiologicsLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 64 R46.htm IDEA: XBRL DOCUMENT v3.6.0.2

Acquisition of Stability Inc. - Goodwill Reconciliation (Details) - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended

Dec. 31, 2016

Dec. 31, 2016

Goodwill [Roll Forward]

Goodwill, Beginning Balance $ 4,040

Goodwill, Ending Balance $ 20,203 20,203

Stability Biologics, LLC

Goodwill [Roll Forward]

Goodwill, Beginning Balance 22,912

Goodwill Adjustments (6,749) (6,749)

Goodwill, Ending Balance $ 16,163 $ 16,163

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64834752&loc=SL49117168-202975
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 25
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=73531572&loc=d3e961-128460

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267
+ Details

Name: us-gaap_GoodwillPurchaseAccountingAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_GoodwillRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=mdxg_StabilityBiologicsLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 65 R47.htm IDEA: XBRL DOCUMENT v3.6.0.2

Acquisition of Stability Inc. - Measurement Period Adjustments (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended

Jan. 13, 2016

Mar. 31, 2016

Dec. 31, 2016

Dec. 31, 2016

Dec. 31, 2015

Intangible assets:

Goodwill $ 20,203,000 $ 20,203,000 $ 4,040,000

Stability Biologics, LLC

Business Acquisition [Line Items]

Cash paid at closing $ 6,000,000 $ 6,000,000 6,000,000

Working capital adjustment (480,000) (480,000) (480,000)

Common stock issued (441,009 shares) 3,345,935 3,346,000 3,346,000

Assumed debt 1,771,000 1,771,000 1,771,000

Fair value of earn-out 17,450,000 25,620,000 17,450,000 17,450,000

Total fair value of purchase price 28,087,000 36,257,000 28,087,000

Net assets acquired:

Debt-free working capital 2,456,000 2,179,000 2,456,000 2,456,000

Other long term assets 199,000 199,000 199,000 199,000

Property, plant and equipment 1,375,000 1,375,000 1,375,000 1,375,000

Deferred tax liability (5,896,000) (8,268,000) (5,896,000) (5,896,000)

Subtotal (1,866,000) (4,515,000) (1,866,000) (1,866,000)

Intangible assets:

Subtotal 13,790,000 17,860,000 13,790,000 13,790,000

Goodwill 16,163,000 22,912,000 16,163,000 16,163,000

Total Assets Purchased 28,087,000 36,257,000 28,087,000 28,087,000

Measurement Period

Fair value of earn-out (8,170,000)

Total fair value of purchase price (8,170,000)

Debt-free working capital 277,000

Deferred tax liability 2,372,000

Subtotal 2,649,000

Subtotal (4,070,000)

Goodwill Adjustments (6,749,000) (6,749,000)

Total Assets Purchased (8,170,000)

Stability Biologics, LLC | Tradenames & Trademarks

Intangible assets:

Indefinite-lived intangible assets 450,000 830,000 450,000 450,000

Measurement Period

Trade names and trademarks (380,000)

Stability Biologics, LLC | Customer relationships

Intangible assets:

Finite-Lived intangibles assets 5,330,000 6,090,000 5,330,000 5,330,000

Measurement Period

Intangible assets, finite lived (760,000)

Stability Biologics, LLC | Patents and know-how

Intangible assets:

Finite-Lived intangibles assets 6,790,000 9,170,000 6,790,000 6,790,000

Measurement Period

Intangible assets, finite lived (2,380,000)

Stability Biologics, LLC | Non-Compete Agreements

Intangible assets:

Finite-Lived intangibles assets 830,000 1,080,000 830,000 830,000

Measurement Period

Intangible assets, finite lived (250,000)

Stability Biologics, LLC | Licenses and permits

Intangible assets:

Finite-Lived intangibles assets $ 390,000 $ 690,000 390,000 $ 390,000

Measurement Period

Intangible assets, finite lived $ (300,000)

X

- Definition
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Fair Value
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableFairValue

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transfered
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransfered

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Contingent Consideration, Liabilities
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentContingentConsiderationLiabilities

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Debt-Free Working Capital
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDebtFreeWorkingCapital

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liabilities Noncurrent
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiabilitiesNoncurrent

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Finite-Lived Intangibles
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFiniteLivedIntangibles

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intefinite-Lived Intangible Assets
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntefiniteLivedIntangibleAssets

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentRecognizedIdentifiableAssetsAcquiredGoodwillandLiabilitiesAssumed

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Tangible Assets, Net
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAssetsNet

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Debt-free Working Capital
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedDebtfreeWorkingCapital

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets, Net
+ References
No definition available.
+ Details

Name: mdxg_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedTangibleAssetsNet

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477
+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferred1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477
+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of liability recognized arising from contingent consideration in a business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472
+ Details

Name: us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472
+ Details

Name: us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of deferred tax liability attributable to taxable temporary difference assumed at the acquisition date that are classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of intangible assets, excluding goodwill, acquired at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of identifiable intangible assets recognized as of the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 55
-Paragraph 37
-URI http://asc.fasb.org/extlink&oid=73531372&loc=d3e2207-128464

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of property, plant, and equipment recognized as of the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 55
-Paragraph 37
-URI http://asc.fasb.org/extlink&oid=73531372&loc=d3e2207-128464
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=64834752&loc=SL49117168-202975
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 25
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=73531572&loc=d3e961-128460

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267
+ Details

Name: us-gaap_GoodwillPurchaseAccountingAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireBusinessesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=mdxg_StabilityBiologicsLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 66 R48.htm IDEA: XBRL DOCUMENT v3.6.0.2

Acquisition of Stability Inc. - Pro Forma Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Business Combinations [Abstract]

Revenue $ 245,563 $ 204,481

Net income $ 12,611 $ 24,960

Income per share, fully diluted (in dollars per share) $ 0.11 $ 0.22

X

- Definition
The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)-(3)
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463
+ Details

Name: us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)-(3)
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463
+ Details

Name: us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)-(3)
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463
+ Details

Name: us-gaap_BusinessAcquisitionsProFormaRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 67 R49.htm IDEA: XBRL DOCUMENT v3.6.0.2

Cash Equivalents and Short Term Investments (Details) - USD ($)

Dec. 31, 2016

Dec. 31, 2015

Cash and Cash Equivalents [Line Items]

Short term investments $ 0 $ 3,000,000

Certificates of Deposit

Cash and Cash Equivalents [Line Items]

Short term investments $ 0 $ 3,000,000

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1)(g))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(4))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 68 R50.htm IDEA: XBRL DOCUMENT v3.6.0.2

Inventories (Details) - USD ($)
$ in Thousands

Dec. 31, 2016

Dec. 31, 2015

Inventory Disclosure [Abstract]

Raw materials $ 1,148 $ 602

Work in process 6,677 3,850

Finished goods 10,817 3,405

Inventory, gross 18,642 7,857

Reserve for obsolescence (828) (397)

Inventory, net $ 17,814 $ 7,460

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryFinishedGoods

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryRawMaterials

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of valuation reserve for inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09)
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312
+ Details

Name: us-gaap_InventoryValuationReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryWorkInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 69 R51.htm IDEA: XBRL DOCUMENT v3.6.0.2

Property and Equipment (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Property and equipment [Line Items]

Property and equipment, gross $ 22,291 $ 14,454

Less accumulated depreciation (8,505) (4,979)

Property and equipment, net 13,786 9,475

Other liabilities 821 1,148

Depreciation expense 3,333 1,799 $ 1,197

Leasehold improvements

Property and equipment [Line Items]

Property and equipment, gross 3,274 2,684

Lab and clean room equipment

Property and equipment [Line Items]

Property and equipment, gross 8,666 4,564

Furniture and equipment

Property and equipment [Line Items]

Property and equipment, gross 7,051 4,577

Construction in Progress

Property and equipment [Line Items]

Property and equipment, gross 3,300 2,629

Capital leases

Property and equipment [Line Items]

Property and equipment, net 427

Other liabilities 31

Leasehold improvements paid for by landlord

Property and equipment [Line Items]

Property and equipment, net 1,000

Other liabilities $ 188 $ 361

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetsHeldUnderCapitalLeasesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=mdxg_LeaseholdImprovementsPaidbyOthersMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 70 R52.htm IDEA: XBRL DOCUMENT v3.6.0.2

Intangible Assets and Royalty Agreement - Intangible Asssets Activity Summary (Details) - USD ($)
12 Months Ended

Jan. 29, 2007

Dec. 31, 2016

Mar. 31, 2016

Jan. 13, 2016

Dec. 31, 2015

Jan. 05, 2011

Finite-Lived Intangible Assets [Line Items]

Intangible assets, gross carrying value $ 30,260,000 $ 15,627,000

Less Accumulated amortization and impairment charges (6,992,000) (4,864,000)

Intangible Assets, Net 23,268,000 10,763,000

Net book value of intangible assets 21,810,000

Stability Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Fair value of earn-out 17,450,000 $ 25,620,000 $ 17,450,000

Tradenames & Trademarks

Finite-Lived Intangible Assets [Line Items]

Gross carrying value, indefinite lived 1,458,000 1,008,000

Tradenames & Trademarks | Stability Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Gross carrying value, indefinite lived 450,000

Tradenames & Trademarks | Surgical Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Gross carrying value, indefinite lived $ 1,008,000

In Process Research & Development

Finite-Lived Intangible Assets [Line Items]

Gross carrying value, indefinite lived 25,000 25,000

In Process Research & Development | Surgical Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Gross carrying value, indefinite lived 25,000

Patents in Process

Finite-Lived Intangible Assets [Line Items]

Gross carrying value, indefinite lived $ 2,618,000 1,823,000

Licenses

Finite-Lived Intangible Assets [Line Items]

Weighted Average Amortization Lives 7 years

Gross carrying value $ 1,399,000 1,009,000

Licenses | Stability Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Gross carrying value 390,000

Licenses | Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.

Finite-Lived Intangible Assets [Line Items]

Acquisition price $ 996,000

Maximum time of approval 30 days

Fair value of earn-out $ 200,000

Contingent royalty to be paid to licensor 3.00%

Annual royalty payment $ 50,000

Net book value of intangible assets $ 10,000

Licenses | Surgical Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Gross carrying value 13,000

Patents and know-how

Finite-Lived Intangible Assets [Line Items]

Weighted Average Amortization Lives 19 years

Gross carrying value $ 14,839,000 8,001,000

Patents and know-how | Stability Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Gross carrying value 6,790,000

Patents and know-how | Surgical Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Gross carrying value 7,690,000

Finite-lived intangible assets, costs $ 48,000

Customer & Supplier Relationships

Finite-Lived Intangible Assets [Line Items]

Weighted Average Amortization Lives 13 years

Gross carrying value $ 9,091,000 3,761,000

Customer & Supplier Relationships | Stability Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Gross carrying value 5,330,000

Customer & Supplier Relationships | Surgical Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Gross carrying value $ 3,761,000

Non-Compete Agreements

Finite-Lived Intangible Assets [Line Items]

Weighted Average Amortization Lives 4 years

Gross carrying value $ 830,000 $ 0

Non-Compete Agreements | Stability Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Gross carrying value $ 830,000

X

- Definition
Royalty payment percentage on all commercial sales revenue from the licensed products.
+ References
No definition available.
+ Details

Name: mdxg_ContingentRoyaltyToBePaidToLicensor

Namespace Prefix: mdxg_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Total of accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance.
+ References
No definition available.
+ Details

Name: mdxg_IntangibleAssetsAccumulatedAmortization

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The maximum amount of time the entity has to obtain approval by the FDA to allow the sale of the product.
+ References
No definition available.
+ Details

Name: mdxg_PeriodOfApprovalMaximum

Namespace Prefix: mdxg_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of liability recognized arising from contingent consideration in a business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.
+ References
No definition available.
+ Details

Name: us-gaap_FinitelivedIntangibleAssetsAcquired1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before accumulated amortization of intangible assets, excluding goodwill.
+ References
No definition available.
+ Details

Name: us-gaap_IntangibleAssetsGrossExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133
+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_RoyaltyExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=mdxg_StabilityBiologicsLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=mdxg_SurgicalBiologicsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=mdxg_PatentsinProcessMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=mdxg_ShrinersHospitalsForChildrenAndUniversityOfSouthFloridaResearchFoundationInc.Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 71 R53.htm IDEA: XBRL DOCUMENT v3.6.0.2

Intangible Assets and Royalty Agreement - Narrative (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Amortization of intangible assets $ 2,127 $ 933 $ 928

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 72 R54.htm IDEA: XBRL DOCUMENT v3.6.0.2

Intangible Assets and Royalty Agreement - Expected Future Amortization of Intangible Assets (Details)
$ in Thousands

Dec. 31, 2016

USD ($)

Goodwill and Intangible Assets Disclosure [Abstract]

2017 $ 2,034

2018 1,829

2019 1,829

2020 1,622

2021 1,622

Thereafter 12,874

Net book value $ 21,810

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 73 R55.htm IDEA: XBRL DOCUMENT v3.6.0.2

Long-Term Debt (Details) - Credit Agreement - Revolving Credit Facility - USD ($)

Oct. 12, 2015

Dec. 31, 2016

Debt Instrument [Line Items]

Maximum borrowing capacity $ 50,000,000

Uncommitted incremental facility 35,000,000

Debt issuance costs $ 500,000

Debt term 3 years

Outstanding line of credit $ 0

London Interbank Offered Rate (LIBOR) | Minimum

Debt Instrument [Line Items]

Basis spread on variable rate 1.50%

London Interbank Offered Rate (LIBOR) | Maximum

Debt Instrument [Line Items]

Basis spread on variable rate 2.25%

X

- Definition
Line of Credit Facility, Uncommitted Incremental Facility
+ References
No definition available.
+ Details

Name: mdxg_LineofCreditFacilityUncommittedIncrementalFacility

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Percentage points added to the reference rate to compute the variable rate on the debt instrument.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DeferredFinanceCostsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_LineOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=mdxg_CreditAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 74 R56.htm IDEA: XBRL DOCUMENT v3.6.0.2

Net Income Per Share - Computation of Basic and Dilutive Net Loss per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended

Dec. 31, 2016

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Earnings Per Share [Abstract]

Net income $ 5,481 $ 3,321 $ 1,975 $ 1,197 $ 13,378 $ 6,551 $ 5,430 $ 4,087 $ 11,974 $ 29,446 $ 6,220

Denominator for basic earnings per share - weighted average shares (in shares) 105,928,348 105,929,205 105,793,008

Effect of dilutive securities: Stock options, warrants, and restricted stock (in shares) 6,513,361 7,699,277 7,502,496

Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities (in shares) 112,441,709 113,628,482 113,295,504

Income per common share - basic (in dollars per share) $ 0.05 $ 0.03 $ 0.02 $ 0.01 $ 0.13 $ 0.06 $ 0.05 $ 0.04 $ 0.11 $ 0.28 $ 0.06

Income per common share - diluted (in dollars per share) $ 0.05 $ 0.03 $ 0.02 $ 0.01 $ 0.11 $ 0.06 $ 0.05 $ 0.04 $ 0.11 $ 0.26 $ 0.05

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=65016374&loc=d3e4984-109258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Weighted-Average Number of Common Shares Outstanding
-URI http://asc.fasb.org/extlink&oid=6528421
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 75 R57.htm IDEA: XBRL DOCUMENT v3.6.0.2

Net Income Per Share - Summary of Antidilutive Securities (Details) - shares
12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of earnings per share (in shares) 6,513,361 7,699,277 7,502,496

Stock Options

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of earnings per share (in shares) 5,845,377 7,121,774 7,035,728

Warrants

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of earnings per share (in shares) 0 33,676 226,926

Restricted Stock Awards

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of earnings per share (in shares) 667,984 543,827 239,842

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Antidilution
-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Diluted Earnings Per Share
-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Contingent Stock Agreement
-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 76 R58.htm IDEA: XBRL DOCUMENT v3.6.0.2

Equity - Narrative (Details)
12 Months Ended

Nov. 18, 2015

$ / shares

shares

Dec. 31, 2016

USD ($)

plan

$ / shares

shares

Dec. 31, 2015

USD ($)

$ / shares

shares

Dec. 31, 2014

USD ($)

$ / shares

shares

May 12, 2014

USD ($)

Class of Stock [Line Items]

Number of share-based compensation plans | plan 4

Intrinsic value of options exercised $ 6,460,000 $ 17,181,000 $ 10,566,000

Intrinsic value of options vested 7,378,000 $ 10,044,000 $ 6,615,000

Total unrecognized compensation expense $ 1,064,000

Weighted-average grant date fair value for options granted during the period (in dollars per share) | $ / shares $ 0.00 $ 5.15 $ 4.18

Shares issued for services performed (in shares) | shares 43,344 16,493 15,958

Shares issued for services performed $ 346,000 $ 164,000 $ 117,000

Authorized share amount for repurchase $ 66,000,000 $ 60,000,000 $ 20,000,000 $ 10,000,000

Stock repurchase (in shares) | shares 1,338,616

Shares repurchased, value $ 10,338,000

Commissions 40,000

Remaining authorizations under the repurchase program, amount $ 9,936,000

Warrants

Class of Stock [Line Items]

Warrants outstanding (in shares) | shares 42,400

Warrants outstanding (in dollars per share) | $ / shares $ 1.09

Warrants term 5 years

Common Stock

Class of Stock [Line Items]

Shares issued for services performed (in shares) | shares 11,321 15,958

Consultant | Common Stock

Class of Stock [Line Items]

Shares issued for services performed (in shares) | shares 43,344

Shares issued for services performed $ 345,700

Restricted Stock

Class of Stock [Line Items]

Total unrecognized stock-based compensation related to time-based, nonvested restricted stock $ 21,905,000

Expenses expected to be recognized over a weighted-average period 1 year 10 months 24 days

Restricted Stock | Minimum

Class of Stock [Line Items]

Vesting period 1 year

Restricted Stock | Maximum

Class of Stock [Line Items]

Vesting period 3 years

X

- Definition
The number of share-based compensation the company maintains.
+ References
No definition available.
+ Details

Name: mdxg_NumberOfShareBasedCompensationPlans

Namespace Prefix: mdxg_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Payments of Stock Repurchase Costs
+ References
No definition available.
+ Details

Name: mdxg_PaymentsofStockRepurchaseCosts

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Term of warrants.
+ References
No definition available.
+ Details

Name: mdxg_WarrantsTerm

Namespace Prefix: mdxg_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Unrecognized cost of unvested options awarded to employees as compensation.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cash outflow to reacquire common stock during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228
+ Details

Name: us-gaap_PaymentsForRepurchaseOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of stock repurchase plan authorized.
+ References
No definition available.
+ Details

Name: us-gaap_StockRepurchaseProgramAuthorizedAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount remaining of a stock repurchase plan authorized.
+ References
No definition available.
+ Details

Name: us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Number of shares that have been repurchased during the period and are being held in treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
+ Details

Name: us-gaap_TreasuryStockSharesAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=mdxg_ConsultantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 77 R59.htm IDEA: XBRL DOCUMENT v3.6.0.2

Equity - Activity of Stock Options (Details)
12 Months Ended

Dec. 31, 2016

USD ($)

$ / shares

shares

Number of Shares

Outstanding, beginning of period (in shares) | shares 14,019,629

Granted (in shares) | shares 0

Exercised (in shares) | shares (1,164,138)

Unvested options forfeited (in shares) | shares (154,200)

Vested options expired (in shares) | shares (148,683)

Outstanding, end of period (in shares) | shares 12,552,608

Vested at end of period (in shares) | shares 11,680,455

Vested and expected to vest (in shares) | shares 12,539,865

Weighted- Average Exercise Price

Outstanding, weighted average exercise price, beginning of period (in dollars per share) | $ / shares $ 3.62

Granted, weighted average exercise price (in dollars per share) | $ / shares 0.00

Exercised, weighted average exercise price (in dollars per share) | $ / shares 3.02

Unvested options forfeited, weighted-average exercise price (in dollars per share) | $ / shares 6.77

Vested options expired, weighted-average exercise price (in dollars per share) | $ / shares 6.16

Outstanding, weighted average exercise price, end of period (in dollars per share) | $ / shares 3.61

Vested at end of period, weighted average exercise price (in dollars per share) | $ / shares 3.33

Vested and expected to vest, weighted average exercise price (in dollars per share) | $ / shares $ 3.60

Stock options, additional disclosures

Outstanding options, weighted average remaining contractual term 5 years 4 months 24 days

Vested at end of period weighted average remaining contractual term 5 years 3 months 18 days

Vested and expected to vest, weighted average remaining contractual term 5 years 4 months 24 days

Outstanding, aggregate intrinsic value | $ $ 66,137,378

Vested at end of period, aggregate intrinsic value | $ 64,733,964

Vested and expected to vest, aggregate intrinsic value | $ $ 66,119,285

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(4)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The number of exercisable share options (fully vested and expected to vest) that may be converted as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
As of the balance sheet date, the weighted-average exercise price (at which grantees can acquire the shares reserved for issuance) for exercisable stock options that are fully vested or expected to vest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 78 R60.htm IDEA: XBRL DOCUMENT v3.6.0.2

Equity - Exercise Price Ranges (Details)
12 Months Ended

Dec. 31, 2016

$ / shares

shares

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Number of outstanding options (in shares) | shares 12,552,608

Outstanding options, weighted average remaining contractual term 5 years 4 months 24 days

Outstanding options, weighted average exercise price (in dollars per share) $ 3.61

Number of exercisable options (in shares) | shares 11,680,455

Exercisable options, weighted average exercise price (in dollars per share) $ 3.33

$0.50 - $0.76

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Exercise price range, lower range limit (in dollars per share) 0.50

Exercise price range, upper range limit (in dollars per share) $ 0.76

Number of outstanding options (in shares) | shares 441,429

Outstanding options, weighted average remaining contractual term 2 years 4 months 24 days

Outstanding options, weighted average exercise price (in dollars per share) $ 0.72

Number of exercisable options (in shares) | shares 441,429

Exercisable options, weighted average exercise price (in dollars per share) $ 0.72

$0.87 - $1.35

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Exercise price range, lower range limit (in dollars per share) 0.87

Exercise price range, upper range limit (in dollars per share) $ 1.35

Number of outstanding options (in shares) | shares 4,385,570

Outstanding options, weighted average remaining contractual term 4 years 8 months 12 days

Outstanding options, weighted average exercise price (in dollars per share) $ 1.19

Number of exercisable options (in shares) | shares 4,385,570

Exercisable options, weighted average exercise price (in dollars per share) $ 1.19

$1.40 - $2.45

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Exercise price range, lower range limit (in dollars per share) 1.40

Exercise price range, upper range limit (in dollars per share) $ 2.45

Number of outstanding options (in shares) | shares 1,362,424

Outstanding options, weighted average remaining contractual term 4 years 1 month 6 days

Outstanding options, weighted average exercise price (in dollars per share) $ 1.92

Number of exercisable options (in shares) | shares 1,362,424

Exercisable options, weighted average exercise price (in dollars per share) $ 1.92

$2.66 - $3.99

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Exercise price range, lower range limit (in dollars per share) 2.66

Exercise price range, upper range limit (in dollars per share) $ 3.99

Number of outstanding options (in shares) | shares 878,680

Outstanding options, weighted average remaining contractual term 5 years 9 months 18 days

Outstanding options, weighted average exercise price (in dollars per share) $ 3.06

Number of exercisable options (in shares) | shares 878,680

Exercisable options, weighted average exercise price (in dollars per share) $ 3.06

$4.19 - $6.38

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Exercise price range, lower range limit (in dollars per share) 4.19

Exercise price range, upper range limit (in dollars per share) $ 6.38

Number of outstanding options (in shares) | shares 3,056,069

Outstanding options, weighted average remaining contractual term 6 years 2 months 12 days

Outstanding options, weighted average exercise price (in dollars per share) $ 5.36

Number of exercisable options (in shares) | shares 2,937,038

Exercisable options, weighted average exercise price (in dollars per share) $ 5.34

$6.45- $9.78

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Exercise price range, lower range limit (in dollars per share) 6.45

Exercise price range, upper range limit (in dollars per share) $ 9.78

Number of outstanding options (in shares) | shares 2,324,103

Outstanding options, weighted average remaining contractual term 7 years

Outstanding options, weighted average exercise price (in dollars per share) $ 7.30

Number of exercisable options (in shares) | shares 1,610,485

Exercisable options, weighted average exercise price (in dollars per share) $ 7.25

$9.90 - $10.99

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

Exercise price range, lower range limit (in dollars per share) 9.90

Exercise price range, upper range limit (in dollars per share) $ 10.99

Number of outstanding options (in shares) | shares 104,333

Outstanding options, weighted average remaining contractual term 7 years 8 months 12 days

Outstanding options, weighted average exercise price (in dollars per share) $ 10.42

Number of exercisable options (in shares) | shares 64,829

Exercisable options, weighted average exercise price (in dollars per share) $ 10.46

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mdxg_PriceRange1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mdxg_PriceRange2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mdxg_PriceRange3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mdxg_PriceRange4Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mdxg_PriceRange5Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mdxg_PriceRange6Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=mdxg_PriceRange7Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 79 R61.htm IDEA: XBRL DOCUMENT v3.6.0.2

Equity - Summary of Unvested Stock Options (Details) - $ / shares
12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Number of Shares

Unvested, beginning of period (in shares) 3,067,935

Granted (in shares) 0

Cancelled (in shares) (154,200)

Vested (in shares) (2,041,582)

Unvested, end of period (in shares) 872,153 3,067,935

Weighted- Average Grant Date Fair Value

Unvested, beginning of period (in dollars per share) $ 3.81

Granted (in dollars per share) 0.00 $ 5.15 $ 4.18

Cancelled (in dollars per share) 6.77

Vested (in dollars per share) 3.61

Unvested, end of period (in dollars per share) $ 4.28 $ 3.81

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of non-vested options outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of non-vested options forfeited.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average grant-date fair value of non-vested options forfeited.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average grant-date fair value of non-vested options outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options vested.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average grant-date fair value of options vested.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

XML 80 R62.htm IDEA: XBRL DOCUMENT v3.6.0.2

Equity - Assumptions (Details)
12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Fair value options valuation assumptions [Abstract]

Expected volatility 0.00%

Expected life (in years) 0 years 6 years 6 years

Expected dividend yield 0.00% 0.00% 0.00%

Risk-free interest rate 0.00%

Risk-free interest rate, minimum 1.51% 1.64%

Risk-free interest rate, maximum 1.68% 1.96%

Minimum

Fair value options valuation assumptions [Abstract]

Expected volatility 54.35% 58.14%

Maximum

Fair value options valuation assumptions [Abstract]

Expected volatility 58.14% 64.50%

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 81 R63.htm IDEA: XBRL DOCUMENT v3.6.0.2

Equity - Summary of Restricted Stock Awards (Details) - Restricted Stock
12 Months Ended

Dec. 31, 2016

$ / shares

shares

Number of Shares

Unvested, beginning of period (in shares) | shares 2,613,267

Granted (in shares) | shares 2,755,426

Vested (in shares) | shares (1,162,931)

Forfeited (in shares) | shares (377,317)

Unvested, end of period (in shares) | shares 3,828,445

Weighted- Average Grant Date Fair Value

Unvested, beginning of period (in dollars per share) | $ / shares $ 9.14

Granted (in dollars per share) | $ / shares 8.05

Vested (in dollars per share) | $ / shares 8.68

Forfeited (in dollars per share) | $ / shares 8.71

Unvested, end of period (in dollars per share) | $ / shares $ 8.53

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(3)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 82 R64.htm IDEA: XBRL DOCUMENT v3.6.0.2

Equity - Recognized Stock-Based Compensation (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Share-based Compensation [Abstract]

Stock-based compensation expense $ 17,818 $ 16,896 $ 11,453

Cost of sales

Share-based Compensation [Abstract]

Stock-based compensation expense 426 352 322

Research and development

Share-based Compensation [Abstract]

Stock-based compensation expense 647 790 660

Selling, general and administrative

Share-based Compensation [Abstract]

Stock-based compensation expense $ 16,745 $ 15,754 $ 10,471

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 83 R65.htm IDEA: XBRL DOCUMENT v3.6.0.2

Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands

Dec. 31, 2016

Dec. 31, 2015

Deferred tax assets and liabilities:

Accruals and prepaids $ 4,992 $ 4,606

Intangible assets (5,130) 146

Property and equipment (1,338) (1,396)

R&D and other tax credits 1,219 3,293

Stock Compensation 7,417 7,063

Net operating loss 2,395 1,763

Other 113 145

Net deferred tax assets 9,668 15,620

Valuation allowance (554) (782)

Deferred tax assets and liabilities, net of valuation allowance $ 9,114 $ 14,838

X

- References
No definition available.
+ Details

Name: us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(c)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=68052875&loc=d3e28680-109314

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32621-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32621-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32632-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=68052875&loc=d3e28680-109314
+ Details

Name: us-gaap_DeferredTaxAssetsOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32621-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32632-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32559-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=68052875&loc=d3e28680-109314

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=68052875&loc=d3e28680-109314

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32632-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32621-109319
+ Details

Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32621-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=68052875&loc=d3e28680-109314
+ Details

Name: us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 84 R66.htm IDEA: XBRL DOCUMENT v3.6.0.2

Income Taxes - Reconciliation of the Federal Statutory Income Tax (Details)
12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Income Tax Disclosure [Abstract]

Federal statutory rate 35.00% 34.00%

State taxes, net of federal benefit 4.78% 3.33%

Non deductible compensation 0.04% 0.63%

Meals & entertainment 3.82% 2.27%

Domestic Production Activities Deduction 5.51% 6.39%

Domestic Production Activities Deduction (4.71%) (0.00%)

Tax Credits (8.79%) (2.84%)

Prior Period Adjustments (3.79%) 0.00%

Other 3.27% (1.74%)

Valuation allowance (1.26%) (63.33%)

Effective income tax rate 33.87% (21.29%)

X

- Definition
Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32698-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32698-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for qualified production activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32698-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to meals and entertainment expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32698-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseMealsAndEntertainment

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity-based compensation costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32698-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32698-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 85 R67.htm IDEA: XBRL DOCUMENT v3.6.0.2

Income Taxes - Schedule of current and deferred income tax expense (benefit) (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Current:

Federal $ 4,700 $ 8,452

State 1,423 1,218

Total current 6,123 9,670

Deferred:

Federal 26 (13,070)

State (16) (1,768)

Total deferred 10 (14,838)

Total expense $ 6,133 $ (5,168) $ 832

X

- Definition
Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6509736

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319
+ Details

Name: us-gaap_CurrentFederalTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6509736

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817
+ Details

Name: us-gaap_CurrentIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6509736

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817
+ Details

Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Deferred Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=63044130

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319
+ Details

Name: us-gaap_DeferredFederalIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Deferred Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=63044130

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817
+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Deferred Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=63044130

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319
+ Details

Name: us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Income Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6515339
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 86 R68.htm IDEA: XBRL DOCUMENT v3.6.0.2

Income Taxes - Narrative (Details) - USD ($)
12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Operating Loss Carryforwards [Line Items]

Federal statutory rate 35.00% 34.00%

Valuation allowance $ 554,000 $ 782,000

Deferred tax assets, operating loss carryforwards, domestic 815,000 197,000

Deferred tax assets, operating loss carryforwards, state 1,580,000 1,566,000

Realized deferred tax assets 1,170,000

Stock compensation 0

Unrecognized tax benefits that would affect effective tax rate 281,000 170,000

Adjustments to tax accounts 281,000 170,000

Federal

Operating Loss Carryforwards [Line Items]

Income tax net operating loss carryforwards 2,327,000 579,000

State

Operating Loss Carryforwards [Line Items]

Income tax net operating loss carryforwards $ 27,912,000 $ 27,552,000

X

- Definition
Deferred Tax Assets that Would Impact Equity, Share-based Compensation
+ References
No definition available.
+ Details

Name: mdxg_DeferredTaxAssetsthatWouldImpactEquitySharebasedCompensation

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Amount
+ References
No definition available.
+ Details

Name: mdxg_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Unrecognized Tax Benefits that Would Impact Other Tax Accounts
+ References
No definition available.
+ Details

Name: mdxg_UnrecognizedTaxBenefitsthatWouldImpactOtherTaxAccounts

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32621-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=68052875&loc=d3e28680-109314

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32632-109319
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32632-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32621-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=68052875&loc=d3e28680-109314
+ Details

Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32559-109319
+ Details

Name: us-gaap_OperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingLossCarryforwardsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 87 R69.htm IDEA: XBRL DOCUMENT v3.6.0.2

Income Taxes - Reconciliation of unrecognized tax benefits (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]

Unrecognized tax benefits, beginning of period $ 170 $ 0

Gross increases - tax positions in current period 111 170

Unrecognized tax benefits, end of period $ 281 $ 170

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of unrecognized tax benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=SL6600010-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Unrecognized Tax Benefit
-URI http://asc.fasb.org/extlink&oid=6527854
+ Details

Name: us-gaap_UnrecognizedTaxBenefits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 88 R70.htm IDEA: XBRL DOCUMENT v3.6.0.2

Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Supplemental Cash Flow Elements [Abstract]

Shares issued in conjunction with acquisition (in shares) 441,009

Cash paid for interest $ 162 $ 86 $ 48

Income taxes paid 642 2,293 384

Retirement of fixed assets 0 319 0

Deferred financing costs 10 504 0

APIC related tax adjustments (424) 7,757 0

Stock issuance of 441,009 shares in connection with acquisition of Stability 3,346 0 0

Stock issuance of 43,344, 16,493 and 15,958 shares in exchange for services performed in 2016, 2015 and 2014, respectively $ 346 $ 164 $ 117

Shares issued for services performed (in shares) 43,344 16,493 15,958

X

- Definition
Write-off of Fixed Assets
+ References
No definition available.
+ Details

Name: mdxg_WriteoffofFixedAssets

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of amortization expense attributable to debt issuance costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(8))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(8))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_AmortizationOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncomeTaxCreditsAndAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585
+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585
+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares of stock issued during the period pursuant to acquisitions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued pursuant to acquisitions during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowElementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 89 R71.htm IDEA: XBRL DOCUMENT v3.6.0.2

401k Plan (Details)
12 Months Ended

Dec. 31, 2016

USD ($)

Compensation and Retirement Disclosure [Abstract]

Minimum age require to qualify for pension plan 21 years

Minimum service period require to qualify for pension plan 3 months

Maximum wages deferred, percent 100.00%

Maximum eligible wages deferred by participants per year $ 18,000

Minimum age for additional contribution beyond normal plan 50 years

Defined benefit plan, contributions by plan participants $ 6,000

Employer matching contribution, percent 6.00%

X

- Definition
The amount of maximum pre tax contributions made by plan participants. This item represents a periodic increase to the plan obligation and an increase to plan assets.
+ References
No definition available.
+ Details

Name: mdxg_DefinedBenefitPlanMaximumPreTaxContributionsByPlanParticipants

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Maximum percentage of employee eligible wages, deferred by participants under contribution plan.
+ References
No definition available.
+ Details

Name: mdxg_DefinedContributionPlanMaximumPercentageOfEligibleWagesDeferredByParticipants

Namespace Prefix: mdxg_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Maximum eligible wages deferred by participants per year under contribution plan.
+ References
No definition available.
+ Details

Name: mdxg_MaximumEligibleWagesDeferredByParticipantsPerYear

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Minimum age required for additional pre-tax contributions by employee beyond normal plan.
+ References
No definition available.
+ Details

Name: mdxg_MinimumAgeForAdditionalContributionBeyondNormalPlan

Namespace Prefix: mdxg_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Minimum age required to qualify for pension under the plan.
+ References
No definition available.
+ Details

Name: mdxg_MinimumAgeRequireToQualifyForPensionPlan

Namespace Prefix: mdxg_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
This line item represents the minimum service period served by the employee require to qualify for pension plan.
+ References
No definition available.
+ Details

Name: mdxg_MinimumServicePeriodRequireToQualifyForPensionPlan

Namespace Prefix: mdxg_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CompensationAndRetirementDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.
+ References
No definition available.
+ Details

Name: us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 90 R72.htm IDEA: XBRL DOCUMENT v3.6.0.2

Related Party Transactions (Details) - Stability Biologics, LLC - USD ($)
12 Months Ended

Dec. 31, 2016

Jan. 13, 2016

Related Party Transaction [Line Items]

Assumed payable $ 1,226,275 $ 5,954,555

Proceeds from related party payable 1,361,030

Decrease in related party payable due to return or destruction of expired inventory $ 3,367,250

X

- Definition
Decrease In Related Party Payable Due To Return Or Destruction Of Expired Inventory
+ References
No definition available.
+ Details

Name: mdxg_DecreaseInRelatedPartyPayableDueToReturnOrDestructionOfExpiredInventory

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds From Related Party Payable
+ References
No definition available.
+ Details

Name: mdxg_ProceedsFromRelatedPartyPayable

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(3),(4))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.17)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_DueToRelatedPartiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=mdxg_StabilityBiologicsLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 91 R73.htm IDEA: XBRL DOCUMENT v3.6.0.2

Commitments and Contingencies - Narrative (Details)
$ in Thousands
12 Months Ended

Dec. 31, 2016

USD ($)

claim

Dec. 31, 2015

USD ($)

Dec. 31, 2014

USD ($)

Aug. 18, 2015

claim

Jul. 10, 2015

claim

Jun. 29, 2015

claim

Loss Contingencies [Line Items]

Lessee expiration period 8 years

Rent and operating leases expense | $ $ 1,764 $ 1,317 $ 1,130

Pending Litigation

Loss Contingencies [Line Items]

Number of patent challenged grounds 4

Pending Litigation | Bone Bank Action

Loss Contingencies [Line Items]

Number of patent challenged grounds 5 7

Opinion allowing a review of patent 2

Pending Litigation | Liventa Action, 701 Patent

Loss Contingencies [Line Items]

Number of patent challenged grounds 6

Pending Litigation | Liventa Action, 437 Patent

Loss Contingencies [Line Items]

Number of patent challenged grounds 7

Opinion allowing a review of patent 1

Product Concentration Risk | Sales Revenue, Net

Loss Contingencies [Line Items]

Percentage of revenue 10.00%

Letters of Credit

Loss Contingencies [Line Items]

Standby letters of credit | $ $ 103

X

- Definition
Loss Contingency Pending Claims Number Allowed for Review
+ References
No definition available.
+ Details

Name: mdxg_LossContingencyPendingClaimsAllowedforReviewNumber

Namespace Prefix: mdxg_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=64851502&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13537-108611
+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
No definition available.
+ Details

Name: us-gaap_LeaseAndRentalExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.
+ References
No definition available.
+ Details

Name: us-gaap_LettersOfCreditOutstandingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LossContingenciesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of pending claims pertaining to a loss contingency.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349
+ Details

Name: us-gaap_LossContingencyPendingClaimsNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LitigationCaseAxis=mdxg_BoneBankActionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LitigationCaseAxis=mdxg_LiventaAction701PatentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LitigationCaseAxis=mdxg_LiventaAction437PatentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_StandbyLettersOfCreditMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 92 R74.htm IDEA: XBRL DOCUMENT v3.6.0.2

Commitments and Contingencies - Estimated Annual Lease, Royalty, and Employment Agreement Expenses (Details)
$ in Thousands

Dec. 31, 2016

USD ($)

Commitments and Contingencies Disclosure [Abstract]

2017 $ 2,827

2018 3,079

2019 2,023

2020 490

2021 141

Thereafter 374

Total Contractual commitments $ 8,934

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.
+ References
No definition available.
+ Details

Name: us-gaap_ContractualObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of contractual obligation due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_ContractualObligationDueAfterFifthYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of contractual obligation due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_ContractualObligationDueInFifthYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of contractual obligation due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_ContractualObligationDueInFourthYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of contractual obligation due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_ContractualObligationDueInNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of contractual obligation due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_ContractualObligationDueInSecondYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of contractual obligation due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_ContractualObligationDueInThirdYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 93 R75.htm IDEA: XBRL DOCUMENT v3.6.0.2

Quarterly Financial Data (Unaudited) (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended

Dec. 31, 2016

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Quarterly Financial Information Disclosure [Abstract]

NET SALES $ 69,877 $ 64,429 $ 57,342 $ 53,367 $ 51,835 $ 49,015 $ 45,679 $ 40,767 $ 245,015 $ 187,296 $ 118,223

GROSS MARGIN 60,807 56,432 49,948 45,421 46,849 44,036 40,590 35,619 212,608 167,094 105,558

NET INCOME $ 5,481 $ 3,321 $ 1,975 $ 1,197 $ 13,378 $ 6,551 $ 5,430 $ 4,087 $ 11,974 $ 29,446 $ 6,220

Net income per common share - basic (in dollars per share) $ 0.05 $ 0.03 $ 0.02 $ 0.01 $ 0.13 $ 0.06 $ 0.05 $ 0.04 $ 0.11 $ 0.28 $ 0.06

Net income per common share - diluted (in dollars per share) $ 0.05 $ 0.03 $ 0.02 $ 0.01 $ 0.11 $ 0.06 $ 0.05 $ 0.04 $ 0.11 $ 0.26 $ 0.05

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=65016374&loc=d3e4984-109258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_QuarterlyFinancialInformationDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 94 R76.htm IDEA: XBRL DOCUMENT v3.6.0.2

Product Revenue Data (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended

Dec. 31, 2016

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Product Information [Line Items]

Net sales $ 69,877 $ 64,429 $ 57,342 $ 53,367 $ 51,835 $ 49,015 $ 45,679 $ 40,767 $ 245,015 $ 187,296 $ 118,223

Wound Care

Product Information [Line Items]

Net sales 183,984 141,096 93,623

Surgical, Sports Medicine & Orthopedics (SSO)

Product Information [Line Items]

Net sales $ 61,031 $ 46,200 $ 24,600

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ProductInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_ProductOrServiceAxis=mdxg_WoundCareMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=mdxg_SurgicalSportsMedicineOrthopedicsSSOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 95 R77.htm IDEA: XBRL DOCUMENT v3.6.0.2

Subsequent Events (Details) - USD ($)
1 Months Ended

Feb. 28, 2017

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

May 12, 2014

Subsequent Event [Line Items]

Authorized share amount for repurchase $ 66,000,000 $ 60,000,000 $ 20,000,000 $ 10,000,000

Subsequent Event

Subsequent Event [Line Items]

Increase in authorized share amount for repurchase $ 20,000,000

Authorized share amount for repurchase $ 86,000,000

X

- Definition
Stock Repurchase Program, Increase (Decrease) in Authorized Amount
+ References
No definition available.
+ Details

Name: mdxg_StockRepurchaseProgramIncreaseDecreaseInAuthorizedAmount

Namespace Prefix: mdxg_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of stock repurchase plan authorized.
+ References
No definition available.
+ Details

Name: us-gaap_StockRepurchaseProgramAuthorizedAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 96 R78.htm IDEA: XBRL DOCUMENT v3.6.0.2

Schedule II - Valuation and Qualifying Accounts (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Allowance for doubtful accounts

Movement in Valuation Allowances and Reserves [Roll Forward]

Balance at Beginning of Year $ 3,270 $ 1,750 $ 407

Additions charged to Expense or Revenue 2,127 1,698 1,357

Deductions and write-offs (555) (178) (14)

Balance at End of Year 4,842 3,270 1,750

Allowance for product returns

Movement in Valuation Allowances and Reserves [Roll Forward]

Balance at Beginning of Year 1,262 841 215

Additions charged to Expense or Revenue 8,319 3,257 2,215

Deductions and write-offs (4,687) (2,836) (1,589)

Balance at End of Year 4,894 1,262 841

Allowance for obsolescence

Movement in Valuation Allowances and Reserves [Roll Forward]

Balance at Beginning of Year 397 527 322

Additions charged to Expense or Revenue 2,280 540 405

Deductions and write-offs (1,849) (670) (200)

Balance at End of Year $ 828 $ 397 $ 527

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_MovementInValuationAllowancesAndReservesRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09)
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690
+ Details

Name: us-gaap_ValuationAllowancesAndReservesBalance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of increase in the allowances and reserves, which consist of the valuation and qualifying accounts that are either netted against the cost of an asset or that reflect a liability established to represent expected future costs, from charges to costs and expenses.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09)
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690
+ Details

Name: us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of the deductions in a given period to allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs, representing receivables written off as uncollectible and portions of the reserves utilized, respectively.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09)
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690
+ Details

Name: us-gaap_ValuationAllowancesAndReservesDeductions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForDoubtfulAccountsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForSalesReturnsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=mdxg_AllowanceforObsolescenceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 97 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 98 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 99 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 101 FilingSummary.xml IDEA: XBRL DOCUMENT 3.6.0.2 html 218 399 1 false 63 0 false 8 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://mimedx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://mimedx.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://mimedx.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://mimedx.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1003000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://mimedx.com/role/ConsolidatedStatementsOfStockholdersEquity CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://mimedx.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 2101100 - Disclosure - Nature of Business Sheet http://mimedx.com/role/NatureOfBusiness Nature of Business Notes 7 false false R8.htm 2102100 - Disclosure - Significant Accounting Policies Sheet http://mimedx.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 2103100 - Disclosure - Liquidity and Capital Resources Sheet http://mimedx.com/role/LiquidityAndCapitalResources Liquidity and Capital Resources Notes 9 false false R10.htm 2104100 - Disclosure - Acquisition of Stability Inc. Sheet http://mimedx.com/role/AcquisitionOfStabilityInc Acquisition of Stability Inc. Notes 10 false false R11.htm 2105100 - Disclosure - Cash Equivalents and Short Term Investments Sheet http://mimedx.com/role/CashEquivalentsAndShortTermInvestments Cash Equivalents and Short Term Investments Notes 11 false false R12.htm 2106100 - Disclosure - Inventories Sheet http://mimedx.com/role/Inventories Inventories Notes 12 false false R13.htm 2107100 - Disclosure - Property and Equipment Sheet http://mimedx.com/role/PropertyAndEquipment Property and Equipment Notes 13 false false R14.htm 2108100 - Disclosure - Intangible Assets and Royalty Agreement Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreement Intangible Assets and Royalty Agreement Notes 14 false false R15.htm 2109100 - Disclosure - Long-Term Debt Sheet http://mimedx.com/role/LongTermDebt Long-Term Debt Notes 15 false false R16.htm 2110100 - Disclosure - Net Income Per Share Sheet http://mimedx.com/role/NetIncomePerShare Net Income Per Share Notes 16 false false R17.htm 2160100 - Disclosure - Equity Sheet http://mimedx.com/role/Equity Equity Notes 17 false false R18.htm 2165100 - Disclosure - Income Taxes Sheet http://mimedx.com/role/IncomeTaxes Income Taxes Notes 18 false false R19.htm 2170100 - Disclosure - Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities Sheet http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivities Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities Notes 19 false false R20.htm 2183100 - Disclosure - 401k Plan Sheet http://mimedx.com/role/A401KPlan 401k Plan Notes 20 false false R21.htm 2184100 - Disclosure - Related Party Transactions Sheet http://mimedx.com/role/RelatedPartyTransactions Related Party Transactions Notes 21 false false R22.htm 2185100 - Disclosure - Commitments and Contingencies Sheet http://mimedx.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 22 false false R23.htm 2186100 - Disclosure - Quarterly Financial Data (Unaudited) Sheet http://mimedx.com/role/QuarterlyFinancialDataUnaudited Quarterly Financial Data (Unaudited) Notes 23 false false R24.htm 2187100 - Disclosure - Product Revenue Data Sheet http://mimedx.com/role/ProductRevenueData Product Revenue Data Notes 24 false false R25.htm 2188100 - Disclosure - Subsequent Events Sheet http://mimedx.com/role/SubsequentEvents Subsequent Events Notes 25 false false R26.htm 2189100 - Schedule - Schedule II - Valuation and Qualifying Accounts Sheet http://mimedx.com/role/ScheduleIiValuationAndQualifyingAccounts Schedule II - Valuation and Qualifying Accounts Uncategorized 26 false false R27.htm 2202201 - Disclosure - Significant Accounting Policies (Policies) Sheet http://mimedx.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Uncategorized 27 false false R28.htm 2304301 - Disclosure - Acquisition of Stability Inc. (Tables) Sheet http://mimedx.com/role/AcquisitionOfStabilityIncTables Acquisition of Stability Inc. (Tables) Uncategorized 28 false false R29.htm 2306301 - Disclosure - Inventories (Tables) Sheet http://mimedx.com/role/InventoriesTables Inventories (Tables) Uncategorized 29 false false R30.htm 2307301 - Disclosure - Property and Equipment (Tables) Sheet http://mimedx.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Uncategorized 30 false false R31.htm 2308301 - Disclosure - Intangible Assets and Royalty Agreement (Tables) Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreementTables Intangible Assets and Royalty Agreement (Tables) Uncategorized 31 false false R32.htm 2310301 - Disclosure - Net Income Per Share (Tables) Sheet http://mimedx.com/role/NetIncomePerShareTables Net Income Per Share (Tables) Uncategorized 32 false false R33.htm 2360301 - Disclosure - Equity (Tables) Sheet http://mimedx.com/role/EquityTables Equity (Tables) Uncategorized 33 false false R34.htm 2365301 - Disclosure - Income Taxes (Tables) Sheet http://mimedx.com/role/IncomeTaxesTables Income Taxes (Tables) Uncategorized 34 false false R35.htm 2370301 - Disclosure - Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Tables) Sheet http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivitiesTables Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Tables) Uncategorized 35 false false R36.htm 2385301 - Disclosure - Commitments and Contingencies (Tables) Sheet http://mimedx.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Uncategorized 36 false false R37.htm 2386301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables) Sheet http://mimedx.com/role/QuarterlyFinancialDataUnauditedTables Quarterly Financial Data (Unaudited) (Tables) Uncategorized 37 false false R38.htm 2387301 - Disclosure - Product Revenue Data (Tables) Sheet http://mimedx.com/role/ProductRevenueDataTables Product Revenue Data (Tables) Uncategorized 38 false false R39.htm 2401401 - Disclosure - Nature of Business (Details) Sheet http://mimedx.com/role/NatureOfBusinessDetails Nature of Business (Details) Uncategorized 39 false false R40.htm 2402402 - Disclosure - Significant Accounting Policies (Details) Sheet http://mimedx.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Uncategorized 40 false false R41.htm 2403401 - Disclosure - Liquidity and Capital Resources (Details) Sheet http://mimedx.com/role/LiquidityAndCapitalResourcesDetails Liquidity and Capital Resources (Details) Uncategorized 41 false false R42.htm 2404402 - Disclosure - Acquisition of Stability Inc. - Narrative (Details) Sheet http://mimedx.com/role/AcquisitionOfStabilityIncNarrativeDetails Acquisition of Stability Inc. - Narrative (Details) Uncategorized 42 false false R43.htm 2404403 - Disclosure - Acquisition of Stability Inc. - Fair Value of Stock Consideration (Details) Sheet http://mimedx.com/role/AcquisitionOfStabilityIncFairValueOfStockConsiderationDetails Acquisition of Stability Inc. - Fair Value of Stock Consideration (Details) Uncategorized 43 false false R44.htm 2404404 - Disclosure - Acquisition of Stability Inc. - Preliminarily Allocation of Purchase Price (Details) Sheet http://mimedx.com/role/AcquisitionOfStabilityIncPreliminarilyAllocationOfPurchasePriceDetails Acquisition of Stability Inc. - Preliminarily Allocation of Purchase Price (Details) Uncategorized 44 false false R45.htm 2404405 - Disclosure - Acquisition of Stability Inc. - Intangible Assets Acquired as Part of Acquisition (Details) Sheet http://mimedx.com/role/AcquisitionOfStabilityIncIntangibleAssetsAcquiredAsPartOfAcquisitionDetails Acquisition of Stability Inc. - Intangible Assets Acquired as Part of Acquisition (Details) Uncategorized 45 false false R46.htm 2404406 - Disclosure - Acquisition of Stability Inc. - Goodwill Reconciliation (Details) Sheet http://mimedx.com/role/AcquisitionOfStabilityIncGoodwillReconciliationDetails Acquisition of Stability Inc. - Goodwill Reconciliation (Details) Uncategorized 46 false false R47.htm 2404407 - Disclosure - Acquisition of Stability Inc. - Measurement Period Adjustments (Details) Sheet http://mimedx.com/role/AcquisitionOfStabilityIncMeasurementPeriodAdjustmentsDetails Acquisition of Stability Inc. - Measurement Period Adjustments (Details) Uncategorized 47 false false R48.htm 2404408 - Disclosure - Acquisition of Stability Inc. - Pro Forma Information (Details) Sheet http://mimedx.com/role/AcquisitionOfStabilityIncProFormaInformationDetails Acquisition of Stability Inc. - Pro Forma Information (Details) Uncategorized 48 false false R49.htm 2405401 - Disclosure - Cash Equivalents and Short Term Investments (Details) Sheet http://mimedx.com/role/CashEquivalentsAndShortTermInvestmentsDetails Cash Equivalents and Short Term Investments (Details) Uncategorized 49 false false R50.htm 2406402 - Disclosure - Inventories (Details) Sheet http://mimedx.com/role/InventoriesDetails Inventories (Details) Uncategorized 50 false false R51.htm 2407402 - Disclosure - Property and Equipment (Details) Sheet http://mimedx.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) Uncategorized 51 false false R52.htm 2408402 - Disclosure - Intangible Assets and Royalty Agreement - Intangible Asssets Activity Summary (Details) Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreementIntangibleAsssetsActivitySummaryDetails Intangible Assets and Royalty Agreement - Intangible Asssets Activity Summary (Details) Uncategorized 52 false false R53.htm 2408403 - Disclosure - Intangible Assets and Royalty Agreement - Narrative (Details) Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreementNarrativeDetails Intangible Assets and Royalty Agreement - Narrative (Details) Uncategorized 53 false false R54.htm 2408404 - Disclosure - Intangible Assets and Royalty Agreement - Expected Future Amortization of Intangible Assets (Details) Sheet http://mimedx.com/role/IntangibleAssetsAndRoyaltyAgreementExpectedFutureAmortizationOfIntangibleAssetsDetails Intangible Assets and Royalty Agreement - Expected Future Amortization of Intangible Assets (Details) Uncategorized 54 false false R55.htm 2409401 - Disclosure - Long-Term Debt (Details) Sheet http://mimedx.com/role/LongTermDebtDetails Long-Term Debt (Details) Uncategorized 55 false false R56.htm 2410402 - Disclosure - Net Income Per Share - Computation of Basic and Dilutive Net Loss per Share (Details) Sheet http://mimedx.com/role/NetIncomePerShareComputationOfBasicAndDilutiveNetLossPerShareDetails Net Income Per Share - Computation of Basic and Dilutive Net Loss per Share (Details) Uncategorized 56 false false R57.htm 2410403 - Disclosure - Net Income Per Share - Summary of Antidilutive Securities (Details) Sheet http://mimedx.com/role/NetIncomePerShareSummaryOfAntidilutiveSecuritiesDetails Net Income Per Share - Summary of Antidilutive Securities (Details) Uncategorized 57 false false R58.htm 2460402 - Disclosure - Equity - Narrative (Details) Sheet http://mimedx.com/role/EquityNarrativeDetails Equity - Narrative (Details) Uncategorized 58 false false R59.htm 2460403 - Disclosure - Equity - Activity of Stock Options (Details) Sheet http://mimedx.com/role/EquityActivityOfStockOptionsDetails Equity - Activity of Stock Options (Details) Uncategorized 59 false false R60.htm 2460404 - Disclosure - Equity - Exercise Price Ranges (Details) Sheet http://mimedx.com/role/EquityExercisePriceRangesDetails Equity - Exercise Price Ranges (Details) Uncategorized 60 false false R61.htm 2460405 - Disclosure - Equity - Summary of Unvested Stock Options (Details) Sheet http://mimedx.com/role/EquitySummaryOfUnvestedStockOptionsDetails Equity - Summary of Unvested Stock Options (Details) Uncategorized 61 false false R62.htm 2460406 - Disclosure - Equity - Assumptions (Details) Sheet http://mimedx.com/role/EquityAssumptionsDetails Equity - Assumptions (Details) Uncategorized 62 false false R63.htm 2460407 - Disclosure - Equity - Summary of Restricted Stock Awards (Details) Sheet http://mimedx.com/role/EquitySummaryOfRestrictedStockAwardsDetails Equity - Summary of Restricted Stock Awards (Details) Uncategorized 63 false false R64.htm 2460408 - Disclosure - Equity - Recognized Stock-Based Compensation (Details) Sheet http://mimedx.com/role/EquityRecognizedStockBasedCompensationDetails Equity - Recognized Stock-Based Compensation (Details) Uncategorized 64 false false R65.htm 2465402 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details) Sheet http://mimedx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails Income Taxes - Deferred Tax Assets and Liabilities (Details) Uncategorized 65 false false R66.htm 2465403 - Disclosure - Income Taxes - Reconciliation of the Federal Statutory Income Tax (Details) Sheet http://mimedx.com/role/IncomeTaxesReconciliationOfFederalStatutoryIncomeTaxDetails Income Taxes - Reconciliation of the Federal Statutory Income Tax (Details) Uncategorized 66 false false R67.htm 2465404 - Disclosure - Income Taxes - Schedule of current and deferred income tax expense (benefit) (Details) Sheet http://mimedx.com/role/IncomeTaxesScheduleOfCurrentAndDeferredIncomeTaxExpenseBenefitDetails Income Taxes - Schedule of current and deferred income tax expense (benefit) (Details) Uncategorized 67 false false R68.htm 2465405 - Disclosure - Income Taxes - Narrative (Details) Sheet http://mimedx.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Uncategorized 68 false false R69.htm 2465406 - Disclosure - Income Taxes - Reconciliation of unrecognized tax benefits (Details) Sheet http://mimedx.com/role/IncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails Income Taxes - Reconciliation of unrecognized tax benefits (Details) Uncategorized 69 false false R70.htm 2470402 - Disclosure - Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Details) Sheet http://mimedx.com/role/SupplementalDisclosureOfCashFlowAndNonCashInvestingAndFinancingActivitiesDetails Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Details) Uncategorized 70 false false R71.htm 2483401 - Disclosure - 401k Plan (Details) Sheet http://mimedx.com/role/A401KPlanDetails 401k Plan (Details) Uncategorized 71 false false R72.htm 2484401 - Disclosure - Related Party Transactions (Details) Sheet http://mimedx.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Uncategorized 72 false false R73.htm 2485402 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://mimedx.com/role/CommitmentsAndContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Uncategorized 73 false false R74.htm 2485403 - Disclosure - Commitments and Contingencies - Estimated Annual Lease, Royalty, and Employment Agreement Expenses (Details) Sheet http://mimedx.com/role/CommitmentsAndContingenciesEstimatedAnnualLeaseRoyaltyAndEmploymentAgreementExpensesDetails Commitments and Contingencies - Estimated Annual Lease, Royalty, and Employment Agreement Expenses (Details) Uncategorized 74 false false R75.htm 2486402 - Disclosure - Quarterly Financial Data (Unaudited) (Details) Sheet http://mimedx.com/role/QuarterlyFinancialDataUnauditedDetails Quarterly Financial Data (Unaudited) (Details) Uncategorized 75 false false R76.htm 2487402 - Disclosure - Product Revenue Data (Details) Sheet http://mimedx.com/role/ProductRevenueDataDetails Product Revenue Data (Details) Uncategorized 76 false false R77.htm 2488401 - Disclosure - Subsequent Events (Details) Sheet http://mimedx.com/role/SubsequentEventsDetails Subsequent Events (Details) Uncategorized 77 false false R78.htm 2489401 - Schedule - Schedule II - Valuation and Qualifying Accounts (Details) Sheet http://mimedx.com/role/ScheduleIiValuationAndQualifyingAccountsDetails Schedule II - Valuation and Qualifying Accounts (Details) Uncategorized 78 false false All Reports Book All Reports mdxg-20161231.xml mdxg-20161231.xsd mdxg-20161231_cal.xml mdxg-20161231_def.xml mdxg-20161231_lab.xml mdxg-20161231_pre.xml true true ZIP 103 0001376339-17-000042-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001376339-17-000042-xbrl.zip M4$L#!!0 ( $N"84JNE#/OX\H! /,0' 1 ;61X9RTR,#$V,3(S,2YX M;6SL?6EW&T>2X.?=7^'5YY6=]^$WXWUY]K!'%F5)'D]_F@%;EO?;O>Z_OL$_HC<_9-UF MK]7N?OW7-[]_>FL^N9N;-__OE__]+__G[=O_M!_?_>![S>%#UAW\X/*L,>_CACU[^9_M;X^W;T4.//R/L#O(G_[US?U@\/CS3S^E2S_VL^:/7WO??AI?_(D@+-XB_);B M-^5CPSP'))<]-[Y:\V K:]<_ Q?2[6S^]NQ[\[[^_G2EYOWM[K>L/ZA_9'0M M/407'NKW&,%R\M1??_WU8_%D+_\*MR/ZT_B.\H%.N_OGBKO3Y2^-?E;>_M#Z M_G5R^T/[(6M]_['9>RC QV0*1[?1;O;K82\NI0?P/.C=7K<[?*B'I37(?QH\ M/68_P4UOX:XL;S>:NT?]2 #*^4",4<"7O=;)^[3/%E?J'$AWJ'RJNU#TTR+.O M2^FD?X+KY:WI0FMA,4SH.;HX=^N@]E8^NG4P>VM[E2!W^X-&MSD1S>\54?Z+ M%G=CK?5/Q=7)K?U6W8WP6OS3?_[Z[E/S/GMH3&]NK[_Y[02:7_[W__J7]*V? M^\6%C]G=#\6W?[XOY"XMH+?E:OD1 'DSOISX\*]O^NV'QPZ@]%-ZS4C%-7O= M0?9]\$,;8(X^/?H;^\=GGSY4W@(*N#UX2K\H?]-NI=_=M;/\AP*.; Z%4B[= MS;^_^04!(E0*2O6__+3X/3 M:S,/9-W6]'9,0/RF7VN5-Y>_FGRO_,68,DM(=5.0BIPCG4;",AA32;RE:/+* M\96=T4Y8R]]PS+Y@?N:HR[>(O,5\;ZB/.<[.'.T%0=\/VOSLT>;[1MN/T+X$ M5.QU MX<>^^=[N3^[ZF T:[6[6"HV\"_%2_]?LX4N6'XW>$V)F7Q.HQ:]&OVO!E[\_ M=MK-]F $TP\M\-N[HQAO#/W/*W%\\TMY6SV2__)3[7=&8/U4@>N2'0KZ&]M2 M+N#7#[WNIT&O^>>+%(D*?H>3AAEK0@]A379:]U?^OMS5SJZK_2Q6.SO$:F>[ MK';3:K4'0+A&YT.CW;KINL9C>]#HO$A>K\3U2%K@U.[@.*3<4DH^YUFC/\R? M7JX>J,'P*)I@[\'SSG;_RN.7:_MW-@]7\_]RS0 [^Q3;WMVD<6;QZB.=FX]T MZ+SJ3A;QRO?C^L;G8"7YU4J>CY4\]3;#;N;BFCB_0 .QT[J_ADPO=^WO+!17 MK^&X7L.I!66WO/K52%Q8AGVWS=(KFR]LVW3,YC-/C!P$[>VW!:ZF[IB)D8/4 MV6UON:Y.[\78K)U]V*O9NGJM5X5_:H5_$!]V>RM_S6Y>A#7?>8_W:M!?]C[O M]AGLJT1<3.YZM[3$E<&7EI"X.FIG[*@=A.G;J^VKHW8Q*GM[+_P:DK\6?_S* MZ9?NE=?DY6*[VQYD[]K?,K!@('E?VU\ZF>GWLT'?/OW:^&\O@\&S M>+P.!H_YZ[,FQ1-^VF$?@@?0;TT(,OI%]J?@=VI&EJ*L+^T.X&C;O4[O:[O9 M?_?.71;KE^#WYI>$X,\K$#R>3+!3]S(0OSU?'I[E.+QK-Q/?NE_-USPK0MX+ M,BN-FRK[V])_-D-ZA74OV3) MOGKIYZ*X]NRJ[%UQO9ILW:F5U#EG"P^HD/::.KB:VW.0Y$LSM]>LR>(R<,/^ MH/>0Y1^S3B-]L7_??KPN@L.K\Q5TOV1WY,32?'5'7K([LE^)/8P[ ME9MQ/F+^OM=M]AX>LT%VW:$YHLPO)_MU 5QW*%^^_)]@A_*LT)OZ*<\!GZJM?=P9>Q""YM M=_#%5VM<%?LK4NP7531YC<0N1IA/'HD=HBH)_[W1Q?2Z#?@Z1/ADQ[,QW=RU MGKM]3]'E.8CY-17\2E+!5_&_^N#GLP#.(KER70)7Q_U5.>XO=@&\:DE].3)Q M#OE<77C85S,'^7O;%P =+]KM?].LCR!Y]]&7Q^>LQF MGKYOY-E]K]/*\G3Q*K?;?+^.K.7'Z^AZE=9J7_7H'O3H--6Y2->K1&XHD;U&M_^A\=2 )7^5R#U*9(6N5XF\)M$O MT,Z?OI#EI4KT=5?TE>R*O@IION[PO)H=G@/*<]U@%D QSYK#/$^+MO5/L$<) MYCGABXUV_A^-SC";7O_%R=*=[]EX?LC_E#X[+DLQ:GF:3D'%*O M0P,6K)?;L+[\)9 J:S;Z%Y:)7","]<@=213D=J(@#]WXP37Z]Z ?TU]I&."W M1B>KC"S-\L0:T+-9__;.9X^]_J7EII=C.9/&6([FD1SE P^HO;+Z7%A]\'&U M8.7@#8.G#QUX+U C4>(QP6R?*OG]4?SX;UFG]7NWE>7CRB@UN'A[SWK=1HB!-Z_[R=#NXS_*7* Q%S+(AXJ]' M,US%X5S$X>!G=+_I7R^9^WOJ],?@4K^:K$7ZW] MKO5K7S#O5^![N>M^5^9???=C^^YGI?:O:_^R^Q%5MVUZ0[B:/S: (NFTVNQ9 MK+S=S?+^O_7Z14:S'WNYNV]W6GG6!;+]WFU_@ZN R^W=I]YP'&K,5HUS1^O-8Q)DU1)/3F?M7=:[ZE*XB(+'_?>PPO)HNZ'Z.NZ MN:Z;%[5N9FL*4%%30-2&-07CV_7T:WMHEX"+A<8W66?#_&N[V>A,"L0JA76O M^ S]JC533[<]R?T%'Y['144-WY^O5=.%?W=Q?C5'E$\FNN=\-OF<1@FUX;-O6:=W@;GGRU/7&Y'_(M7VS=7=/]NU<'7W][9N%KWWO9P/ MW)]9>*7GMB_+^3GU@>T#J/X3B_"+UM[G)\"G352^//&]!IPO)> \9%YD<0_J M&@*^C$CLX%4JKT8E78AF.'AIPK::H3!L8SJTRW5Q6:S?6@\4AJH>YY>QZJ]" MT?;D7TW+Q>;H+ M3)?MW>3L29-<9>%DXYXN7(M<;= +G5C]JFL/+[@$\&RCFJM@G%8P#GX&[W7V M0;[$/L1GF>JZBL(U(KE*PUF,H#UQ3/))99<)4"E=R894<;O']*@_'&\FU3-S31R?HR8.+X0AH?'3N\IRSX- M>LT_;Q_3FZX"61'(I51Z)9LH23C9\873];K?TC0I" 7>]P99_T/C*84%5P&M M".A*2AU)2-EV0LI>B)!>S?@YF?%S$,(3F/&K$)Z3$)Z#N3Z!$%[-]269ZW,0 MTA.8ZVO 0G">0ZIHA,(Y]6\7Y)Y/P''"[EVO65!Y3L@^99T.$/QO63?+&QW3;9G60[O;[@_R1J)X^/X('+V\0SY+ M$9\*S5:8OR(?<0Y"M$Y"=$Y M^#$["-'5++U 8;@IK!+YM?&$R='XN06M9NK20??R?1Z>JMT'_ZN1MRHCO,&C M'>3MYB!K%7L*VQU\NI15,H?ZG#=?Q7W5VMCBD\\Y+_3"$A&'D-][QM64Z.?NCWUF]KKPX^)>[L-#KUNG9#ZW!YWL]NZFVVI_:[>&X%)/ M3U[UNOUA9W!QLK"2)+,.X@)-]J1\:BE:'KM:(.GK4$25HZM;6,-+$;I]6;F] M*9_#G/J\6I.3GEF;LR<;A):SMY_:K[T4YI_'2CYK_3VJC6KTLU8RKD# (O]2 M_+9OAH/[7M[^GZSU>[>5Y3-%>Q\ZC6[?/H7O6=YL][,/0,UL&N.,1A9-?BM2ZKH>7(G:5HD4I8J]*^_$]][,R?J<1.W$5NT6Q$Z]*[$Y@ M,,E5YA9ECERRP3R!"-&K""V*$+V*T#7)=>9)KATU?'35E>QNWKN)_#,+RRN 7=.!MPQ5\B2>XSN0XU66LX"N#+W8%+R:\1N=[/S>^C_W2A7E" M'B[V!^VFZPV[@_SILEA>C]N4_[7(7682:M$_OK+U%&P]R&#M+59K<1K+=%OI ME'[G[\.\W6]!Y'!QG6[7,7@-FJ]B!5]9?;&K>CP&^>_##D;3 :[M0?MKD29R MC?Y,#LSVNIEM=/\T,UC7/)3H-)P_A_H!G(5V]^OTGLN2C"I!QBFP.HJLDH.= MOCFEYU06EQ#T2#*(Y%N,#F=9WO7Z?05Y_]#(_YS7 M3*D3U<<,V#',WF>+PEGSFLI.PH>\UQHV!Y5;+TM4UQ%L1J?546Q/0KN"WC.R MNY+@KV.7:Z2'R=^'7:*OCN'5,=Q0[XJW1!_0,7P5HG1N;#T?%T\B?'7Q:EV\ M!P9A4]$)();8?NA_^G3[8N1AKJ)Q25$ZL5=)> M@OP-Q^P+F>XE?!I^Z6?_/0140DJ15S;4%ZY?EG L06YF^[P.NZ,DY>5;1-Z2 M_27E_82Y(&-7%I^,Q7,+OF#RY@M^02;VP)_T>C,QR-@>MT>G\UNLVL M;[JM-+LV_Y;U*X(QN2OVOGMEWX/ MJ-C,X,>7*3E%^+(:Y50/]M-;*ZFZN2FZAR$9SHEG,!+.(A [&FW^*H9+GV7 M>'_9TZMR.$D0>NHLZH[:Y!ISG"SFV+L>V6/,<54B)_ P#CZUZZH3SETG'$0$ M]I2;O#J9EYZ3W$$0KKK@9+I@'R(P[+9'_+?#?KN;]?O_]6D$UBS3'K)&?YAG MX^Y@"S>6KRYOFGXLO;OF2\-^ZT.6%T.<9C_2:G\#;LZBFIYX/WS(\L:@-]O^ M9_JM=K_'")8___[)5\'X7W. S+]HY@L^Z_8>VMVEWQ@SJY@YM>XC"^\J+TU0 M6T.9QTZCNY3NZ>+6M.X.%Q?@/%J/\,^M7]I?(R']W06C[ITKF;P.U()MR_%? MQM8UKVUV&NV'I?@75]>_LY6U?S9 J%8B5NPTOOXP7IT?L[NYG> M2F1YX H'*3P73%%&H[74R^@]0EJ]^>6NT>D#2RLO+[_HAGF>?M7N-QN=?V2- M/(PBRPT^'HDUSC'#,*&>>,N54^./!^%4>//+VU(CK?I2"8GO-8F7%L%(MFZ#KQM)B3!":T.,Y\A3'B;2B#ER;W[!Z.V_SW\WO;K\7"C,G5??_W[&F3[RH9:7"6$VZXHSA$C4M!E";&>4]AZ9<6P.@]/*1><;WF MGZ,!@[?#03*HJ4W<'$S38WN8O_FAE37;#[#FX/?OXRQG+ 7"( Y 8BTTAS_< M&$87$(,GDQXH7E@J*8R48D@MP+P"K 4$1NOM8Y:.5\+54=N[382(L1 E#@QQ MYIG'A$^5BM(.%M,_DHY<]Z5Y:&*[D^4.9.MK+]^$IU+(@)F0VDH-&D8S3-?*OV0\0=F>=9,FSU@_%-V8!F_OH/#P?AE_ $8N=7F,P#\TH!B:S MG'Q+9P!#WA-"C$/.4R0EI0S1$C!*@IYA9&' 0!,()4 9P&;^?H\6!^SK^T^ M"&5W\+[QL,F:8\@31R,6@3$?$#5>AA(<%R-_\\NO-[\&_Y\__.WC[>\?_N\/ M-^_=C[.0S']P'IC_Z'6&W4$C']%Q$]&)SAEK532!$TO /H!]&D,CJ(N@?][W M9K^^\(7YS_^1=3K_WNW]U?T$-K/7S5HW_?X07/4-% (*FB%K I4>@PPQ/>41 M.:<7%A]7Y(_ESI8]B!<:&6CCLJ?@8#]NPR602O\]Q!>> ,@ MPN(<](L7M2!N2/]H?.ED'C1^2A3-H3%N&/?W1A?32<15?M0TX97]=A&)3$^* M#QI?VAWXDFWW.KVO[6;_W3LWCJ]F1!?-4,4B$ VA7;!<&N*9EI()*CS1\#OM M^:+D4HFE!#-Q* KLC;J-Z;MCHYVGN"T[/GF1MH\ ((/*=Z'1(T$@E4=CI:PE0 >::@9C121&E40^&1XGT! M%"Y[2LYN^NV=P 3;((,"]]D:K#B870L:0C&LC%>@#5X!@=E!":R#\4@+HA!5 MG @>+ /#J(2**F (H_UO>Z_<_Y+V[]N#786?0 M?NRTL_SF[GTV*/*@GY./-GC?&YCF?3O[!C[:4N.]S'%V'$<:F==8*Q<=Q%?: M"PG!+8BH%='-D*S,;J ?5VO5?2.U PW?M&^[._WB]K0"]2B]X,QA M:P1CL( I%R(R%9%F8LXW+6FUVK[O"OK1*"+G%VPQUBSQ\%,SZS8@HIUOI#'^ M9>SE6;/1'U07ZSPYD=)"(21<9-+8P+G!X$TBB",)!5-TUN0NW6QRPUYX';;[JU0F\>*J[J1H(($;@3&%&!'=7>P+H%)2>B M-B8@8TU^-9.VP,I77#7RQ\:H]>!36B46[\ 7C%V M[[&3#3+3^N>P/WA8A+=4T0N:<$Q3GS4I/J!Y5U)1L#MC4+KPOIH'Z-0 M5"URY:W")K9_T3\,-HB!BH--QSZ@W26&I:\ ."5V>M.38_ MUE#H0*SQV9=!S+/LCU[^)]SB&H_M0:-S G9$#5HK$LZ5L:#Q.7AG*+'#"&"4 M$F&1'43*0S&CGB8'8\#(9_S<^#[#[?>];G.4USL!*S C(GK, Z-6(.(#!6T(E.1PS5M/G0&R)8-H&69J,T@(_'IS3-OCM!U13DQ?4?MCT M^]F@;Y]^;?RSE[M.HS\_F,8!T+V'+/^8=0H,^_?MQ_X:)E-*)7:6@4GR$-4C MXXQ-3':"^QAT)1AZ*\7!M%\]L:^<3?.(FJDPHOO5? 6%5,1'Z](TE C/%08,80$REUH;UWG.)B MP?K@) FRXM6_)?S*V*,S=C0[:QTO S,J8DI4I$(S@X,QJE"^SF$N=64;"RRL M>AG,3$FQN^5T/0)7TX;S"@B6'0/LZ4+-2 M&Z*H,<6JE13\*4JJZOAPC%Y#^P-Q_&/6['WMMO\'/CBN#VQ,/EDP$9R[O_5Z MK;_:G4ZCVYIQ\N">X<-)8G6!-%6*,@@\+&%,*^.+6#UZQ!'#E6#DH+'ALPEX M(,9^GI.>]]DI0A6N&'=<@NI/61^. M=>1I5[KBL#*.^6&H?APW:"."'U#'2(R4B8@JB.% R[B <>%X.DIYU*A2K/,6 M*W$@,3\'@A_)TR38!6XBP1H9AXG'*9@FS#G*F-3XQ1']Y,K<(4>"T$XYS)63 MTBH;"V7N%%C6:C99J -IE24Z?+IO^K'WU.@,GC[W;/:AT6Y][HU2Y[U\D6I( M%E0C>KI]DN*$+']LY(.GE-.9(=E]#ACD_7_K]8OOIA('=]_NM,"K-=W6[]WV M-[@*)+V]^]0;#NYCIY>W6XUT2K&1-^]C&L\V#B";/QYK.V"A*HE$'0F/#NP" MMQ)X:" P5L9PZB0$R;457(B.6;@!?:>\F'7VYYFX3#\O=YX9<5HI*;0UG)%( M#/."((YD#*!X*RM=E--XW,67&@XF#%SD(X!'9&.QX-H.-FA'1%\<-\8_-$;=EHW#X\ [J@:LC@O\P4^ MVW)IXZ/;+];%6JF8%V:)0)))D""^S H5D 6V"^^]5I)'6O'LIRCO#N(LGL#% MELVZ\(_!ATZC^VOC>ZI_^I"GJ#8ME;S]95ALP-JG=#T1MMUL/S:Z@Q7G-Y8A MZR%PY\*S5-$N4 DV>0/ONN+ <-,&A\S4 X.NU" M?_T!/_5+:L.;GT4 0:1@G$7F@\(8>8,YGIQ"BBL+*O<*^80>X>XN@]7P+9ND M,C["^DDVK=N$)5R(2[T0A>]-6/_PP)@EFY?VS:E%9HTW"D%DRVQ4RD4M+,B_ M$YXS:6EEX>.YM/2^P9_09=%^F69S^# L= O<"83\GR6+G:\P <081%3$!%FJ M$(F1J?) ITCBL(@K4X)-<=T0I.>CL,J* 8=0P%H3#9YK8D74?H1"8"96$Q$" M;MT=A7<@\;T[!^+;'L#G"YOR>^+T0WLP2(H;U'YR&1J=\FK%H>2_T=OF ).I M:S3WMCE?Y&/VK=?YEGRRN7L6O)P4@]]TDQE)GYY:O=%#$S=FG1?CP.I[ZZ/G MWJ0(UQ"")Y0,AE4L'I\K:=V>-%.J]I(#._:"FD\?LN*PITNGROM%VXFL==?+ M@1CM[*_WA1:JHZH9?L5JQHT;M+^."FMAI4V)DIQ! ,(4%I=1.=I,7J#H].'1 M2<_Y[><1>--[UA+61,5]P(I2&S5U,1 'SH)U+ 3KYA('XW/VI8K=GC![ING? MAQV,UM+4]KJ9;73_'!'UH+0,)#AB,8U.8*V(<-C$1$MM Y8.JRHMR?-I.39I M&Y@QL'KIJ/L.=M@;HP@24BO/N 574Y;GVAV.OK+!@V=V$[8&;XK8J+CI]VZ3K)O&]P.-5SRF+B!K,NK07G.8#SU8!'(YU"3&#'0,<0^];HC(W M8GW("\W$35>D84:P5-070(\$Z1D(N% :18R9\"$I0>1+TM;3;$K3O-?,LE8_ MYKV'FKS-T7-01"@'H4V #U%.!8;5RJ5SX")$!&:U4B*%:3J2-A&DU=A,L"[$ M;'1^U@]! KZ.R#1JOA*^0QS?[D,0_T7F>5)&*]< MX>&+@ EBE',T83GSTE>3,)BB=4@M 6[/.&W)[:G+FU+^-]WQ[LO:>K!4\NJB M8\!YBDU L&MX-5S F%PF?5;JB7D?!_P!1$GT45H42< LG0$M?!PKN:O2 MY.0$6>.TI3/&W+&H@U-:*8BI?-GSS3%G*[[/;">%DV)TE"4@0-,RYXL@<2@D3&7<71 M9X3OARA3/Q7\CJ]YXZ%(^,&/TZTP SXC>(S_4^16ZQI$C9K,(?P6_B335-ZG MX9<^Q*J)3-_&#?7FNQ[,7U]G,B-E"DF+"9"&:*R(^S62CB^!FLG1N\X_MK_>#.2$>7ZH$.%1%X!C1$M:QXN#J M<>)3#"!1$!A^D9)I95YJ%J8IH#D$7KV[N]Y=;'\'8:R> =K$(0,+Q"CS1CDA M!9(NT7JD;2-+#?F6[0K7?GU;V-9(.DV=)H-&&,P!(0I"0L)+V#2N-BRD>,80 M[ 7 =4F,H *-U$@PWU*3*(1D)8#!59N%K(5MTI9]+)7CD*XLR4C)TMJS[6LW M!#&SA+M(K .[2B&F$(:7B8L@727!)00=^=U;0/1L!%9M!^+4H\Y$C2DGU/,@ M$4%EOD@R7PV9,:-B'QA,R^W?9P.W"^TYD124M10T@KT&J#T:Y^@"*')9J0/C M5')>"WH=++O#O'+W-0@;K)$DL*(KH)G&(4(&5-DS%!*/,XL[P)P/BVW$\H## M3D1F 2L4O -OB,I1Z,1YX%0[;ZQ3U;."0BZ"6P_&CK"N(BX*1A$(YW#*9AD? MI QL!&L4%KE*$,RE4#L#.U.^M1-A"0K*N$@A4@$8E)8\EA$[]PQ5*FF88*P. MV"H<.P*[BK+@&1.G!$$Q(!X%L=*62XU353WGC9%F%;'="-JRFL!GC^!NC.H_ MX-^=K$@.=N>J#,"5?,Q2@J[3*!1."@H>'[;F1+1& T(X28X CX@Q5H:--BI; M#0'T.##:-]C'(<5*:X"4CR(B&:D+,C)DZ;B\*W)L=46E*HXJ&O4 I!C5X*Y( MB?^1)?\0+/ZW+&]\S7[O9W?#SKOVW?H4]-Y;FTPSC0B\9X:\$,F+ 6<&HJ?2 M-5 ((W!$,?W'+.EV1_.LR;7)MD1$7"(-?Q B#14RU7A/_"A!&1!+O@9:K>K! M,9/,U.!". Z>6]JWCD0$*@B$KA MV G4E?Z6P0%%S:,E06)B5?3C&IS@&*O&D5A@(O#VH$X.L_>6W#YQV$;5I&D# MK[[>H5+SOT&TC,!+]-QC)*G@41+PA*3 %B&JHM:V$LE+R1=*IA$G%!0:09P2K2;U2I:C:@^DD]"Y/ZY.^-R#M_S1 M'MS?]SJI-C/-&JQ]T];R9BQ#+.T!>NS3X28(BD!Y6ZFB!0W/*W$ QH(OHKK\U?$__K'') MUJ2TA0K$*T!,,>L,EH*BB6<2P .I217R!<=D(\#VA\I,?ZVTYB8K4"4(NAPQE=1I$XS[[EG5Z M13P^_L+:S51J.).,&^4IC\K#/\>$"4+B2II(C-MW7@1A/F6=#JS OV5=" $Z M*9'1>H" (8U*2N>7QI]:)SLIB\H0V'%8,UZ'H)/[/)8=Y4359P8]C$]$I#6. M,9.@!I1G"G,96'J.&'C3I3Y0 MKMID!TN%U4E1.9 ^L!0'3*, G:"H]A1-S@B'P *O1+*,G$HM[D"&Y^@#K 01 MAJ>M6F\#Q!+BZ19G9D;N]BN]OH-M-1O_JC'&NB!(\$Y8A[\ V(4PQA;C(%(UR"*'+CR3@ABO"J3F!#4L,J.?"IZ0P<'>HVJY2P:"#() M4J!T"0)]$\HR@@C.9U+L"OC:48IYS&B'6D]0%8[$HY2BPB"I:7R_N^!P8\ W'J7W(TR2U MA\8:&P<*5S$<+8?@T3JK:,144%)L:1I5[02+L11'0G=M'EX)E4K '?S+>"Q1 M.> ^,$=J^DAB(G>%O#MHM]J=8?(=/F7-85X4S83OS%@_*HT MY Q66SJQ7MC]9DHR1%A M6LR@N _ CT:)Z8;!\[YBG^I?L!!"=+]EP/]4M-<;9&7)Y.I#C2&FV8(F8O@K M^2:@'4+!$_@==Y+6\(30E(>^LF0#EH2'QT[O*QD MP0..) >GN&Y)$ '->,*Q.$3\*)H@L6^3KAY(PJ#A_BGA@Z"8R %OE1*G+^Z=A!X>\H4 M"V!)8Y L%6T4LNFQARBHCB>IZ]@%JH<3L&1K=1T!3,N(5MP1DOIU65JR@W(4 M8IWU5(S32_1H3L"/C=2U 7(J[P-H;<^Q]@98,N8!"334>97HD-2OR=6LJZ+6 M4:4&=99[^,-'5^Q#C!,U@I%*@AE3KO%"3JV:DED"R*H::9FJ8&@B7+1224^T M+;.J >&:7)>F1&P&R$['SCR.# .NV/'(4X-J/#DTR;$-E5/N6M#%S8/9CV\! MU2HJ!N8"$[59F#5-)D:5?RET8,@O(/^J(/# M;9[^+@Y4SO;,&U^MF2-W@#D'"YW%"14F!!65"$HC+<%A$)1I@D!!1E;G+K!T M[$Y/J;(?Y->0LTS[+BYEG[3 NF6!+5DUDO"%)/(D-#1"R!T%,&E 3Y2&6TK M0V7+CZ41 82LQ'P-G/O&LNH+SF+I!+-:.IVFLP2N@]!I6 M@*:U!TO+E6&)\ M0"R+6S_D[>:11L3-2SPSV&NI(7;&#IQEK5$B"I-.1FYB,,N(HGYD="51IFBM MP;]?DN]]-ACM^J<^N-NW(K)2:X,,QI(CX67P@B?N<@A$'?652H>40I]7LQO# MME>$9@^BYIFMNA],HIA79V#E,@+'$@J"G-6IMZ/ M:0_(*,X),=5:::;X2>FSK@L^""UU',([*4!FL4.B6,[<:F5HM=0MG83"AT7H M8P:L&&Y?UVF5AC7(A")<:,LIF%J14*&66 ,R7>WWPYC:')O#[DD&D1GHF0H&%H=PX5W%T".-\P?':$8N9T4(S3XX+^JOU'@=S)N;]/@GN ME/8!>XD,8:!0M9HCS8-1V(+/M5I87/WR&V*\_ZG..3R"#SG-0+*!4P,M'8,^E MH,DHT@A!)M>Q.AA9(277D64I@GLAS%C3X'UWK9VW'4XJ3# ."@LD+',0%Z8& MSBK20'FHQ(A4$'X>=-E[-]_Y(%YC"0Y!E"$XB! -2[V'TLQ4#$+C8W6(\RGD MI3:< KU1QE/'66>SZ1MM$0;+!XH'.QL,\\@ V40$7U2ZB"M54%3"!21VHMHZ M['#S3CQ$99P2Y @6FK'(P)5/^LI3Z@6KZBL@8[T;M!O& M!Z+=451:.B6OM/328<8]!+<&IW''C-I(A#(5&;PHTAU6ZU&L=)J/Z"7S2@?E ML/CBW#O+%SW5Y?T..&,X$)1.6 @GN?3$L)H=*#@ M?$CT&N:CSOO)'#%B*=-!$R:%-]&E0C/M@7.PUBNQ&D'GQJ]CC'3'X"KSJ R" MI:XAG$"X""8(B@J"K^K8P3,0Z]UV;(3'1LL@G9'1(R*90Q 4()&&T6JQZJS$ M[B >"M&56V7&>3!W8.+2GB-*QW'P&-$ /FI%[)5DSV;H?M#=N7NL@@#8:N0M MN)0B-3_C"6,P40[KZ/;,VOI^K'M&=Q6#B2,N[7I*11$S@6(:U!A=SG"LM+Q4 M$C^;P1LC_2'O?6NG85ZI0\M=2O&-; "HJD9GW'05/E3DD%(SPYFL]S+OZA0I M%JXDMJU87'$A*C4,U%HE!*/2B@)<;RK-FQY<:R8 M.JMU>7;FLR8]8)"6P@T4L(\D_0XTU)/\X MF7APTX('VW?MQLSHXU'72(@I9L)HN#9\R%JNT;\?][/]UNADB^[T_MD2 '(_VX 7UQYX<\>VRT6^-M&[B_ MF$]14\AU'(Z88"DQV&ECJ<),2*I%P1'O;=H'KSVW?2B.;$JG S-J]L+\*(%3 M1)4H,H@KA(M>8\Q 3Q&?&"0I"I['BJI2"M>7)1R%0,?CS+M>]VN:DI)&IY^ M+=A$JH+S/#!M"$3^6+N"+8(CS5DUAZ79$;DR2YQ#L:2<3_VY\7WFXNI([( F M70OI>%0I'06V14',#FX551"^&NIL-2FAB%B[P7TPVIP33PZ8Z$5:.DD#@\4A M XTRG19.;I9U*I7T5,)KOMB.[=7QY#C*RSNI- 576UJL/?R9SG-3PEPZ&:BJ M:8\7R9>;;BN[6YX]/XSZFJG\6?GUI;E[",Y:V4,C_S-U,"E^2'L-Z_+W04+ MSY0CD44B,8M(VZ0<;3K)%:OQCJ*'\_+68'Y&['Z^9CP1NWE,(]YX\A3!*EI$ M451)[WJGL0JZ.G9T_3[$2V;W7I7NB5ANM%*$1:FY8T@CY4,J'B4I7H +U1VZ M%\GR^>^,!C_>-[I_Z_5:?[4[M;,D#NB1$HICZH>&.,363!JGN2J4KG'!@A:N MZ3ZYI.+^*-0Y*[8(I(8%8:0I3IH0,HGIZ M0%S9=SCVK9K(MJR"DX)ELXPA&A3PAO/412_QCZ=VCM6=7XS6;S=>&;@K Q>F MQ"US'Z43TC./E-;$FZ LP07/D$SS8RMK3N/U6Y07S+,]!N/'LGI:ZXCA?R)H M+E$ $Z@*3],9:2PA->.@#YIV>>4I-CALUO.5\V\SH^=]<-Q: M8)=2WK,T;C$4F4N+59C#B. '@T7EVF)3DL0P?=X%X:TVPG)-(,'*C.!Y^ M#;]BE87W4@W?^7!QAY"/$T' TAD>.8?XG09?[!%Z!JZ+1Y4]PA=J_,Z'A;L8 M0*4A\K-4B\ 5$4F32V8U78@#/AX>;&4$!ZTU%2F,Z><*HPYZ(0GU& MI[%7E9J\RS>"XPX]IZA_=.G,ED!6AJ 1YA4U!Y0F!Z3UF!"' MHO2TJF+FV@FHSBP/GA)D,06MQ&V@R"J$74@M_Y"O.2JW_D3Q?HER5 XIP[J=K(LS38-\O3Q77#51EX>=$YL!HJ$FDY4KQ8.P:\>%^= M'+JD7]91R/KJ^#GU_+K9[9T#^-OK^)DZOCCEG.=..I2B,#4J-=;@_($/49WY M&7H4H;V&MWEC:3G4\A11H&4WX>HA_'&\/ON&1%U%KJTR0')N BWA& M,1<,KI9UO!0&?,A[CUD^>/K0:<"G1F?-BN&T1U8_ROB8>J<[$;$!U1\5+2K1 M,"$T"E]M!4KEX5RUI40Y"RX!!258W *^3" M<122 K.+'$(^'810)$A;M/I-14HJ:%1MAGFIG"@KU>H]LNS8>H@+!K&^2%." MG0>BZ\B*,UHVX*!DM8_O1FTE]T&'$Y'Z@,H&_!QGN,",J@#1FR/1I@8#$A$D MJ*F>Z]VH4^4EDOI()ZJ(]QC,K"5:^<@IUFDP F%>!GWA/?\V< M>C<#U\CSIW;W:]$ZO2JG=$4#G4A,#(09\"B(44P@@LO9ZD(A7FD4RQB2\\&D(L3\W-*#BE)1924U4Y.\H$5^0D6*SJW22)-"%X[!6E MJ9<>,Z(/,F62NX$IEMAQ/<$'1*N"#^&(;8!. M/73[PVI-1WXNK58\1N])#%I%XV#QC-<]YJ;BR[[%"NE-A.W0>*WIT2^8<*#% M(##RU#G./;%A/ ]/6&$J)^?2AM'>L(K^QMUT^\/D*58'=*6%@WZC?Q]VGBA> M/K D%:E1#4M>:$L) ,WX6 MXJT7-0/"%@V"U@"Q"^GNWO13.]>T#C>2.,4'! MZZ8 ;* 1">RE-VF,N:UH6R(EJL*X ,+6$*[204X3*@,R7CLK($;&@?D$H98H M1!ZK.H@N-KQ#\+W+&^V^Z.A,).+_?'5/JY( Q#Y M?>\;5M-:G;K7;C9M;5Z(TA$-@:)1X*!'XXG3T4GG% [>4FZ7#CS"/\Z.>MH) MR[5DNAT.^H-&MP6:_(@4@=#%6_C/2$25ECA&88$B@B(=N#1U0QD987,BL0:9 M.<1[#P_MHC-4.@0ZZ2C87-RMG:ZUJ08CD6(L1(*7@K?E!!O[,I%Y4VE,\L/W M?OOG;KOSKV\&^3![\\-/.X,AYL&0AA,KL8R$&%CDUB,_5D,.,;ZXA-:"T>L6 M QL_-/+;O)B7T2K,>"EZ:S70/#(A5>#AFP,MVC'+OA1+.&S-V+N!G+]G!\1C-9#/#P7TO3X'*EGQ0SH%V MEXH(22F2./6SG\!/@JY9545WHP5ENQR>G<%>278K.?@^F@1$@I1$(.]-*=PV M"G]8L&O&_ZVG-%5@72,S!J)_S9&)8&C+0;],25X',M),2(;%"I"KT_@V!G5!"NRL M-AQS6@HS ?[7DEA2@9FL7XL5@'8'?"6Q@X30/8!=(]8XAQ25(I0A"O)XB6PH M0:1:1>SU@.\0Y'*)%5?!0?QM%>4*!<_*4)WXJH..D5ZVZ*IQX%K(5CF---+H M(0;W(1C&M)%&ETD$KYFKSE7%2]5!#63=)ECA47_.C^W^GZ"6TR\:7[/U4W J M#]LG"T;\/O68F)\T!<%*?SQ&['TV6"A*J'E-I3;A0]YK#9N#RJU5[VIV\&3T MV%#!.9;,(ZZY>19("/:>)<; %V!:1,L;KH[HA"P,%R# MNV:LUN!9EE#,# M?F@ER:@7]<-ZB#;#X#W _/FOK/,M^Q7NN=]R?C0+&NF(G6& #=BOJ9D+3(+W M7$TS$KDA(HN ;8;.IPS@;VW/$ ,+ES&>NC=&Q@B8$U_F2UDT-4/.D%RT)>M! MV@R%S_?M? <,2-2*8&P"B1AKXE(]RV1-:%,S%Y/0#3&80#2/0']P>Y>V'/J? M>IV:MMEKY->RC(:#/)[N+ M5H%?K"QF'OQ/Q8R/DYP\JL[NT$+6@KX$GN= OE:ZC83H@V(K'=,,13#R90!B MP56I''C!BWIL6\B+#$?:,^TU]R'Q&AEE&4H;5T1"T,I4*?'IU#^KM//'!*LZ M!%:#M0<\UC B-6BU5+DD/! 4>AJF68(TS:CJ9-4S8G,\4N7O3;<_R(-5JWW?]HY,6&]T=X5W4X+/^-WC8'F$SCDZ+$'= H]N[GPA*(:7J= M;Q"'SM^S$.#,@S*M!Q@]-#ETM_#4QT;WZWP0]&OC>_MA^+!PWRPV"_7])=&]\_;N[L,/IAN>W=C;S^N2TR#?L)81HC>!:+$>["8=&)3T=Q^Z31X M0H3P*=,VY<%+YUN[>T2^Z93K[AO;(ME=Z?&X-F M#"E*\^>4#_<B3L>.S+Z>&^D PQ&G>" @DTZ'T."F?\(Y4'-^WF"Z.:MD,LGW@ MLL:Z)D!J=)+@*B#5$M!Q+[P:'<;W696<+"N/N[D2WZ96V73 M:!)!#!$Z*FZTH1,=*06NA&0<+>'\//YU)-J7O$:5>LW "E.<%ODJC,K5YI6N MCNMXBYFBJA;J+1B\+PD5.C5$)0 Q-\+"3S'*L81&X52U-VH]O7>!/"O:'3>^ MCR2DOW5N(;4V",B'""8C(AU$E!B"9>&C,&!>*R[X*K 78'D>W&L$QD0P&MH0 MZE+:P>@8E1C!+6ETJ#H?3R*%5U-]K^"ODQ@O/37,44D@>H-HQR(Z E\Q8E0E M!?66ZWKSL@WT<^'%OE:NM$%3$"&I57#(2._D9"\Z6E91-F^Q%/4+=Q/P]H?6 M&@8I#\9&,VO 7*:C]IZ5"@D<&5I=TF]QO=79%2FX:>0LS%0JKV^^O\H!0RQ0 MJRSG'F$<#2/I+,'8H:&NFE["K!ZC32#;'T8K]S:D9:!UH]9$,Z<-XZ(L1W%@ M_*I& ^*#>LW[;)QF1W#4'5I8Q1C#4OX9"P>R9FQPRIDR>^#T?%G$B#&5T>=K MP'D6Y"MW]:) CF(;&=-*NT"<+1T-+V5U5UF+)4M_%\"WIK,U:=@.R:*"/XL285IQ,G@+5)2C9"$8)^'ZN%P+M:8\PW! M/ RJ*RN$./"180G.BR-2D$@"':$JK=2^QCZJ->9Q+ZBF?,Z6*E*#YQC3V@L" M&X*-]4BD[6KO=$5_MQ$*P/B5CYNW$LXU*3Q6Z_*(6 M!30.;?I%3:-M]%,B='I#2BEMJ>]DVF,#C8Z5Q@P[@7Q9LNTX4A5])]$Z]V(/ M*!R?1*L$Q','-V@!H7BD1B(NO9U(/D04%1(QO,:P'Y]$2?CR;T4NPS2;^1"P M+/[.9H_I;BDY*!#JA)$15 ,%"Z+#)+P2P552X1#VKK&4.X)]'%*LDA#.TFD! M4(K!@@D22NC)/K633%8L*3@3Y/BD2&6\(P'K='I_I0STEK7.#H-/JR0'[G(& MKH.D95UVB+Y:52#5&B2K #T;_I65@N";@V8/$:N(@2O!3'/AS.KJ_(,E.T_; MPS_#H2VZOZR,-=)!2HR03$,!* XTNDF&(#!3=7FH7KKX-H%NKXBMK"'$$!-Z MP57J!Z1MC)R6YT4=Z)=J-HTNSR7L@%B[FQ4'R_+VEV'B;+H_/#QV>D]9_FMC MT+Q/.TVSUT>5W9ND01=.9Q!$< !7FQF(@;% )$P8"*[3;'74S'Z[F,-S1V#G M47[, <*:RO,-]CB<3 ?I(D=2>F2DB9*5N5R.HZ[&2M6(=_KUS:%:5^[G);;@ MJWJA>I?929=T9U]4M6BSUHC^W"U3K\MY$"$F92DU](T:TT)WC<] 6I+UZ MAI:.<\XHJEI0=H"5_X9_6PZK<1[4:*3@?-NB?0JXZ^5!+ B\]0I8V2%@)2M@ ME1;+J T 25(G:2N"+4MV!$@%7@$K/P2L= 6L7H$WFY:P("X@JQG5D\X:Q-%5 M=#V(#+ 5L#K/(]9&2V*PYQ@#5:>:/ZH5QZ@Q/0BL*]86,ZPXSXK2QC2-FFKF MR[5%\&*GHEE8B=H_K&+EVN(T:(XTQTD&)#)@QDO'WY%*&<:<#.!#P+IJ;?E@ M/8@H$IQAID :0'3+8X^4+G;SF(.5' +656L+8A&M/ -W'8'J,I98/J&KCEJL M@/4 \BI6KJV@L8@&]"MH = (1"E4%HOYH"PZKLZJ.EMD/AQG(2(65!IMQ\#K M*WM.!$H9=BOTP'/DU;<[P\'BT?+U5C: *Q"C(,I;&H1SD>/28:XJ,AVLK0,DD.]CH5 7#2OEU5J[R9E:MMF?"NV*]28ZU0PY MA!RI*[/DP+D@- J>2 'HN]J MZPN!$P$O3',)@JO2L./)05V)Y&*>=5/K^SQX5ZTWA,&]!35F>.K*1A!RDXYY M@D2]HP5^'KRKUAOC ):S"ADGJ0O>,U2V<' 8*[N;%7X>O"LM,:**(ID":L)@ MB05N)UZ#6DW? ^FSU=;81(53#28)J>L]L:GU7FF-4YW3_O3#W5W6'+2_99-R MP'3>9-0F:@C/CG>G>]V-JF)GNT8 MS'0?VQRZ?>%49:RW52[ M/TJHEP=64]W ,(V@FKMY$_[-IULAT$X)& %A3%0$4T3PI!FI!U-0CRU;A^M6 M4!^<".MRSEP;GZHA.9$*(R.4*&.CR+V6N)X(_*1$CR!8H')4ZJ_4#UAB!KO:@\M+I;0V1 MJIGHO&!0/740GG.23DL=GZ7N/TG__#9L=-IW[:*[_?AW)CU=L]>[@=Q82SS$ M#@8L;RJ?0#R4#B]'#"_9NIE+YN\1^J,19;6X1&RE#,QP0Z@$*4#63S:'/>;U MN@7-M1H[(5'>][JMT9N_=++QAONO6=IB[[9".E([:+2[U%6Y(P)4U,4N(EO*3CG0NB K-*ISZ_4\_$U_F629N(+8W04G@/B/AJ"3"I M\%MX0BD*7%&I .%2 B#:]#H>FH(NC;"> X2QR;1:H$AE*?!GBX("(%!CZ:3#F,2(1GF2D-F2,3Y MEB;FL"0:'5=O_7/8'S4RWE9.L#".^E2C;0QFD2JGRVPFN!ZNC@B%6R:W7#:+ M<.X?SS7^A'3@5Q%%(M8$K&9$SI7:@9&YEH1=B,HM5=T^\*T_9;H]BWW*A =C0<5S8@7<7O;"\EX3O\0[WCK2 M7 ;NX=!>S6H%QCWU\Y2:.F89Z&A1IOX"U:Z.U450H$Z#]JISY^M"0F;!@46) MK=$HB[!G NPX(9Q3B9?PEZ@ME7+],?3GHK9&$:=V+8Y%HYU/NC=U"QVCIIRQ M2QQUM>UJ78+:J)HQ&Q<_S11TNF5E;:NJ9C%UD4G*-5*,(F]3$XR)45&AYL03 M6FB7NQ:@9T*_\E0P0IRED!D%$Z106DZST(97!RIA0A?:5>X$_:/-;L'B^6A6]%^V?DQ*ZE5:1?( C=XVL.:]!N. MB%6;P^+%648G(\YQ.)1HN(H;RWO\I+([!W8RL4^&;_WL[MA MYUW[+CL<028O6 Y&WS[]VOAG+R_&!\VI P/W[<=^12$S+,%K MD%'+@)EB(F"O!81MC#D-XAJ30B8S7?0V(<@+(> [6'M=^.[723^R*OD4!T?AB@$/*::/\,!V5A(98Z3W*7MFO-!,DDC*&5LF"E;UGM7"U(EG M@+H[QL\;CN"\=A("< N(,T88UW%R:)\(4=.1GSX'YU4#$[9[TXX\EI@XCC @ MJ(P(Z5 :G_"8A.I1?HABGX'N\[E;O*$WW+*3A&!"&:U%FN\D,'<0_4UF:I(8 MJR?<]H F /D\-#_?@U;>LE-0H, WXS1%&IS9%#!,#[F::M,FK(A^)IX%E,]$ M]*_>=F@JAU$JC'.:*82"HX),VJTEI^@0:/[5VQ#)O^6]?GUC@,,YB\OHQ#0S M+ U)(2 6&A'B)EL?FE;//%,I\*9T*M \+4E6N']+STJ'-*4*G)H8#>6"PIJ8 MC(V,KMH:#*&-!><,"++*HUO:B"&D$1F6J8 )P3%$*9+R$VGNJ*AV+[T86BRX M9TL[.BF.-,::6H+ :>-@\R85;5I7\IN@;HZY0L0)E(9E7'!0')ZDHC5$!9^. M5D6&5ELI(GU))-E>:6!F",4F!.&-538Y?.5!+F:4J"H-JH^I-)Y+D!V4AHHL M*"^")%A8C#C$A*%0&NDLBW&5O+I::'9ZW@393',8I-*1:1J$%=%'*PC'DZ:, MDE:Z#:<>GD<2BT0$7,3(?&;XXS 5;STV\L'3^\9#-A,?#W,(BAN=27A\Z,S6 M,DNDC58LG445EELLF3,0/BM')8M$+)[B.J:S M.W OVJSUUPV!4I!&Q M$ LK;#GBB:J*@-_B:55WOCYAW<'-(9A:&R7&+FG3J T&BP14I81I(:OE T=S M<\Z'JILI4T0\A!3(6>,@I%",*4V D!*4*?4"5XR1D(>1S^W;RH-N8HAQ1=,< M=>4Q5>6D@M3_M)(W)%CAC2%?Z(>^ ]R;6-#['*0B[_];K__8'@"&$=AXW^ZT M\BRUS?R]"]_+05J>;N\^]8:#^]CIY>U6HVR]&N'%K4*YWW2;/YY$MPE#P H' M(:W$4B(5F+;2.10]BQ">5KL 'X !HS(4($&>-?J9ST9_+^M;<805120ED3ON MBB,A2FO03V6BUR!9Z2R^.+1E:USW3"A^+$*E%#C23!L![1S#" '>@XE!.[!VZ?_2H+2WE XPX8!QS:S!&J*NILLL'.214,,T "1B>5Z+1[O8"6XTD)P^ M#Y;#$5832AP$8Y'+U(T_.LH)$%9$"Y+C8B4MC 46.R)SL!Z3"T6 @0A'(L:2 M@(KCV@H&$13STCNB284[VR%T\_#8:.?)OWE725)NTGX!3'L01AI'E5$H37&. M2"%,@[2&$5.)/6K F@>A#L@/0W#Q0!6;9E%LE[RR)>>/QNH6=#<]X.(%RXRY M@A4I7&J@J:7CMI Q(7W:[ZV,T1*2Z5J6K,3L>:2H,SU[IX3RX/6*%&,XAFD$ M&P+N"I4Z"H-3_X5#4"(%4A_R7NV,NC5]C8FUJ191:9Z.8F*%8$%-!OVJFNZU M" S@O*F;^?S&4%7;KLUG18)TFH&"(D@C4+F!ETYR\)Y7-_B;)! ME+T(A.'5L?&,(2KV -1BUZ:%L5=!!PC]').:$>J0G&E#QQ8;**9Q"6IQ#>P& MU"I)1\);KQ #KT)BY1D/DW-I07%9;2,O)%J(O7:!JMKP;'[@AA"8"JX\M]AR MD@*=LC&+ WU1%2K."-X#4*LE':!RAN'41,@B%JR?-D&-PE4B"J8U>[Y.J+8N MFZ>4(5$A(8@R(%N*@'"5K4@$\+6B$[A@E.P!J)62'@"8).S@28%I5]0Z-7' MI=:5:%Z *R#W =3J<:K&U]0K(/LGK6'<(R-<-P4FMMU5JN0P. M(K-"J> $1![:..J\KVQ OF6$/1?R=?/JUPA("#35<'&?MNH,(T*&B49/IV6J MN^9U"KT"QTZ@KI$+DYIH:1P@J'.2(XNGYPB"IM4:OK<0]=4IROT NT84'*(1 M?": UT@4_/]G[UV;$[FR1-'/]_P*PG-G3D]$5?5^/]S3';&?9SS7=OG8U>/H M3R7UCF[2M "R%26<5%;N'7Q_(- M:],!D4=&.+>487"FN0RZGJP2" M0!IE%FH)MD5D&D%;NW7[9K1,!,([O_3!G3Q2'6=&OX69K$,!04J MU<6HN5<>6U/O%$X9'K@+14;0TTZ0N#'XJ88?#Z*APP"4X8]-T'J*(-1A#T- M^;2B80 #EWI/')[ >CX:+:P$89T+ 3.MJ(XZ4C#15882%$U>7$ D4IE2.0,: M;1P59+38$H\A5H#0@0I=Q0L@)C'O&LQV8W:"QLZ%LGLPE?;@H'L=I"0Q56SI M=#59+6:.K.$20F?&O!6JYV/1PE,,:4FI("):IZP0'J2W7N?I\ZPWP1N7\>?! MHH6E2*2!$Q6TQ> RF=1\6I^%D/E*24'T'D;B&"R65O$X6T=(JJI%3@!;8>LP M>+95#M2I(#-;Q_+D1#M4':#1PE-@LI'CSDIC4, R+42IU"V8/Y'Y%^#G[J%M M3X!'"U>)Y).QU-TT)(_CRKK-CO&HIJZO3O(YF*^452[HY(L" M'M0SC7#54B9 #V>JBNM61)K@Z@*3-G5%L;9(,$9E .7+!41\]>X:;+,0BG*, M7PB3%N9B+"+AG)+"LJ AJ(J< M*LLI#XB;M!U&4B1Q%4<(U- S!PIT'UR:8.L,I3;/*6+)0)Z5",(1XGR*C)8U M#' 0V?&T!12G1ZB%WXP(S@1@-$F0@P )?JBRLP(W\!OXZJ=!Z8=)\=@?W"YS MD8=G&L$7A"##&VR5H*DXR(#WW)!OSE(I.7;LF+_LGYS6>D_ "C'-\6TM9&".(MPFJ"+G+4* M$T/KVU?34+F+529BAZ%\.>1Z^MR25%4;F1G=^N)S,1P_IFNGMMXFYVWPEEIC ME3;(<%ZORV4\JMRN;X9&KYU\'R;]V^*A/_DEW=:5OZ1VEM;Y"11+GAQZQS#W M\"^L6!7DCRU\"H+'RY*3+L@WW%BZ@CWGDI+-#CYW)G4(%21 MS5F:BRGC%$WW8[N>!FF3<$A43[JJ%$ IY$;JB#J#2$H29R[6-MR&;0_CN.- MI#A-6N8<2!Z#T"FK+6=\TUE_#O$;9C7LYT1M3Q:";XBB=H(+;[46J96R"F!5D/DX "ZR M;.$^4'6!Q\X=!"0PZ0(EPOA4HRZ2D%2S.0&G+/&#B-@\F>?B\7TQ>^9I4(+! M3?.IIL)IZ^O*("98 M7@5&X,PV%=3!.)3EG,)J'T*SS(=@&;BKCS\(LI;, M!F&ID]8[2:W#X 9Z&ZN6.T9E/C!%;68 CX>L[>[0@)H @!BCT00K/:JWJ5 I M\TU&E&Y>[K2"=E3)G(Q"4QW!)?'@AGBFP3VI2N9DR'>1;#G+O.YK%TPMIR@A M)C(2@B!B*?BI@=82$5ET+I^*VGR*A\'4EG5BEH.#+'V(P=$0)./58';.#,[U MOMB\V]H&U.+&Y4MJCYG>%[=)8)OGT6Z'S0B @D1FA9-&$0(6IXHE<2"9C:4, M;?J534 < ^;.L=D0XK+(/48.1RN$Y;R:1R!"T'G:$2F\:3KWAG/[6-_M.5WC M-(HJ6&<\B19\2( XR6,,(!K*P6>7I)Y&#=*0YP9P M9@WV!3+M6BK+$5(8/?F\>9/4KO$">*PB&#!71K-T=5E5XG#+\KMCFI5W;8/C M6&AWT17L1O14*>65-J#SL*LG. L%$I39,[*%K/M!^_-X\DN=ICA0!8)=4W#\ MR,94'T0DKPIC0VI6SKT4E85K34 < ^;.?1KTVSIQ\*6UO- M"U=6I#5I05L([< R"[>$S0 +9+JR4]A:7*URR _F2L"I2B(DC6H)6U+K**\' M9FJ+.],(X;?ISL^,;G^$]_2'Q\9 D:3)6CZE,Z@@!#-NI2 Q(JTBXC[OQ\,; MTSD;P3@"SI:#IA0E3Q0#2(8+#0XB\PE.'*(2#65EF&[X7%W!V58$+L"YH4RG M72$Q;2#F1"EIN[$3< TX(CHOTMC2$9C*!D'DQ /*I>"!]Q?1# M,7EX?Y?Z(R< V'9$GH).19TPR"N35KIIC=.S47WYZ=B=#,HIO;+]_W9?%(L M'K9X^-8(KAHAT:9F#X!%Y7KO3W)J&"T&Z<:"[L5RC MR+:2E#:#QU*I$*A!J]*Z$0-'*.IQ.$3$?$::U!LY^2T5)SLAVNGN!R*8I2QU MIFB11JCKZOK9"97?WX.CN)'2:H<(Q*3<]'D_'MX"B1==O =FWK!BX$![\%52 M^1Y5B%?WEXQATK"5 H*5K7 V O0\X'?16'MN4?+%TO8Q:W1 VM8!CZ6PR3RKYZ6)E\:%Z:'#;.EJP90J$(- T5,*3U/!'!&'6,",M MSCLJUTCQA.PV(M3 ]W\;/,P?['@R&?^:4.L_PE\VI&'!7?3]S0R3RR-4@!C< M6Y!";)PBAM>S(GQ(XZYSUD$;U5R'T&6-GFMF\,L/16E:W+ _>)A^7ZX(;C&C MP*V?RF ,K.-LOC&==?%M3^]IHX.1 OZG/ *W%T%H0TV,0A(C0M0LKOGC-PG$ MK_[&5DC0BLHS$%^P#_F/^8CH!N1=\KKJT[?C46'[HU_,S1/2)Z*8BXX&1:S@ M*-W(.4; 8$O01 ;'M!9<8QY4%<2R&?3! (77R/E),)GH!P6@E*A+9>"IQM'[[U)/,=5VD>L M&Z14G)=R_S$?8G1)4LIY %W.4(!@'FR?8VG!'U L@G8G8JW4>$DQ?BS%OB]F M@.;]#Y/QY\%M<6N__'V:Z@7B8-2', >B!L#V\W&=!2%2I8(48*BBX=)@;Y[Z MY9C,!W40S-;OI/8'KBN46O("&$R+QEHFXT*U(\#653Y:^,#R=K.4Y> OC%-+ M#H%C;'4UCC%,./>,,JLYQJ"!EO[?!:"B.PJY*W8& ]V M?HS:QB1)JSP7-!C/*#(&,*KRT4Y)GV4LW^*TW^MT.-69I&=P7II3!7Z4-BR5 M+<34'%:E;QPS>8]P&DVT%TH-P'6%4EMUB '%H$!+L,A%RE/PH.M[&&SS7*C: MG'-Z?I3:>D"QY)8B9"/3%!LO3=6[&J1Q.4J$;UXN'8W2TR2X@WG+.PGQCM-< M,9"-H$^NGQ!\.UFM>3VJ3!-1K-IAL!\:P/ M0>9MZ$]&0)#6BD>CHD2>RU3A:X+TRM=COR&\S6I\.T.N91PYH M9A6QM0Q4GW5.XJA)D)5H>:WSO;N"\\R9.!*NG=.:K7).J#2.#^, 3R3$U'.M M,5>9EX,IS>WGL8#M[J-G,E6U.:H5\V B7#TZ)@3@_4P7:99[R<\ [+1B33#5 M:9@,8\X&L(8B;8=8%OZF)7VGPZYE^#HA3(,@$R69UL"PUM33NQUX]7E9%=;= MR'7+_'4#ZD:K=+.BE2.".EI/E0."^9Q/M18A&/)2JFHY.7Q\3?2K=I;_\].Q<-=_?(9#&CV0UTA@ M T:-!,L*7EO=\^OR;DR)-VXA&H X&,:VL#D$XX)VG#+LI%, 6+WZ(P4 >=\[ MW2B1Z +(MA2,0='A2*QVP=+H@JF<)@BY9+YJ%:M-*[DOD&5RL#^9?+D;3W[M M3[;43*]T/2UGE)KY[+X<:KVF-3S\$>+LF[*I;?*E16EX:2':PEZE8F%E.#80 M*N*T9B1(2O/FF"F.9>[T> -#G#: M8TDI3:8=!TT3T@[B:'! &J9-\HU,5/=HBY.=,#@(4D1J)4^)44((395\@)"F M!ER_UIE0+XKKL4>,,(+X$")#+*AU1(+SYI98 M6X X"LY=M(0H,M*@0;\ZJ@3U@E2C\X/C$67Y;\P4>2Z@:57[,31E6&((RPF. M&.((",[YT[Y-!(1N+9_?#L@SP'VZNYN,03AG7WX8]D=IDT/RHLN>=?OEPY?' MU8O55'Z8BIF^>7BNU"<_UX,;_\^NBTFKE\NGE_4U+80P4:+ ME*6$1VJ+P82&.NU!D=^U;6P'&$=#VW:%A! $MIHBK#CBD7$6 MZO9_BT,F)ARQ1CIW"7+;8%F2,MD"_-<8D&3"V%3_(R%B],2 R+?"4'I14IHLN%L\6]HR, M8LE[K6OTE+%-._8]5V.9=E>H,.< M#LRF$$QJQUG$1H,0$XTLZ!R=7R-N%L:VX70T_M6EQ$DW4#N4)IYZ$'9PJHDV M3C$$810$Y$)'G2^A/#OZIUW G68,8.0E!-T\8'!/P1-+J\@5 K_\R^$#)G#"!$.P;@T.V!AE6-)C8#,U3=-=]]!C^\#5'3YMPRG M\X7W:14-$XP$04-8X*.L;A@/^>+XM TFL=II:A3 +@D&-##22WS2%4B6K9!B MP^OM#*O:J7\_*KWUPXOE'/ : H<@6*P5L@0"W]:J MB;SR)J0YCSIB0:11HL[)D'RDPKG!;]VY0@)-6[:-8I;R*/G31$OB&](?&^5B MSP-_S^[C<#P9W/:KB8 1OOBV=#&^&=V\VRBOCD=,7OMV< -.2ZK% MJMIJ6E,P01!@GDB0C%@S3'200BC)N)1!J$P2],9"I5;R[CR+[_HW]XF 7U8C M]V A<=XESB2)I@22.A]<8QBO,LD2 ;.TJ. MP&2R7&)29B%^Z$_>3\KKC=LT#*/XH5AX]ZV9VO4+:@)^-!@+ZAB$P"%5S;AJ M"9]G66U*]1 PYN\06KF?W@^V+K 1N[!Q"B.F'?,:/!(C*+>J/A63E1^?#)OR MS]/EC=1_;[HBK6>"P#LDT3H)03Q("9?UA#1O)96KCLBT?%+=#;@-A4V G@/Z MS@- H'H!O9/0&GDCG "F,%Z9-!Y:55ZT%WRM9:M+ ML$LE<]B%&V98111CQ,J"LHA*\+K,"-,\&;L5S/+9!X.VZU8)84U53&.?*/?$ M1 L@UA,&?)YT/0BTE5T51UW^@OW&7$M0JI([3*,U42E.'28\>,SR>8%4LTU= ME<-P!)"[*(B5=\8$9R&(BUAZ*:)8 "F!.?.E@5P=#N3XIBANRT7VJY<>31,E M]FD2!*>4>R8DR':PCNM83T'@TN:)S+?@SVY$0#L!>@[H+0XJQ G@4J=E!$93 M(9'7LC($PLA\+/E;ALA&2=/I8&]=RDB\0%Y*R\%E8 X)4^6/!0>+EO=>HZMR9. +.$R#:UC$@!0/'@Q@:N#-:L]03N'3YO&^8XW:I>+9518*B M#4J"^I).*\\QL6QY9Q49STNHZ6GQ3';E_6-*4$S#;\7D9C ](J\;P69HE:KC MM'>B;\;4$Y W>FP3X-D(ZX7A7HL&SI6-B9'[8+F>*C;5LUR'""TAN"40Y0*K"]E M'9^"L<\D3,0.R^33T]]4K+?#!\\M.D?3L4 MHTXR([RQR.H8P%?WU;1QYVS>TT4:E-.%T:'^6POJ- 2%D5/@QCF+0:VE^5!+ MU W-EQ,R+BZ=!>)\ B#/)\ELQ\%OZ:?6\D M3HG]"Z="8X5B"QG2=&2?[I&H003B9B59W;/,P<[E)*\)\00X;54V8TJ/@\TY [OA=& MAWWUF%:(:F!"YX;# $ZL4Y(@S3C MII($)[G(4G02\4L7A*/T&*/2$Q*TL"RWBE*9.=Z[. 5#\PJ M)23"2(-33L$@2UL)+R4X'UNOV48#]RY0C@=YYR12J@B$HAQ Q!&!H0SLJ:U% MD+R$ L1S3ZE[+LSG*>D7:TVM$C$KL(^<8B324J2J'P6<")43HR'K< &TJ-[[ MC+I^R9@QEJ&@J$.1"FSJ400^E19DWM3F_?MS"?'W:7$W'WX[N-M:5O/4OY[F M@:\AOIQF6N&XTI )@;^/Z:HAI$#)B?KZS@%3DZ_^]H/\QQY(/ %W!EP&HT9< M% &=*%("-W *AM/6V23ON<44<*''X]*\J_/8T?_20L@!+,(MQTI[*V4U1BI= MF^(L6R[1QI*,G> \ ^ZVW@5PF=,.)BT$9R*"(7:N]D@HR3N=V$;:Y51PMTU7 MPS2R8$Q(^YG C7*T[E5DP/_Y J"-KI;#@!\?7B$N;F9/\S+NG)?W UNFN9/ M[TQH4"*T8SIXR55,*S9,-;D; H.&BQ6J\$8DWP[2^1@U!)= 5"73 M,HDZ(P-6:/E*I73'<+T1Q"%T;PH=ZAEEGJ_SBU'TRV CQ(%C8DC5:8& MM$QH2.,J0M8U2A,SFN-"O2LP M=\["DHY$.'*;7"P"CI<-KDZX.Y*/WV>)]4\"YL[16,Q()4,$!EX[11AC 3N. Q;5E2('?RL/N)0D&X777<)Y'H7H M-)P-"I9("*:MHH%06NH-8V+:2]IPCWH2A;@WSGLK1 6.CR!1,S!T7#+JM"L1 M0]8SH7.WDV%TDM-LF?^'=9J>:E1RACVX:"SH>L^2DOF])*?T)!JQ91P@53XM MME",."DL,DS2>I*'CR3K,^*2;HQ([@K,G1JQ#!ZX3E/AG*.>8%9OXQ98F_[, M..^K$5T$^V^Q9A0+!V(;*#P$$+-.&QQ8/BM1I4FPAV%6#(=I:WT!D5M_"&&: MN7U(NYYG::K4Y^+8E$V:&L3@3)#VBEF3L@9U"D'*O E5HW(TSRK@>P'6!2HM M3@;85VE=TIQHQOQ$NM8PDZ M&B7AHN""1:E0U,082S2_E< X/ %&;PEH-(8G*J(O+Y7Y! :;:3-N\3\M5-TRT4$ MAU FY?3!VXN""B*PKBI.&)'6 T7Q)5-T4;/^M)EO6EX5?KCOCY;EG7$\N2L& MLY2X7#RW2X+OZ%&T&!%G<%00 T 8'Q!ZLL!Q+=-0=151L,Q8=D#KPVERUJ-( M910_%X-/]P" ^0QF[%/QOU*YI>_/BM@?3!K:C[H[);+:W9M*,RS7A&),.%.> M/TU!)BILF+2G/E+U3N(S'M->]#K/"9;/G9Y7DB":XIQ1B.R9B(IC17"5LV," M^] @26D4+R/B'&>T3I&7.(6+$*5@P10CIU+EM3.I2M^*6I2,)=M%"?'S'].% M2-/WXW+;57&[;?_J:NEI)[(DG!(T;9ZED1!E@R)"U_D),%%-LB0P)>(L9FF# M'A=R"*+S0U <14G!]( BBX@&Y.HD$:>\2:%1111C9Y&4ESV$ Y591T*RJLG@ M'*@47L/AA.0=$.QL+2)DLX3A29/I=YB=]7PN38D=<70=B-;JT1%#0G1<8H=1 M3#.9M*JU&\.;&[]6C1"G?\2C^\\2F#/'19@Y3[61DKD8J.!&/E4&D[7%WY7R MPU@03<_B<:]3Y"5.X2*\.><$TR8HIA!#@3HL9*@ME ]JNR )=?YC.H\TU=]F MIM/Y0]4Z^E@DDOI!VB4YNOT1GKI/8G5=)(R28-Y!*)B.6EM/*:HFLEMGPJI( MC$J;O-:W>'*$7IAZ>:YWHV8, ]%HFF0/)(Q@JUU5]>T%F /^QZ9>^^8J;9QV M7C&.A K84F8$D0%KHITE]/=.O?\<#^%KTK#:7;*[?Z;ZB3V(W$YM81@(7DG C4B,]C;BJ MF$MSI!M9^AU7G7COKXC8O!/.3NWH++4\"BI=5-%J6@_/@E?-E=A[$GL?S@XA MQ!"-]CH*ZZ@5IAY!PM-&]F9B,]I%WN 5$3NW>:M$I%$:R4 E&(@.?8@"7"Y! M%#"PY<*O57$_$1'M<>7Z.HCXXV#Z2YP4:S$G"I*O=Q_5?IR!1GVDL$K.3D+6BR;GPK8< MRITTIB':Q DAF-/1F*BK/=N>B+4B]#5RGLJT[T#M,LBYFSMUFM#/*6:2!&I4 MZB&J"BV"@O_?0D[>1=[K)^FF.@I,.-5*=.'U;$/B1!3:R&15\Z=^F QNVN>QKB;P4ATWEQHB3:$= M!VLB'5E0345AT-8)V?0=[2(3?AAF)R!F45_U?AC/^D/@\.?(ODF8(RXV*>>L%NT7IZ,+669V"B1UN)8",VQ]-&* ML"R)B@Q"F9R,$BO\!R1C2\FH]@K"E, L4Q$%AVQ]@Q*9)OD"3['HR'S-5'P< M3,K/M%8>[; C::.E2KU" =G4F5,NVB@UHF>,-=H1IH3J5!UF>'1)II5JL6>0 M"8A!@4"121M /!6'"+DDDT$*L:;:!,Q3WU)W9&K HTLRK5<"[5QWMB-M;K3T MC)!R CLQGB*\(),)R%#<,C/^!"BRG4:5D:]5P2H']+NB[ MLMYBERO3$**@U1!%1$YXT"J8=&T05!KUL3#(#)SL;&* $)A**CM4 5OQ.!&Q M=E1Y;K4(B3X)I;J/?_>@T.Y%.8I% M<(8A1%/@X2F'51I]5S*2\U8TNBPIFA/H-+QT4@H=EB'@VS,$TC%MHXJ16&XI M<@I7XJ=CFINW/4,@R$G(=JX,P='$W)%N@1!+4Q$(]3:M!:!"!+\D)GB)VVM& M@9A=I/=>CIB+0JPTD&YYB_5AG%Y:2?R83Y\FQ2L MDW9)7N) [AM,!=9$=>C-'(WG>8E]E/X40%9)?;1!*F\]5]17%H:BZ)L6C6$L M(!CD9R5P]VJU_9F=*0CD5=HI!6SKL#/(1JZ6^5@-GN3F,) U!=&AS_@\A,] M^A4-UH7><-0+T _@)P7EC=7E$KV%9R -5MFT)\$@7M*=7& ]%\^#B#T]-&&W M/U^WAT/&8$_*!N+@(OS(@UG:/D4"5GX[:Z-#'(E.<>R8NEE:KTOZ@L4CW-. M((S'D=(08^5;<&PWYRX\T5>\PX?4"72,9:<4;L@(=DEA%S@SR"2-'#R80LQT M=5D&GL8N"LM#VN(ZQK)3"N_,)CQ//8!N\!KYLEX-,Z'2QKH%<0407G>4+>D. MP7:ZEJ^N[*HMQW.O;)1*0YJG:]]9UOM]._ZUF"Q^&CQLSJ5MZ.-XQL/ME_SQ M3^./GE[#N]M O%-.*B.Y=2B IZV-JMI N&)R:U,O>M=>N=P-$?](AT5V'Q;' MX$=J&:UF.A@GM-35Y@G.Z>9NP=7#4JU:['I8AQX6W7U8QD7.+)).>?B!@V2% MI\/RF^N.G@X+OV-7R>K\L%A+6RD!/2C N;4A37VV+CP=EC>;R\F>#HN\$ZT> MV/6P#CTLWM*^320S1+$@63HE'Z*I9W\A+;;F-=D[W)HPOQ[6H8"1:$E"&AA+WU- 0XN9.U57/NWT6PO6P#CTLV6*S;(S6"*JB0-$*CU+%__*P M+/QK^V $_=IMUB+W^/YN)5.VC"L.S+4&["-S@0B'C90F$/A?-3';R]!XF[=G MKK5SU"Z%FB\<$&U>Q^HT(9N$M'+%>4MT]%7QG:5$-!P@8YBU7\9>C^\T(=+Z M\4G.A$BKEZRATJ,T*?:IXP:9IND3C"K.Y:DTV/7\6J*FS;LJY3@)SBN4>AX- MX:X:!LR=CK9)?U)!&&G-Z5_/[S2!U,;YL8 "$DC!D;A@F='5 .00A!--=9-* M*C" U^-[F=!JH]0&W'6LC5-*"J*X#DQ4114.$"1A54QJC#VO3/FKU*3!B[:44U_,[30"V?G[EDB5JB.&2D9BS6CLNC(5H&D>I"'&5*Q%2&?:+16+7\]LK M$HO6@I0I@:,&J>(Q1E7O[DNSNU\J$KL>WUZ1F&0."Q,90I*FL44!X6IU08P6 M^X;CHX@+)*[F[R(BL6!D)$YR,('*.BLHX]5ZD,C@Q:9(FA*&46L_\O7\SA&) M12205#I2HQD(T?;I&J_G^/[^^'AI-Y@M]6S:&,6:"MC7<]&T=;: /1.GJJ08X.(?Z3#:JEG,ZF-.42I#4:(&LMMK&L#(I-X M>XE4^[S#ZV%U$ ^L'A;#-@B=-K3JM,V.,H^JR?N<8K%UWA Y72'''_BP6NK9 M3!2861^-50"?H=H&5Q\6]UL+.>@[?2KO\0]\6"WU;%Q'Y86VQ%L::/22,%$? MEO5T>XG4R2Y=_L"'U5+/AHW1P4 XC75TRNM@!:]+I,3:3>8*JY(X)Z*Z10MCXLH]36XD.,7DX/?FQO1?RXV0&S:^CPAV+RT+"! MM!K@L[*$F3N)D1((G#$7J=)J2:O((YCZK_[V@]C<$GH26%^*(GR3(@0$G8#7 M@P*57#/.9%6)$CP#_^=W3Q&Q29%H$;>:>1,))L O'&F]6"4!:M&C"!1!KXDK[5. M;0UU&[J%7P3?DU#]N+6-VUL9M:6$$H.0URQHC)8324QY/;75,Z/OU.8XG;,@ M=RDDW36 A(;H&-$E22CC;&O.S=V0S,GEU)#UX[,F/Q4-_,!J, M/CF@\ 3(-^\/]_6"J#!,1MGOKD #!_""^#_H=UCY[LC:'8)G M(/OV*57/(KN5CF%"HXB1I$C%8[Q#@H9=D9]\1=GJR'X%@]V2O)AW4 K4C MRMLR9]IJ0L#4\;0*+G :-9=/Q89.;1EJM0PW=X0J,%B* M&@TD<@)I7L6#3'N33>6&.)JQWS&Y6H:8<_"A&/&,>:J)1((:XJH^*LPWFPF_ M^EN:_/E*J?5^ M>B 81TD,]XY:I:V.42]))U#0A\QE/#UR[?0\,JF8EV?OFG^##_(K241&VQ 4 MQX@A"Q&[J9<1..FWWM(V+!IY(70OFNP75#SA/0XL8NN)!Q6$F%*XKEB"4'AK M!('>R59%=#WIER[.7KL?Q@I\/X%J]X/>F7KC=?T][:NLB) M 64M< B<"LG MG# :OG+"BT3+W@7JTJ6JPY8$1J1V]4P4)O'6 MT31LM73GB1:-I:C;A##FGO MB12*,%]?F#FMMK87G3":OG+"BT3;UC+O(.1V5@FD.+?,5?5^D1JRX][A9-'V ME1->)!IG)EB&K$P[8AD*\&]AZS$):GNU&$3C5TYX79S0%JTCZG@D4F%)@\7& M255;!^3%UBGB\AUMO?:^Q2-.>>]DI*DJ5Z42YU6>5=F&B,<]R\:.SMVKXC@+Q*U/YVQT40$ M%D*T2E/IO>?59690RA@X8W(]X]=TQB0[XV@)IEP'$Y0-/EA'ZN[SB(U,W6GL M'^H[3*YG_$K.F&9GS&+T 5SHJ'%D6&L7J*D2;G#$OCQC_)VX'O$K.6*6'3$R M5C$04J)0-"P:IZKAT)Y3@U!ICO4^I?/7,[Z,,^;9&:M(E9)&@[?% E8F.O&4 M&7%ZT39+KJKZ]9RQR,XX.!FPB$:F=71$H\!M'=]X6;K5LK41^'J\EW&\,CM> M :$K<2:B&)5F7ELDR=/Q4E8>[ROQMJ8KWY6G#>AJVF#6GY7%WN&_YH/9EX3& M>)06CY9$J]X%+S\ 7@F%]E46F K,E,4A;0*TROA*$WHI>=,L;XP8(QP^M$'8 M52Q.CN*'2=&?SB=?]D)21TXM<$>T3J MH?.6B<@Y39,.C"4!65-G=XUM[+5&2DI!V&8O\%E1/.@,95"8)>/L'/8&4&6\ MFA3K#!=-*X^T$B++7S\#0W[*0V3!6:2%09('8C @BT/E=@;IFR918Z29D"Q; ML'U6% \Z1&8Q98X%Q*@)U'$;GBI7F+%-AT@P2H--ND-1G/(424QM41(3"!N0 M81H9O(NQ:=HL@S$BF/ N1?%P% \Z1:RXCA(B)&:5B(('7>U?\18QU#1U ME((3)@[3IS_T![=Q//G0_^WGP>S^?CQ,;X,7FKV-=B>E>SH8ZI%BPC'%8D!( M8XZ%P%8R0VT,K'%Y T@KWVQE/Q#5=5*-)[/D5'Q3MK27.\A;AQRLM4"B8*GB MCB6- X&NY-C6V[4%]WRS!9(BM&D:S.Z3?])A_6Y/\Q%LIC, M!G>#&SC3Z?L[7SR.IX-9?EYOQ:IL&F>UC=% :$^5H,H&(@B6)G))P^8\AY-A M*G8 K@3',.ZV"!" Z->""*T _R,9P[. M01$4L.:*/@?))+;?3*?SXM;/)R!$B[[:I8=_ U@ ?(-LM/,^_:^*4D6!8VBT M6E+C#+$4_$=I,%%>BBV+/D KK$"_+W2=HG1*#6@=%Y1KH4SR6B@*:9(4*!&( MR< H-*Y?.#U1%J\G]5E,/D.TUD"9?.; AK.IP8>F8,4%YMY3; 52@@3+ S<$ M&*!Q>I%>4^P'0=@];J=S<20*0BLBP& MW,[[PZ=DI0,;-1]".-/J (%;%U!:L*&<42(8"()1G8XBMGGIU&NFYT&2A+3P MD484/%-8*_"TC*@2/5[0)MO[]CSD^1%AVNF%$KNHK!$0H 5$DZL?;'7;XBUK%$HJ)<7RQX M35C%8$$JL>+.U,E]Y9LSBH2CWPVM#A-&(1TCP$46"T)B!'_<)%^34<$P-4U+ M\]YBG<:\721S=>.B[1A%C+QP$ED%D8NC\*.MQEX# ;Z4?)HO538&5]OYX;?79/F>DM(NE \'W>MW,[7-_,-=O'42AYK)*60 MY7S@J*D22E05G\$T"R(6G J]K^)JQ+-K*IU:N5-@)B=BI,&Y$-*N"UD/??&8 M-"6,!)."BU=/I,-ND[0W'*(_'I#TQF%$C4Q:G=B@#'!8HU;GDI*U,1HO3JCV M.9($QQBP8T8C'#C!N,%Q"F-,F,!N]R[V3! ML71:; ;9>3O3,O>8>$FU(FG&,45&$4I)2'MN'#'::F)WW9+M"5,W>+1,)+88 M2QOAW]:#5^^QUX0M\+!8NS5Y?UD\6D8%*^:CB^!B8RZ\U):[5#AG%:=$"DOS M>W+*Q/KM\0M@9T" )B-VVPHQ&! M0"KK%I2A#OG- 5 I6R?(:Z-,BU9:HT?2U#+H=,OMG $NT0$MZ<$4)3FG**1. M2H^C+D374(IAM99I, CQJ(, MCKD0C83@7,5ZB&6P(:MJN!02M:AO'63P)H ;"B$.EJFBS=86EKG\Y 6[(+3. M&XXN@2XLC$$Q@Q$>!T\6!JV]EK;.4FB5XQ@3J_*GZ[,1G9(\J5E19,2M+ O-I/P6.4F5&A MC,M72\I#5 O2X(]H*@)+U\40([-8.21".Y/[6 R=GL=V7&+-)T?87N0=Q893 M:RR#2!"$"(4$EO/%ALYZ*$N"6UR%)=4HTX2JW(?+W70+0V8XX4 MPPP;Z<&B>TPI8 \H:V8D:);-[4L8%KG9SG.4T//P'/?"\3C,#Q/(BU-G= $668B!144,4U6B_$T,\CD MJ^[>[A\O73S%=MZ-K-MVSB&JU)QX[J-!5,FRYX!Q'8G"4F7A]D42J<7U4Y1H MZ<#Y9ZFP&+Q=[^LB2&XVA[-=I."YAQ MMG_Z[>*I=H@!$EAZI(T24A/F/(@K3=EI^#4&;F5F@"Z75"VNG=').V'4:P@ M@A66B&H5IO<*94F(R]039_3H9"1<<(.,04YC;9E63\TO.&:)K;=8\@-R6Q=/ MM?U-$ (]X[0D$M0Q1)0D8)E,D,4(5#.+F:'^';'6(:J&&F E!0XN6&D*<59, M5P?+[)61,K\[."\_[=M(WN+CB1.DDPL "VI+X; PV4K]P%C;J_2[]' M"WAG*)Y%RS#-,3BYZ8+,&B_3J/I:+8.+\RK(U>*\8:6\ 7LJF3,D O<3KZNK MP%3\E]^9*;T_WY\3Q?.$/9PXB'L\DP$;;1"X]O7<3*M9=DUTB>1JVS.MHD(. M8GZ# P3^.F)=3=V.B-CAD448ZXUJY+O@6"<^YZOGSB' MQ&NI04K8A9[%(0H1<#G#0"HA.'<-J2%&+LLJM;AAB 5@ 858M%QYI[2O5HJ7 M2_0:J@;T_M5LY\/O+,I$:1E0ZI3&UD7!K==5&Y@76N0NZUM:=D*]=F(=(B^< M8AXI"2X( =X]TN8I20^>269X)1%=:Y0?B\?YY.:^GP;3CC]-^@]/8VS-PW@^ MFC6LH6'K \@VVN,AML*8ZA!3Y9Z@BK!JND^@C.:.*H\%VH XZ M3;/S7.'H.1*8U&,V.$997"E>%!6Q"Q6,?3"@ACV!8U#"14<(.#J2"6,08)FA M(EX(E05_D>_Z7U)GQ];F>.E!$2.2IGQH[3VE=5%QE,PWYD]?#!WYOW$L/A+U MI$CF'Z?%?\V3)OD,__KPY;%84R$;?V]O(A444^<]"S8:.%B6QIR8-&<,1RXR M#U>=[FSKB=5/GWUZS[Z7>X&2J 8WZA==A$Q'R:VK=TOJ+DN7]*NL:/[5 8)!HA&,6> M> -.M/+4UM.\?429P5::-N4MG@O?>:K]C712,8,1QM(0@R!@K*\[U.;JZ92_ M)XPV7.F<&=G]%89-*]H4"YI$KJ.Q@E=;UD',2)Y@PTW]?&?&[D"%D0JHE'(L M3R! )U0H5!,$H5(49)BT'_0]1FZDRBC'GRYRWX M7@T![;,PW#6(.X#/EY2%PP 006"@*KL;N .//^G"2K:\6Q7%,;68 M@#E?'+L#=4;$+C!%@R"&*(*8=5+6Z6;P._(,D<*=&[G.%U:L^_V26.0QLYI3 M'H4&WI3UGC!$[N:+69D7N1&\ZGV70!X MGI8#++367#O'4R\])_YIBSD-.(O"L,"-&;A7K* MHA H2[YA_/)'>:#2L!$+$272WH/NIPS,G7Z*+EV&XELX07X"B3II&Y6D((Z& M6,>DDII05RF-$"3+K^$(P0U)CZT8KL&R&%-S8&84B:"E,$J O\$AS@<=[JJ. M=6KI7FMX&J X&,B=.<^ E>#4*^.CL JX(-K*)?6GL M$O^PY4@B@,,7'7;6&(8Y0Q!H8!., M0N U(.$YV+1ZGU!D30,:&>AU4"2GQ3R_342K4"MAM &5%<$4!<($K>()'\SZ M0*!ZD!E-#3UG@?JD$[HA?"(ZIO8DB\'E8$C7V5 68^/.P"XP+^_%#@NJ*,N-Y(XG@ /Y-9:JLXB&/P M/+/KMDU3<2AX%9'=>#K[KIC=CP^O79/(&#AY[M**+IXVPUS#E576)QRO(F3 ?PR'3A8^^B4%9Z4^EH&S%">@7PA.K046%&I$;"; ML,2D>@ZI;%U=!Y;'9VD'AHC4+X;&*?-#7J<^LG0Y!9&M+9-@M=LF5'9=_%*$ M:.MH3S&1)VF)#<)(I,&KU4+7P'!#-36B4KT8&J<43^,A2D0>C#.GFJO@ZY'U M@2+6<,G\7$+\?30I;L:?1NDZ\D/_-UN,BKM!TY:U73<'$B>7UQKG/-?!0!CH MJFFYGBF4:=<5>+<\_R@0=QE5G^;1,IF4GN#.II%@5<<+N#YYZS_>J%WN$LY= MQE4RFP;D2LV)\HXIRU@UHB!BV5#+HG!'<'XSNDF\4XZZG@]G$!?'R?C!S2<3 M8.E%D0^\^X?QL4,U@4&TB6!RF58ZE(/SZ\LO1'&>*][O! X$^QR$:&OR9!A9 M89T+V!A"E*'D*9(%IR_/F.QUQ-T3XL-]?_;S>#Z\_>;A$0 /=W?%S6SPN8"W M_ B:[T !U,(CXXA*ZPBY=P(Q(X0/*B@2!T/ MTTN[+[YW?T5=.U2.!:O?>O/\X'0^+Z4T!O[8EJ=-0* B>:9JMGM:Q1%JO M<%><9W2B9-T-W0O+ER%+G2^NWA7'$S^>?YS=S8?FYB;5^;3>;$IO*+CCC",6 ME4Y35JI;"D>LS"YO&9*OF3H_]8=):\WFDU$;93##JBS:Q3XZ#DSA1.YVYFXKA%Z$, M/[-YPL0YL-T(64HUIA!@UPHX2I//2]4O(T]'D*4#>0)FH88'2A11FF#C:FWC MG70ZNRRB1+Z,/'5$G@/D*2!@'"9BRO7;U$QOHZXMMU1Y"041+^/8B/,*%$M+ M812FW(/XI!Y/[*B@V"@K(R$NL]O 6:^%+!T(%,?,"DR,55HQJ@@)C"^HHR!J MTAEUF&*OAFN>*5 H(.&L))9C+@.W#D*I)6E !:%,US"UT?[6,6GOAM]2-7[2F\L\@8\1;!(9I*# 4!:!XU'.(;;T'\8BC7 M@1@28CR2U .;4<:P%)I7:4R7FDGSPB1^B-E_C10\0%(A$*/6*XR9C%KJ:#2J M0S/-\Y)JN81R//L2_>(T4/"2I8@Q"7E)K9' RY>)TM0S$ M*6FSA#0E%ZKWQ-DE5P8EG8^&($,Y\)[PJE9ZV/JL0)^4?NWOAG1=!)-!><6$ MTP+,+X-PV[K::\&QP6S@@W)7KY&"A^1OP%OQ%EO#DJ\2+>;!//E\>>2@*-;G MI)XO;N*4N^8#L;;H,73#D\:,D;"7!TB M=EW3Z/P>K8I.:.*]U51; 981D9J%+'/Y\(>#,H2709\.)$V9R#VB 6F;%J1J M1:L>?>^P";G?*@]Q6R^73 >(&G@%#F.=YN;;E$,4Z*DVC'*1!>5$;4QC."^- MSN^" L?(P, KHD* (VJPKWH.@$#2Y%D+Q5Y2%[V8HRDU=2&"@XD(1T83864= MY6C3L-F/'Y*>N%PR'>)-NHATP Z<(#3 M_:RX-9^+2?]3\?T\@>@'PWF:DET6V;^?SZ:S_N@VS4ZY_;_SZ2S57.Y3 K[: M^D"-U@@80'MBO70V4E&)B?1>K7K*50. Y(@PO=( <"2H)\$VK[9;Q38*!298 M>\E"FAM%6+"U_<7$-K6G2*$UD?(RL=W=UI(6J5"'$?R/,\P%H3(*DD8!8@O. M:U/;E>"84H%/C^W[NVU?XTRR"D"[/E F$F[#$Z>H:]!AK MP7,[D)WBMYMG)?C10F(NL?;8E6NFJKK($/C: )@5_, E8(I+OSQNN[D2"PJ\B+4QX!-1(2ES53&'X $UL/@X=BVON^^+7WX_BA M/_I+^;?IX+^+KS%ZG/WEJW_Y-/O+QL>'@U'Q]KY$^6L0WW_>^IGT>M,S!Z/[ M8C*8;7ZN_/77Q?=^' ]O%U]44ZD'9.HMZ=2K"96>\^?TR>JA?P9(]P'ZL7^; MCN3MQ_%L-G[X&M/'W^K7AL7=[&O"X)5$^K>#T2W8NJ_?EJ^<%-G>\O^^+V:] MG\>37Y*>7:+<*:(E6OWAX-/HZX3K&II=8EE^SDQ[X[M>!O\Q7^6+F]*'_Y?^ MP^-?_@D+]!>*W_224'3R]6]ZL_NBESJ9^J,OO?O^;:__^#@9_P:*8U8,OW2# MP_]+V1NJ\1L('3KYOD3;)SDZF;1,-'K3Z?%K#RW4U $_&&4]4="4K4EZ /!_V/@^%@-BA.!C]' M;R0EW8*?N&T$8O_K4NQOEIKN1"A(_D8AT2$*KT;(W[U*3;K%7KQ/'L=PV#NG ME3RK\6C17_]SVANF2[KI;*'Z)D79[EF&T7?C2:G/9[\6P\]%[P&^_7[:*P#0 MVU?!J+U?0:A*K!(FGXI1.NI,/XR*XG::Q ^P'*;_)I3[J>MUT>J6Q/*GV4(E M?@$O>'HS&7P$"@Q&O>_'LZ+'WO5ZWXQZ_>5\IS43"-0=PZ^3C+93^/C-<)XH M6<%1I,O1V\7:XCSY\[N M)^/YI_ORK\5O@^EL08OR;8L\V^+AZ>_C1Z!8^89^ZA=;F(1?[PBF*T>69HS!H:\TFE+'D\PSY=G^SCLCT8E&P/> MFV=<2?X(-%/O2]&?[-;YU<__]N?]X[(ZBOOIYKZXG0^+]W??C"#,^S0 ]$SI M/9D%0%\^)(P/">BX-8@0)Z(1%&-GM4!540B3@?.3!W0OKO6?2%EYHA!)]Z;S MAX=^.3H\L=W=.&79I[T_@2:;W8_G4SBNZ;]^?2I3=P.(%I-]R+D61:*-(#+] MOOKHT7CRT!_6#Y^-'],7__;TQ;-27FY UI;O*1,8Z??I8_^F^OUP1@!*?AJ, M%D#VY[-Q]<*D!*M\Y=?![>P>W@W$^3B>@%R_O0&:]Q^GQ=?5#QE;/,$]J7]* MLR02M*._?I7RM!,XM<4O]9O_/+M]^G'2^!5+#!:L;WN)79^&J["^6/B\@A"WT.ZU 5B55 MZ?,?)[V;8=&?_/6KT7A4?/7G]/=EJ=76/S^,@8K_75XE;'O/MX//+3>C5_Y] MQ09E^90RHYX]XF6M3>HGO3+>E?$NFO&.WZ:YH//GZGVYN MBN+N[F7M4WDS=2@=][E(_79PDSK"I[T_]?^U]Z>/\,\-_'/[KYU9_E^FC\^ M#@?PTH_%L+PXG=X/'J==>W@71.>+TU.OA7 G]@GI-:=]<9:Q4R*^J,G4;Y#N MS&1>T[A7X;H*U]/GZ!LIKL)U33$>[(]^F/1!9OOIC4\>:?GB0W_RR_2:8[SF M&(^E4.J\OQN,!K/B]5+HXCCH]YM2P6\85]>4RE4BKA*QAMFO)4S(JG.5#7O,Y+.W@71+C3>G[LFDB\..OW^\EU*)J/][MF.JZB=16M MCNBD"":GY[#?BXA=DXGUY[\9]7Z8C&^*Z32-0 9ZWMRO9!5]\;D8CA_+F:1_ M^GA-*U[3BD=1Z'-_,AC/KY6+UPS*'N-%]AXN\D=)GUS%X2H.5W&X9A/WH&W5 M?3)X\NK^='.M1WQI?^Z""/>J'+T+HMO%,=S^J8Z622Z_GU0(>2-P9Y=O1Y/M M4FS!-0]Y%G>FBZ T1 MG5U@7XK^O*8EKR)QO#?'WP@BKR)Q34VNTG:O.: I*6EN;N8/\^%BJ^C*_.G% M/M*'Q_Y@4MXYW]R7&VNO(>LU@7DEW.^-<-Q;9O>8___)],>M=8_5K>N]*G\NGS[HVIZ#-;\?S MM*S^.>M47L5HX>X&4N]+PE<_F)K0-T2JK KLJL%>BP#!Z M(\6):CW^J IL)>#Y\ZP/Z#>]_VR E1#T;HKA<,FD?_T*?57^#N2]J7Y?0K+! MQQB.\"^[;@UZV\!LBO1^'=S.[K]F:A_MN\YT^[_YL& 3^/ 0IAL.1L7;^W*% MY]>8H'_>/*1UQ7_RI4?TFQY! M2+[IS>Z+7IJNT1]]Z?5O_FL^F*2+I]YPL9.N=S<9/_1^NI\ G)-I[]_'T\?! MK#^< B-.>NY^,+R=%(NKJ;^/!D"+Z6#VI3>^Z_TTGL_N>W$XG@QN^T_MDS%E M9];T8W[U(U?@*@_P!_F*4/9B=PE&'26KP!%=?)E[U;<1GJGWX>S.X! M]DX>0%'OMO\EO\D[YKMZ_;M9,2EI.BENBL'CK/?QR]H9 XW[CX^3\>?^L/I3 M]*;7'X+#!<)4OC#M@PJ#-Z:?[P:3Z:QBA]L>?/)V?C-;YYO!%)ZV9)W9N/?8 M!U8"K@#I3$<-#^KF5(%A.SO5!&="88'8>-)XRGY>I/<-9E,0X]$,R)-N7D?] MV7Q2) H WDO.A9]&XUFB>;*X($#34H;Z'P=#D(AWO0\KU/IU,!P"O:?CWL!A_@#L#'IS6)\-@%M>PJ=(98GS M72TQ2_S?]1!#A\^POLH3CH7B]4W]>[[2=M.BH<^/ G$;U2 Q(['O_1 M/N=%+:V_#1Z 5,,O'9$(=T>B=\]VTZX>TZOUF#J8>_!:/"9>"B_>XC#]-)]\ M2DCU[& \',./TS>];[]UC5;%3$N)G\Z'&V:TMAZ#T:P_^C1(8M&?3HO9TMW: M>]E"9WY4.8BY,U7QIM>\ NQM6@'6&-/]M%>,DA!W M\HC*>7C2'I47T1'WG,*[8!UR"9S[S7@**@,4X1B\SN0O_@K!%[A@"U7R:=(? MI1=OYY,J?'F$KQO#VXH)N!7],F"%;[U=5%".;H;SA8[=I8VF\X__M[B9)==T MK0BST>%;@G+UA/[ GE 'HP0NVA-J&)\ (?%T,"U5\ZJ4 1#%) 7]P^(3_#L) MW1BD9 +NS2=X^V0A2 NA'J0?1B.0M/1:*=>#T>+CH(UN%_H_18B#Z71>O/W8 M+\/*)2BS^_ZLUY\D>1^ELWS7>S^Z*7KE6V\7GE6SZNCW/@T@9EU^T2(>AU!\ M3]4P!^T^:7#1MJB,JU;X VN%#M9-7+166(F/P*R$[#ASIJ.U&(QM]0VB6\WX,B?INR?.6\[7X];[O#\$=U"O#9XA_6 M96(QF<75R+*C>+U#UGV^X=JEE9KLU*:F6M/&I=7I4G>ESQU\N_MW3US_=W!>W\V'Q_NZ;6MF:4M<:<,8^@Z+^D([R M \!KA^.;7_[V/_Z??YM/WW[J]Q^_MO,IX#Z%=X)RGY9W/. 30BS\T/]F=)?^ MDUZJ/UK>G< O/Q9W?_TJ^F0D_C?[QP?_56]P"R_T;V9OC20,&XXXU=8;CBEB M5!#,#/P7,\N^^ML&\7>Y--M(TVHDE^?2.:?]?=2?WPYFBQN17DD@,'$UH4KC MENQ@)V+;E(K(KB"ZTV&=?!. E,_R.PJD/Y47RN/Y%&";_FMYUY2?S+8RK>L:2]4Z8(ECZ7?5Q\S2LPP7*MSPFC5_3PH"#A .L!&?AJ,%D#V MY[-Q]<*B'U:??_L_>FS6TCU\+PYWM_19=KIN*I M@C@$=WJ2U*O%RG6>67QM)ZG44^^')M 4>PP"'#0@6?GUSSFG 1!<)%%40P3( MOI4[%DDLW:?/ONZO4]OF+,^&XR>=WF8,#>L#M8;QOOH KM(*D>\ZO;[3-U@C M R?T&G;=IW>(3*G(65A=5QP\HJ;H\W 9&A%\VM[G9H MDJT1X*K505R#3OM\W&D/ M.N[5Y>NDKYGGQO3Q3K]G$@6^?E )TM3J(\_LIHX>CY[\H=+4\3ZCJ9ZEQ?Z> MJD1.[UA=XS"P%],Q*<8K>#ECN N1R(Z)0@9SF'MXL!?R-V8$^%OS(29I$ ML6)*Q+=YB9[*ZJ4=IA8 7'UU%"1'ESKT3U9A=U,\""9>5CL R &B,>K M=03Z.@FKB7FHN*<[S&QO;1,$^5.C-%$)I]HAK6BH56C)D(EOWHR'-P)S-$UB MBU&.2[UNS*6F>US-'&,%Y-V>N58\>"(J 9[LP+DOX+P$E7Y.#!6N]GI8XCPV ML]0E0D5I3%U3HF+QB.PZQ%7/![2OB%97#*&$\##JB2B!A>KU%>=]\)J!(3-$Y.W"I; M39Y1?D]9;M1T!A(9=OR!0PO/0#BM]DU*%35F ]2,L08V!@&E M%@(;,6$1+E:=*BK'3=62!O&1N@J5'K5(8Q!G"J6W] 3U_/*R$@1YDR*[@G6F M@8\8R!,MN75_IA51"EO"9E?9U^4%%>_#MF'S'5#-"W#54[G9,JNNTK;QNF09 MIP 9F-"'EJF.#YX6LA3N>=CM#/4E0*5%A*Q&ET/_[?S\(R$&/K'$IZA&^]'G M2I7S6TT:P"61!LX_7[+>J,W>@$6&-X(^.\/W_IPAB$0NAQW'WH->!]HJNX,= MBPEV$9N"+1=2@S(9 J-.D0$[60TZK ?;%6ZJ?HY>*O""R,=GP)^\@)6FZN'< _NO;\03I@ M9!&V-FCONHKZ'%^-,.;R1#0G'W7 JH>MLA;DS'( MY#4B8M,'L"Q 4LBL.\/J":*:3/IQKDNA#I4?;!H &P*2=++)6C)9T@/X9'D@9AI+"M:7A]LH5X@_;88"%>WT@A7F_@ MOK ,KOO2.KH75_*UNR]\PG-K$>L8 FQ$P_A+[4SYC$*=?=2F3,(N@TB1FA R M]T>W^Z/1XA$+]9KD SQX$HV H;F)&4\A9.,G98Q:O>IK(!J!-'MI46 M!QV#^E!\J:**UKH0WT'X5SW3;2I(E?-A[^AA^&?N0M .48PPE7P(;W%Z [N. M!?H"L3D:6;$?T(06*F$77$EEIT-;A=@JQ+55B+O.T!TZPW;U1FTC,,=JQ2\& MX<]"J7?L%QY_%47.$R9 TD2C_X^Y[ZN$V__E_[_5=W=I?]P=4C[2 M:RF\FQCS7 @=$*EVUK[V4X>? %V-5+8J@7R-P;;'->6R#^"U$/=$H-^,AEC- M5HLJFLF\!\X>@<+=[?6=<7?G-EJ5@;01F%>50EX.5;^VDOGZBF7NBDX>=$53 MKC)Z;6+I49*Q\-)8)\0MTEBE/*34S$^88.KV>E0GH5)OYFP\9$&C._$9E$F7 MY3OK/#R]"DKZR^WIF:0H*IOS%6580%E*E"\7N M9M*;%:O/F"MKG2O%KW;EZ>OG+.]4?9%+XD2;F5+'>A_/+ M,-]T(D28)S/K!*FLX_=:.W";)W52>5+=0?WRI(;M ZJ":;4(U-3&--Q>TFH:(G4Y^ZHLNQ,*&?PKBK^B M\9(-R@3+"?5(K$PZ)-B-C[,9&29J@\KQ"_KRN-=+C!(?1C).Z4,%! M&$F-1'?E.2$;O5>L_E,C)O2J^3.'Y5[4*,I:E89JX1&#T.*#22_ M&DF'*NGR2DS@NE@(=K<:MC\!*7MPJK6I5:>=6M5Q>GT;(;1:U.ZS4:@M]5 G;CS&.\$CN';8(L,H.^U!C@_&% MR3S.&L&RN9SHB *"3G=HK@#9JD.U$/'5&J]YU3#_MAPC8=6A S"AH^OGTW=& M8W.VF>WF8_6M1X'X.9W0X#BK6M6)JQV-:O76=4:#UQL18/E8#;2):GOQ)CR\ MD9B0H7U0-IAG@WDVF'?H8K=4P2)%S&(1Z*ER,[DPYAZN$1#KA9*GJ5+TG6[7 M]@6P.L/N+F6>T'AH="5_#:.[LUET9[4&&[K:H0/)<&R,T]2%&@["4&HDPBNM M XFY+UC(L;D:C"YFL8[.:4"WD>Z7)T#@?.IHO1"(8 MOXF%P*"Z3>.QNM .HR+-V5QUH0:K"54X]D9Z(E29&K3 L>KF^$R-0-AL-;E=ZT*RBM-S8/NW*/+O9&#S<>K$=TY'67(' MCCOH6GW)ZDMF>R.=ZQ+\CUE3)-]J3\:XV#,HT/9#LOV03(.F+LAPZDII?;O0 M6"#:?DCU *)5QS:'I(0^BZBZ/^N2="=B04'""-2T?!#D M\XQ608+&\K[_MECF&FE;QDOC6(2)X3YE-8)K[3CQ"29?NW8\K57]GC%ES?/@ M@!/%8N$)>A:@SLOJ0U8=V!>&'\!9,M"BV?1.M%O0T.,:@!76L%F2UH&>;6PM^ MSZE?&*A#W//B5/A,9"XCJPC5B">=3I;UVY$SMF39 MG U%'E4HTNB$I+JMI@#C9// M&$T^\T&5LEJ3U9JLUK3-KG7'/=/[ML9IG;6!2GM(%>,F33+=&@&O=MSX!&.6 M;_N#ZK.X+"^KD0Y4;=N[4*"^>!D+7UH]T08V=V! XZZQN*;E,TT0^Y5VIYOQ M6,RBP*=QW3RT6E.->-,I!3AM=+/&S/"X>-ZY4NE<^-8U9UUSUC7WR"#.X=!8 M&8'EK4W4E.H39;) M/'.>@#1ZD\__2H2FQ=V1.TYLX?B%9OF4EV0KE:].ZN M6 7C"*LRJK< K1$XA/?9?+8Z2E4+1*O?U0.()1K_,:':YRW7OQKS*8$LD*$X MR^#D=MK?_U3BE)X($Q$?GE?NN%QB[/19AG#ZR;M>Q_"Y?YD)QKT_4JDDI>3= M<86U7%C@)7PVC;![*>-LD;679Y-4P7J5PD:F$QG23'J\Q!=3^-YGDWMV??[Y M@GV)%M)CHW:?G;$W%_E-E\N;U)L6PY=/N8S9+0]2D;=$]6"90"28* A_*HDU M]_0:J=A<<)7&\!Y:U<_B5@2LRV2HDCC%D8OZF0\^(9!\(@.9W..S8N&A+(9G M)2NK"&D59:#X/!$M]B'T8GB]4 R@XHO\@]37K^[CP15X/(07JS2 =\;1G %4 MX3)Z"H=;/+G@"/@8=A;"HP+Z_5+XR]\M*12>%<^!DY.OKX$5"M=BY6E]6 M 3O8^X13#]J0*4 S.06V!T^1X2)-\#8 "(\%"Z.$11,E8FIMD&\4I^Z*Q,&_ M[^DR#UYX$\6 5W0LV:'HDY AX(F@!62HLEC$$?=F&M$6BT#B@@#$ O.19(BF MTB8X'T4+1*X;P(8<&O! CZL90[99>G,BO%DH_X 'WLEDMK+Q-%S9)D$!&_7& M,NO4"VO^77CX9,6#K!^6!^*"P\KSBD>]85JRPA."Y\/U200/3.#D)%5*ZD[ M"#653O"1> &?8S[L?VB9.=C6;Z'FP;R5L MAG&6GK(B%U%,E?D7?BZ_)HSB.0]61*>+UQ0/)LD"L Z"[)J_O&F_H<\@-+W\ M\Q:F]T7BK.A?Q1W[%,WYAKD*6'PC0[U(GB91_H66S/3-G?23V;N!.US:,: ! M!'RAQ+O\CPUFO5QX_("VL47>[ZXYZS7U>KU==+&M:F/VA/8+'^!VN\]\0D/\ M0[2H*%@^R THK^&T=W9++JSLL *T=>AX<[.14E6?/[T)>:^8"&?ZR9?]!'] M?U:"6@FZI_5$@0*9[-PIUTK21_*+,* 0S1BLPG+. N/CF84Y%]JG(T%C$P&D8S6]"*J4?)2Y-3B4%4T.1%(%HX$5Y M3H1$WH1)#_%Z2D2+%6N0<$V2Q'*2ZL!L$NED"7C<'#[[E.X\C6*/PO:?DSS= M E^$%ZK[4,0W^"H,FU-$'0/@&&@O!;37\B]6WX]9">6;)X+YPD^]A'SR& 5/ M^+L+E(9I&_S([@(<-C70@Z6TI>X%+! MA1G0GP)CEC*1Q#Q4W-O<2R)4GF8CYW!D,2IPV8MY&.*28"T(](Q-KB9F5C\Z:9;=$<&TRWZ M-4FW<%^:;C%^Z0*&+UW!/PF M0NUGZ9@K!7H*K9I0J-WI../=(WAVD)+UV10:W[G_>ZH2\JZRMWSG/*KZ0:MV M3/F(VX\-G&%O;!I5;%^(.NL\KZ0TNAVK-=9":ZRFRORATVA$Z?#KE9^_1"EM M1EVZ.W#<0??P &T$XE6E[Y:=2:^MS;TR"$&U775/:]\X%BM&4\:7?G+8NY?J MA-H]P-N<4)0M%]Y2+EPJ1*7 4RP".9::,5<*2NTC7WC ^3;)@7"FRY>@OBFWG#X;-L!GW ML:A5UQECI HC1%Z2UR>+HM9GLU2V6#+HBMMJF1UV-Y/>+*-M':?B#+0N7&&4 M &R+:.)JJ2U-^H3;*-RF![@\M9:5T.-&7:NYL%2E:-]LHKU*XSS2F=6 $Z[I MHG$'$#?D-_JK4G24JL#I $- '$ )Q$DUB]+ QY"KQMD\ FN*XO0; 9G$"OO( MB:6TT@DP'7&;KS.OQ5[G.9@F5YK!K@"0@- M9ZQ:[)?E&U4Z4>*/%/X,[I$LO"#U2W""?2YOI+?@<<(%&*^^%[AB 03DS6C9 ML-= 14Y.H _LN/SZ[1L&B*13X KZA&&3F!*0D,L\JCW'!9RJY,1J9X=<0 6&<4(F%NQE>_D'0^2 MF&-=? 32)!'QTZ "_^](GO#C' MX;D-(8X/!(=' K<)61[6JVSA\P1\=F[/]^I.-[,N(?IXIV7W) K\K$(6U&
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�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end

Document and Entity Information - USD ($) $ in Thousands	12 Months Ended
Document and Entity Information - USD ($) $ in Thousands	Dec. 31, 2016	Feb. 15, 2017	Jun. 30, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	MIMEDX GROUP, INC.
Entity Central Index Key	0001376339
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		108,840,839
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 787,686

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 34,391	$ 28,486
Short term investments	0	3,000
Accounts receivable, net	67,151	53,755
Inventory, net	17,814	7,460
Prepaid expenses	5,894	3,394
Other current assets	1,288	215
Total current assets	126,538	96,310
Property and equipment, net of accumulated depreciation	13,786	9,475
Goodwill	20,203	4,040
Intangible assets, net of accumulated amortization	23,268	10,763
Deferred tax asset, net	9,114	14,838
Deferred financing costs and other assets	354	487
Total assets	193,263	135,913
Current liabilities:
Accounts payable	11,436	6,633
Accrued compensation	12,365	15,034
Accrued expenses	10,941	4,644
Current portion of earn out liability	8,740	0
Income taxes	5,768	(67)
Other current liabilities	1,482	533
Total current liabilities	50,732	26,777
Earn out liability	8,710	0
Other liabilities	821	1,148
Total liabilities	60,263	27,925
Commitments and contingencies
Stockholders' equity:
Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding	0	0
Common stock; $0.001 par value; 150,000,000 shares authorized; 110,212,547 issued and 109,862,787 outstanding at December 31, 2016 and 109,467,416 issued and 107,361,471 outstanding at December 31, 2015	110	109
Additional paid-in capital	161,261	163,133
Treasury stock at cost: 349,760 shares at December 31, 2016 and 2,105,945 shares at December 31, 2015	(2,216)	(17,125)
Accumulated deficit	(26,155)	(38,129)
Total stockholders' equity	133,000	107,988
Total liabilities and stockholders' equity	$ 193,263	$ 135,913

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	110,212,547	109,467,416
Common stock, shares outstanding (in shares)	109,862,787	107,361,471
Treasury stock, shares (in shares)	349,760	2,105,945

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Net sales	$ 245,015	$ 187,296	$ 118,223
Cost of sales	32,407	20,202	12,665
Gross margin	212,608	167,094	105,558
Operating expenses:
Research and development expenses	12,038	8,413	7,050
Selling, general and administrative expenses	179,997	133,384	90,480
Amortization of intangible assets	2,127	933	928
Operating income	18,446	24,364	7,100
Other expense, net
Interest expense, net	(339)	(86)	(48)
Income before income tax provision	18,107	24,278	7,052
Income tax provision (expense) benefit	(6,133)	5,168	(832)
Net income	$ 11,974	$ 29,446	$ 6,220
Net income per common share - basic (in dollars per share)	$ 0.11	$ 0.28	$ 0.06
Net income per common share - diluted (in dollars per share)	$ 0.11	$ 0.26	$ 0.05
Weighted average shares outstanding - basic (in shares)	105,928,348	105,929,205	105,793,008
Weighted average shares outstanding - diluted (in shares)	112,441,709	113,628,482	113,295,504

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in	Treasury Stock	Accumulated Deficit
Balance, beginning of period (in shares) at Dec. 31, 2013		104,425,614		50,000
Balance, beginning of period at Dec. 31, 2013	$ 73,568	$ 104	$ 147,284	$ (25)	$ (73,795)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	11,453		11,453
Exercise of stock options (in shares)		1,653,690
Exercise of stock options	2,470	$ 2	2,468
Exercise of warrants (in shares)		1,242,416
Exercise of warrants	1,113	$ 1	1,112
Issuance of restricted stock (in shares)		1,438,569
Issuance of restricted stock	$ 0	$ 1	(1)
Shares issued for services performed (in shares)	15,958	15,958
Shares issued for services performed	$ 117		117
Stock repurchase (in shares)				936,636
Stock repurchase	(5,612)			$ (5,612)
Shares issued in conjunction with acquisition	0
Net income	6,220				6,220
Balance, end of period (in shares) at Dec. 31, 2014		108,776,247		986,636
Balance, end of period at Dec. 31, 2014	89,329	$ 108	162,433	$ (5,637)	(67,575)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	16,896		16,896
Exercise of stock options (in shares)		647,656		(1,573,225)
Exercise of stock options	4,629	$ 1	(9,792)	$ 14,420
Exercise of warrants (in shares)				(42,400)
Exercise of warrants	46		(379)	$ 425
Issuance of restricted stock (in shares)		34,250		(1,940,009)
Issuance of restricted stock	$ 0		(14,547)	$ 14,547
Shares issued for services performed (in shares)	16,493	11,321		(5,172)
Shares issued for services performed	$ 164		113	$ 51
Stock repurchase (in shares)				4,610,166
Stock repurchase	(40,279)			$ (40,279)
Tax benefit of share-based compensation expense	7,757		7,757
Restricted stock shares canceled/forfeited (in shares)		(2,058)		69,949
Restricted stock shares canceled/forfeited	0		652	$ (652)
Shares issued in conjunction with acquisition	0
Net income	29,446				29,446
Balance, end of period (in shares) at Dec. 31, 2015		109,467,416		2,105,945
Balance, end of period at Dec. 31, 2015	107,988	$ 109	163,133	$ (17,125)	(38,129)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	$ 17,818		17,818
Exercise of stock options (in shares)	1,164,138	243,928		(918,544)
Exercise of stock options	$ 3,494		(3,767)	$ 7,261
Issuance of restricted stock (in shares)		501,203		(2,210,879)
Issuance of restricted stock	$ 1	$ 1	(17,546)	$ 17,546
Shares issued for services performed (in shares)	43,344			(43,344)
Shares issued for services performed	$ 346		6	$ 340
Stock repurchase (in shares)	1,338,616			1,338,616
Stock repurchase	$ (10,378)			$ (10,378)
Tax benefit of share-based compensation expense	(424)		(424)
Restricted stock shares canceled/forfeited (in shares)				377,317
Restricted stock shares canceled/forfeited	0		2,503	$ (2,503)
Shares repurchased for tax withholding (in shares)				141,658
Shares repurchased for tax withholding	$ (1,165)			$ (1,165)
Shares issued in conjunction with acquisition (in shares)	(441,009)			(441,009)
Shares issued in conjunction with acquisition	$ 3,346		(462)	$ 3,808
Net income	11,974				11,974
Balance, end of period (in shares) at Dec. 31, 2016		110,212,547		349,760
Balance, end of period at Dec. 31, 2016	$ 133,000	$ 110	$ 161,261	$ (2,216)	$ (26,155)

Nature of Business	12 Months Ended
Nature of Business	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business	Nature of Business The Company operates in one business segment, Regenerative Biomaterials, which includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. The MiMedx allograft product families include our: dHACM family with AmnioFix® ans EpiFix® brands; Amniotic Fluid family with OrthoFlo brand; Umbilical family with EpiCord® and AmnioCord® brands; Placental Collagen family with CollaFix™ and AmnioFill™ brands; and Bone family with Physio® brand. AmnioFix and EpiFix are our tissue technologies processed from human amniotic membrane; OrthoFlo is an amniotic fluid derived allograft; EpiCord and AmnioCord are derived from the umbilical cord; Physio is a bone grafting material comprised of 100% bone tissue with no added carrier; and CollaFix, our next brand we plan to commercialize, is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair. The Company is focused primarily on the United States but is actively exploring international expansion opportunities. The adoption of the technologies may vary depending on each country’s regulations, but the opportunities to help individuals in the different disease states remain similar and large.

Liquidity and Capital Resources	12 Months Ended
Liquidity and Capital Resources	Dec. 31, 2016
Liquidity and Capital Resources [Abstract]
Liquidity and Capital Resources	Liquidity and Capital Resources Net Working Capital As of December 31, 2016, the Company had approximately $34,391,000 of cash and cash equivalents. The Company reported total current assets of approximately $126,538,000 and current liabilities of approximately $50,732,000 and had net working capital of approximately $75,806,000 as of December 31, 2016. Overall Liquidity and Capital Resources The Company's largest cash requirement for the twelve months ended December 31, 2016 was cash for general working capital needs as well as the acquisition of Stability described in Note 4. In addition, the Company's other cash requirements included capital expenditures, and repurchases of the Company's common stock. The Company funded its cash requirements through its existing cash reserves, and its operating activities which generated approximately $25,828,000 during the period. The Company believes that its anticipated cash from operating and financing activities and existing cash and cash equivalents, as well as availability under the Credit Agreement will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next year.

Cash Equivalents and Short Term Investments	12 Months Ended
Cash Equivalents and Short Term Investments	Dec. 31, 2016
Cash and Cash Equivalents [Abstract]
Cash Equivalent and Short Term Investments	Cash Equivalents and Short Term Investments Short term investments consisted of approximately $3,000,000 of FDIC insured certificates of deposit held with various financial institutions as of December 31, 2015. The cost of these instruments approximated their fair market value at December 31, 2015. There were no short term investments as of December 31, 2016.

Long-Term Debt	12 Months Ended
Long-Term Debt	Dec. 31, 2016
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt Credit Facility On October 12, 2015, the Company and its subsidiaries entered into a Credit Agreement (the "Credit Agreement") with certain lenders and Bank of America, N.A., as administrative agent. The Credit Agreement establishes a senior secured revolving credit facility in favor of the Company with a maturity date of October 12, 2018 and an aggregate lender commitment of up to $50 million. The Credit Agreement also provides for an uncommitted incremental facility of up to $35 million, which can be exercised as one or more revolving commitment increases or new term loans, all subject to certain customary terms and conditions set forth in the Credit Agreement. The obligations of the Company under the Credit Agreement are guaranteed by the Company's subsidiaries. The obligations of the loan parties under the Credit Agreement and the other credit documents are secured by liens on and security interests in substantially all of the assets of each of the loan parties and a pledge of the equity interests of each subsidiary owned by a loan party, subject to certain customary exclusions. Borrowings under the facility will bear interest at LIBOR plus 1.5% to 2.25%. Fees paid in connection with the initiation of the credit facility totaled approximately $500,000. These deferred financing costs are being amortized to interest expense over the three-year life of the facility. The Credit Agreement contains customary representations, warranties, covenants, and events of default, including restrictions on certain payments of dividends by the Company. As of December 31, 2016, there were no outstanding revolving loans under the credit facility. As of December 31, 2016, the Company was in compliance with all covenants under the Credit Agreement.

401k Plan	12 Months Ended
401k Plan	Dec. 31, 2016
Compensation and Retirement Disclosure [Abstract]
401k Plan	401k Plan The Company has a 401(k) plan (the “Plan”) covering employees who have attained 21 years of age and have completed three months of service. Under the Plan, participants may defer up to 100% of their eligible wages to a maximum of $18,000 per year (annual limit for 2015). Employees age 50 or over in 2016 may make additional pre-tax contributions up to $6,000 above and beyond normal plan and legal limits. Annually, the Company may elect to match employee contributions up to 6% of the employee’s compensation. Additionally, the Company may elect to make a discretionary contribution to the Plan. The Company did not provide matching contributions for the years ended December 31, 2016, 2015, and 2014.

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions On January 13, 2016, when the Company completed the acquisition of Stability Inc., d/b/a Stability Biologics ("Stability") there was an assumed payable of $5,954,555 to a related party. The Company made payments of $1,361,030 during 2016. The payable was further reduced by $3,367,250 as a result of the return or destruction of expired inventory. The outstanding payable at 12/31/16 is $1,226,275 and is included in Accounts Payable. The related party is a limited liability company that is controlled by a former stockholder of Stability Inc. who is now an employee of the Company.

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events The Board of Directors in February 2017 authorized an increase of $20 million to the Company's Share Repurchase Program. This action brings the total amount authorized to $86 million since the Share Repurchase Program commenced in May 2014.

Nature of Business (Details) - 12 months ended Dec. 31, 2016	Business_Segment	segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of business segments	1	1

Significant Accounting Policies (Details)	12 Months Ended
Significant Accounting Policies (Details)	Dec. 31, 2016 USD ($)	Dec. 31, 2016 USD ($) Business_Segment	Dec. 31, 2016 USD ($) segment	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Jul. 31, 2010 USD ($)
Market Concentrations and Credit Risk [Line Items]
Number of business segments		1	1
FDIC insured amount							$ 250,000
Cash and cash equivalents uninsured amount	$ 33,200,000	$ 33,200,000	$ 33,200,000	$ 33,200,000	$ 27,700,000
Goodwill impairment					0
impairment of indefinite useful lives intangible				0	0
Impairment of intangible assets with finite lives				0	0
Patents
Market Concentrations and Credit Risk [Line Items]
Intangible assets, net of accumulated amortization				$ 842,000	$ 851,000	$ 594,000
Minimum
Market Concentrations and Credit Risk [Line Items]
Property and equipment estimated useful life	3 years
Maximum
Market Concentrations and Credit Risk [Line Items]
Property and equipment estimated useful life	7 years

Acquisition of Stability Inc. - Narrative (Details)		3 Months Ended	12 Months Ended
Acquisition of Stability Inc. - Narrative (Details)	Jan. 13, 2016 USD ($) shares	Mar. 31, 2016 USD ($)	Dec. 31, 2017	Dec. 31, 2016 USD ($) Business_Segment	Dec. 31, 2016 USD ($)	Dec. 31, 2016 USD ($) segment	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Business Acquisition [Line Items]
Gross profit margin multiplier					1
Net sales for earn-out period (less than)							$ 12,000,000
Gross profit margin multiplier, low					0.5
Amortization of intangible assets							2,127,000	$ 933,000	$ 928,000
Net income							12,611,000	24,960,000
Number of business segments				1		1
Fair Value Adjustment to Inventory
Business Acquisition [Line Items]
Net income								1,485,000
Forecast
Business Acquisition [Line Items]
Gross profit margin multiplier			1
Pro Forma
Business Acquisition [Line Items]
Amortization of intangible assets								$ 1,176,000
Stability Biologics, LLC
Business Acquisition [Line Items]
Cash paid at closing	$ 6,000,000	$ 6,000,000					6,000,000
Fair Value of Equity Consideration Transferred	$ 3,345,935	3,346,000					3,346,000
Common stock issued (in shares) \| shares	441,009
Assumed debt	$ 1,771,000	1,771,000					1,771,000
Acquisition related costs	1,088,000
Fair value of earn-out	17,450,000	$ 25,620,000		$ 17,450,000	$ 17,450,000	$ 17,450,000	$ 17,450,000
Stability Biologics, LLC \| Selling, general and administrative
Business Acquisition [Line Items]
Acquisition related costs	$ 1,088,000

Acquisition of Stability Inc. - Fair Value of Stock Consideration (Details) - Stability Biologics, LLC - USD ($)		3 Months Ended	12 Months Ended
	Jan. 13, 2016	Mar. 31, 2016	Dec. 31, 2016
Business Acquisition [Line Items]
Common stock issued, price per share (in dollars per share)	$ 8.43
Common stock issued (in shares)	441,009
Common stock issued in acquisition	$ 3,717,706
Less: Marketability Discount @ 10%	(371,771)
Fair Value of Equity Consideration Transferred	$ 3,345,935	$ 3,346,000	$ 3,346,000
Marketability discount	10.00%

Acquisition of Stability Inc. - Intangible Assets Acquired as Part of Acquisition (Details) - Stability Biologics, LLC	Jan. 13, 2016
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)	12 years
Patents and know-how
Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)	20 years
Non-Compete Agreements
Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)	4 years
Licenses and permits
Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)	2 years

Acquisition of Stability Inc. - Goodwill Reconciliation (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2016
Goodwill [Roll Forward]
Goodwill, Beginning Balance		$ 4,040
Goodwill, Ending Balance	$ 20,203	20,203
Stability Biologics, LLC
Goodwill [Roll Forward]
Goodwill, Beginning Balance	22,912
Goodwill Adjustments	(6,749)	(6,749)
Goodwill, Ending Balance	$ 16,163	$ 16,163

Acquisition of Stability Inc. - Pro Forma Information (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Business Combinations [Abstract]
Revenue	$ 245,563	$ 204,481
Net income	$ 12,611	$ 24,960
Income per share, fully diluted (in dollars per share)	$ 0.11	$ 0.22

Cash Equivalents and Short Term Investments (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Cash and Cash Equivalents [Line Items]
Short term investments	$ 0	$ 3,000,000
Certificates of Deposit
Cash and Cash Equivalents [Line Items]
Short term investments	$ 0	$ 3,000,000

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 1,148	$ 602
Work in process	6,677	3,850
Finished goods	10,817	3,405
Inventory, gross	18,642	7,857
Reserve for obsolescence	(828)	(397)
Inventory, net	$ 17,814	$ 7,460

Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Property and equipment [Line Items]
Property and equipment, gross	$ 22,291	$ 14,454
Less accumulated depreciation	(8,505)	(4,979)
Property and equipment, net	13,786	9,475
Other liabilities	821	1,148
Depreciation expense	3,333	1,799	$ 1,197
Leasehold improvements
Property and equipment [Line Items]
Property and equipment, gross	3,274	2,684
Lab and clean room equipment
Property and equipment [Line Items]
Property and equipment, gross	8,666	4,564
Furniture and equipment
Property and equipment [Line Items]
Property and equipment, gross	7,051	4,577
Construction in Progress
Property and equipment [Line Items]
Property and equipment, gross	3,300	2,629
Capital leases
Property and equipment [Line Items]
Property and equipment, net	427
Other liabilities	31
Leasehold improvements paid for by landlord
Property and equipment [Line Items]
Property and equipment, net	1,000
Other liabilities	$ 188	$ 361

Intangible Assets and Royalty Agreement - Intangible Asssets Activity Summary (Details) - USD ($)		12 Months Ended
	Jan. 29, 2007	Dec. 31, 2016	Mar. 31, 2016	Jan. 13, 2016	Dec. 31, 2015	Jan. 05, 2011
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross carrying value		$ 30,260,000			$ 15,627,000
Less Accumulated amortization and impairment charges		(6,992,000)			(4,864,000)
Intangible Assets, Net		23,268,000			10,763,000
Net book value of intangible assets		21,810,000
Stability Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Fair value of earn-out		17,450,000	$ 25,620,000	$ 17,450,000
Tradenames & Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, indefinite lived		1,458,000			1,008,000
Tradenames & Trademarks \| Stability Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, indefinite lived				450,000
Tradenames & Trademarks \| Surgical Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, indefinite lived						$ 1,008,000
In Process Research & Development
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, indefinite lived		25,000			25,000
In Process Research & Development \| Surgical Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, indefinite lived						25,000
Patents in Process
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, indefinite lived		$ 2,618,000			1,823,000
Licenses
Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Lives		7 years
Gross carrying value		$ 1,399,000			1,009,000
Licenses \| Stability Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross carrying value				390,000
Licenses \| Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.
Finite-Lived Intangible Assets [Line Items]
Acquisition price	$ 996,000
Maximum time of approval	30 days
Fair value of earn-out	$ 200,000
Contingent royalty to be paid to licensor	3.00%
Annual royalty payment	$ 50,000
Net book value of intangible assets		$ 10,000
Licenses \| Surgical Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross carrying value						13,000
Patents and know-how
Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Lives		19 years
Gross carrying value		$ 14,839,000			8,001,000
Patents and know-how \| Stability Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross carrying value				6,790,000
Patents and know-how \| Surgical Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross carrying value						7,690,000
Finite-lived intangible assets, costs		$ 48,000
Customer & Supplier Relationships
Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Lives		13 years
Gross carrying value		$ 9,091,000			3,761,000
Customer & Supplier Relationships \| Stability Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross carrying value				5,330,000
Customer & Supplier Relationships \| Surgical Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross carrying value						$ 3,761,000
Non-Compete Agreements
Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Lives		4 years
Gross carrying value		$ 830,000			$ 0
Non-Compete Agreements \| Stability Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross carrying value				$ 830,000

Intangible Assets and Royalty Agreement - Expected Future Amortization of Intangible Assets (Details) $ in Thousands	Dec. 31, 2016 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2017	$ 2,034
2018	1,829
2019	1,829
2020	1,622
2021	1,622
Thereafter	12,874
Net book value	$ 21,810

Long-Term Debt (Details) - Credit Agreement - Revolving Credit Facility - USD ($)	Oct. 12, 2015	Dec. 31, 2016
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 50,000,000
Uncommitted incremental facility	35,000,000
Debt issuance costs	$ 500,000
Debt term	3 years
Outstanding line of credit		$ 0
London Interbank Offered Rate (LIBOR) \| Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	1.50%
London Interbank Offered Rate (LIBOR) \| Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	2.25%

Net Income Per Share - Computation of Basic and Dilutive Net Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Earnings Per Share [Abstract]
Net income	$ 5,481	$ 3,321	$ 1,975	$ 1,197	$ 13,378	$ 6,551	$ 5,430	$ 4,087	$ 11,974	$ 29,446	$ 6,220
Denominator for basic earnings per share - weighted average shares (in shares)									105,928,348	105,929,205	105,793,008
Effect of dilutive securities: Stock options, warrants, and restricted stock (in shares)									6,513,361	7,699,277	7,502,496
Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities (in shares)									112,441,709	113,628,482	113,295,504
Income per common share - basic (in dollars per share)	$ 0.05	$ 0.03	$ 0.02	$ 0.01	$ 0.13	$ 0.06	$ 0.05	$ 0.04	$ 0.11	$ 0.28	$ 0.06
Income per common share - diluted (in dollars per share)	$ 0.05	$ 0.03	$ 0.02	$ 0.01	$ 0.11	$ 0.06	$ 0.05	$ 0.04	$ 0.11	$ 0.26	$ 0.05

Equity - Narrative (Details)		12 Months Ended
Equity - Narrative (Details)	Nov. 18, 2015 $ / shares shares	Dec. 31, 2016 USD ($) plan $ / shares shares	Dec. 31, 2015 USD ($) $ / shares shares	Dec. 31, 2014 USD ($) $ / shares shares	May 12, 2014 USD ($)
Class of Stock [Line Items]
Number of share-based compensation plans \| plan		4
Intrinsic value of options exercised		$ 6,460,000	$ 17,181,000	$ 10,566,000
Intrinsic value of options vested		7,378,000	$ 10,044,000	$ 6,615,000
Total unrecognized compensation expense		$ 1,064,000
Weighted-average grant date fair value for options granted during the period (in dollars per share) \| $ / shares		$ 0.00	$ 5.15	$ 4.18
Shares issued for services performed (in shares) \| shares		43,344	16,493	15,958
Shares issued for services performed		$ 346,000	$ 164,000	$ 117,000
Authorized share amount for repurchase		$ 66,000,000	$ 60,000,000	$ 20,000,000	$ 10,000,000
Stock repurchase (in shares) \| shares		1,338,616
Shares repurchased, value		$ 10,338,000
Commissions		40,000
Remaining authorizations under the repurchase program, amount		$ 9,936,000
Warrants
Class of Stock [Line Items]
Warrants outstanding (in shares) \| shares	42,400
Warrants outstanding (in dollars per share) \| $ / shares	$ 1.09
Warrants term	5 years
Common Stock
Class of Stock [Line Items]
Shares issued for services performed (in shares) \| shares			11,321	15,958
Consultant \| Common Stock
Class of Stock [Line Items]
Shares issued for services performed (in shares) \| shares		43,344
Shares issued for services performed		$ 345,700
Restricted Stock
Class of Stock [Line Items]
Total unrecognized stock-based compensation related to time-based, nonvested restricted stock		$ 21,905,000
Expenses expected to be recognized over a weighted-average period		1 year 10 months 24 days
Restricted Stock \| Minimum
Class of Stock [Line Items]
Vesting period		1 year
Restricted Stock \| Maximum
Class of Stock [Line Items]
Vesting period		3 years

Equity - Activity of Stock Options (Details)	12 Months Ended
Equity - Activity of Stock Options (Details)	Dec. 31, 2016 USD ($) $ / shares shares
Number of Shares
Outstanding, beginning of period (in shares) \| shares	14,019,629
Granted (in shares) \| shares	0
Exercised (in shares) \| shares	(1,164,138)
Unvested options forfeited (in shares) \| shares	(154,200)
Vested options expired (in shares) \| shares	(148,683)
Outstanding, end of period (in shares) \| shares	12,552,608
Vested at end of period (in shares) \| shares	11,680,455
Vested and expected to vest (in shares) \| shares	12,539,865
Weighted- Average Exercise Price
Outstanding, weighted average exercise price, beginning of period (in dollars per share) \| $ / shares	$ 3.62
Granted, weighted average exercise price (in dollars per share) \| $ / shares	0.00
Exercised, weighted average exercise price (in dollars per share) \| $ / shares	3.02
Unvested options forfeited, weighted-average exercise price (in dollars per share) \| $ / shares	6.77
Vested options expired, weighted-average exercise price (in dollars per share) \| $ / shares	6.16
Outstanding, weighted average exercise price, end of period (in dollars per share) \| $ / shares	3.61
Vested at end of period, weighted average exercise price (in dollars per share) \| $ / shares	3.33
Vested and expected to vest, weighted average exercise price (in dollars per share) \| $ / shares	$ 3.60
Stock options, additional disclosures
Outstanding options, weighted average remaining contractual term	5 years 4 months 24 days
Vested at end of period weighted average remaining contractual term	5 years 3 months 18 days
Vested and expected to vest, weighted average remaining contractual term	5 years 4 months 24 days
Outstanding, aggregate intrinsic value \| $	$ 66,137,378
Vested at end of period, aggregate intrinsic value \| $	64,733,964
Vested and expected to vest, aggregate intrinsic value \| $	$ 66,119,285

Equity - Exercise Price Ranges (Details)	12 Months Ended
Equity - Exercise Price Ranges (Details)	Dec. 31, 2016 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of outstanding options (in shares) \| shares	12,552,608
Outstanding options, weighted average remaining contractual term	5 years 4 months 24 days
Outstanding options, weighted average exercise price (in dollars per share)	$ 3.61
Number of exercisable options (in shares) \| shares	11,680,455
Exercisable options, weighted average exercise price (in dollars per share)	$ 3.33
$0.50 - $0.76
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	0.50
Exercise price range, upper range limit (in dollars per share)	$ 0.76
Number of outstanding options (in shares) \| shares	441,429
Outstanding options, weighted average remaining contractual term	2 years 4 months 24 days
Outstanding options, weighted average exercise price (in dollars per share)	$ 0.72
Number of exercisable options (in shares) \| shares	441,429
Exercisable options, weighted average exercise price (in dollars per share)	$ 0.72
$0.87 - $1.35
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	0.87
Exercise price range, upper range limit (in dollars per share)	$ 1.35
Number of outstanding options (in shares) \| shares	4,385,570
Outstanding options, weighted average remaining contractual term	4 years 8 months 12 days
Outstanding options, weighted average exercise price (in dollars per share)	$ 1.19
Number of exercisable options (in shares) \| shares	4,385,570
Exercisable options, weighted average exercise price (in dollars per share)	$ 1.19
$1.40 - $2.45
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	1.40
Exercise price range, upper range limit (in dollars per share)	$ 2.45
Number of outstanding options (in shares) \| shares	1,362,424
Outstanding options, weighted average remaining contractual term	4 years 1 month 6 days
Outstanding options, weighted average exercise price (in dollars per share)	$ 1.92
Number of exercisable options (in shares) \| shares	1,362,424
Exercisable options, weighted average exercise price (in dollars per share)	$ 1.92
$2.66 - $3.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	2.66
Exercise price range, upper range limit (in dollars per share)	$ 3.99
Number of outstanding options (in shares) \| shares	878,680
Outstanding options, weighted average remaining contractual term	5 years 9 months 18 days
Outstanding options, weighted average exercise price (in dollars per share)	$ 3.06
Number of exercisable options (in shares) \| shares	878,680
Exercisable options, weighted average exercise price (in dollars per share)	$ 3.06
$4.19 - $6.38
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	4.19
Exercise price range, upper range limit (in dollars per share)	$ 6.38
Number of outstanding options (in shares) \| shares	3,056,069
Outstanding options, weighted average remaining contractual term	6 years 2 months 12 days
Outstanding options, weighted average exercise price (in dollars per share)	$ 5.36
Number of exercisable options (in shares) \| shares	2,937,038
Exercisable options, weighted average exercise price (in dollars per share)	$ 5.34
$6.45- $9.78
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	6.45
Exercise price range, upper range limit (in dollars per share)	$ 9.78
Number of outstanding options (in shares) \| shares	2,324,103
Outstanding options, weighted average remaining contractual term	7 years
Outstanding options, weighted average exercise price (in dollars per share)	$ 7.30
Number of exercisable options (in shares) \| shares	1,610,485
Exercisable options, weighted average exercise price (in dollars per share)	$ 7.25
$9.90 - $10.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price range, lower range limit (in dollars per share)	9.90
Exercise price range, upper range limit (in dollars per share)	$ 10.99
Number of outstanding options (in shares) \| shares	104,333
Outstanding options, weighted average remaining contractual term	7 years 8 months 12 days
Outstanding options, weighted average exercise price (in dollars per share)	$ 10.42
Number of exercisable options (in shares) \| shares	64,829
Exercisable options, weighted average exercise price (in dollars per share)	$ 10.46

Equity - Assumptions (Details)	12 Months Ended
Equity - Assumptions (Details)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Fair value options valuation assumptions [Abstract]
Expected volatility	0.00%
Expected life (in years)	0 years	6 years	6 years
Expected dividend yield	0.00%	0.00%	0.00%
Risk-free interest rate	0.00%
Risk-free interest rate, minimum		1.51%	1.64%
Risk-free interest rate, maximum		1.68%	1.96%
Minimum
Fair value options valuation assumptions [Abstract]
Expected volatility		54.35%	58.14%
Maximum
Fair value options valuation assumptions [Abstract]
Expected volatility		58.14%	64.50%